Index AR1 - Anticancer Research
Index AR1 - Anticancer Research
Index AR1 - Anticancer Research
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ANTICANCER RESEARCH<br />
International Journal of Cancer <strong>Research</strong> and Treatment<br />
INDEX<br />
VOLUME 28<br />
2008<br />
ISSN: 0250-7005
ANTICANCER RESEARCH<br />
International Journal of Cancer <strong>Research</strong> and Treatment<br />
ISSN: 0250-7005<br />
VOLUME 28<br />
2008
Editorial Board<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
B. B. Aggarwal Cytokine <strong>Research</strong> Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson<br />
Cancer Center, Houston, TX, USA<br />
J. P. Armand Institut Gustav-Roussy, Villejuif, France<br />
D. Assimakopoulos Department of Otorhinolaryngology, Medical School, University of Ioannina, Greece<br />
V. I. Avramis Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA<br />
R. C. Bast Department of Translational <strong>Research</strong>, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA<br />
G. Bauer Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany<br />
E. E. Baulieu INSERM U488 and College de France, Le Kremlin-Bicetre, France<br />
Y. Becker Department of Molecular Virology, Hebrew University of Jerusalem, Israel<br />
E. J. Benz, Jr. Dana-Farber Cancer Institute, Boston, MA, USA<br />
J. Bergh Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden<br />
J. L. Biedler Department of Biological Sciences, Fordham University, Bronx, NY, USA<br />
D. D. Bigner Department of Pathology, Duke University Medical Center, Durham, NC, USA<br />
A. Böcking Institute for Cytopathology, University of Düsseldorf, Germany<br />
G. Bonadonna Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy<br />
F. T. Bosman Institute of Pathology, University of Lausanne, Switzerland<br />
G. Broich ASL Lodi, Lodi, Italy<br />
J. M. Brown Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA<br />
Ø. S. Bruland Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway<br />
M. M. Burger Novartis, Basel, Switzerland<br />
M. Carbone Cancer <strong>Research</strong> Center of Hawaii, Honolulu, HI, USA<br />
J. Carlsson Department of Biomedical Radiation Sciences, Uppsala University, Sweden<br />
A. F. Chambers Department of Oncology, London Regional Cancer Center, London, Ontario, Canada<br />
P. Chandra Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany<br />
L. Cheng Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA<br />
J.-G. Chung Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC<br />
E. De Clercq Rega Institute for Medical <strong>Research</strong>, Katholieke Universiteit Leuven, Belgium<br />
W. De Loecker Department of Biochemistry, Katholieke Universiteit Leuven, Belgium<br />
W. Den Otter VUMC, Department of Urology, Amsterdam, The Netherlands<br />
E. P. Diamandis Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada<br />
G. Th. Diamandopoulos Department of Pathology, Harvard Medical School, Boston, MA, USA<br />
W. Ebert Thoraxclinic HD-Rohrbach, Heidelberg, Germany<br />
U. Eppenberger Laboratory of Biochemistry/Endocrinology, University Clinic, Basel, Switzerland<br />
J. A. Fernandez-Pol Metalloproteomics, LLC, Chesterfield, MO, USA<br />
I. J. Fidler Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA<br />
W. Fiers Department of Molecular Biomedical <strong>Research</strong>, Ghent University and VIB, Belgium<br />
N. E. Fusenig Division of Differentiation, DKFZ, Heidelberg, Germany<br />
G. Gabbiani Department of Pathology, University of Geneva, Switzerland<br />
A. F. Gazdar Hamon Center for Therapeutic Oncology <strong>Research</strong>, University of Texas Southeastern Medical Center, Dallas,<br />
TX, USA<br />
A. Giordano Sbarro Institute for Cancer <strong>Research</strong>, Temple University, Philadelphia, PA, USA<br />
G. Gitsch Department of Gynecology and Obstetrics, University of Freiburg, Germany<br />
R. H. Goldfarb Sopherion Therapeutics, Inc., Princeton, NJ, USA<br />
J. W. Gorrod Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UK<br />
S. Hammarström Department of Immunology, University of Umeä, Sweden<br />
I. Hart Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart’s and The London, Queen<br />
Mary’s School of Medicine and Dentistry, London, UK<br />
4173
4174<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
I. Hellström Harborview Medical Center, Seattle, WA, USA<br />
L. Helson Department of Experimental Therapeutics, New York Medical College, Valhalla, NY, USA<br />
R. B. Herberman Pittsburgh Cancer Institute, Pittsburgh, PA, USA<br />
R. M. Hoffman Department of Surgery, University of California, San Diego, CA, USA<br />
C. G. Ioannides Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA<br />
S. C. Jhanwar Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New<br />
York, NY, USA<br />
J. V. Johannessen Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway<br />
B. Kaina Institute of Toxicology, University of Mainz, Germany<br />
B. K. Keppler School of Medicine, University of Vienna, Austria<br />
D. G. Kieback Department of Obstetrics and Gynecology, HELIOS Medical Center, Carl Gustav Carus University Dresden,<br />
Germany<br />
J. Kieler Danish Cancer Society, Copenhagen, Denmark<br />
R. Klapdor Medical Clinic, University of Hamburg, Germany<br />
U. R. Kleeberg Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany<br />
P. Kleihues Department of Pathology, University Hospital Zürich, Switzerland<br />
E. Klein Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden<br />
S. von Kleist Institut für Immunologie der Universität der Freiburg, Germany<br />
S. D. Kottaridis Department of Virology, Hellenic <strong>Anticancer</strong> Institute, Athens, Greece<br />
G. R. F. Krueger Center of Anatomy II, University of Cologne Medical School, Cologne, Germany<br />
D. W. Kufe Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA<br />
Pat Kumar Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK<br />
Shant Kumar Department Pathology, University of Manchester Medical School, Manchester, UK<br />
M. Kuroki Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan<br />
O. D. Laerum Department of Pathology, The Gade Institute, University of Bergen, Norway<br />
F. J. Lejeune Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland<br />
C. J. Link Iowa Cancer <strong>Research</strong> Foundation, Clive, IA, USA<br />
L. A. Liotta Center of Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA<br />
L. F. Liu Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA<br />
D. M. Lopez Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA<br />
E. Lundgren Unit of Applied Cell and Molecular Biology, University of Umeä, Sweden<br />
H. T. Lynch Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA<br />
J. Marescaux IRCAD, University of Strasbourg, France<br />
J. Mark Department of Pathology, Kärnsjukhuset, Skövde, Sweden<br />
J. F. Marshall Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart’s and The London, Queen<br />
Mary’s School of Medicine and Dentistry, London, UK<br />
D. Medina Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA<br />
S. Mitra Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX, USA<br />
F. M. Muggia New York University Cancer Institute, School of Medicine, NY, USA<br />
M. J. Murphy, Jr. Hipple Cancer <strong>Research</strong> Center, Dayton, OH, USA<br />
R. Narayanan Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA<br />
K. Nilsson Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden<br />
J. F. Novak Department of Biology, Bucknell University, Lewisburg, PA, USA<br />
S. Pathak Department of Cell Biology, University of Texas, Houston, TX, USA<br />
S. Pestka Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey,<br />
Piscataway, NJ, USA<br />
G. J. Pilkington Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences,<br />
University of Portsmouth, UK<br />
C. D. Platsoucas College of Sciences, Old Dominion University, Norfolk, VA, USA
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
F. Podo Laboratory of Cell Biology, Istituto Superione di Sanità, Rome, Italy<br />
A. Polliack Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel<br />
M. F. Rajewsky Institute of Cell Biology, University of Essen Medical School, Essen, Germany<br />
G. Rebel IRCAD, Hopitaux Universitaires, Strasbourg, France<br />
M. Rigaud Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France<br />
U. Ringborg Department of General Oncology, Karolinska Hospital, Stockholm, Sweden<br />
M. Roselli Department of Medical Oncology, University of Rome “Tor Vergata”, Italy<br />
A. Schauer Zentrum Pathologie, Georg-August Universität, Göttingen, Germany<br />
M. Schneider Department of Organic Chemistry, Bergische University, Wuppertal, Germany<br />
A. Seth Laboratory of Molecular Pathology, Sunnybrook <strong>Research</strong> Institute and University of Toronto, Ontario, Canada<br />
G. V. Sherbet Cancer <strong>Research</strong> Unit, University of Newcastle-upon-Tyne, UK<br />
G.-I. Soma Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan<br />
G. S. Stein Department of Cell Biology, University of Massachusetts Medical Center, Worcester, MA, USA<br />
T. Stigbrand Department of Immunology, Umeä University, Umeä, Sweden<br />
K. Takagi Kennan Takagi Clinic, Kumamoto, Japan<br />
D. Tarin University of California at San Diego, Cancer Center, La Jolla, CA, USA<br />
G. B. de The’ Institut Pasteur, Paris, France<br />
T. M. Theophanides Department of Chemistry, Technical University of Athens, Greece<br />
B. Toth The Eppley Institute for <strong>Research</strong> in Cancer and Allied Diseases, Omaha, NE, USA<br />
E. Trell Department of General Practice and Primary Care, Faculty of Health Sciences, University of Linköping, Sweden<br />
P. M. Ueland Clinical Pharmacolocy Unit, Department of Pharmacology, University of Bergen, Norway<br />
P. T. Vihko Department of Clinical Chemistry, University of Oulu, Finland<br />
M. Volm German Cancer <strong>Research</strong> Center, Heidelberg, Germany<br />
G. Weber Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA<br />
I. B. Weinstein Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons,<br />
New York, NY, USA<br />
B. Westermark Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden<br />
B. Zumoff Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA<br />
4175
Acknowledgements<br />
Aase og Ejnar Danielsens Fond, Denmark<br />
Abraxis Bioscience, Bridgewater, NJ, U.S.A.<br />
Academia Sinica, Taipei, Taiwan, R.O.C.<br />
Aim for the Top University Plan, National Sun Yat-Sen<br />
University, Taiwan, R.O.C.<br />
Ajinomoto Co., Japan<br />
Akademisch Ziekenhuis Maastricht, The Netherlands<br />
Alliance for Cancer Gene Therapy Young Investigator<br />
Award, U.S.A.<br />
Alma Toorock Memorial for Cancer <strong>Research</strong>, Brooklyn,<br />
NY, U.S.A.<br />
American Cancer Society, U.S.A.<br />
American Laser Foundation, U.S.A.<br />
Amgen, Norway<br />
Anna and Bror Bjorusson Foundation, Sweden<br />
ANPCyT, Argentina<br />
Association pour la Recherche contre le Cancer (A.R.C),<br />
France<br />
Association pour la Recherche sur le Cancer, Villejuif,<br />
France<br />
Associazione Malattie del Sangue (AMS), Milan, Italy<br />
Associazione per la Lotta contro i Tumori Infantili (ALTI),<br />
Italia<br />
AstraZeneca International<br />
Austrian Cancer Aid/ Styria<br />
AVIS Monsummano Terme Onlus “Per Elisa Contro il<br />
Medulloblastoma”, Italia<br />
Bavarian <strong>Research</strong> Foundation<br />
Behörde für Wissenschaft und Forschung (BWI) der<br />
Hansestadt Hamburg, Germany<br />
Bengt Ihre Foundation of the Swedish Society of Medicine<br />
BMWi/AIF ProINNO II initiative, Germany<br />
Boel Foundation, Denmark<br />
Bristol-Myers Squibb AB, Bromma, Sweden<br />
Bundesministerium für Forschung und Technik, Germany<br />
Bureau of Science & Technology Guangdong<br />
Province/R&D Planning Funds, China<br />
Bureau of Science & Technology Shenzhen Nanshan<br />
District/ R&D for Company Funds, China<br />
Canadian Institute of Health <strong>Research</strong><br />
Cancer Association of South Africa<br />
Cancer <strong>Research</strong> Foundation, Northern Sweden<br />
Cancer <strong>Research</strong> Foundation, U.S.A.<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
The following Organisations supported many of the works published in <strong>Anticancer</strong> <strong>Research</strong>, Volume 28, 2008.<br />
Cancer Society of Northern Finland<br />
Cancer Standards Institute of New Zealand<br />
Cancerföreningen, Stockholm, Sweden<br />
Cancéropôle Lyon-Auvergne-Rhône-Alpes (CLARA),<br />
France<br />
Carlsberg Foundation, Copenhagen, Denmark<br />
Center for Innovation in Immunoregulative Technology and<br />
Therapeutics, Graduate School of Medicine, Kyoto<br />
University, Japan<br />
Center of Excellence for Environmental Medicine,<br />
Kaohsiung Medical University, Kaohsiung, Taiwan,<br />
R.O.C.<br />
Central <strong>Research</strong> Fund of the University of the Free State,<br />
South Africa<br />
Centre National de la Recherche Scientifique, France<br />
Centre République, France<br />
Centro Odontolόgico Universita΅rio Norte do Paran, Brazil<br />
Centro Regionale di Competenza Produzioni<br />
Agroalimentari, Italy<br />
Chang Gung Memorial Hospital, Taiwan, R.O.C.<br />
Chiba Cancer Center, Japan<br />
Children’s Cancer Foundation of Sweden<br />
Children’s Hospital, University of North Carolina (UNC),<br />
Chapel Hill, NC, U.S.A.<br />
Children’s Miracle Network, Salt Lake City, UT, U.S.A.<br />
China Medical University Hospital, Taichung, Taiwan,<br />
R.O.C.<br />
China Medical University, Taichung, Taiwan, R.O.C.<br />
China National Natural Science Foundation<br />
China Postdoctoral Science Foundation<br />
Clayton Foundation for <strong>Research</strong>, Houston, TX, U.S.A.<br />
CNPq, Brazil<br />
Comenius University, Bratislava, Slovak Republic<br />
Comités du Haut-Rhin et du Bas-Rhin, France<br />
Committee of Scientific Investigations, Poland<br />
Compagnia di San Paolo, Turin, Italia<br />
Cooperative Foundation of the School of Life Sciences<br />
Coordenaça΄o de Aperfeiçoamento de Pessoal de Nivel<br />
Superior (CAPES), Brazil<br />
Czech Academy of Sciences<br />
Czech Ministry of Education<br />
Dagmar Marshalls Fond, Denmark<br />
Department of Biotechnology, New Delhi<br />
Department of Defense (DoD), U.S.A.<br />
4177
Department of Health, Executive Yuan, Taipei, Taiwan,<br />
R.O.C.<br />
Department of Hygiene Toxicology, Department of<br />
Nutrition and Food Hygiene of Harbin Medical<br />
University, China<br />
Department of Science & Technology, New Delhi<br />
Department of Trade and Industry, South Africa<br />
Department of Veterans Affairs, Charleston, SC, U.S.A.<br />
Deutsche Forschungsgemeinschaft, Germany<br />
Deutsche Krebshilfe, Germany<br />
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg,<br />
Germany<br />
Dietmar Hopp Stiftung, Germany<br />
Dir. Ib Henriksens Foundation, Denmark<br />
Dong-A University, Bosan, Korea<br />
Dr. Robert Pfleger-Stiftung, Germany<br />
Eastern Norway Regional Health Authority<br />
Eli Lilly & Co.<br />
Elsa U. Pardee Foundation, Midland, MI, U.S.A.<br />
European Association of Cancer <strong>Research</strong> (EACR)<br />
European Social Fund and National Resources (EPEAEK<br />
II "Pythagoras")<br />
European Sunlight Association<br />
Fabrikant Einar Willumsens Mindelegat, Denmark<br />
Faculty of Medicine, NTNU, Norway<br />
Faculty of Medicine, Uppsala University, Sweden<br />
FAPESP, Brazil<br />
Ferrocene Chemical Enterprises<br />
Finnish Cancer Society, Finland<br />
Finska Läkaresällskapet, Finland<br />
First Affiliated Hospital, Sun Yat-Sen University, China<br />
First Department of Internal Medicine, Nagasaki University<br />
School of Medicine, Japan<br />
Fondazione Carime, Bari, Italy<br />
Förderung für Forschung und Lehre (FöFoLe), Germany<br />
Foundation for Polish Science<br />
Foundation for Promotions of Cancer <strong>Research</strong>, Japan<br />
Foundation of Jiangsu Province Health Bureau, P.R. China<br />
Foundation of Nanjing Municipal Health Bureau, P.R.<br />
China<br />
Frænkels Mindefond, Denmark<br />
French Association for Surgical <strong>Research</strong>, France<br />
Friedrich Baur-Stiftung, Germany<br />
Fujita Health University, Aichi, Japan<br />
Fukuoka Cancer Society, Japan<br />
Fundaça΄o Arauca΅ria/Conselho Nacional de<br />
Desenvolvimento Cientifico e Tecnolόgico CNPq, Brazil<br />
4178<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Fundação de Amparo à Pesquisa do Estado de Minas<br />
Gerais (FAPEMIG), Brazil<br />
Galician administration Xunta de Galicia, Spain<br />
General Clinical <strong>Research</strong> Centers (GCRC), U.S.A.<br />
General Secretariat of <strong>Research</strong> and Technology,<br />
Greece<br />
German <strong>Research</strong> Association<br />
GlaxoSmithKline, UK<br />
Guang Dong Province Technology Project Foundation,<br />
China<br />
Gunnar, Arvid and Elisabeth Nilsson Foundation, Sweden<br />
Health Centre of the Third XiangYa Hospital, ChangSha,<br />
China<br />
Hellenic <strong>Anticancer</strong> Institute, Athens, Greece<br />
Hellenic Cooperative Oncology Group, Greece<br />
Hochschuljubiläumsstiftung der Stadt Wien, Austria<br />
Hochschul-Wissenschafts Programm, Germany<br />
Hoffmann-La Roche Ltd, Basel, Switzerland<br />
Hôpitaux Universitaires de Strasbourg, France<br />
Hormel Foundation, Austin, MN, U.S.A.<br />
Hospices Civils de Lyon, France<br />
Hospital do Câncer de Londrina , Brazil<br />
Hospital Erasto Gaertner, Brazil<br />
HRH Crown Princess Lovisa’s Association for Child<br />
Medical Care, Sweden<br />
Hungarian Ministry of Health<br />
Hungarian Scientific <strong>Research</strong><br />
HYGEIA Diagnostic & Therapeutic Center of Athens,<br />
Greece<br />
HYGEIA Hospital, Athens, Greece<br />
Hyogo Prefecture Health Promotion Association, Japan<br />
Ichou Association for Promotion of Medical Science,<br />
Japan<br />
IDUN Pharmaceuticals, La Jolla, CA, U.S.A.<br />
Innovative Project of Talent in Medical Science from<br />
Henan Province, P.R. China<br />
Institut de Chimie des Substances Naturelles, CNRS,<br />
France<br />
Institut National de la Santé et de la Recherche Médicale<br />
(INSERM), France<br />
Institute for Medical <strong>Research</strong>, Kuala Lumpur, Malaysia<br />
Instituto de Salud Carlos III, Spain<br />
Internal Grant Agency, Ministry of Health, Czech Republic<br />
International Agency for <strong>Research</strong> on Cancer (IARC),<br />
France<br />
IRCCS Burlo Garofolo, Trieste, Italy
Istituto Oncologico Romagnolo (IOR), Forlì FC, Italy<br />
Italian Ministry of Education and <strong>Research</strong><br />
Italian Ministry of University and Scientific <strong>Research</strong><br />
Japan Scientific Society<br />
Japan Society for the Promotion of Science (JSPS)<br />
Japanese Smoking Society Foundation<br />
John Sealy Memorial Foundation, University of Texas<br />
Medical Branch, Galveston, TX, U.S.A.<br />
Joseph Nelson Undergraduate Mentorship Award, U.S.A.<br />
K. Albin Johansson Foundation, Finland<br />
Kaibara Morikazu Medical Science Promotion Foundation,<br />
Fukuoka, Japan<br />
Kanazawa Medical University, Japan<br />
Kaohsiung Medical University <strong>Research</strong> Foundation,<br />
Kaohsiung, Taiwan, R.O.C.<br />
Karolinska Institute, Stockholm, Sweden<br />
King Gustaf V`s Jubilee Foundation, Sweden<br />
Kinki University Medical School, Japan<br />
Kirstins Weg, Germany<br />
Kitasato University <strong>Research</strong> Grant for Young <strong>Research</strong>ers,<br />
Japan<br />
Kitasato University, School of Medicine, Kanagawa, Japan<br />
Købmand Sven Hansen og hustru Ina Hansens Fond,<br />
Denmark<br />
Korean Government<br />
Korean Science and Engineering Foundation (KOSEF),<br />
Daejeon, Republic of Korea<br />
Krebsliga Zurich, Switzerland<br />
L’Association pour la Recherche sur le Cancer, France<br />
La Ligue Nationale contre le Cancer, France<br />
La Ligue Nationale Française de Lutte Contre le Cancer,<br />
France<br />
Laboratory of High Voltage & Electrotechnics New<br />
Technology, Chongqing University, P.R. China<br />
Leading Science School, Russia<br />
Leukemia and Lymphoma Society (LLC), Toronto, ON,<br />
Canada<br />
Leukemia Society Scholarship, U.S.A.<br />
Liaoning BaiQianWan Talents Program, China<br />
Libyan Ministry of Health<br />
Ligue Nationale Française contre le Cancer, France<br />
LMU excellent Monitoring Programme, Ludwig-<br />
Maximilians University, Munich, Germany<br />
Londrina State University (UEL), Brazil<br />
Ludwig Boltzmann Institute of Gynecology and<br />
Gynecologic Oncology, Vienna, Austria<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Lydia Hochstrasser Foundation to Support Cancer<br />
<strong>Research</strong>, Switzerland<br />
M.D. Anderson Cancer Center, Houston, TX, U.S.A.<br />
Margaret Duffey and Robert Cameron Troupe Memorial<br />
Fund, Buffalo General Hospital, NY, U.S.A.<br />
Max Planck Society, Germany<br />
Medical Faculty Charité, Humboldt University, Berlin,<br />
Germany<br />
Medical Faculty of the University of Wuerzburg, Germany<br />
Medical <strong>Research</strong> Fund of New Brunswick, NJ, U.S.A.<br />
Medicinska Understödsföreningen Liv och Hälsa, Finland<br />
Medinet Co., Ltd.<br />
Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters<br />
der Bundeshauptstadt Wien, Austria<br />
Menschen für Kinder e.V., Germany<br />
Milênio/Conselho Nacional de Desenvolvimento Científico<br />
e Tecnológico (CNPq), Brazil<br />
Millennium Pharmaceuticals, Inc, Cambridge, MA,<br />
U.S.A.<br />
Ministero dell’ Universitá e della Ricerca (M.I.U.R.), Italia<br />
Ministero della Salute, Roma, Italy<br />
Ministry of Education, Culture, Sport, Science and<br />
Technology, Japan<br />
Ministry of Education, Taiwan, R.O.C.<br />
Ministry of Health and Welfare, Japan<br />
Ministry of Health, Labour and Welfare, Japan<br />
Ministry of Health, Malaysia<br />
Ministry of Health, Social and Family Affairs, Hungary<br />
Ministry of Science and Technology, Israel<br />
Mitsui Life Social Welfare Foundation, Japan<br />
Mitsui Memorial Hospital, Japan<br />
MolMed - Centre of Excellence<br />
MURST, Italy<br />
National Cancer Institute (NCI), NIH, Bethesda, MD,<br />
U.S.A.<br />
National Center for Complementary and Alternative<br />
Medicine, U.S.A.<br />
National Committee for Scientific <strong>Research</strong><br />
National Consortium of Oncology, Hungary<br />
National Institute of Biomedical Innovation, Osaka, Japan<br />
National Institute of Craniofacial Dental <strong>Research</strong>,<br />
Bethesda, MD, U.S.A.<br />
National Institute of Neurological Disorders and Stroke,<br />
U.S.A.<br />
National Institute on Aging, Bethesda, MD, U.S.A.<br />
National Institutes of Health (NIH), U.S.A.<br />
National Institutes of Health Cancer Center, U.S.A.<br />
4179
National R&D Program for Cancer Control, Ministry of<br />
Health & Welfare, Republic of Korea<br />
National <strong>Research</strong> Foundation of South Africa<br />
National Science Council, Taiwan, R.O.C.<br />
National Science Foundation (NSF), Arlington, VA, U.S.A.<br />
National Science Foundation of China<br />
National Science Fund of Henan Province for<br />
Distinguished Young Scholars, P.R. China<br />
National Taiwan University Hospital, Taipei, Taiwan,<br />
R.O.C.<br />
Natural Science Foundation of the P. R. China<br />
Natural Scientific Foundation of China<br />
Nebraska Tobacco Settlement Biomedical <strong>Research</strong><br />
Program, U.S.A.<br />
New Brunswick Innovation Foundation, NJ, U.S.A.<br />
New Industry Creative-Type Technology R&D Promotion<br />
Programs from the Ministry of Economy, Trade and<br />
Industry, Japan<br />
North Glasgow University Hospital, U.K.<br />
Norwegian Cancer Society<br />
Norwegian Foundation for Health and Rehabilitation<br />
Norwegian <strong>Research</strong> Council<br />
Norwegian Women’s Public Health Association<br />
Novo Nordisk Foundation, Denmark<br />
Office of the Commission for Higher Education, Ministry<br />
of Education, Thailand<br />
Oncologia Ca’ Granda Onlus Fondazione, Milano, Italia<br />
Pathology Section, Kanazawa University Hospital,<br />
Ishikawa, Japan<br />
Peter-Escher-Stiftung für krebskranke Kinder, Germany<br />
Pfizer, France<br />
Philip Morris International, New York, NY, U.S.A.<br />
Philip Morris USA Inc., U.S.A.<br />
Polish Committee for Scientific <strong>Research</strong><br />
Polonium Program<br />
Precision Therapeutics, Inc., Pittsburgh, PA, U.S.A.<br />
Prostate Cancer Foundation (CaPCURE), Santa Monica,<br />
Ca, U.S.A.<br />
Quilmes National University, Buenos Aires, Argentina<br />
<strong>Research</strong> Council for Nature and the Universe (FNU),<br />
Denmark<br />
<strong>Research</strong> Foundation of Kaohsiung Veterans General<br />
Hospital, Taiwan, R.O.C.<br />
<strong>Research</strong> Service, Minneapolis VA Medical Center<br />
(VAMC), Minneapolis, MN, U.S.A.<br />
4180<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
RIKEN BioResource Center, Tsukuba, Japan<br />
Romanian National Agency for Scientific <strong>Research</strong><br />
Romikin S.A., Argentina<br />
Ruth and Rickard Juhlin Foundation, Sweden<br />
Sagawa Foundation for Promotion of Cancer <strong>Research</strong>,<br />
Japan<br />
Schweizerischer Verein Balgrist, Zurich, Switzerland<br />
Shenyang Outstanding Talent Foundation, China<br />
Shinshu University Graduate School of Medicine, Japan<br />
Sino-Swed Tongkang Bio-Tech. Inc, Shenzhen, China<br />
Snedkermester Sophus og hustru Astrid Jacobsens Fond,<br />
Denmark<br />
Software AG-Stiftung, Germany<br />
Spanish Ministerio de Educación y Ciencia<br />
Spanish Society of Medical Oncology<br />
St. Baldrick’s Foundation, U.S.A.<br />
Stavros Niarchos Foundation, Athens, Greece<br />
Sterix Ltd, member of the Ipsen Group, Slough, UK<br />
Stockholm Cancer Society, Sweden<br />
Stockholm City Council, Sweden<br />
Surgery Foundation Heidelberg, Germany<br />
Susan G. Komen Breast Cancer Foundation, TX, U.S.A.<br />
Svenska Kulturfonden, Finland<br />
Swedish Cancer Foundation<br />
Swedish Cancer Society<br />
Swedish Institute<br />
Swedish <strong>Research</strong> Council<br />
Taiho Pharmaceutical Co. Ltd., Osaka, Japan<br />
Technology and Human Resources for Industry Programme<br />
of the National <strong>Research</strong> Foundation, South Africa<br />
Telemark University College, Norway<br />
Terry Fox Cancer <strong>Research</strong> Foundation, Taichung, Taiwan,<br />
R.O.C.<br />
Texas Food and Fiber Commission, U.S.A.<br />
Texas Southern University<br />
Texas Woman's University <strong>Research</strong> Enhancement, U.S.A.<br />
The Cancer <strong>Research</strong> Fund, Norway<br />
The Else Kröner-Fresenius-Foundation, Germany<br />
Thompson Cancer Survival Center, Knoxville, TN, U.S.A.<br />
Trondheim University Hospital, Norway<br />
U.S. Army Medical <strong>Research</strong> and Acquisition Activity, Fort<br />
Detrick, MD, U.S.A.<br />
U.S. National Institutes of Health<br />
United States Department of Agriculture<br />
Universidade Federal do Paraná (UFPR), Brazil<br />
University of Athens, School of Medicine, Athens, Greece
University of Bologna, Italy<br />
University of Genova, Italy<br />
University of North Carolina (UNC), Chapel Hill, NC,<br />
U.S.A.<br />
University of Oklahoma Health Sciences Center (OUHSC),<br />
College of Pharmacy, OK, U.S.A.<br />
University of Zurich, Switzerland<br />
Uppsala University Hospital, Sweden<br />
US Department of Energy, Office of Biological and<br />
Environmental <strong>Research</strong><br />
UV Foundation, McLean, VA, U.S.A.<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Vehicle Racing Commemorative Foundation, Tokyo, Japan<br />
Vidacare Corporation, San Antonio, Texas, U.S.A.<br />
Vitamin D Society, Canada<br />
Wakayama Medical University, Japan<br />
Walter L. and Johanna Wolf Foundation, Zurich,<br />
Switzerland<br />
WESCO Scientific Promotion Foundation, Japan<br />
Western Norwegian Health Authorities<br />
Willner Family Center for Vascular Biology, Rehovot,<br />
Israel<br />
4181
Number 1A<br />
Experimental Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Contents, Volume 28, 2008<br />
Inhibition of Both Mesothelioma Cell Growth and Cdk4 Activity following Treatment with a TATp16 INK4a<br />
Peptide. S.P. FRIZELLE, M.G. KRATZKE, R.R. CARREON, S.C. ENGEL, L. YOUNGQUIST, M.A. KLEIN,<br />
L. FOURRE, L.L. SHEKELS, R.A. KRATZKE (Minneapolis, MN, USA)......................................................................<br />
Cell Cycle Perturbation and Acquired 5-Fluorouracil Chemoresistance. X. GUO, E. GOESSL, E. COLLIE-<br />
DUGUID, J. CASSIDY, W. WANG, V. O’BRIEN (Wolverhampton; Aberdeen; Glasgow, UK) ......................<br />
Proliferation and Programmed Cell Death: Role of p53 Protein in High and Low Grade Astrocytoma.<br />
A. FACOETTI, E. RANZA, R. NANO (Pavia, Italy)...................................................................................<br />
Chemotherapy-induced Bystander Effect in Response to Several Chloroethylnitrosoureas: An Origin<br />
Independent of DNA Damage? P. MERLE, D. MORVAN, J.C. MADELMONT, D. CAILLAUD,<br />
A. DEMIDEM (Clermont-Ferrand, France)...............................................................................................................<br />
Identification of Glutathione Sulfotransferase-apple (GSTP1) as a New Resveratrol Targeting Protein<br />
(RTP) and Studies of Resveratrol-responsive Protein Changes by Resveratrol Affinity Chromatography.<br />
T.-C. HSIEH, Z. WANG, H. DENG, J.M. WU (Valhalla; New York, NY, USA).......................................<br />
Induction of Necrosis in Human Myeloma Cells by Kigamicin. M. NAKAMURA, H. ESUMI, L. JIN,<br />
H. MITSUYA, H. HATA (Kumamoto; Chiba, Japan) ............................................................................................<br />
The Utility of Vitamin K3 (Menadione) against Pancreatic Cancer. S. OSADA, H. TOMITA, Y. TANAKA,<br />
Y. TOKUYAMA, H. TANAKA, F. SAKASHITA, T. TAKAHASHI (Gifu, Japan) .........................................<br />
Adenovirus Vector-mediated Gene Therapy Using Iodized Oil Esters for Hepatocellular Carcinoma in Rats.<br />
H. SHIBA, T. MISAWA, T. IIDA, T. OKAMOTO, Y. FUTAGAWA, M. SAKURAI, T. OHASHI,<br />
Y. ETO, K. YANAGA (Tokyo, Japan).......................................................................................................................<br />
Effect of pO 2 on Antitumor Drug Cytotoxicity on MDR and Non-MDR Variants Selected from the LoVo<br />
Metastatic Colon Carcinoma Cell Line. I. LELONG-REBEL, C. BRISSON, M. FABRE, J.-P. BERGERAT,<br />
G. REBEL (Strasbourg; Lyon, France)...........................................................................................................................<br />
Feasibility of Induction Heating Using a Sintered MgFe2O4 Needle for Minimally Invasive Breast Cancer<br />
Therapy. S. YUKUMI, Y. WATANABE, A. HORIUCHI, T. DOI, K. SATO, M. YOSHIDA, T. MAEHARA,<br />
H. AONO, T. NAOHARA, K. KAWACHI (Ehime, Japan)...........................................................................................<br />
Volume-sensitive Cl – *<br />
Channel as a Regulator of Acquired Cisplatin Resistance. T. SHIMIZU, E.L. LEE,<br />
T. ISE, Y. OKADA (Okazaki, Japan).........................................................................................................................<br />
Delta(9)-tetrahydrocannabinol Inhibits 17‚-Estradiol-induced Proliferation and Fails to Activate Androgen<br />
and Estrogen Receptors in MCF7 Human Breast Cancer Cells. A.O. VON BUEREN, M. SCHLUMPF,<br />
W. LICHTENSTEIGER (Zurich, Switzerland) .........................................................................................................<br />
Parasporin-1Ab, a Novel Bacillus thuringiensis Cytotoxin Preferentially Active on Human Cancer Cells In Vitro.<br />
A. UEMORI, A. OHGUSHI, K. YASUTAKE, M. MAEDA, E. MIZUKI, M. OHBA (Fukuoka; Kurume,<br />
Fukuoka, Japan) ........................................................................................................................................................................<br />
Polymorphisms of Death Pathway Genes FAS and FASL and Risk of Premalignant Gastric Lesions. P.-I. HSU,<br />
P.-J. LU, E-M. WANG, L.-P. GER, G.-H. LO, F.-W. TSAY, T.-A. CHEN, H.-B. YANG, H.-C. CHEN,<br />
W.-S. LIN, K.-H. LAI (Kaohsiung; Hsin-Chu County; Tainan, Taiwan, ROC)..........................................................<br />
4182<br />
1<br />
9<br />
15<br />
21<br />
29<br />
37<br />
45<br />
51<br />
55<br />
69<br />
75<br />
85<br />
91<br />
97
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
A New Peritoneal Carcinomatosis Model in Cyclosporine Immunosuppressed Rats. J. AKHTER, P. YAO,<br />
L.A. JOHNSON, S.M. RIORDAN, D.L. MORRIS (Sydney, NSW, Australia)....................................................<br />
Survivin Expression in Glioblastomas Correlates with Proliferation, but not with Apoptosis. M. MELLAI,<br />
V. CALDERA, A. PATRUCCO, L. ANNOVAZZI, D. SCHIFFER (Vercelli, Italy)...............................................<br />
Unlocking Pathology Archives for MicroRNA-profiling. K.P. HOEFIG, C. THORNS, A. ROEHLE, C.<br />
KAEHLER, K.O. WESCHE, D. REPSILBER, B. BRANKE, M. THIERE, A.C. FELLER, H. MERZ<br />
(Luebeck; Dummerstorf, Germany) ..............................................................................................................................<br />
EpCAM Overexpression is Associated with High-grade Urothelial Carcinoma in the Renal Pelvis. A. BRUNNER,<br />
G. SCHAEFER, L. VEITS, B. BRUNNER, M. PRELOG, C. ENSINGER (Innsbruck, Tirol, Austria)...................<br />
Effects of ·-Santalol on Proapoptotic Caspases and p53 Expression in UVB Irradiated Mouse Skin. B.L.<br />
ARASADA, A. BOMMAREDDY, X. ZHANG, K. BREMMON, C. DWIVEDI (Brookings, SD, USA)...........<br />
Wilms’ Tumor 1 Protein and Focal Adhesion Kinase Mediate Keratinocyte Growth Factor Signaling in<br />
Breast Cancer Cells. X.-P. ZANG, J.T. PENTO, A.M. TARI (Oklahoma City, OK; Houston, TX, USA) ......<br />
Overexpression of the Mitotic Spindle Assembly Checkpoint Genes hBUB1, hBUBR1 and hMAD2 in<br />
Thyroid Carcinomas with Aggressive Nature. N. WADA, A. YOSHIDA, Y. MIYAGI, T. YAMAMOTO,<br />
H. NAKAYAMA, N. SUGANUMA, K. MATSUZU, K. MASUDO, S. HIRAKAWA, Y. RINO,<br />
M. MASUDA, T. IMADA (Yokohama, Kanagawa, Japan)..................................................................................<br />
New Method for Colorectal Cancer Diagnosis Based on SSCP Analysis of DNA from Exfoliated Colonocytes in<br />
Naturally Evacuated Feces. S. ONOUCHI, H. MATSUSHITA, Y. MORIYA, T. AKASU, S. FUJITA, S.<br />
YAMAMOTO, H. HASEGAWA, Y. KITAGAWA, Y. MATSUMURA (Kashiwa; Tokyo, Japan) .......................<br />
Tumor-specificity and Type of Cell Death Induced by Vitamin K 2 Derivatives and Prenylalcohols.<br />
H. SAKAGAMI, K. HASHIMOTO, F. SUZUKI, M. ISHIHARA, H. KIKUCHI, T. KATAYAMA,<br />
K. SATOH (Saitama; Tokyo, Japan)...........................................................................................................................<br />
Expression of the Serine Protease Hepsin and Clinical Outcome of Human Endometrial Cancer.<br />
T. MATSUO, K. NAKAMURA, N. TAKAMOTO, J. KODAMA, A. HONGO, F. ABRZUA, Y. NASU,<br />
H. KUMON, Y. HIRAMATSU (Okayama, Japan) .................................................................................................<br />
Preoperative Serum Vascular Endothelial Growth Factor-C (VEGF-C) Levels Predict Recurrence in<br />
Patients with Esophageal Cancer. H. KIMURA, H. KATO, N. TANAKA, T. INOSE, A. FARIED,<br />
M. SOHDA, M. NAKAJIMA, Y. FUKAI, T. MIYAZAKI, N. MASUDA, R. MANDA, M. FUKUCHI,<br />
H. OJIMA, K. TSUKADA, H. KUWANO (Maebashi, Japan) ..............................................................................<br />
Inhibition of NO Production in LPS-stimulated Mouse Macrophage-like Cells by Trihaloacetylazulene<br />
Derivatives. J. TAKAHASHI, T. SEKINE, M. NISHISHIRO, A. ARAI, H. WAKABAYASHI,<br />
T. KURIHARA, K. HASHIMOTO, K. SATOH, N. MOTOHASHI, H. SAKAGAMI (Saitama; Tokyo;<br />
Kiyose, Japan)...........................................................................................................................................................<br />
Pretreatment with S-1, an Oral Derivative of 5-Fluorouracil, Enhances Gemcitabine Effects in Pancreatic<br />
Cancer Xenografts. S. NAKAHIRA, S. NAKAMORI, M. TSUJIE, S. TAKEDA, K. SUGIMOTO,<br />
Y. TAKAHASHI, J. OKAMI, S. MARUBASHI, A. MIYAMOTO, Y. TAKEDA, H. NAGANO, K. DONO,<br />
K. UMESHITA, M. SAKON, M. MONDEN (Osaka; Hyogo, Japan) .....................................................................<br />
Human Monocytes Both Enhance and Inhibit the Growth of Human Pancreatic Cancer in SCID Mice. B.<br />
MYTAR, M. BAJ-KRZYWORZEKA, M. MAJKA, D. STANKIEWICZ, M. ZEMBALA (Cracow, Poland) .....<br />
Morphological Events Found at the Invading Edge of Colorectal Carcinomas in Baboons. C.A. RUBIO,<br />
E. DICK Jr., G.B. HUBBARD (San Antonio, TX, USA)........................................................................................<br />
105<br />
109<br />
119<br />
125<br />
129<br />
133<br />
139<br />
145<br />
151<br />
159<br />
165<br />
171<br />
179<br />
187<br />
193<br />
4183
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Establishment of Three Novel Human Malignant Pleural Mesothelioma Cell Lines: Morphological and<br />
Cytogenetical Studies and EGFR Mutation Status. M. KOBAYASHI, T. TAKEUCHI, Y. OHTSUKI<br />
(Kochi; Matsuyama, Ehime, Japan)..............................................................................................................................<br />
Curcumin Induces Apoptosis in Human Neuroblastoma Cells via Inhibition of NFÎB. C. FREUDLSPERGER,<br />
J. GRETEN, U. SCHUMACHER (Hamburg; Heidelberg, Germany; Porto, Portugal) ..............................................<br />
Frequent Splicing Aberration of the Base Excision Repair Gene hMYH in Human Gastric Cancer.<br />
K. KOBAYASHI, A. SHIDA, H. YAMADA, Y. ISHIBASHI, R. NAKAYAMA, Y. TORIUMI,<br />
N. MITSUMORI, H. KASHIWAGI, K. YANAGA (Tokyo, Japan).....................................................................<br />
PAI-1, t-PA and Circulating hTERT DNA as Related to Virus Infection in Liver Carcinogenesis.<br />
R. DIVELLA, R. LACALAMITA, S. TOMMASI, M. COVIELLO, A. DANIELE, V.M. GARRISI,<br />
I. ABBATE, G. SIMONE, C. GADALETA, A. PARADISO, M. QUARANTA (Bari, Italy).........................<br />
Tumor-specific Cytotoxicity and Type of Cell Death Induced by ‚-Cyclodextrin Benzaldehyde Inclusion<br />
Compound. Y. LIU, H. SAKAGAMI, K. HASHIMOTO, H. KIKUCHI, O. AMANO, M. ISHIHARA, Y.<br />
KANDA, S. KUNII, M. KOCHI, W. ZHANG, G. YU (Beijing, China; Saitama; Chiba, Japan).....................<br />
Keratin Profiling in the Developing Human Prostate. A Different Approach to Understanding Epithelial Lineage.<br />
M. TROMPETTER, F. SMEDTS, J. VAN DER WIJK, C. SCHOOTS, H.-J. DE JONG, A. HOPMAN, J. DE<br />
LA ROSETTE (Stadskanaal; Winschoten; Maastricht; Amsterdam, The Netherlands) .....................................................<br />
Stage-related Decorin and Versican Expression in Human Laryngeal Cancer. M. STYLIANOU, S.S.<br />
SKANDALIS, T.A. PAPADAS, N.S. MASTRONIKOLIS, D.A. THEOCHARIS, N. PAPAGEORGA-<br />
KOPOULOU, D.H. VYNIOS (Patras, Greece) ........................................................................................................<br />
Comparative Analysis of Cell Death Induction by Cisplatin and 5-FU in Human Oral Squamous and<br />
Hepatocellular Carcinoma Cell Lines. M. OKAMURA, J. SHIMADA, H. SAKAGAMI (Saitama, Japan).........<br />
Adhesion to Fibronectin Induces Megakaryocytic Differentiation of JAS-REN Cells. H. YAMADA, T.<br />
SEKIKAWA, M. AGAWA, S. IWASE, H. SUZUKI, J. HORIGUCHI-YAMADA (Tokyo, Japan)..............<br />
A New Single Nucleotide Polymorphism in XRCC4 Gene is Associated with Breast Cancer Susceptibility<br />
in Taiwanese Patients. C.-F. CHIU, H.-C. WANG, C.-H. WANG, C.-L. WANG, C.-C. LIN, C.-Y. SHEN,<br />
S.-Y. CHIANG, D.-T. BAU (Taichung; Taipei, Taiwan, ROC) ...........................................................................<br />
A DNA Polymorphism of Stromal-derived Factor-1 is Associated with Advanced Stages of Oral Cancer. E.<br />
VAIRAKTARIS, A. VYLLIOTIS, S. SPYRIDONODOU, S. DERKA, S. VASSILIOU, E. NKENKE, C.<br />
YAPIJAKIS, Z. SEREFOGLOU, F.W. NEUKAM, E. PATSOURIS (Athens, Greece; Erlangen, Germany) .......<br />
Quantitative Structure–Cytotoxicity Relationship Analysis of 3-Formylchromone Derivatives by a<br />
Semiempirical Molecular-orbital Method with the Concept of Absolute Hardness. M. ISHIHARA,<br />
H. SAKAGAMI (Saitama, Japan)...............................................................................................................................<br />
Growth Inhibition and Proapoptotic Activity Induction by IIF and Valproic Acid on RA-resistant Leukemia<br />
Cells. G. BARTOLINI, M. ORLANDI, A. PAPI, K. AMMAR, R. TONELLI, M. FRANZONI,<br />
A. PESSION, P. ROCCHI, A.M. FERRERI (Bologna, Italy)................................................................................<br />
Antiangiogenic Properties of Lupulone, a Bitter Acid of Hop Cones. L. SIEGEL, A. MITERNIQUE-<br />
GROSSE, C. GRIFFON, C. KLEIN-SOYER, A. LOBSTEIN, F. RAUL, D. STEPHAN (Strasbourg;<br />
Illkirch, France)...............................................................................................................................................................<br />
Immunohistochemical Expression Patterns of Neural and Neuroendocrine Markers, the Neural Growth Factor<br />
Receptors and the ‚-Tubulin II and IV Isotypes in Human Thymus. M. BAI, A. PAPOUDOU-BAI,<br />
G. KARATZIAS, M. DOUKAS, A. GOUSSIA, K. STEFANAKI, D. RONTOGIANNI, Y. DALAVANGA,<br />
N.J. AGNANTIS, P. KANAVAROS (Ioannina; Athens, Greece) ...............................................................................<br />
4184<br />
197<br />
209<br />
215<br />
223<br />
229<br />
237<br />
245<br />
253<br />
261<br />
267<br />
271<br />
277<br />
283<br />
289<br />
295
BRAF and K-RAS Mutation in a Greek Papillary and Medullary Thyroid Carcinoma Cohort. N. GOUTAS,<br />
D. VLACHODIMITROPOULOS, M. BOUKA, A.C. LAZARIS, G. NASIOULAS, M. GAZOULI (Athens,<br />
Greece).............................................................................................................................................................................<br />
The Interleukin-10 (–1082A/G) Polymorphism is Strongly Associated with Increased Risk for Oral Squamous<br />
Cell Carcinoma. E. VAIRAKTARIS, C. YAPIJAKIS, Z. SEREFOGLOU, S. DERKA, S. VASSILIOU,<br />
E. NKENKE, A. VYLLIOTIS, S. SPYRIDONIDOU, F.W. NEUKAM, K.A. SCHLEGEL, E. PATSOURIS<br />
(Athens, Greece; Erlangen, Germany) ..........................................................................................................................<br />
Pro-apoptotic Activity of Cyclopentenone in Cancer Cells. M. ROSETTI, M. FRASNELLI, F. FABBRI,<br />
C. ARIENTI, I. VANNINI, A. TESEI, W. ZOLI, M. CONTI (Meldola; Brescia; Ravenna, Italy).......................<br />
Elevated Serum-circulating RNA in Patients with Conventional Renal Cell Cancer. G. FENG, G. LI,<br />
A. GENTIL-PERRET, J. TOSTAIN, C. GENIN (Saint-Etienne, France)...........................................................<br />
Overexpression of Vimentin Contributes to Prostate Cancer Invasion and Metastasis via Src Regulation.<br />
J. WEI, G. XU, M. WU, Y. ZHANG, Q. LI, P. LIU, T. ZHU, A. SONG, L. ZHAO, Z. HAN, G. CHEN,<br />
S. WANG, L. MENG, J. ZHOU, Y. LU, S. WANG, D. MA (Wuhan, Hubei, China).......................................<br />
Valproate Protective Effects on Cisplatin-induced Peripheral Neuropathy: An In Vitro and In Vivo Study.<br />
V. RODRIGUEZ-MENENDEZ, A. GILARDINI, M. BOSSI, A. CANTA, N. OGGIONI, V. CAROZZI,<br />
L. TREMOLIZZO, G. CAVALETTI (Monza, Italy) ..............................................................................................<br />
Prognostic Impact of Lymphangiogenesis and Lymphatic Invasion (CD105 Expression) in Small Cell Lung<br />
Carcinoma. G. HARDAVELLA, E. ARKOUMANI, Y. DALAVANGA, P. GALANIS, N.J. AGNANTIS,<br />
S. CONSTANTOPOULOS, D. STEFANOU (Ioannina; Athens, Greece)............................................................<br />
Lack of Genotoxicity of Carbon Nanotubes in a Pilot Study. K. SZENDI, C. VARGA (Pécs, Hungary)...........<br />
* Review (page 75)<br />
Number 1B<br />
Clinical Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
*<br />
Confocal Endomicroscopy: In Vivo Diagnosis of Neoplastic Lesions of the Gastrointestinal Tract. M. GOETZ,<br />
R. KIESSLICH (Mainz, Germany) ....................................................................................................................................<br />
Pancreatic Resection for Metastatic Renal Cell Carcinoma: A Single Center Experience and Review of the<br />
Literature. M. SCHAUER, H. VOGELSANG, J.R. SIEWERT (Munich, Germany)........................................<br />
Comparative Analysis of Four Histopathological Classification Systems to Discriminate Benign and Malignant<br />
Behaviour in Gastrointestinal Stromal Tumors. D. VALLBÖHMER, H.E. MARCUS, S.E. BALDUS,<br />
J. BRABENDER, G. LURJE, U. DREBBER, R. METZGER, A.H. HÖLSCHER, P.M. SCHNEIDER<br />
(Cologne; Düsseldorf, Germany; Zurich, Switzerland)......................................................................................................<br />
Changes of Immunological Parameters Reflect Quality of Life-related Toxicity during Chemotherapy in Patients<br />
with Advanced Colorectal Cancer. K. YOSHIMATSU, K. KUHARA, H. ITAGAKI, M. AIZAWA, H.<br />
YOKOMIZO, T. FUJIMOTO, T. OTANI, G. OSAWA, R. KOBAYASHI, K. OGAWA (Tokyo, Japan)...........<br />
Adoptive Immunotherapy for Pancreatic Cancer Using MUC1 Peptide-pulsed Dendritic Cells and Activated<br />
T Lymphocytes. H. KONDO, S. HAZAMA, T. KAWAOKA, S. YOSHINO, S. YOSHIDA, K. TOKUNO,<br />
M. TAKASHIMA, T. UENO, Y. HINODA, M. OKA (Ube, Yamaguchi, Japan)...............................................<br />
305<br />
309<br />
315<br />
321<br />
327<br />
335<br />
343<br />
349<br />
353<br />
361<br />
367<br />
373<br />
379<br />
4185
*<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
5-Fluorouracil-related Gene Expression in Hepatic Artery Infusion-treated Patients with Hepatic Metastases from<br />
Colorectal Carcinomas. S. SAMESHIMA, S. TOMOZAWA, H. HORIKOSHI, K. MOTEGI, I. HIRAYAMA,<br />
S. KOKETSU, T. OKADA, M. KOJIMA, Y. KON, T. SAWADA (Ota, Gunma, Japan)............................................<br />
Alpha 1 Antichymotrypsin Genotype is Associated with Increased Risk of Prostate Carcinoma and PSA Levels.<br />
F. LICASTRO, A. BERTACCINI, E. PORCELLINI, M. CHIAPPELLI, R. PERNETTI, F. SANGUEDOLCE,<br />
D. MARCHIORI, G. MARTORANA (Bologna, Italy) ......................................................................................................<br />
The ATM Gene and Ataxia Telangiectasia. A. MAVROU, G.T. TSANGARIS, E. ROMA, A. KOLIALEXI<br />
(Athens, Greece) .............................................................................................................................................................<br />
Metastatic Adenocarcinoma in the Brain: Magnetic Resonance Imaging with Pathological Correlations to<br />
Mucin Content. S. OSHIRO, H. TSUGU, F. KOMATSU, H. ABE, T. OHMURA, S. SAKAMOTO,<br />
T. FUKUSHIMA (Fukuoka, Japan) ...........................................................................................................................<br />
High Serum Level of Plasminogen Activator Inhibitor-1 Predicts Histological Grade of Intracerebral Gliomas.<br />
Y. IWADATE, M. HAYAMA, A. ADACHI, T. MATSUTANI, Y. NAGAI, T. HIWASA, N. SAEKI (Chiba,<br />
Japan) ......................................................................................................................................................................................<br />
Axillary and Subcutaneous Breast Metastases from Rhinopharyngeal Carcinoma: A Case Report and<br />
Literature Review. F. TOMAO, E. MIELE, G.P. SPINELLI, G. CAPRIO, E. RANIERI, P. MINGAZZINI,<br />
A. ZULLO, S. TOMAO (Rome, Italy)..............................................................................................................................<br />
Prognostic Value of the Androgen Receptor and its Coactivators in Patients with D1 Prostate Cancer.<br />
R. MORI, Q. WANG, M.L. QUEK, C. TARABOLOUS, E. CHEUNG, W. YE, S. GROSHEN, D. HAWES,<br />
S. TOGO, H. SHIMADA, K.D. DANENBERG, P.V. DANENBERG, J.K. PINSKI (Los Angeles, CA, USA;<br />
Yokohama, Japan) .............................................................................................................................................................<br />
Dysphagia Severity and Aspiration Following Postoperative Radiation for Locally Advanced Oropharyngeal<br />
Cancer. N.P. NGUYEN, C. FRANK, C.C. MOLTZ, P. VOS, C. MILLARD, H.J. SMITH, S. DUTTA,<br />
H. LEE, T. MARTINEZ, U. KARLSSON, L.M. NGUYEN, S. SALLAH (Tucson, AZ; Dallas, TX;<br />
Greenville, NC; Los Angeles, CA; Ann Arbor, MI, USA; Athens, Greece)...............................................................<br />
Lymph Node Metastasis Density (ND)-factor Association with Malignant Degree and ND40 as “Noncurative<br />
Factor” in Gastric Cancer. K. YAMASHITA, A. OOKI, S. SAKURAMOTO, S. KIKUCHI,<br />
N. KATADA, N. KOBAYASHI, M. WATANABE (Kanagawa, Japan) ..............................................................<br />
*<br />
DNA Image Cytometry in Bladder Cancer: State of the Art. C.A. PALMEIRA, P.A. OLIVEIRA, F. SEIXAS,<br />
M.A. PIRES, C. LOPES, L. SANTOS (Porto; Vila Real, Portugal)................................................................................<br />
MCM-2, Ki-67 and PCNA Protein Expressions in pT3G2 Colorectal Cancer Indicated Lymph Node<br />
Involvement. K. GUZIN ’ KA-USTYMOWICZ, E. STE È PIEN ’ , A. KEMONA (Bialystok, Poland) ....................<br />
Practice and Costs of Red Blood Cell (RBC) Transfusion in an Oncological Unit. J. NORUM, M.-A.N. MOEN<br />
(Tromsø, Norway)......................................................................................................................................................................<br />
94% Accuracy of Intraoperative Imprint Touch Cytology of Sentinel Nodes in Skin Melanoma Patients.<br />
D. NEJC, G. PASZ-WALCZAK, J. PIEKARSKI, P. PLUTA, P. SEK, A. BILSKI, A. DURCZYNSKI,<br />
A. BERNER, T. JASTRZEBSKI, A. JEZIORSKI (Lodz; Gdansk, Poland).......................................................<br />
Expression of Maspin in Papillary Ta/T1 Bladder Neoplasms. S. BLANDAMURA, E. D'ALESSANDRO,<br />
L. GIACOMELLI, V. GUZZARDO, W. BATTANELLO, M. REPELE, V. NINFO (Padova, Italy)...........<br />
ER-·36, a Novel Variant of ER-·, is Expressed in ER-positive and -negative Human Breast Carcinomas.<br />
L.M.J. LEE, J. CAO, H. DENG, P. CHEN, Z. GATALICA, Z.-Y. WANG (Omaha, NE, USA; Hangzhou;<br />
Wuhan, China)................................................................................................................................................................<br />
4186<br />
389<br />
395<br />
401<br />
407<br />
415<br />
419<br />
425<br />
431<br />
435<br />
443<br />
451<br />
459<br />
465<br />
471<br />
479
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Photodynamic Therapy of Barrett's Esophagus: Ablation of Barrett's Mucosa and Reduction in p53 Protein<br />
Expression after Treatment. M. PANJEHPOUR, D. COPPOLA, B.F. OVERHOLT, T. VO-DINH,<br />
S. OVERHOLT (Knoxville, TN; Tampa, FL; Durham, NC, USA) .........................................................................<br />
Relationship between Oral Contraceptive Therapy and Estrogen Receptor Status in Patients with Breast Cancer.<br />
F. LUMACHI, M. ERMANI, F. MARINO, L. DI CRISTOFARO, V. TOMBOLAN, A. BRUNELLO,<br />
A. ROMA, U. BASSO (Padova, Italy).....................................................................................................................................<br />
Gemcitabine plus Oxaliplatin (GEMOX) in Pretreated Patients with Advanced Ovarian Cancer:<br />
A Multicenter Phase II Study of the Hellenic Oncology <strong>Research</strong> Group (HORG). A. KALYKAKI,<br />
P. PAPAKOTOULAS, S. TSOUSIS, I. BOUKOVINAS, K. KALBAKIS, L. VAMVAKAS, A. KOTSAKIS,<br />
N. VARDAKIS, P. PAPADOPOULOU, V. GEORGOULIAS, D. MAVROUDIS (Heraklion; Thessaloniki;<br />
Kavala, Greece)...............................................................................................................................................................<br />
Stress Proteins HSP27 and HSP70i Predict Survival in Non-small Cell Lung Carcinoma. E. MALUSECKA,<br />
S. KRZYZOWSKA-GRUCA, J. GAWRYCHOWSKI, A. FISZER-KIERZKOWSKA, Z. KOLOSZA,<br />
Z. KRAWCZYK (Gliwice; Katowice, Poland)...........................................................................................................<br />
Predictive and Prognostic Significance of Neuron-specific Enolase (NSE) in Non-small Cell Lung Cancer.<br />
M. TISEO, A. ARDIZZONI, M.A. CAFFERATA, M. LOPREVITE, M. CHIARAMONDIA,<br />
R. FILIBERTI, P. MARRONI, F. GROSSI, M. PAGANUZZI (Parma; Genova, Italy)..................................<br />
Inguinal Sentinel Lymph Node Dissection vs. Complete Inguinal Lymph Node Dissection in Patients with<br />
Vulvar Cancer. L.A. HEFLER, C. GRIMM, L. SIX, V. SEEBACHER, S. POLTERAUER, E. JOURA,<br />
C. TEMPFER, G. SLIUTZ, A. REINTHALLER (Vienna, Austria) ....................................................................<br />
Necessity of Colposcopy and Biopsy prior to Large Loop Excision of the Transformation Zone (LLETZ).<br />
L. HEFLER, S. POLTERAUER, G. NOWOTNY, C. TEMPFER, P. KOHLBERGER, G. SLIUTZ,<br />
P. SPEISER, E. JOURA, A. REINTHALLER (Vienna, Austria) .........................................................................<br />
Impact of Complementary Treatment of Breast Cancer Patients with Standardized Mistletoe Extract during<br />
Aftercare: A Controlled Multicenter Comparative Epidemiological Cohort Study. J. BEUTH, B. SCHNEIDER,<br />
J.M. SCHIERHOLZ (Köln; Hannover; Rosenfeld, Germany) .........................................................................................<br />
Safety and Efficacy of Zoledronic Acid Rapid Infusion in Lung Cancer Patients with Bone Metastases:<br />
A Single Institution Experience. E. KOTTEAS, C. ALAMARA, M. KIAGIA, K. PANTAZOPOULOS,<br />
A. BOUFAS, A. PROVATA, A. CHARPIDOU, K.N. SYRIGOS (Athens, Greece).........................................<br />
Clinicopathological Features of Lipomas with Gene Fusions Involving HMGA2. H. HATANO, T. MORITA,<br />
A. OGOSE, T. HOTTA, H. KOBAYASHI, H. SEGAWA, T. UCHIYAMA, T. TAKENOUCHI, T. SATO<br />
(Niigata, Japan)..........................................................................................................................................................................<br />
Low-dose Capecitabine in Breast Cancer Patients with Symptomatic Bone Marrow Infiltration: A Case<br />
Study. A. ARDAVANIS, P. KOUNTOURAKIS, G. ORPHANOS, G. RIGATOS (Athens, Greece) ...........<br />
Prognostic Factors in Patients with Locally Advanced (Unresectable) or Metastatic Pancreatic Adenocarcinoma:<br />
A Retrospective Analysis. N. PAPADONIOU, C. KOSMAS, K. GENNATAS, A. POLYZOS, D.<br />
MOURATIDOU, E. SKOPELITIS, M. TZIVRAS, S. SOUGIOULTZIS, G. PAPASTRATIS, G. KARATZAS,<br />
E. PAPALAMBROS, N. TSAVARIS (Athens; Piraeus; Thessaloniki, Greece) ..............................................................<br />
Laryngeal Carcinoma Recurrence Rate and Disease-free Interval are Related to CD105 Expression but not to<br />
Vascular Endothelial Growth Factor 2 (Flk-1/Kdr) Expression. G. MARIONI, L. GIACOMELLI, E.<br />
D'ALESSANDRO, C. STAFFIERI, V. GUZZARDO, A. STAFFIERI, S. BLANDAMURA (Padova, Italy).....<br />
Successful Treatment with S-1 plus CPT-11 for Lymph Node Metastasis from Colon Cancer: Report of a Case. K.<br />
YOSHIMATSU, H. YOKOMIZO, T. FUJIMOTO, T. OTANI, A. MATSUMOTO, G. OSAWA, H. ITAGAKI,<br />
A. UMEHARA, S. SHIOZAWA, T. KATSUBE, Y. NARITAKA, K. OGAWA (Tokyo, Japan) .............................<br />
485<br />
491<br />
495<br />
501<br />
507<br />
515<br />
519<br />
523<br />
529<br />
535<br />
539<br />
543<br />
551<br />
559<br />
4187
Amelanotic Metastasis of Melanoma Mimicking Ovarian Cancer: A Case Report and Review of the<br />
Literature. K. PIETZNER, A. NOSKE, C.H. CHO, F. KIECKER, J. SEHOULI (Berlin, Germany) ............<br />
Errata ......................................................................................................................................................................................<br />
*<br />
Reviews (pages 353, 401, 443)<br />
Number 2A<br />
Experimental Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Boron Nanoparticles Inhibit Tumour Growth by Boron Neutron Capture Therapy in the Murine B16-OVA<br />
Model. M.S. PETERSEN, C.C. PETERSEN, R. AGGER, M. SUTMULLER, M.R. JENSEN, P.G.<br />
SØRENSEN, M.W. MORTENSEN, T. HANSEN, T. BJØRNHOLM, H.J. GUNDERSEN, R. HUISKAMP,<br />
M. HOKLAND (Aarhus; Aalborg; Hørsholm; Copenhagen, Denmark; Petten, The Netherlands) ...........................<br />
A New Micronized Formulation of 2-Methoxyestradiol-bis-sulfamate (STX140) is Therapeutically Potent<br />
against Breast Cancer. P.A. FOSTER, S.P. NEWMAN, M.P. LEESE, S. BERNETIERE, C. DIOLEZ,<br />
J. CAMARA, B. HACHER, M.-M. BARONNET, T. ALI, B.V.L. POTTER, M.J. REED, A. PUROHIT<br />
(London; Bath; Slough, Berkshire, UK; Les Ulis; Dreux, France).............................................................................<br />
Cellular Response to Irinotecan in Colon Cancer Cell Lines Showing Differential Response to<br />
5-Fluorouracil. K. HAUG, K.L. KRAVIK, P.M. DE ANGELIS (Oslo, Norway) ...............................................<br />
Acquired Resistance to Fas/CD95 Ligation in U937 Cells is Associated with Multiple Molecular<br />
Mechanisms. J. BLOMBERG, K. RUUTH, D. SANTOS, E. LUNDGREN (UmeaÆ, Sweden) ........................<br />
Adenovirus-mediated Inhibitor ÎB Gene Transfer Improves the Chemosensitivity to <strong>Anticancer</strong> Drugs in<br />
Human Lung Cancer In Vitro and In Vivo. J. NI, K. TAKAYAMA, R. USHIJIMA, N. INOSHIMA,<br />
J. UCHINO, T. HARADA, T. MINAMI, M. TAKESHITA, C. ZHOU, Y. NAKANISHI (Fukuoka, Japan;<br />
Shanghai, China) ............................................................................................................................................................<br />
Apoptosis Induced by an Alkylated Purine, 6-Dimethylaminopurine, and Changes in Gene Expression in<br />
Human Lymphoma U937 Cells. M. NAKASHIMA, Z.-G. CUI, Y. TABUCHI, I. TAKASAKI, Q.-L.<br />
ZHAO, T. KONDO, D.-Y. YU, M. SHOJI, T. HONDA, H. KITAGAWA, Y. KOJIMA, T. NAKANO<br />
(Toyama; Hakusan, Ishikawa; Kobe, Japan)...............................................................................................................<br />
Antisense-Snail Transfer Inhibits Tumor Metastasis by Inducing E-cadherin Expression. A. ZHANG,<br />
G. CHEN, L. MENG, Q. WANG, W. HU, L. XI, Q. GAO, S. WANG, J. ZHOU, G. XU, L. MENG,<br />
D. MA (Hubei, China; Houston, TX, USA)................................................................................................................<br />
Combination Therapy of S-1 with Selective Cyclooxygenase-2 Inhibitor for Liver Metastasis of Colorectal<br />
Carcinoma. A. TACHIMORI, N. YAMADA, R. AMANO, M. OHIRA, K. HIRAKAWA (Osaka, Japan) ......<br />
DNA Damage Response in Prostate Cancer Cells after High-intensity Focused Ultrasound (HIFU)<br />
Treatment. H. IDE, T. NAKAGAWA, Y. TERADO, M. YASUDA, Y. KAMIYAMA, S. MUTO,<br />
S. HORIE (Tokyo, Japan).............................................................................................................................................<br />
Identification of Novel Genes Involved in the Synergistic Antitumor Effect of Caffeine in Osteosarcoma<br />
Cells Using cDNA Macroarray. S. II, Y. UEDA, M. SHIMAZAKI, S. KATSUTA, K. TAKAZAWA,<br />
Y. KANAZAWA, K. TOMITA, H. TSUCHIYA (Kanazawa; Ishikawa, Japan) .................................................<br />
Down-regulation of Plakoglobin in Soft Tissue Sarcoma is Associated with a Higher Risk of Pulmonary<br />
Metastasis. Y. KANAZAWA, Y. UEDA, M. SHIMASAKI, S. KATSUDA, N. YAMAMOTO,<br />
K. TOMITA, H. TSUCHIYA (Kanazawa; Ishikawa, Japan) ..................................................................................<br />
4188<br />
563<br />
567<br />
571<br />
577<br />
583<br />
593<br />
601<br />
609<br />
621<br />
629<br />
639<br />
645<br />
655
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Role of Histone Deacetylase Inhibitor in Adenovirus-mediated p53 Gene Therapy in Esophageal Cancer.<br />
I. HOSHINO, H. MATSUBARA, Y. AKUTSU, T. NISHIMORI, Y. YONEYAMA, K. MURAKAMI,<br />
H. SAKATA, K. MATSUSHITA, A. KOMATSU, R. BROOKS, T. OCHIAI (Chiba, Japan; East Lansing,<br />
MI, USA) .........................................................................................................................................................................<br />
Identification of Potential Chemoresistance Genes in Osteosarcoma. D.K. WALTERS, P. STEINMANN,<br />
B. LANGSAM, S. SCHMUTZ, W. BORN, B. FUCHS (Zurich, Switzerland) ....................................................<br />
Implications of the Involvement of the Endoplasmic Reticulum Stress Pathway in Drug-induced Apoptosis.<br />
A.H. CORY, J. CHEN, J.G. CORY (Greenville, NC, USA)...................................................................................<br />
Effect of Bortezomib on EGFR Expression in Head and Neck Squamous Cell Carcinoma Cell Lines.<br />
J. WAGENBLAST, M. HAMBEK, M. BAGHI, R. KNECHT (Frankfurt am Main, Germany) ......................<br />
Intraperitoneal Infusion of Recombinant Plasminogen Activator Inhibitor Type 2 Induced Apoptosis in<br />
Implanted Human Colon Cancer and Inhibited its Growth and Liver Metastasis. D. SUWA, H. KONNO,<br />
T. TANAKA, T. URANO (Shizuoka, Japan)............................................................................................................<br />
Comparative Anti-inflammatory Activities of Curcumin and Tetrahydrocurcumin Based on the Phenolic<br />
O-H Bond Dissociation Enthalpy, Ionization Potential and Quantum Chemical Descriptor. Y. MURAKAMI,<br />
H. ISHII, N. TAKADA, S. TANAKA, M. MACHINO, S. ITO, S. FUJISAWA (Saitama; Tokyo, Japan)........<br />
Involvement of the Estrogen Receptor ‚ in Genistein-induced Expression of p21 waf1/cip1 in PC-3 Prostate<br />
Cancer Cells. K. MATSUMURA, T. TANAKA, H. KAWASHIMA, T. NAKATANI (Osaka, Japan)..........<br />
Changes to N-linked Oligosaccharide Chains of Human Serum Immunoglobulin G and Matrix<br />
Metalloproteinase-2 with Cancer Progression. Y. KANOH, T. OHARA, T. TADANO, M. KANOH,<br />
T. AKAHOSHI (Kanagawa; Tochigi; Higashimatsuyama, Japan) ..........................................................................<br />
Transforming Growth Factor-‚1 Modulates Tumor-Stromal Cell Interactions of Prostate Cancer through<br />
Insulin-like Growth Factor-I. M. KAWADA, H. INOUE, M. ARAKAWA, D. IKEDA (Shizuoka, Japan) .......<br />
Novel Link between Estrogen Receptor · and Hedgehog Pathway in Breast Cancer. K. KOGA,<br />
M. NAKAMURA, H. NAKASHIMA, T. AKIYOSHI, M. KUBO, N. SATO, S. KUROKI, M. NOMURA,<br />
M. TANAKA, M. KATANO (Fukuoka, Japan)........................................................................................................<br />
Prediction of Tumour Regrowth of Pontine Glioma Using a Two-term Model. M. ZHANG, F. SEGERER,<br />
L. KETONEN, A. MAHAJAN, J. WOLFF (Houston, TX, USA)..........................................................................<br />
Role of DNA Content Analysis and Immunohistochemistry in the Evaluation of the Risk of Unfavourable<br />
Outcome in Wilms’ Tumours. M.-C. OSTERHELD, L. CARON, K. MEAGHER-VILLEMURE<br />
(Lausanne, Switzerland).................................................................................................................................................<br />
Gene Polymorphisms of the NOD-2/CARD-15 Gene and the Risk of Gastric Cancer in Germany. T. WEX,<br />
M.P.A. EBERT, S. KROPF, J. DIERKES, K. SCHÜTTLER, C. RÖCKEN, M. HÖCKER,<br />
P. MALFERTHEINER (Magdeburg; München; Berlin, Germany) ........................................................................<br />
Up-regulation of EphB and Ephrin-B Expression in Rhabdomyosarcoma. A.C. BERARDI,<br />
S. MARSILIO, C. ROFANI, O. SALVUCCI, P. ALTAVISTA, F.M. PERLA, F. DIOMEDI-CAMASSEI,<br />
S. UCCINI, G. KOKAI, L. LANDUZZI, H.P. McDOWELL, C. DOMINICI (Rome; Brescia; Bologna,<br />
Italy; Liverpool, UK) ................................................................................................................................................<br />
Bone Marrow-derived Endothelial Cells Contribute to Angiogenesis in Murine WEHI and JC Tumors.<br />
S. STOELTING, G. HEINZE, R. NADROWITZ, T. WAGNER, S.O. PETERS (Luebeck, Germany) ........<br />
Down-regulation of CD28, TCR-zeta (˙) and Up-regulation of FAS in Peripheral Cytotoxic T-cells of<br />
Primary Breast Cancer Patients. I.V GRUBER, S.E. YOUSFI, S. DÜRR-STÖZER, D. WALLWIENER,<br />
E.F. SOLOMAYER, T. FEHM (Tuebingen, Germany)...........................................................................................<br />
665<br />
673<br />
681<br />
687<br />
693<br />
699<br />
709<br />
715<br />
721<br />
731<br />
741<br />
751<br />
757<br />
763<br />
771<br />
779<br />
4189
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
<strong>Anticancer</strong> Mechanism of Plumbagin, a Natural Compound, on Non-small Cell Lung Cancer Cells. R.<br />
GOMATHINAYAGAM, S. SOWMYALAKSHMI, F. MARDHATILLAH, R. KUMAR, M.A.<br />
AKBARSHA, C. DAMODARAN (Lexington, KY, USA; Tiruchirappalli, India) ................................................<br />
Effect of Depsipeptide on In Vitro Transfection Efficiency of PEI/DNA Complexes.<br />
W. WEECHARANGSAN, P. OPANASOPIT, R.J. LEE (Nakhon Nayok; Nakhon Pathom, Thailand;<br />
Columbus, OH, USA).....................................................................................................................................................<br />
Tumor Cell-specific Gene Expression by 5’-Flanking DNA of Murine Q5 Gene in an Adenoviral Vector<br />
System. E. KUWADA, K. NOGUCHI, K. HASEZAWA, K. EGAWA (Tokyo; Yokohama, Japan)...............<br />
A Histochemical Approach to the Evaluation of the In Vivo Cytotoxicity of the Nitrobutadienes (1E,3E)-1,4bis(1-naphthyl)-<br />
2,3-dinitro-1,3-butadiene and Methyl (2Z,4E)-2-Methylsulfanyl-5-(1-naphthyl)-4-nitro-<br />
2,4-pentadienoate in Mice Liver and Kidney. C. FENOGLIO, A. GROSSO, G. PETRILLO,<br />
E. BONCOMPAGNI, C. AIELLO, C. CORDAZZO, D. SPINELLI, E. OGNIO, M.A. MARIGGIO’,<br />
A. CASSANO, M. VIALE (Pavia; Genova; Bologna; Bari, Italy) ..........................................................................<br />
Inhibition of PKC· Activation in Human Bone and Soft Tissue Sarcoma Cells by the Selective PKC<br />
Inhibitor PKC412. T. KAWAMOTO, T. AKISUE, K. KISHIMOTO, H. HARA, M. IMABORI,<br />
T. FUJIMOTO, M. KUROSAKA, T. HITORA, Y. KAWAGUCHI, T. YAMAMOTO (Kobe, Hyogo;<br />
Kagawa, Japan) .....................................................................................................................................................<br />
Bee Venom Induced Cell Cycle Arrest and Apoptosis in Human Cervical Epidermoid Carcinoma Ca Ski<br />
Cells. S.-W. IP, H.-C. WEI, J.-P. LIN, H.-M. KUO, K.-C. LIU, S.-C. HSU, J.-S. YANG, M.-DUEYANG,<br />
T.-H. CHIU, S.-M. HAN, J.-G. CHUNG (Taichung, Taiwan, ROC; Suwon, South Korea)...............................<br />
Culture of Primary Epithelial Adenoma Cells from Familial Adenomatous Polyposis Patients.<br />
F. FOSTIRA, A. APESSOS, E. OIKONOMOU, P. KOUKLIS, S. BARATSIS, G. MANIFIKOS,<br />
L. ANDERA, D. YANNOUKAKOS, A. PINTZAS G. NASIOULAS (Maroussi; Athens; Ioannina,<br />
Greece; Prague, Czech Republic) .........................................................................................................................<br />
Prognostic Value of Protease-activated Receptor-1 (PAR-1) and Matrix Metalloproteinase-1 (MMP-<br />
1) in Gastric Cancer. D. FUJIMOTO, Y. HIRONO, T. GOI, K. KATAYAMA, A. YAMAGUCHI<br />
(Fukui, Japan)....................................................................................................................................................<br />
Valproic Acid Sensitizes K562 Erythroleukemia Cells to TRAIL/Apo2L-induced Apoptosis. G. IACOMINO,<br />
M.C. MEDICI, G.L. RUSSO (Avellino, Italy).................................................................................................................<br />
IMUP-1 and IMUP-2 Overexpression in Endometrial Carcinoma in Korean and Japanese Populations.<br />
S.J. KIM, H.J. AN, H.J. KIM, H.M. JUNG, S. LEE, J.J. KO, I.H. KIM, N. SAKURAGI, J.K. KIM<br />
(Sungnam, South Korea; Sapporo, Hokkaido, Japan)................................................................................................<br />
Prognostic Value of Eicosanoid Pathways in Extrahepatic Cholangiocarcinoma. C. MÖBIUS, G. AUST, M.<br />
WIEDMANN, C. WITTEKIND, J. MÖSSNER, J. HAUSS, H. WITZIGMANN (Leipzig; Dresden, Germany)....<br />
Radiofrequency Ablation of Experimental Bone Metastases in Nude Rats. D. PROSCHEK, M.G. MACK, A.A.<br />
KURTH, P. PROSCHEK, B. MARTIN, M.L. HANSMANN, T.J. VOGL (Frankfurt am Main, Germany) .........<br />
Sensitivity of Hodgkin's Lymphoma Cell Lines to the Cell Cycle Inhibitor Roscovitine. J.L. FOELL,<br />
D. MAX, C. GIERSBERG, D. KORHOLZ, M.S. STAEGE (Halle, Germany) .................................................<br />
Rosiglitazone Induces Caveolin-1 by PPARÁ-dependent and PPRE-independent Mechanisms: The Role of<br />
EGF Receptor Signaling and its Effect on Cancer Cell Drug Resistance. L. TENCER, E. BURGERMEISTER,<br />
M.P. EBERT, M. LISCOVITCH (Rehovot, Israel; Munich, Germany).........................................................................<br />
miR-21 MicroRNA Expression in Human Gastric Carcinomas and its Clinical Association. S.-H. CHAN,<br />
C.-W. WU, A.F.-Y. LI, C.-W. CHI, W.-C. LIN (Taipei, Taiwan, ROC) ...............................................................<br />
4190<br />
785<br />
793<br />
799<br />
813<br />
825<br />
833<br />
843<br />
847<br />
855<br />
865<br />
873<br />
879<br />
887<br />
895<br />
907
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Analysis of EGFR Overexpression, EGFR Gene Amplification and the EGFRvIII Mutation in Portuguese<br />
High-grade Gliomas. M. VIANA-PEREIRA, J.M. LOPES, S. LITTLE, F. MILANEZI, D. BASTO,<br />
F. PARDAL, C. JONES, R.M. REIS (Braga; Porto, Portugal; Sutton, Surrey, UK).............................................<br />
Positive Correlation of Cell-free DNA in Plasma/Serum in Patients with Malignant and Benign Breast<br />
Disease. R. ZANETTI-DÄLLENBACH, E. WIGHT, A.X.-C. FAN, O. LAPAIRE, S. HAHN,<br />
W. HOLZGREVE, X.Y. ZHONG (Basel, Switzerland)..........................................................................................<br />
<strong>Anticancer</strong> Activity of 3-Demethylubiquinone Q2. In Vivo Experiments and Probable Mechanism of Action.<br />
S.N. FEDOROV, O.S. RADCHENKO, L.K. SHUBINA, N.N. BALANEVA, I.G. AGAFONOVA, A.M.<br />
BODE, J.-O JIN, J.-Y. KWAK, Z. DONG, V.A. STONIK (Vladivostok, Russian Federation; Austin, MN,<br />
USA; Busan, South Korea) ............................................................................................................................................<br />
Antitumoral and Antiangiogenic Efficacy of Bisphosphonates In Vitro and in a Murine RENCA Model.<br />
J. SOLTAU, U. ZIRRGIEBEL, N. ESSER, C. SCHÄCHTELE, F. TOTZKE, C. UNGER, I. MERFORT,<br />
J. DREVS (Freiburg, Germany) ...................................................................................................................................<br />
A Facile Microfluidic Method for Production of Liposomes. P. PRADHAN, J. GUAN, D. LU, P.G. WANG,<br />
L.J. LEE, R.J. LEE (Columbus, OH, USA) .....................................................................................................................<br />
Predicting Resistance to Platinum-containing Chemotherapy with the ATP Tumor Chemosensitivity Assay<br />
in Primary Ovarian Cancer. H. NEUBAUER, M. STEFANOVA, E. SOLOMAYER, C. MEISNER,<br />
M. ZWIRNER, D. WALLWIENER, T. FEHM (Tuebingen, Germany)...............................................................<br />
Characterization of Akt Overexpression in MiaPaCa-2 Cells: Prohibitin Is an Akt Substrate both In Vitro and in<br />
Cells. E.K.-H. HAN, T. MCGONIGAL, C. BUTLER, V.L. GIRANDA, Y. LUO (Abbott Park, IL, USA)..........<br />
<strong>Anticancer</strong> Effects of Annona glabra Plant Extracts in Human Leukemia Cell Lines. C.B. COCHRANE, P.K.<br />
RAVEENDRAN NAIR, S.J. MELNICK, A.P. RESEK, C. RAMACHANDRAN (Miami, FL, USA)................<br />
HER3 Expression in Cutaneous Tumors. E. WIMMER, G. KRAEHN-SENFTLEBEN, W.J. ISSING<br />
(Munich; Blaubeuren, Germany; Newcastle-upon-Tyne, UK)....................................................................................<br />
18 F-FDG Small Animal PET for Early Detection of Human Anaplastic Large Cells Lymphoma Xenograft<br />
in Immunocompromised Mice. V. AMBROSINI, C. QUARTA, PL. ZINZANI, M. FINI, G. GIAVARESI,<br />
P. TORRICELLI, D. MALVI, C. NANNI, G. GRASSETTO, D. RUBELLO, S. FANTI (Bologna; Rovigo,<br />
Italy) .................................................................................................................................................................................<br />
Loss of Heterozygosity, Microsatellite Instability and TP53 Gene Status in Ovarian Carcinomas.<br />
J. PLISIECKA-HALASA, A. DANSONKA-MIESZKOWSKA, E. KRASZEWSKA, A. DAN ’ SKA-<br />
BIDZIN ’ SKA, J. KUPRYJAN ’ CZYK (Warsaw, Poland) ..................................................................................<br />
Quantitative Structure–Cytotoxicity Relationship Analysis of 5-Trifluoromethyloxazole Derivatives by a<br />
Semiempirical Molecular-orbital Method with the Concept of Absolute Hardness. M. ISHIHARA,<br />
M. KAWASE, H. SAKAGAMI (Saitama; Ehime, Japan).......................................................................................<br />
Biphenylalkylacetylhydroquinone Ethers Suppress the Proliferation of Murine B16 Melanoma Cells.<br />
N. FERNANDES, M. JUNG, A. DAOUD, H. MO (Denton, TX, USA; Freiburg, Germany) ...........................<br />
Hypoxia Increases Adhesion and Spreading of MG-63 Three-dimensional Tumor Spheroids. P. INDOVINA,<br />
G. RAINALDI, M.T. SANTINI (Rome; Naples, Italy)..................................................................................................<br />
Lack of Association among Polymorphic Xenobiotic-metabolizing Enzyme Genotypes and the Occurrence and<br />
Progression of Oral Carcinoma in a Brazilian Population. R. LOSI-GUEMBAROVSKI, I.M. DE SYLLOS<br />
CÓLUS, R.P. DE MENEZES, F. POLISELI, V.N. CHAVES, H. KUASNE, A. LEICHSENRING, A.L.<br />
GUEMBAROVSKI, B.W. OLIVEIRA, G. RAMOS, T.C.S. CAVALCANTI, L.T. MIZUNO, I.J. CAVALLI,<br />
E.M. DE SOUZA FONSECA RIBEIRO (Curitiba; Londrina, Brazil).........................................................................<br />
913<br />
921<br />
927<br />
933<br />
943<br />
949<br />
957<br />
965<br />
973<br />
981<br />
989<br />
997<br />
1005<br />
1013<br />
1023<br />
4191
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
A Prenylation Inhibitor (Sodium Phenylacetate) Differently Affects MCF-7 Cell Death when ras is<br />
Overexpressed, Partly Involving P42/44, JNK and P38 Kinase Activations. M. DI BENEDETTO, M.<br />
CRÉPIN, M. KRAEMER, O. OUDAR (Bobigny; Paris, France)..........................................................................<br />
p53Arg72 Homozygosity and its Increased Incidence in Left-sided Sporadic Colorectal Adenocarcinomas, in<br />
a Greek-Caucasian Population. A. DAKOURAS, N. NIKITEAS, E. PAPADAKIS, M. PERAKIS,<br />
D. VALIS, G. RALLIS, N. TZANAKIS, G. PEROS, C. TSIGKRIS, C. KITTAS, P. KARAKITSOS<br />
(Maroussi; Athens, Greece)............................................................................................................................................<br />
Crude Extracts of Solanum lyratum Induced Cytotoxicity and Apoptosis in a Human Colon Adenocarcinoma<br />
Cell Line (Colo 205). S.-C. HSU, J.-H. LU, C.-L. KUO, J.-S. YANG, M.-W. LIN, G.-W. CHEN, C.-C. SU,<br />
H.-F. LU, J.-G. CHUNG (Taichung; Kaohsiung; Hualien; Taipei, Taiwan, ROC)...............................................<br />
Cell Proliferation and Migration in Glioblastoma Multiforme Cell Lines are Influenced by Insulin-like Growth<br />
Factor I In Vitro. A. SCHLENSKA-LANGE, H. KNÜPFER, T.J. LANGE, W. KIESS, M. KNÜPFER (Leipzig;<br />
Regensburg, Germany) ..............................................................................................................................................................<br />
The Clinicopathological and Prognostic Significance of MUC-1 Expression in Japanese Gastric Carcinomas:<br />
An Immunohistochemical Study of Tissue Microarrays. X.-H. LI, H.-C. ZHENG, Z.-G. WANG,<br />
H. TAKAHASHI, X.-H. YANG, Y.-F. GUAN, Y. TAKANO (Toyama, Japan; Shenyang, China) ................<br />
Tumor-specific Cytotoxicity and Type of Cell Death Induced by Benzocycloheptoxazines in Human Tumor<br />
Cell Lines. H. MURAYAMA, K. MIYAHARA, H. WAKABAYASHI, T. KURIHARA, K. HASHIMOTO,<br />
O. AMANO, H. KIKUCHI, Y. NAKAMURA, Y. KANDA, S. KUNII, N. MOTOHASHI, H. SAKAGAMI<br />
(Saitama; Tokyo, Japan)................................................................................................................................................<br />
Immunohistochemical Expression of P15 (INK4B) and SMAD4 in Advanced Gastric Cancer.<br />
S. SAKELLARIOU, T. LIAKAKOS, I. GHICONTI, S. HADJIKOKOLIS, L. NAKOPOULOU,<br />
K. PAVLAKIS (Haidari; Nea Ionia, Athens, Greece) ...............................................................................................<br />
Detection of Cell-free ERCC1 and Thymidylate Synthase (TS) mRNA in Malignant Effusions and its<br />
Association with <strong>Anticancer</strong> Drug Sensitivity. L. WANG, B. LIU, T. WANG, Y. DING, X. QIAN,<br />
Y. ZHAO (Nanjing, China)..........................................................................................................................................<br />
Gypenosides Inhibited Invasion and Migration of Human Tongue Cancer SCC4 Cells through Downregulation<br />
of NFÎB and Matrix Metalloproteinase-9. K.-W. LU, M.-L. TSAI, J.-C. CHEN, S.-C. HSU, T.-C.<br />
HSIA, M.-W. LIN, A.-C. HUANG, Y.-H. CHANG, S.-W. IP, H.-F. LU, J.-G. CHUNG (Taichung; Changhwa;<br />
Taipei, Taiwan, ROC) ...........................................................................................................................................................<br />
Genetic Polymorphisms of Carcinogen Metabolizing Enzymes are Associated with Oral Leukoplakia<br />
Development and p53 Overexpression. E.C. BARROSO DUARTE, D.C. RIBEIRO, M.V. GOMEZ,<br />
M.L. RAMOS-JORGE, R.S GOMEZ (Belo Horizonte, Brazil) .............................................................................<br />
Circulating Microparticles in Breast Cancer Patients: A Comparative Analysis with Established Biomarkers.<br />
B. TOTH, R. NIEUWLAND, S. LIEBHARDT, N. DITSCH, K. STEINIG, P. STIEBER, A. RANK,<br />
P. GÖHRING, C.J. THALER, K. FRIESE, I. BAUERFEIND (Amsterdam, The Netherlands; Munich,<br />
Germany) .........................................................................................................................................................................<br />
Prognostic Significance of Ki-67 Antigen Expression in Non-Hodgkin’s Lymphomas. K. SZCZURASZEK,<br />
G. MAZUR, M. JELEŃ, P. DZIĘGIEL, P. SUROWIAK, M. ZABEL (Wrocław; Poznań, Poland) ..............<br />
Silibinin Restores Paclitaxel Sensitivity to Paclitaxel-resistant Human Ovarian Carcinoma Cells. L. ZHOU,<br />
P. LIU, B. CHEN, Y. WANG, X. WANG, M.C. INTERNATI, M.S. WACHTEL, E.E. FREZZA (Jinan,<br />
China; Lubbock, TX, USA) ...........................................................................................................................................<br />
Surgical Stress and Accelerated Tumor Growth. H.B. KAL, H. STRUIKMANS, A. D. BARTEN-VAN<br />
RIJBROEK (Utrecht; Leiden, The Netherlands)........................................................................................................<br />
4192<br />
1029<br />
1039<br />
1045<br />
1055<br />
1061<br />
1069<br />
1079<br />
1085<br />
1093<br />
1101<br />
1107<br />
1113<br />
1119<br />
1129
*<br />
*<br />
*<br />
Number 2B<br />
Clinical Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Human Papillomavirus Accounts both for Increased Incidence and Better Prognosis in Tonsillar Cancer.<br />
H. DAHLSTRAND, A. NÄSMAN, M. ROMANITAN, D. LINDQUIST, T. RAMQVIST, T. DALIANIS<br />
(Stockholm, Sweden)......................................................................................................................................................<br />
Peripheral Blood CD8highCD57+ Lymphocyte Levels May Predict Outcome in Melanoma Patients Treated<br />
with Adjuvant Interferon-·. D. CHARACIEJUS, V. PASˇUKONIENE Ø , R. JONUSˇAUSKAITE, N.<br />
KAZLAUSKAITE Ø , E. ALEKNAVIČIUS, M. MAURICAS, W. DEN OTTER (Vilnius, Lithuania; Utrecht,<br />
The Netherlands).............................................................................................................................................................<br />
The Role of Regulatory T Cells in Malignant Glioma. A.M. SONABEND, C.E. ROLLE, M.S. LESNIAK<br />
(Chicago, IL, USA) ........................................................................................................................................................<br />
Comparison of Apolipoprotein D Determination Methods in Breast Cancer. H. SØILAND, I. SKALAND,<br />
E.A.M. JANSSEN, E. GUDLAUGSSON, H. KÖRNER, J.E. VARHAUG, J.A. SØREIDE, J.P.A. BAAK<br />
(Stavanger; Bergen, Norway; Amsterdam, The Netherlands)......................................................................................<br />
Protein Abundance of Class III Beta-tubulin but Not ¢2-Alpha-Tubulin or Tau is Related to Paclitaxel Response<br />
in Carcinomas of Unknown Primary Site. P. SÈVE, T. REIMAN, S. ISAAC, V. TRILLET-LENOIR, L.<br />
LAFANÉCHÈRE, M. SAWYER, C. DUMONTET (Lyon; Grenoble, France; Edmonton, AB, Canada) ..............<br />
Overexpression of RegIV in Peritoneal Dissemination of Gastric Cancer and Its Potential as A Novel Marker<br />
for the Detection of Peritoneal Micrometastasis. K. MIYAGAWA, C. SAKAKURA, S. NAKASHIMA, T.<br />
YOSHIKAWA, K. FUKUDA, S. KIN, Y. NAKASE, K. SHIMOMURA, N. OUE, W. YASUI, H.<br />
HAYASIZAKI, Y. OKAZAKI, H. YAMAGISHI, A. HAGIWARA, E. OTSUJI (Kyoto; Hiroshima;<br />
Yokohama; Saitama, Japan)..........................................................................................................................................<br />
Metastatic Embryonal Carcinoma in the Maxillary Gingiva. F. ANGIERO, M. STEFANI (Monza; Milan,<br />
Italy) .................................................................................................................................................................................<br />
Chemotherapy Using Hybrid Liposomes along with Induction of Apoptosis. H. ICHIHARA, H. NAGAMI,<br />
T. KIYOKAWA, Y. MATSUMOTO, R. UEOKA (Kumamoto Japan) ...............................................................<br />
Update on Molecular Pathology in Oral Cancer and Precancer. J. CAMPO-TRAPERO, J. CANO-<br />
SÁNCHEZ, B. PALACIOS-SÁNCHEZ, J.J. SÁNCHEZ-GUTIERREZ, M.A. GONZÁLEZ-MOLES, A.<br />
BASCONES-MARTÍNEZ (Madrid; Granada, Spain) .............................................................................................<br />
Influence of Resection Volume on Locoregional Recurrence of Breast Cancer after Breast-conserving<br />
Surgery. D.U. BOEHM, A. LEBRECHT, T. MALTARIS, M. SCHMIDT, W. SIGGELKOW, S. FISCHER,<br />
E. KANDELHART, H. KOELBL (Mainz; Halle, Germany)..................................................................................<br />
*<br />
Chemotherapy in Gastric Cancer. E. WÖLL, A. DEVRIES, W. EISTERER, M. HEJNA, F. KEIL, H.<br />
STEIN, J. ZACHERL, R. GREIL (Zams; Feldkirch; Innsbruck; Vienna; Leoben; Salzbuirg, Austria).............<br />
POLR2F, ATP6V0A1 and PRNP Expression in Colorectal Cancer: New Molecules with Prognostic<br />
Significance? A.G. ANTONACOPOULOU, P.D. GRIVAS, L. SKARLAS, M. KALOFONOS, C.D.<br />
SCOPA, H.P. KALOFONOS (Rion, Patras, Greece) ...............................................................................................<br />
Prospective Phase II Study of Post-surgical Adjuvant Chemo-immunotherapy Using Autologous Dendritic<br />
Cells and Activated Killer Cells from Tissue Culture of Tumor-draining Lymph Nodes in Primary Lung<br />
Cancer Patients. H. KIMURA, T. IIZASA, A. ISHIKAWA, M. SHINGYOUJI, M. YOSHINO, M.<br />
KIMURA, Y. INADA, K. MATSUBAYASHI (Chiba, Japan)..............................................................................<br />
1133<br />
1139<br />
1143<br />
1151<br />
1161<br />
1169<br />
1181<br />
1187<br />
1197<br />
1207<br />
1213<br />
1221<br />
1229<br />
4193
*<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Neoadjuvant Paclitaxel for Operable Breast Cancer: Multicenter Phase II Trial with Clinical Outcomes. M.<br />
KIMURA, M. SANO, M. FUJIMORI, H. NAKAGOMI, T. NEGISHI, Y. YANAGITA, N. SATO (Ota;<br />
Isesaki, Gunma; Niigata; Matsumoto, Nagano; Kofu,Yamanashi, Japan) ...............................................................<br />
Taxanes and Gemcitabine Doublets in the Management of HER-2 Negative Metastatic Breast Cancer:<br />
Towards Optimization of Association and Schedule. G. METRO, A. FABI, M. RUSSILLO, P. PAPALDO,<br />
M. DE LAURENTIIS, G. FERRETTI, D. PELLEGRINI, C. NUZZO, V. GRAZIANO, P. VICI, M.<br />
INTRONA, A. FELICI, F. COGNETTI, P. CARLINI (Rome; Naples, Italy).....................................................<br />
Adjuvant Tamoxifen in Breast Cancer Patients Affects the Endometrium by Time, an Effect Remaining Years<br />
after End of Treatment and Results in an Increased Frequency of Endometrial Carcinoma. B. LINDAHL, E.<br />
ANDOLF, C. INGVAR, J. RANSTAM, R. WILLÉN (Lund; Stockholm; Uppsala, Sweden).................................<br />
Development of Cancer in Patients with Primary Immunodeficiencies. K. SALAVOURA, A. KOLIALEXI,<br />
G. TSANGARIS, A. MAVROU (Athens, Greece)...................................................................................................<br />
Gender-specific Association between Polymorphism of Vascular Endothelial Growth Factor (VEGF 936<br />
C>T) Gene and Colon Cancer in Korea. S.J. BAE, J.W. KIM, H. KANG, S.G. HWANG, D. OH, N.K.<br />
KIM (Seongnam, South Korea) ....................................................................................................................................<br />
Prognostic Significance of the Local Expression of Interleukin-12 in Patients with Advanced Gastric Cancer.<br />
N. NAGASHIMA, Y. NAKAYAMA, Y. INOUE, J. NAGATA, K. MATSUMOTO, N. MINAGAWA, T.<br />
KATSUKI, K. SHIBAO, K. HIRATA, T. SAKO, T. HAMADA, N. NAGATA (Kita-Kyushu; Kurate-machi,<br />
Japan)...............................................................................................................................................................................<br />
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Squamous<br />
Cell Carcinoma. C. BARONE, R. GRILLO, D. DONGIOVANNI, N. BIROCCO, M. RAMPINO, M.G. RUO<br />
REDDA, E. GARIBALDI, F. MUNOZ, G. PECORARI, A. CAVALOT, P. GARZINODEMO, L. BUFFONI,<br />
L. CIUFFREDA, U. RICARDI, G. CORTESINA, C. GIORDANO, M. FASOLIS, S. BERRONE, O.<br />
BERTETTO, M. SCHENA (Torino, Italy).............................................................................................................................<br />
Weekly 24-hour Infusional 5-Fluorouracil as Initial Treatment for Advanced Gastric Cancer with Acute<br />
Disseminated Intravascular Coagulation. T.-C. HUANG, K.-H. YEH, A.-L. CHENG, C.-H. HSU (Taipei;<br />
Yun-lin, Taiwan, ROC) ..................................................................................................................................................<br />
Squamous Cell Lung Carcinoma Metastatic to the Breast. W. HSU, S.-M.S.-CHEN, J.-L. WANG, C.-C.<br />
HUANG, S.-F. KO (Kaohsiung, Taiwan, ROC) ........................................................................................................<br />
*<br />
Present Treatment and Future Expectations in Advanced Pancreatic Cancer. G.P. STATHOPOULOS, N.<br />
ANDROULAKIS, J. SOUGLAKOS, J. STATHOPOULOS, V. GEORGOULIAS (Athens; Heraklion,<br />
Greece).............................................................................................................................................................................<br />
Impact of Palliative Gastrectomy in Patients with Incurable Advanced Gastric Cancer. C. KUNISAKI, H.<br />
MAKINO, R. TAKAGAWA, T. OSHIMA, Y. NAGANO, S. FUJII, H. AKIYAMA, Y. OTSUKA, H.A.<br />
ONO, T. KOSAKA, Y. ICHIKAWA, H. SHIMADA (Yokohama, Japan) ..........................................................<br />
Association of the Myeloperoxidase Polymorphism with the Risk of Gastric Cancer. P.-I HSU, J.-J. JWO,<br />
C.-L. YANG, P.-N. HSU, H.-B. YANG, K.-H. LAI, I.-S. CHEN, S.-K. CHUAH, D.-C. WU, A. CHEN<br />
(Kaohsiung; Taipei; Hsin-chu, Taiwan, ROC) ............................................................................................................<br />
Disease Presentation and Outcome in Young Patients (
*<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Biweekly Pegylated Liposomal Doxorubicin as Second-line Treatment in Patients with Relapsed Ovarian<br />
Cancer after Failure of Platinum and Paclitaxel: Results from a Multi-center Phase II Study of the NOGGO.<br />
G. OSKAY-OEZCELIK, D. KOENSGEN, H.-J. HINDENBURG, P. KLARE, B. SCHMALFELDT, W.<br />
LICHTENEGGER, R. CHEKEROV, S.-E. AL-BATRAN5, U. NEUMANN, J. SEHOULI; The Ovarian<br />
Cancer Study Group of the North Eastern German Society of Gynecological Oncology (NOGGO) (Berlin;<br />
Munich; Frankfurt, Germany) .......................................................................................................................................<br />
Radiotherapy and Chemotherapy in the Conservative Treatment of Anal Canal Carcinoma. N.<br />
RAFFETTO, A. MONACO, E. BANELLI (Rome, Italy) ......................................................................................<br />
Inherited Cancer Predisposition Syndromes in Greece. A. APESSOS, E. PAPADOPOULOU, I.<br />
BELOGIANNI, S. BARATSIS, J.K. TRIANTAFILLIDIS, P. KOSMIDIS, E. KARYDAS, E. BRIASOULIS,<br />
C. PISIOTIS, K. PAPAZISIS, G. NASIOULAS (Maroussi, Athens; Ioannina; Thessaloniki, Greece)....................<br />
Hypofractionated/Accelerated Radiotherapy with Cytoprotection (HypoARC) Combined with Vinorelbine and<br />
Liposomal Doxorubicin for Locally Advanced Non-small Cell Lung Cancer (NSCLC). P.G. TSOUTSOU, M.E.<br />
FROUDARAKIS, D. BOUROS, M.I. KOUKOURAKIS (Alexandroupolis, Greece)...............................................<br />
Role of Twist in Head and Neck Carcinoma with Lymph Node Metastasis. D.-L. OU, H.-F. CHIEN, C.-L.<br />
CHEN, T.-C. LIN, L.-I. LIN (Taipei, Taiwan, ROC) ...............................................................................................<br />
Solitary Metastasis of a Merkel Cell Tumor to the Urinary Bladder. H. STRASSER, K. AMANN, K.-M.<br />
SCHROTT, F.S. KRAUSE (Erlangen, Germany).....................................................................................................<br />
Malignant Mesothelioma of the Tunica Vaginalis Testis in a Petrochemical Worker Exposed to Asbestos.<br />
S.M. CANDURA, A. CANTO, A. AMATU, M. GERARDINI, G. STELLA, M. MENSI, G. POGGI<br />
(Pavia; Voghera, Italy)....................................................................................................................................................<br />
Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Review of the Literature. A.<br />
BERTACCINI, D. MARCHIORI, A. CRICCA, M. GAROFALO, C. GIOVANNINI, F. MANFERRARI,<br />
T.G. GERACE, R. PERNETTI, G. MARTORANA (Bologna, Italy)..................................................................<br />
Increased Cancer Mortality in Type 2 Diabetes (ZODIAC-3). G.W.D. LANDMAN, L.J. UBINK-<br />
VELTMAAT, N. KLEEFSTRA, B.J. KOLLEN, H.J.G. BILO (Zwolle; Hattem; Groningen, The<br />
Netherlands).................................................................................................................................................................<br />
Neuroimmunomodulation in Medical Oncology: Application of Psychoneuroimmunology with Subcutaneous<br />
Low-dose IL-2 and the Pineal Hormone Melatonin in Patients with Untreatable Metastatic Solid Tumors.<br />
P. LISSONI, F. BRIVIO, L. FUMAGALLI, G. MESSINA, L. VIGORÉ, D. PAROLINI, M. COLCIAGO,<br />
F. ROVELLI (Monza; Lecco, Italy) ............................................................................................................................<br />
Neoadjuvant Carboplatin and Vinorelbine Followed by Chemoradiotherapy in Locally Advanced Head<br />
and Neck or Oesophageal Squamous Cell Carcinoma: A Phase II Study in Elderly Patients or Patients<br />
with Poor Performance Status. H. KOUSSIS, A. SCOLA, F. BERGAMO, S. TONELLO, U. BASSO,<br />
P. KARAHONTZITIS, V. CHIARION-SILENI, L. PASETTO, A. RUOL, L. LOREGGIAN, O. LORA,<br />
R. BOTTIN, G. MARIONI, M. DONACH, A. JIRILLO (Padova, Italy; Athens, Greece) .........................<br />
*<br />
Biological Activity and Clinical Implications of the Matrix Metalloproteinases. M. RYDLOVA, L.<br />
HOLUBEC Jr., M. LUDVIKOVA Jr., D. KALFERT, J. FRANEKOVA, C. POVYSIL, M. LUDVIKOVA<br />
(Ostrava; Plzen; Hradec Kra’lové; Prague, Czech Republic) .......................................................................................<br />
Expression of EGF and EGFR Strongly Correlates with Metastasis of Pancreatic Ductal Carcinoma. A.<br />
PRYCZYNICZ, K. GUZIN ’ SKA-USTYMOWICZ, A. KEMONA, J. CZYZ · EWSKA (Bialystok, Poland) ..........<br />
1329<br />
1335<br />
1341<br />
1349<br />
1355<br />
1361<br />
1365<br />
1369<br />
1373<br />
1377<br />
1383<br />
1389<br />
1399<br />
4195
Detection of Oncogenic DNA Viruses in Colorectal Cancer. L. GIULIANI, C. RONCI, D. BONIFACIO, L. DI<br />
BONITO, C. FAVALLI, C.F. PERNO, K. SYRJÄNEN, M. CIOTTI (Rome; Trieste, Italy; Turku, Finland) .........<br />
Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Detection in Cancer Patients: A<br />
Prognostic Marker For Lung Metastases from Solid Malignancies. E.M. KARAPANAGIOTOU, E.<br />
PELEKANOU, A. CHARPIDOU, T. TSAGANOS, V. ANAGNOSTOU, D. PLACHOURAS, E.J.<br />
GIAMARELLOS-BOURBOULIS, K.N. SYRIGOS (Athens, Greece).................................................................<br />
Krukenberg Tumour of the Ovary: A Case Report with Light Microscopy, Immunohistochemistry and<br />
Electron Microscopy Study. C. FAZZARI, F. FEDELE, G. PIZZI, C. CRISAFULLI, A. PARISI, R.A.<br />
CARUSO (Messina, Italy) ............................................................................................................................................<br />
Adult Granulosa Cell Tumors of the Ovary: A Clinicopathological Study of 34 Patients by the Hellenic<br />
Cooperative Oncology Group (HeCOG). D. PECTASIDES, G. PAPAXOINIS, G. FOUNTZILAS, G.<br />
ARAVANTINOS, E. PECTASIDES, D. MOURATIDOU, T. ECONOMOPOULOS, CH. ANDREADIS<br />
(Athens; Thessaloniki, Greece)......................................................................................................................................<br />
Unexpected Clinical Outcome in a Patient with Liver and Brain Metastasis from Melanoma. C. NUZZO,<br />
M. ZEULI, V. FERRARESI, M. CICCARESE, D. PELLIGRINI, F. COGNETTI (Rome, Italy) ................<br />
Combination Chemotherapy of S-1 and Low-dose Twice-Weekly Cisplatin for Advanced and Recurrent<br />
Gastric Cancer in an Outpatient Setting: A Retrospective Study. A. TSUJI, Y. SHIMA, S. MORITA, M.<br />
UCHIDA, K. OKAMOTO, M. MORITA, T. HORIMI, T. SHIRASAKA (Kochi; Tokyo, Japan)..................<br />
Errata ......................................................................................................................................................................................<br />
*<br />
Reviews (pages 1133, 1143, 1197, 1213, 1245, 1303, 1341, 1389)<br />
Number 3A<br />
Experimental Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Role of Pur· in the Modulation of Homologous Recombination-directed DNA Repair by HIV-1 Tat.<br />
H. WANG, M.K. WHITE, R. KAMINSKI, N. DARBINIAN, S. AMINI, E.M. JOHNSON, K. KHALILI,<br />
J. RAPPAPORT (Philadelphia, PA; Norfolk, VA, USA) ..........................................................................................<br />
The Antitumor Effect of Liposome-encapsulated Cisplatin on Rat Osteosarcoma and its Enhancement by<br />
Caffeine. M. KARITA, H. TSUCHIYA, M. KAWAHARA, S. KASAOKA, K. TOMITA (Kanazawa; Kure,<br />
Hiroshima, Japan) ..........................................................................................................................................................<br />
Invasion Front-specific Overexpression of Tissue Inhibitor of Metalloproteinase-1 in Liver Metastases from<br />
Colorectal Cancer. C. KAHLERT, O.R. BANDAPALLI, P. SCHIRMACHER, J. WEITZ, K. BRAND<br />
(Heidelberg, Germany) ...................................................................................................................................................<br />
IFN-Á Enhances TH1 Polarisation of Monocyte-derived Dendritic Cells Matured with Clinical-grade<br />
Cytokines Using Serum-free Conditions. B. HILDENBRAND, D. LORENZEN, B. SAUER,<br />
C. HERTKORN, M.A. FREUDENBERG, J.H. PETERS, T. NESSELHUT, C. UNGER, M. AZEMAR<br />
(Freiburg; Duderstadt, Germany) ..................................................................................................................................<br />
5-Fluorouracil-related Gene Expression in Primary Sites and Hepatic Metastases of Colorectal Carcinomas.<br />
S. SAMESHIMA, S. TOMOZAWA, M. KOJIMA, S. KOKETSU, K. MOTEGI, H. HORIKOSHI,<br />
T. OKADA, Y. KON, T. SAWADA (Ota; Gunma, Japan) ....................................................................................<br />
4196<br />
1405<br />
1411<br />
1417<br />
1421<br />
1429<br />
1433<br />
1439<br />
1441<br />
1449<br />
1459<br />
1467<br />
1477
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
A Comparison of Two Orally Bioavailable Anti-cancer Agents, IRC-110160 and STX140. P.A. FOSTER,<br />
C. STENGEL, T. ALI, M.P. LEESE, B.V.L. POTTER, M.J. REED, A. PUROHIT, S.P. NEWMAN<br />
(London; Slough; Bath, UK) .........................................................................................................................................<br />
Mammaglobin and Lipophilin B Expression in Breast Tumors and their Lack of Effect on Breast Cancer<br />
Cell Proliferation. A. SJÖDIN, I. LJUSLINDER, R. HENRIKSSON, H. HEDMAN (Umeå , Sweden) .......<br />
Interferon-alpha Restitutes the Chemosensitivity in Pancreatic Cancer. K. HOFFMANN, S. MEHRLE,<br />
J. SCHMIDT, M.W. BÜCHLER, A. MÄRTEN (Heidelberg, Germany)..............................................................<br />
IGF-I Receptor Inhibition Combined with Rapamycin or Temsirolimus Inhibits Neuroblastoma Cell Growth.<br />
D.W. COULTER, J. BLATT, A.J. D’ERCOLE, B.M. MOATS-STAATS (Chapel Hill, NC, USA)....................<br />
Inhibition of Steroid Sulphatase Activity via the Percutaneous Route: A New Option for Breast Cancer<br />
Therapy. A. PUROHIT, S.K. CHANDER, L.W.L. WOO, M.F.C. PARSONS, R. JHALLI, B.V.L. POTTER,<br />
M.J. REED (London; Bath, UK) ....................................................................................................................................<br />
Up-regulation of Survivin mRNA Might Be a Marker for Non-invasive Detection of Non-small Cell Lung<br />
Cancer Rather than for Prognosis. U. WARNECKE-EBERZ, S.E. BALDUS, E. BOLLSCHWEILER,<br />
A.H. HOELSCHER, R. METZGER (Cologne; Duesseldorf, Germany)...............................................................<br />
* TGF‚-regulated Gene Expression by Smads and Sp1/KLF-like Transcription Factors in Cancer.<br />
V. ELLENRIEDER (Marburg, Germany)..................................................................................................................<br />
*<br />
Molecular Biology of Pancreatic Cancer – New Aspects and Targets. G. SCHNEIDER, R. HAMACHER,<br />
S. ESER, H. FRIESS, R.M. SCHMID, D. SAUR (Munich, Germany) ................................................................<br />
The Bisphosphonate, Zoledronic Acid Reduces Experimental Neuroblastoma Growth by Interfering with<br />
Tumor Angiogenesis. U. BÄCKMAN, Å. SVENSSON, R.H. CHRISTOFFERSON, F. AZARBAYJANI<br />
(Uppsala, Sweden) ..........................................................................................................................................................<br />
Targeting of CDC20 via Small Interfering RNA Causes Enhancement of the Cytotoxicity of<br />
Chemoradiation. K. TANIGUCHI, N. MOMIYAMA, M. UEDA, R. MATSUYAMA, R. MORI, Y. FUJII,<br />
Y. ICHIKAWA, I. ENDO, S. TOGO, H. SHIMADA (Yokohama, Japan) .........................................................<br />
Flow Cytometric Phenotype of Rhabdomyosarcoma Bone Marrow Metastatic Cells and its Implication in<br />
Differential Diagnosis with Neuroblastoma. F. BOZZI, P. COLLINI, A. AIELLO, E. BARZANÒ,<br />
F. GAMBIRASIO, M. PODDA, C. MEAZZA, A. FERRARI, R. LUKSCH (Milan, Italy)............................<br />
Do Stem Cells Participate in Cell Turnover in Duodenal Adenomas? A Preliminary Study on Paneth Cells.<br />
C.A. RUBIO (Stockholm, Sweden) .............................................................................................................................<br />
Messenger RNA Expression of Translationally Controlled Tumor Protein (TCTP) in Liver Regeneration<br />
and Cancer. W.-L. ZHU, H.-X. CHENG, N. HAN, D.-L. LIU, W.-X. ZHU, B.-L. FAN, F.-L. DUAN<br />
(Xinxiang; Zhengzhou, P.R. China)..............................................................................................................................<br />
Aberrant Methylation of the HACE1 Gene is Frequently Detected in Advanced Colorectal Cancer.<br />
K. HIBI, M. SAKATA, K. SAKURABA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO,<br />
K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (Yokohama, Japan)..............................................<br />
Suberoylanilide Hydroxamic Acid (SAHA) Induces Apoptosis or Autophagy-associated Cell Death in<br />
Chondrosarcoma Cell Lines. S. YAMAMOTO, K. TANAKA, R. SAKIMURA, T. OKADA, T. NAKAMURA,<br />
Y. LI, M. TAKASAKI, Y. NAKABEPPU, Y. IWAMOTO (Fukuoka, Japan)...........................................................<br />
Changes of Gene Expression of Thymidine Phosphorylase, Thymidylate Synthase, Dihydropyrimidine<br />
Dehydrogenase after the Administration of 5’-Deoxy-5-Fluorouridine, Paclitaxel and its Combination in Human<br />
Gastric Cancer Xenografts. Y. SAKURAI, I. YOSHIDA, S. KAMOSHIDA, K. INABA, J. ISOGAKI,<br />
Y. KOMORI, I. UYAMA, Y. TSUTSUMI (Toyoake, Aichi, Japan).............................................................................<br />
1483<br />
1493<br />
1499<br />
1509<br />
1517<br />
1525<br />
1531<br />
1541<br />
1551<br />
1559<br />
1565<br />
1571<br />
1575<br />
1581<br />
1585<br />
1593<br />
4197
Gross Thymic Extract, Thymax, Induces Apoptosis in Human Breast Cancer Cells In Vitro through the<br />
Mitochondrial Pathway. M. GHONEUM, Y. SETO, S. SATO, A. GHONEUM, M. BRAGA, S. GOLLAPUDI<br />
(Los Angeles; Irvine, CA, USA; Tokyo, Japan) .....................................................................................................................<br />
ABSTRACTS OF THE THIRD INTERNATIONAL SYMPOSIUM ON VITAMIN D ANALOGS IN<br />
CANCER PREVENTION AND THERAPY. (17-18 May, 2008, Krefeld, Germany) ........................................<br />
Establishment of Transplantable Murine Osteosarcoma Cell Line with Endochondral Ossification. T. NISHI,<br />
T. KUSUMI, M. TANAKA, F. SATO, M. SASAKI, H. KUDO, H. KIJIMA (Hirosaki, Japan) .......................<br />
Vinorelbine is Effective for the Malignant Pleural Effusion Associated with Lung Cancer in Mice. R. CUI, M.<br />
YOSHIOKA, F. TAKAHASHI, H. ISHIDA, S. IWAKAMI, K. TAKAHASHI (Tokyo; Shizuoka, Japan)...........<br />
Apoptosis Regulation and Spontaneous Apoptosis <strong>Index</strong> of Testicular Germ Cell Tumors are Associated<br />
with Differentiation and Resistance to Systemic Treatment. L. MÁNDOKY, B. SZENDE, L. GÉCZI,<br />
I. BODROGI, M. KÁSLER, M. BAK (Budapest, Hungary)...................................................................................<br />
Development of 36 Clones Producing Human Monoclonal Antibodies Specific to Cancer Cells and their<br />
Ability to Inhibit Cancer Cell Growth. R. NAKAMURA, Y. SAIKAWA, S. HOSOKAWA, K. FUKUDA,<br />
K. KUMAI, T. KUBOTA, M. KITAJIMA, Y. KITAGAWA (Tokyo; Yokohama, Japan) ................................<br />
Hypoxia Inducible Factor-1alpha Expression Correlates with Vascular Endothelial Growth Factor-C<br />
Expression and Lymphangiogenesis/Angiogenesis in Oral Squamous Cell Carcinoma. X. LIANG, D. YANG,<br />
J. HU, X. HAO, J. GAO, Z. MAO (Chengdu Sichuan, P.R. China) .....................................................................<br />
Identification and Characterization of Two Splicing Variants of Human Noxa. Z. WANG, Y. SUN (Ann<br />
Arbor, MI, USA) .............................................................................................................................................................<br />
Angiotensinogen Polymorphism is Associated with Risk for Malignancy but not for Oral Cancer.<br />
E. VAIRAKTARIS, C. YAPIJAKIS, A. VYLLIOTIS, S. DERKA, S. VASSILIOU, E. NKENKE,<br />
Z. SEREFOGLOU, V. RAGOS, E. CRITSELIS, D. AVGOUSTIDIS, F. NEUKAM, E. PATSOURIS<br />
(Athens, Greece; Nurnberg, Germany)..........................................................................................................................<br />
Caffeine Dose-dependently Potentiates the Antitumor Effect of Cisplatin on Osteosarcomas.<br />
M. KAWAHARA, Y. TAKAHASHI, K. TAKAZAWA, H. TSUCHIYA, K. TOMITA, K. YOKOGAWA,<br />
K.-I. MIYAMOTO (Kanazawa, Japan) ......................................................................................................................<br />
Association of XRCC4 Codon 247 Polymorphism with Oral Cancer Susceptibility in Taiwan. H.-C. TSENG,<br />
M.-H. TSAI, C.-F. CHIU, C.-H. WANG, N.-W. CHANG, C.-Y. HUANG, C.-W. TSAI, S.-Y. LIANG,<br />
C.-L. WANG, D.-T. BAU (Taichung, Taiwan, ROC) ..............................................................................................<br />
Enhancement of Sodium Butyrate-induced Cell Death by Hyperthermia in HCT 116 Human Colorectal<br />
Cancer Cells. Z.-L. WEI, Q.-L. ZHAO, D.-Y. YU, M.A. HASSAN, T. KONDO (Toyama, Japan)...............<br />
The Role of Ca 2+ in Baicalein-induced Apoptosis in Human Breast MDA-MB-231 Cancer Cells through<br />
Mitochondria- and Caspase-3-dependent Pathway. J.-H. LEE, Y.-C. LI, S.-W. IP, S.-C. HSU, N.-W. CHANG,<br />
N.-Y. TANG, C.-S. YU, S.-T. CHOU, S.-S. LIN, C.-C. LIN, J.-S. YANG, J.-G. CHUNG (Taichung; Fong Yuan<br />
City; Wufeng, Taiwan, ROC) ...................................................................................................................................................<br />
Induction of Apoptosis by Epigallocatechin Gallate and Autophagy Inhibitors in a Mouse Macrophage-like<br />
Cell Line. K. HASHIMOTO, H. SAKAGAMI (Saitama, Japan) ..........................................................................<br />
Expression of VEGFR-1 (Flt-1) in Breast Cancer is Associated with VEGF Expression and with Nodenegative<br />
Tumour Stage. M. SCHMIDT, H.-U. VOELKER, M. KAPP, J. DIETL, U. KAMMERER<br />
(Wuerzburg, Germany) ...................................................................................................................................................<br />
*<br />
Reviews (pages 1531, 1541)<br />
4198<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
1603<br />
1611<br />
1627<br />
1633<br />
1641<br />
1651<br />
1659<br />
1667<br />
1675<br />
1681<br />
1687<br />
1693<br />
1701<br />
1713<br />
1719
Number 3B<br />
Clinical Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Fibromatosis of the Head and Neck: Morphological, Immunohistochemical and Clinical Features.<br />
F. ANGIERO, S. BENEDICENTI, M. STEFANI (Monza; Genova; Milan, Italy) .............................................<br />
Feasibility Assessment of a Chemoresponse Assay to Predict Pathologic Response in Neoadjuvant<br />
Chemotherapy for Breast Cancer Patients. Z. MI, F.A. HOLMES, B. HELLERSTEDT, J. PIPPEN,<br />
R. COLLEA, A. BACKNER, J.E. BUSH, H.H. GALLION, A. WELLS, J.A. O'SHAUGHNESSY<br />
(Pittsburgh, PA; Houston; Dallas, TX; Albany, NY, USA).........................................................................................<br />
Expression of Thymidylate Synthase in Liver and Lung Metastases of Colorectal Cancer and their Matched<br />
Primary Tumours. K. ÖHRLING, D. EDLER, M. HALLSTRÖM, P. RAGNHAMMAR (Stockholm,<br />
Sweden)............................................................................................................................................................................<br />
Impact of Fresh Frozen Plasma on Hepatectomy for Hepatocellular Carcinoma. M. KAIBORI, T. SAITO,<br />
K. MATSUI, M. YAMAOKA, Y. KAMIYAMA (Osaka, Japan)..........................................................................<br />
Matrix Metalloproteinase-9 (MMP-9) Immunoreactive Protein in Urinary Bladder Cancer: A Marker of<br />
Favorable Prognosis. K. VASALA, P. PÄÄKKÖ, T. TURPEENNIEMI-HUJANEN (Oulu, Finland)..............<br />
Natural History of Established Low Grade Cervical Intraepithelial (CIN 1) Lesions. N. BANSAL,<br />
J.D. WRIGHT, C.J. COHEN, T.J. HERZOG (New York, NY, USA) ..................................................................<br />
Darbepoetin Alfa Administered Every Three Weeks (Q3W) in Anemic Cancer Patients Receiving<br />
Chemotherapy (CT). O. MARTELLI, M. GARASSINO, S. SACCHETTA, R. CARISTO, A. ZIVI,<br />
L. CERBONE, A. MANCUSO (Rome; Milan, Italy)...............................................................................................<br />
The Depth of Tumor Invasion Beyond the Outer Border of the Muscularis Propria as a Prognostic Factor<br />
for T3 Rectal/Rectosigmoid Cancer. K. YOSHIDA, K. YOSHIMATSU, T. OTANI, H. YOKOMIZO,<br />
K. OGAWA (Tokyo, Japan) .........................................................................................................................................<br />
Retrospective Study of S-1 versus Tegafur/Uracil and Oral Leucovorin in Patients with Metastatic<br />
Colorectal Cancer. K. SHIBAHARA, M. YAMAMOTO, Y. KAKEJI, H. SAKATA, Y. MAEHARA<br />
(Fukuoka; Oita, Japan) .....................................................................................................................................<br />
Postoperative Adjuvant Chemotherapy in Surgically Staged Grade 3 Endometrial Cancer. N. TAKESHIMA,<br />
T. OTA, K. OMATSU, K. HASUMI, K. TAKIZAWA (Tokyo, Japan) ...............................................................<br />
Polymorphism in MHC Class II Transactivator Gene is Not Associated with Susceptibility to Colorectal<br />
Cancer in Swedish Patients. M. MUMTAZ, S. LÖFGREN, A. HUGANDER, J. DIMBERG (Baghdad,<br />
Iraq; Jönköping, Sweden) ...............................................................................................................................................<br />
Differences in Expression of Tumor Markers Between Pre- and Postmenopausal Women with Invasive<br />
Cervical Cancer. D. HELLBERG, T. TOT, U. STENDAHL (Falun; Uppsala; Umeå , Sweden)......................<br />
Changes in Tumour Biological Markers during Primary Systemic Chemotherapy (PST). H. NEUBAUER,<br />
C. GALL, U. VOGEL, R. HORNUNG, D. WALLWIENER, E. SOLOMAYER, T. FEHM (Tübingen<br />
Germany) .........................................................................................................................................................................<br />
Rectal Cancer Adjuvant Chemotherapy: When is More Useful? L.M. PASETTO, U. BASSO, G. SINIGAGLIA,<br />
S. PUCCIARELLI, M.L. FRISO, M. RUGGE, P. TOPPAN, M. AGOSTINI, S. MONFARDINI (Padova;<br />
Aviano, Italy) ..................................................................................................................................................................................<br />
1725<br />
1733<br />
1741<br />
1749<br />
1757<br />
1763<br />
1767<br />
1773<br />
1779<br />
1785<br />
1789<br />
1793<br />
1797<br />
1805<br />
4199
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Palliative Treatment for Elderly Patients with Colon Cancer in Ten Italian Medical Oncology Units.<br />
L.M. PASETTO, C. FALCI, E. RIZZO, G.L. DE SALVO, G. GASPARINI, M. D’ANDREA, E. BAJETTA,<br />
M. PLATANIA, O. ALABISO, S. MIRAGLIA, F. ONIGA, R. BIASON, M.C. CHETRÍ, P. FEDELE,<br />
G. MASSARA, I. ROMANIELLO, M. GIORDANO, G. LUCHENA, F. BUZZI, R. RICOTTA, S. SIENA,<br />
S. MONFARDINI (Padova; Rome; Milan; Novara; Venice; Brindisi; Borgomanero; Como; Terni, Italy)..................<br />
Nuclear ‚-Catenin Expression at the Invasive Front and in the Vessels Predicts Liver Metastasis in<br />
Colorectal Carcinoma. H. SUZUKI, N. MASUDA, T. SHIMURA, K. ARAKI, T. KOBAYASHI,<br />
S. TSUTSUMI, T. ASAO, H. KUWANO (Maebashi, Japan) ................................................................................<br />
Prognostic Value of Immunohistochemical Analysis of Tumor Budding in Colorectal Carcinoma.<br />
K. OHTSUKI, F. KOYAMA, T. TAMURA, Y. ENOMOTO, H. FUJII, T. MUKOGAWA, T.<br />
NAKAGAWA, K. UCHIMOTO, S. NAKAMURA, A. NONOMURA, Y. NAKAJIMA (Nara, Japan) .......<br />
Complete Response Obtained and Maintained by Combination of S-1 and CPT-11 in Hepatic Metastases of<br />
Colon Cancer: A Case Report. Y. TOKUNAGA, H. SASAKI, T. SAITO (Osaka, Japan)..............................<br />
Occult Lung Cancer Incidentally Found during Surgery for Esophageal and Gastric Cancer: A Case Report.<br />
N. ISOHATA, Y. NARITAKA, T. SHIMAKAWA, S. ASAKA, T. KATSUBE, S. KONNO, M. MURAYAMA,<br />
S. SHIOZAWA, K. YOSHIMATSU, M. AIBA, H. IDE, K. OGAWA (Tokyo, Japan)...........................................<br />
The Perioperative Morbidity of Laparoscopic Pelvic Lymph Node Staging in Patients with Advanced<br />
Cervical Cancer. S. POLTERAUER, L.A. HEFLER, M. PETRY, V. SEEBACHER, C. TEMPFER,<br />
A. REINTHALLER (Vienna, Austria) .......................................................................................................................<br />
DNA Repair Gene ERCC2, XPC, XRCC1, XRCC3 Polymorphisms and Associations with Bladder Cancer Risk<br />
in a French Cohort. L. FONTANA, R. BOSVIEL, L. DELORT, L. GUY, N. CHALABI, F. KWIATKOWSKI,<br />
S. SATIH, N. RABIAU, J.-P. BOITEUX, A. CHAMOUX, Y.-J. BIGNON, D.J. BERNARD-GALLON<br />
(Clermont-Ferrand, France).........................................................................................................................................................<br />
*<br />
Cancer Chemoprevention: A Summary of the Current Evidence. S. BONOVAS, A. TSANTES,<br />
T. DROSOS, N.M. SITARAS (Athens, Greece) .......................................................................................................<br />
Better Assessment of Nodal Metastases by PET/CT Fusion Compared to Side-by-Side PET/CT in<br />
Oesophageal Cancer. L.M. SCHREURS, B.B. PULTRUM, K.P. KOOPMANS, C.C. VERHOEF,<br />
P.L. JAGER, G.M. VAN DAM, H. GROEN, E.J. VAN DER JAGT, J.TH.M. PLUKKER (Groningen, The<br />
Netherlands) ....................................................................................................................................................................<br />
The Expression of Matrix Metalloproteinases-2 and -9 and their Tissue Inhibitor 2 in Pancreatic Ductal and<br />
Ampullary Carcinoma and their Relation to Angiogenesis and Clinicopathological Parameters.<br />
G. GIANNOPOULOS, K. PAVLAKIS, A. PARASI, N. KAVATZAS, D. TINIAKOS, A. KARAKOSTA,<br />
N. TZANAKIS, G. PEROS (Athens; Piraeus, Greece).............................................................................................<br />
Accuracy of a New Echographic Method (RULES, Radiofrequency Ultrasonic Local Estimators) in Prostate<br />
Cancer Diagnosis. A. BERTACCINI, A. FRANCESCHELLI, R. SCHIAVINA, D. MARCHIORI,<br />
A. BACCOS, R. PERNETTI, S. GRANCHI, E. BIAGI, L. MASOTTI, G. MARTORANA (Bologna;<br />
Florence, Italy) ................................................................................................................................................................<br />
Weekly Cisplatin, Infusional High-dose 5-Fluorouracil and Leucovorin for Advanced, Recurrent and<br />
Metastatic Cervical Carcinoma. S.-M. HSIAO, C.-A. CHEN, C. HSU, H.-H. LIN, C.-Y. HSIEH, L.-H. WEI<br />
(Taipei, Taiwan, ROC)...................................................................................................................................................<br />
Local Reactions to Treatments with Viscum album L. Extracts and their Association with T-Lymphocyte<br />
Subsets and Quality of Life. A. BÜSSING, W. TRÖGER, C. STUMPF, M. SCHIETZEL (Herdecke;<br />
Bochum; Freiburg, Germany) ........................................................................................................................................<br />
4200<br />
1813<br />
1821<br />
1831<br />
1837<br />
1841<br />
1849<br />
1853<br />
1857<br />
1867<br />
1875<br />
1883<br />
1887<br />
1893
Clinical Efficacy of Proton Magnetic Resonance Spectroscopy ( 1 H-MRS) in the Diagnosis of Localized<br />
Prostate Cancer. K. SAITO, T. KAMINAGA, S. MUTO, H. IDE, K. NISHIO, Y. KAMIYAMA,<br />
H. OKADA, Y. TERADO, S. FURUI, S. HORIE (Tokyo; Saitama, Japan) ......................................................<br />
Prognostic Significance of Fascin Expression in Advanced Poorly Differentiated Serous Ovarian Cancer. A.<br />
DAPONTE, E. KOSTOPOULOU, M. MINAS, G. KOUKOULIS, I.E. MESSINIS (Larissa, Greece) .................<br />
Assessing Polyp Size by Improved Digitalized Computed Tomography (CT). C. SUZUKI, L. MATSSON,<br />
C.A. RUBIO (Stockholm, Sweden) .............................................................................................................................<br />
GSTM, GSTT and p53 Polymorphisms as Modifiers of Clinical Outcome in Colorectal Cancer. A. CSEJTEI,<br />
A. TIBOLD, Z. VARGA, K. KOLTAI, A. EMBER, Z. ORSOS, G. FEHER, O.P. HORVATH, I. EMBER,<br />
I. KISS (Pécs, Hungary).................................................................................................................................................<br />
Irinotecan plus Capecitabine as First-line Chemotherapy in Advanced Colorectal Cancer. C. GENNATAS,<br />
V. MICHALAKI, S. GENNATAS, E. PAPALAMBROS (Athens, Greece) ........................................................<br />
Prognostic Impact of Combined Fludarabine, Treosulfan and Mitoxantrone Resistance Profile in Childhood<br />
Acute Myeloid Leukemia. J. STYCZYNSKI, M. WYSOCKI, A. DLU�NIEWSKA, E. JURASZEWSKA,<br />
W. BALWIERZ, K. CZYZEWSKI, M. WIECZOREK, I. OLEJNIK, M. KRAWCZUK-RYBAK,<br />
M. KUZMICZ, J. KOWALCZYK, J. STEFANIAK, W. BADOWSKA, D. SONTA-JAKIMCZYK,<br />
T. SZCZEPANSKI, M. MATYSIAK, E. STANCZAK, I. MALINOWSKA, J. WACHOWIAK,<br />
B. KONATKOWSKA, L. GIL, A. BALCERSKA, L. KAPUSCINSKA, J. SZCZEPANEK, B. KOLODZIEJ,<br />
B. RAFINSKA, M. KUBICKA (Bydgoszcz; Cracow; Chorzow; Bialystok; Lublin; Olsztyn; Zabrze; Warsaw;<br />
Poznan; Gdansk, Poland) ..............................................................................................................................................<br />
Diminishing Impact of Preoperative Carcinoembryonic Antigen (CEA) in Prognosis of Dukes’ C Colorectal<br />
Cancer. H. KATOH, K. YAMASHITA, Y. KOKUBA, T. SATOH, H. OZAWA, K. HATATE, A. IHARA,<br />
T. NAKAMURA, W. ONOZATO, M. WATANABE (Kanagawa, Japan) ..........................................................<br />
Brain Metastases in Relapsed Epithelial Ovarian Cancer after Chemotherapy with Pegylated Liposomal<br />
Doxorubicin. N.S. KASPROWICZ, C. FOTOPOULOU, G. OSKAY-ÖZCELIK, K. EL KHALFAOUI,<br />
D. BOEHMER, J. SEHOULI (Berlin, Germany).....................................................................................................<br />
Impact of Preoperative Hemoglobin Level on Survival of Non-small Cell Lung Cancer Patients.<br />
M. TOMITA, T. SHIMIZU, M. HARA, T. AYABE, T. ONITSUKA (Miyazaki, Japan).................................<br />
Free-from-progression Period and Overall Short Preoperative Immunotherapy with IL-2 Increases the<br />
Survival of Pancreatic Cancer Patients Treated with Macroscopically Radical Surgery. R. CAPROTTI,<br />
F. BRIVIO, L. FUMAGALLI, C. NOBILI, L. DEGRATE, P. LISSONI, D. PAROLINI, G. MESSINA,<br />
M. COLCIAGO, M. SCOTTI, F. UGGERI (Milan; Lecco, Italy).........................................................................<br />
An Ecological Study of Cancer Mortality Rates Including Indices for Dietary Iron and Zinc. W.B. GRANT<br />
(San Francisco, CA, USA).............................................................................................................................................<br />
Erratum ...........................................................................................................................................................................<br />
*<br />
Review (page 1857)<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
1899<br />
1905<br />
1911<br />
1917<br />
1923<br />
1927<br />
1933<br />
1943<br />
1947<br />
1951<br />
1955<br />
1965<br />
4201
*<br />
Number 4A<br />
Special Issue on Prostate Cancer <strong>Research</strong> in Taiwan<br />
Edited by Tai C. Chen and Yi-Fen Lee<br />
Prostate Specific Antigen Gene Expression in Androgen Insensitive Prostate Carcinoma Subculture Cell<br />
Line. K.-H. TSUI, T.-H. FENG, L.-C. CHUNG, C.-H. CHAO, P.-L. CHANG, H.-H. JUANG (Tao-Yuan,<br />
Taiwan, ROC) .................................................................................................................................................................<br />
Down-regulation of Matriptase by Overexpression of Bikunin Attenuates Cell Invasion in Prostate<br />
Carcinoma Cells. K.-H. TSUI, P.-L. CHANG, T.-H. FENG, L.-C. CHUNG, S.-Y. HSU, H.-H. JUANG<br />
(Tao-Yuan, Taiwan, ROC) ............................................................................................................................................<br />
Evaluation of Resistance <strong>Index</strong> in Patients with Prostate Cancer. S.-T. HUANG, M.-L. HSIEH (Taoyuan,<br />
Taiwan, ROC) .................................................................................................................................................................<br />
Laparoscopic Radical Prostatectomy: Initial Experience of Robotic Surgery in Taiwan. S.-T. WU, K.-H.<br />
TSUI, S.-H. TANG, D.-L. CHAR, D.-S. YU, C.-Y. YEN, S.-Y. CHANG, H.-I CHEN, G.-H. SUN (Taipei;<br />
Taoyuan, Taiwan, ROC)................................................................................................................................................<br />
Evaluating the Function of Matriptase and N-Acetylglucosaminyltransferase V in Prostate Cancer<br />
Metastasis. K.-H. TSUI, P.-L. CHANG, T.-H. FENG, L.-C. CHUNG, H.-C. SUNG, H.-H. JUANG (Tao-<br />
Yuan, Taiwan, ROC)......................................................................................................................................................<br />
Restriction Enzyme Mining for SNPs in Genomes. L.-Y. CHUANG, C.-H. YANG, K.-H. TSUI, Y.-H.<br />
CHENG, P.-L. CHANG, C.-H. WEN, H.-W. CHANG (Kaohsiung; Taoyuan; Taiwan, ROC).........................<br />
Prostate 25-Hydroxyvitamin D-1·-Hydroxylase is Up-regulated by Suberoylanilide Hydroxamic Acid<br />
(SAHA), A Histone Deacetylase Inhibitor. L. WANG, K.S. PERSONS, D. JAMIESON, J.N. FLANAGAN,<br />
H.H. HSU, M.F. HOLICK, Z. LUO, T. SAKAKI, N. URUSHINO, D.V. FALLER, T.C. CHEN (Boston,<br />
MA, USA; Toyama, Japan) ...............................................................................................................................................<br />
25-Hydroxyvitamin D-1 Alpha-hydroxylase (CYP27B1) is a New Class of Tumor Suppressor in the Prostate.<br />
T.C. CHEN (Boston, MA, USA) ..................................................................................................................................<br />
Book reviews<br />
*<br />
Review (page 2001)<br />
Number 4B<br />
Experimental Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
RET Activation Inhibits Doxorubicin-induced Apoptosis in SK-N-MC Cells. M.A. SKINNER, K.E. LACKEY,<br />
A.J. FREEMERMAN (Dallas, TX; <strong>Research</strong> Triangle Park; Durham, NC, USA) ....................................................<br />
Dual Targeting of Tumor Vasculature: Combining Avastin and Vascular Disrupting Agents (CA4P or<br />
OXi4503). D.W. SIEMANN, W. SHI (Gainesville, FL, USA) ................................................................................<br />
Subcellular Colocalization of Hypericin with Respect to Endoplasmic Reticulum and Golgi Apparatus in<br />
Glioblastoma Cells. R. RITZ, F. ROSER, N. RADOMSKI, W.S.L. STRAUSS, M. TATAGIBA,<br />
A. GHARABAGHI (Tübingen; Münster; Ulm, Germany)..................................................................................<br />
4202<br />
1969<br />
1977<br />
1985<br />
1989<br />
1993<br />
2001<br />
2009<br />
2015<br />
2019<br />
2027<br />
2033
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Down-regulated Expression of RhoA in Human Conventional Renal Cell Carcinoma. Y.-S. PU, C.-W. WANG,<br />
G.-Y. LIU, Y.-Z. KUO, C.-Y. HUANG, W.-Y. KANG, C.-T. SHUN, C.-C. LIN, W.-J. WU, T.-C. HOUR<br />
(Taipei; Kaohsiung; Taichung, Taiwan, ROC)......................................................................................................................<br />
Long-term Postoperative Adjuvant Chemotherapy of UFT/LV Improves Survival in a Primary Tumor Amputation,<br />
Pulmonary Metastasis Model. S. SADAHIRO, T. SUZUKI, Y. MAEDA, A. TANAKA, H. MAKUUCHI,<br />
A. KAMIJ, C. MURAYAMA (Tokai, Japan) ........................................................................................................<br />
EMMPRIN Modulates Migration and Deposition of TN-C in Oral Squamous Carcinoma. D. DANG,<br />
A. ATAKILIT, D.M. RAMOS (San Francisco, CA, USA)......................................................................................<br />
SPMSP: A Solid-phase PCR with Colorimetric Read-out for Quantitative Methylation Analysis. S. SIEVERS,<br />
C. FRITZSCH, C. KUHNEN, O. MÜLLER (Dortmund; Bochum, Germany)........................................................<br />
Aberrant Gene Promoter Methylation in Sputum from Individuals Exposed to Smoky Coal Emissions.<br />
Y. LIU, Q. LAN, M. SHEN, J. JIN, J. MUMFORD, D. REN, P. KEOHAVONG (Pittsburgh, PA; Bethesda,<br />
MD; Triangle Park, NC, USA) ......................................................................................................................................<br />
Inhibition of Growth and Induction of Differentiation of Colon Cancer Cells by Peach and Plum Phenolic<br />
Compounds. M.A. LEA, C. IBEH, C. desBORDES, M. VIZZOTTO, L. CISNEROS-ZEVALLOS,<br />
D.H. BYRNE, W.R. OKIE, M.P. MOYER (Newark, NJ, New York, NY; College Station, TX; Byron, GA;<br />
San Antonio, TX, USA; Pelotas, Brazil).......................................................................................................................<br />
Human Papillomavirus Frequency in Oral and Oropharyngeal Cancer in Greece. M. ROMANITAN,<br />
A. NÄSMAN, T. RAMQVIST, H. DAHLSTRAND, L. POLYKRETIS, P. VOGIATZIS, P. VAMVAKAS,<br />
G. TASOPOULOS, C. VALAVANIS, P. ARAPANTONI-DADIOTI, K. BANIS, T. DALIANIS<br />
(Stockholm, Sweden; Piraeus, Greece) .........................................................................................................................<br />
The Synthesis and Activity of Lipoprotein Lipase in the Subcutaneous Adipose Tissue of Patients with<br />
Musculoskeletal Sarcomas. K. SAKAYAMA, T. KIDANI, N. TANJI, H. YAMAMOTO, H. MASUNO<br />
(Toon; Iyo-gun, Ehime, Japan) .....................................................................................................................................<br />
Oxaliplatin in Treatment of the Cisplatin-resistant MKN45 Cell Line of Gastric Cancer. K. TOZAWA,<br />
T. OSHIMA, T. KOBAYASHI, N. YAMAMOTO, C. HAYASHI, T. MATSUMOTO, H. MIWA<br />
(Nishinomiya, Hyogo; Sapporo, Hokkaido, Japan) ..............................................................................................................<br />
Regulation of Inflammation- and Angiogenesis-related Gene Expression in Breast Cancer Cells and<br />
Co-cultured Macrophages. G.T. BURNETT, D.C. WEATHERSBY, T.E. TAYLOR, T.A. BREMNER<br />
(Washington DC; Houston, TX, USA) .........................................................................................................................<br />
Lipopolysaccharide Induces Aberrant Hypermethylation of Hic-1 in Mouse Embryonic Fibroblasts Lacking<br />
p53 Gene. M. TATEMICHI, H. HATA, H. TAZAWA, T. NAKADATE (Tokyo; Okayama, Japan).............<br />
Investigation of MMP-2 and -9 in a Highly Invasive A431 Tumor Cell Sub-line Selected from a Boyden<br />
Chamber Assay. W.-T. KAO, C.-Y. LIN, L.-T. LEE, P.-P.H. LEE, C.-C. HUNG, Y.-S. LIN, S. CHEN,<br />
F.-C. KE, J.-J. HWANG, M.-T. LEE (Taipei; Chia-Yi, ∆aiwan, ROC) .................................................................<br />
HOXB2, an Adverse Prognostic Indicator for Stage I Lung Adenocarcinomas, Promotes Invasion by<br />
Transcriptional Regulation of Metastasis-related Genes in HOP-62 Non-small Cell Lung Cancer Cells.<br />
K. INAMURA, Y. TOGASHI, H. NINOMIYA, T. SHIMOJI, T. NODA, Y. ISHIKAWA (Tokyo, Japan) ....<br />
The Anti-aromatase Effect of Progesterone and of its Natural Metabolites 20·- and 5·-Dihydroprogesterone<br />
in the MCF-7aro Breast Cancer Cell Line. J.R. PASQUALINI, G. CHETRITE (Paris, France) ..........................<br />
Evidence of a Tumour Suppressive Function of E2F1 Gene in Human Breast Cancer. D. WORKU, F. JOUHRA,<br />
G.W. JIANG, N. PATANI, R.F. NEWBOLD, K. MOKBEL (Uxbridge, Middlesex; London; Cardiff, UK) ..............<br />
2039<br />
2045<br />
2049<br />
2055<br />
2061<br />
2067<br />
2077<br />
2081<br />
2087<br />
2093<br />
2101<br />
2109<br />
2121<br />
2129<br />
2135<br />
4203
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Restoration of FGF Receptor Type 2 Enhances Radiosensitivity of Hormone-refractory Human Prostate<br />
Carcinoma PC-3 Cells. A. MATSUBARA, J. TEISHIMA, S. MIRKHAT, H. YASUMOTO,<br />
H. MOCHIZUKI, M. SEKI, K. MUTAGUCHI, W.L. MCKEEHAN, T. USUI (Hiroshima; Hatsukaichi,<br />
Japan; Houston, TX, USA) ...............................................................................................................................................<br />
Efficacy of the Third-generation Bisphosphonate Risedronate Alone and in Combination with <strong>Anticancer</strong><br />
Drugs Against Osteosarcoma Cell Lines. T. MURAYAMA, Y. KAWASOE, Y. YAMASHITA, Y. UENO,<br />
S. MINAMI, M. YOKOUCHI, S. KOMIYA (Kagoshima, Japan) ........................................................................<br />
The Wilms’ Tumor Suppressor WT1 Inhibits Malignant Progression of Neoplastigenic Mammary Epithelial<br />
Cells. L. WANG, Z.-Y. WANG (Omaha, NE, USA) ...............................................................................................<br />
Aberrant Methylation of p16, DLEC1, BLU and E-Cadherin Gene Promoters in Nasopharyngeal<br />
Carcinoma Biopsies from Tunisian Patients. W. AYADI, H. KARRAY-HAKIM, A. KHABIR, L. FEKI,<br />
S. CHARFI, T. BOUDAWARA, A. GHORBEL, J. DAOUD, M. FRIKHA, P. BUSSON, A. HAMMAMI<br />
(Sfax, Tunisie; Villejuif, France)....................................................................................................................................<br />
Follow-up of HPV DNA Copy Number in Cidofovir Therapy of Recurrent Respiratory Papillomatosis. T.<br />
MAJOR, I. SZIKLAI, J. CZEGLÉDY, T. GÁLL, L. GERGELY, K. SZARKA (Debrecen, Hungary) .........<br />
Resistance of Colorectal Cancer Cells to 5-FUdR and 5-FU Caused by Mycoplasma Infection. L. JETTÉ, S.<br />
BISSOON-HAQQANI, B. LE FRANÇOIS, J.A. MAROUN, H.C. BIRNBOIM (Ottawa, ON, Canada).............<br />
Abrogation of Estrogen Receptor Signaling Augments Cytotoxicity of <strong>Anticancer</strong> Drugs on CaSki Cervical<br />
Cancer Cells. M.Y. HEO, S.A. SALAMA, N. KHATOON, A. AL-HENDY, W.W. AU (Chuncheon, Korea;<br />
Galveston, TX, USA)......................................................................................................................................................<br />
Comparison of 111 In-DOTA-NOC and 111 In-DOTA-TATE Distribution in the Target and Dose-limiting<br />
Tissues: Conflicting Results In Vitro and In Vivo. J. CIHLO, L. MELICHAROVÁ, M. PETRIK,<br />
A. LAZNICKOVA, M. LAZNICEK (Hradec Kralove, Czech Republic)...............................................................<br />
Tumor-specific Cytotoxicity and Type of Cell Death Induced by Peplomycin in Oral Squamous Cell Carcinoma<br />
Cell Lines. Y. LIU, H. SAKAGAMI, O. AMANO, H. KIKUCHI, Y. NAKAMURA, M. ISHIHARA,<br />
Y. KANDA, S. KUNII, W. ZHANG, G. YU (Beijing, China; Sakado, Saitama, Japan)........................................<br />
Down-regulation of Deoxycytidine Kinase Enhances Acquired Resistance to Gemcitabine in Pancreatic<br />
Cancer. S. OHHASHI, K. OHUCHIDA, K. MIZUMOTO, H. FUJITA, T. EGAMI, J. YU, H. TOMA,<br />
S. SADATOMI, E. NAGAI, M. TANAKA (Fukuoka, Japan)...............................................................................<br />
The Growth-promoting Action of Individual Women’s Sera on Mammary Carcinoma Cells. D. AUER,<br />
M. HUBALEK, M. FLEISCHER, J. ROESSLER, G. DAXENBICHLER (Innsbruck, Austria) ....................<br />
Measurement of Serum and Tissue Des-Á-carboxyprothrombin in Resectable Hepatocellular Carcinoma.<br />
C.-H. XIANG, W. ZHANG, Y. INAGAKI, K.-M. ZHANG, Y. NAKANO, N. KOKUDO, Y. SUGAWARA,<br />
J.-H. DONG, M. NAKATA, W. TANG (Tokyo; Hiratsuka, Japan; Beijing; Shanghai, China)..............................<br />
Arp2/3 Overexpression Contributed to Pathogenesis, Growth and Invasion of Gastric Carcinoma.<br />
H.-C. ZHENG, Y.-S. ZHENG, X.-H. LI, H. TAKAHASHI, T. HARA, S. MASUDA, X.-H. YANG,<br />
Y.-F. GUAN, Y. TAKANO (Shenyang, China; Toyama; Takaoka, Japan) ..........................................................<br />
Prevalence of HPV Types in a Cohort of Greeks with Clinical Indication of Infection. C. YAPIJAKIS, M.<br />
ADAMOPOULOU, G. ANTONOPOULOS, N. KOUFALIOTIS, E. VAIRAKTARIS (Athens, Greece) .........<br />
Effect of Bortezomib and Cetuximab in EGF-stimulated HNSCC. J. WAGENBLAST, M. BAGHI,<br />
C. ARNOLDNER, S. BISDAS, W. GSTÖTTNER, H. ACKERMANN, A. MAY, R. KNECHT, M. HAMBEK<br />
(Frankfurt am Main, Germany) ....................................................................................................................................<br />
4204<br />
2141<br />
2147<br />
2155<br />
2161<br />
2169<br />
2175<br />
2181<br />
2189<br />
2197<br />
2205<br />
2213<br />
2219<br />
2225<br />
2233<br />
2239
Effect of Steep Pulsed Electric Field on Proliferation, Viscoelasticity and Adhesion of Human Hepatoma<br />
SMMC-7721 Cells. G. SONG, J. QIN, C. YAO, Y. JU (Chongqing, P.R. China; Nagoya, Japan)....................<br />
Metastases following Biopsy of Oral Carcinoma in Hamsters and the Role of Local Prebiopsy Bleomycin.<br />
G. RALLIS, C. MOUROUZIS, V. PAPAKOSTA, I. DONTA, D. PERREA, E. PATSOURIS,<br />
E. VAIRAKTARIS (Athens, Greece) .........................................................................................................................<br />
Multitarget siRNA Inhibition of Antiapoptotic Genes (XIAP, BCL2, BCL-X L) in Bladder Cancer Cells.<br />
D. KUNZE, D. WUTTIG, S. FUESSEL, K. KRAEMER, M. KOTZSCH, A. MEYE, M.-O. GRIMM,<br />
O.W. HAKENBERG, M.P. WIRTH (Dresden; Rostock, Germany)......................................................................<br />
PCR-based Testing for Therapy-related EGFR Mutations in Patients with Non-small Cell Lung Cancer.<br />
R. DAHSE, A. BERNDT, H. KOSMEHL (Erfurt; Jena, Germany)......................................................................<br />
Cathepsin B Expression in Prostate Cancer of Native Japanese and Japanese-American Patients: ∞n<br />
Immunohistochemical Study. A.A. SINHA, J.L. MORGAN, K. BETRE, M.J. WILSON, C. LE, L.S. MARKS<br />
(Minneapolis, MN; Los Angeles, LA; Culver City, CA, USA) .........................................................................................<br />
Number 4C<br />
Clinical Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Comparison of the Prognostic Value of a Panel of Tissue Tumor Markers and Established<br />
Clinicopathological Factors in Patients with Gastric Cancer. J.-P. WIKSTEN, J. LUNDIN, S. NORDLING,<br />
A. KOKKOLA, C. HAGLUND (Helsinki, Finland) ................................................................................................<br />
CYP1A2 164 A ➞C Polymorphism, Cigarette Smoking, Consumption of Well-done Red Meat and Risk of<br />
Developing Colorectal Adenomas and Carcinomas. M. SÆBØ, C.F. SKJELBRED, K. BREKKE LI, I.M.<br />
BOWITZ-LOTHE, P.C. HAGEN, E. JOHNSEN, K.M. TVEIT, E.H. KURE (Bø i Telemark; Skien; Oslo,<br />
Norway)............................................................................................................................................................................<br />
Value of Serum S-100B for Prediction of Distant Relapse and Survival in Stage III B/C Melanoma. L.H.M.<br />
SMIT, O.E. NIEWEG, W.J. MOOI, J.M.G. BONFRER, J.B.A.G. HAANEN, B.B.R. KROON, G.C. DE<br />
GAST (Amsterdam, The Netherlands).........................................................................................................................<br />
PET-CT in Recurrent Ovarian Cancer: Impact on Treatment Planning. M.S. LENHARD, A. BURGES, T.R.C.<br />
JOHNSON, P. STIEBER, C. KÜMPER, N. DITSCH, R. LINKE, K. FRIESE (Munich, Germany) .....................<br />
Huge Primary Retroperitoneal Mucinous Cystadenoma of Borderline Malignancy Mimicking an Ovarian<br />
Mass: Case Report and Review. G. BIFULCO, V.D. MANDATO, P. GIAMPAOLINO, C. NAPPI, R. DE<br />
CECIO, L. INSABATO, F. TARSITANO, C. MIGNOGNA (Naples, Italy) ......................................................<br />
Complete Response after Imatinib Mesylate Administration in a Patient with Chemoresistant Stage IV<br />
Seminoma. D. PECTASIDES, M. NIKOLAOU, E. PECTASIDES, A. KOUMARIANOU, C.<br />
VALAVANIS, T. ECONOMOPOULOS (Athens; Piraeus, Greece)......................................................................<br />
Neoadjuvant Chemotherapy (FAP) for Advanced Esophageal Cancer. T. SHIMAKAWA, Y. NARITAKA,<br />
S. ASAKA, N. ISOHATA, M. MURAYAMA, S. KONNO, K. YOSHIMATSU, S. SHIOZAWA, T.<br />
KATSUBE, K. OGAWA (Tokyo, Japan)...................................................................................................................<br />
Weekly Irinotecan Plus Protracted Venous Fluorouracil Infusion (WI-FI) in Advanced Colorectal Cancer:<br />
A Phase II Study. C. OLIVA, P. POCHETTINO, P. BERGNOLO, A. BOGLIONE, S.C. CUTIN, M.<br />
INGUÌ, O. DAL CANTON, F. GARETTO, M. BISCARDI, E. BERNO, A. COMANDONE; ON<br />
BEHALF OF THE ITALIAN GROUP FOR RARE TUMORS (Torino, Italy)................................................<br />
2245<br />
2253<br />
2259<br />
2265<br />
2271<br />
2279<br />
2289<br />
2297<br />
2303<br />
2309<br />
2317<br />
2321<br />
2327<br />
4205
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
*<br />
How the Measurements of a Few Serum Markers Can Be Combined to Enhance their Clinical Values in the<br />
Management of Cancer. O.J. CORDERO, L. DE CHIARA, Y. LEMOS-GONZÁLEZ, M.P. DE LA<br />
CADENA, F.J. RODRÍGUEZ-BERROCAL (Santiago de Compostela; Vigo, Spain) .......................................<br />
Clinical Significance and Pathogenic Function of Connective Tissue Growth Factor (CTGF/CCN2) in Osteolytic<br />
Mandibular Squamous Cell Carcinoma. T. SHIMO, S. KUBOTA, T. GODA, Y. YOSHIHAMA, N. KURIO,<br />
T. NISHIDA, P.-S. NG, K. ENDO, M. TAKIGAWA, A. SASAKI (Okayama; Yokohama, Japan) ......................<br />
Craniofacial Reconstructions with Bone-anchored Epithesis in Head and Neck Cancer Patients – A Valid Way<br />
Back to Self-perception and Social Reintegration. J. WAGENBLAST, M. BAGHI, M. HELBIG, C.<br />
ARNOLDNER, S. BISDAS, W. GSTÖTTNER, M. HAMBEK, A. MAY (Frankfurt am Main, Germany)........<br />
The Impact of Surgical Treatment and Poor Prognostic Factors for Patients with Intrahepatic<br />
Cholangiocarcinoma: Retrospective Analysis of 60 Patients. Y.-I. YAMASHITA, A. TAKETOMI, K.<br />
MORITA, T. FUKUHARA, S. UEDA, K. SANEFUJI, T. IGUCHI, H. KAYASHIMA, K. SUGIMACHI,<br />
Y. MAEHARA (Fukuoka, Japan)...............................................................................................................................<br />
A Complete Remission of Sclerosing Rhabdomyosarcoma with Multiple Lung and Bone Metastases Treated<br />
with Multi-agent Chemotherapy and Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report.<br />
K. SAKAYAMA, H. TAUCHI, Y. SUGAWARA, T. KIDANI, K. TOKUDA, T. MIYAZAKI, Y.<br />
WATANABE, H. YAMAMOTO (Toon, Ehime, Japan) ........................................................................................<br />
Comparison of Hyper-fractionated Accelerated and Standard Fractionated Radiotherapy with Concomitant<br />
Low-dose Gemcitabine for Unresectable Pancreatic Cancer. K. MAEMURA, H. SHINCHI, H. NOMA, Y.<br />
MATAKI, H. KURAHARA, S. MAEDA, Y. HIRAKI, M. NAKAJO, S. NATSUGOE, S. TAKAO<br />
(Kagoshima, Japan)........................................................................................................................................................<br />
Phase 2 Trial of Oral S-1 Combined with Low-dose Cisplatin for Unresectable Advanced Pancreatic Cancer.<br />
S. INA, M. TANI, M. KAWAI, S. HIRONO, M. MIYAZAWA, R. NISHIOKA, Y. FUJITA, H. YAMAUE<br />
(Wakayama, Japan)........................................................................................................................................................<br />
The Significance of Gastrectomy in Advanced Gastric Cancer Patients with Non-curative Factors. H.<br />
MIYAGAKI, K. FUJITANI, T. TSUJINAKA, M. HIRAO, M. YASUI, M. KASHIWAZAKI, M.<br />
IKENAGA, M. MIYAZAKI, H. MISHIMA, S. NAKAMORI (Osaka, Japan) ..................................................<br />
Feasibility Study of Docetaxel and Nedaplatin for Recurrent Squamous Cell Carcinoma of the Uterine<br />
Cervix. Y. WATANABE, H. NAKAI, T. ETOH, K. KANEMURA, I. TSUJI, A. ISHIZU, H. HOSHIAI<br />
(Osaka, Japan)................................................................................................................................................................<br />
Urinary Neopterin, Hemoglobin and Peripheral Blood Cell Counts in Breast Carcinoma Patients Treated<br />
with Dose-dense Chemotherapy. B. MELICHAR, L. URBÁNEK, L. KRČMOVÁ, H. KALÁBOVÁ, K.<br />
MELICHAROVÁ, E. MAL¡ŘOVÁ, H. HORNYCHOVÁ, A. RYŠKA, R. HYŠPLER, D. SOLICHOVÁ<br />
(Hradec Králové; Olomouc, Czech Republic)..............................................................................................................<br />
Staging Procedures in Primary Breast Cancer. D. MÜLLER, G. KÖHLER, R. OHLINGER (Greifswald,<br />
Germany) .........................................................................................................................................................................<br />
Regulatory T-Cells Are Possible Effect Prediction Markers of Immunotherapy for Cancer Patients. J.<br />
WADA, A. YAMASAKI, S. NAGAI, K. YANAI, K. FUCHINO, C. KAMEDA, H. TANAKA, K. KOGA,<br />
H. NAKASHIMA, M. NAKAMURA, M. TANAKA, M. KATANO, T. MORISAKI (Fukuoka, Japan) ......<br />
Erlotinib Monotherapy in Patients with Advanced Non-small Cell Lung Cancer: An Effective Approach<br />
with Low Toxicity. A. ARDAVANIS, S. KOUMNA, I. FRAGOS, S. MALLIOU, F. KYRIAKOU, I.<br />
MANTZARIS, A. SCORILAS, G. RIGATOS (Athens, Greece)...........................................................................<br />
4206<br />
2333<br />
2343<br />
2349<br />
2353<br />
2361<br />
2369<br />
2373<br />
2379<br />
2385<br />
2389<br />
2397<br />
2401<br />
2409
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Arrest of Cell Proliferation in Budding Tumor Cells Ahead of the Invading Edge of Colonic Carcinomas.<br />
A Preliminary Report. C.A. RUBIO (Stockholm, Sweden).....................................................................................<br />
*<br />
Predictive Markers of Radiation Pneumonitis. X. PROVATOPOULOU, E. ATHANASIOU, A.<br />
GOUNARIS (Athens, Greece) .....................................................................................................................................<br />
Clonazepam for Chemotherapy-induced Nausea and Vomiting (CINV). M. KOGA, M. NAKADOZONO,<br />
K. NUKARIYA, H. NOGI, T. KOBAYASHI, K. NAKAYAMA (Tokyo, Japan)..............................................<br />
Influence of Valproic Acid on Outcome of High-grade Gliomas in Children. A. MASOUDI, M. ELOPRE,<br />
E. AMINI, M.E NAGEL, J.L. ATER, V. GOPALAKRISHNAN, J.E.A. WOLFF (Houston, TX, USA) ......<br />
Value of Procollagen Type 1 Amino-terminal Propeptide in Patients with Renal Cell Carcinoma. M.<br />
KLEPZIG, H. SAUER-EPPEL, D. JONAS, G.M. OREMEK (Frankfurt am Main, Germany).......................<br />
Pregnancy and Post-partum Breast Cancer: A Prospective Study. C. MATHELIN, K. ANNANE, A.<br />
TREISSER, M.-P. CHENARD, C. TOMASETTO, J.-P. BELLOCQ, M.-C. RIO (Strasbourg; Illkirch,<br />
France; Monaco).............................................................................................................................................................<br />
Preoperative Transvaginal Ultrasound (TVS) in the Description of Pelvic Tumor Spread in Endometrial<br />
Cancer: Results of a Prospective Study. C. FOTOPOULOU, J. SEHOULI, J.C. SCHEFOLD, C. WOLF, C.<br />
DENKERT, W. LICHTENEGGER, W. HENRICH (Berlin, Germany)..............................................................<br />
Cetuximab with Hepatic Arterial Infusion of Chemotherapy for the Treatment of Colorectal Cancer Liver<br />
Metastases. B. NEYNS, M. AERTS, Y. VAN NIEUWENHOVE, C. FONTAINE, L. DE COSTER, D.<br />
SCHALLIER, J. VANDERAUWERA, F. DE MUNCK, F. VANDENBROUCKE, H. EVERAERT, V.<br />
MEERT, J. DE MEY, M. DE RIDDER, G. DELVAUX, J. DE GRÈVE (Brussels, Belgium) .......................<br />
Squamous-cell Carcinoma of the Anus with High Intratumoral Lymphocytosis and its Clinical Implications.<br />
C.A. RUBIO, P.J. NILSSON (Stockholm, Sweden) .................................................................................................<br />
Phase I Study of Biweekly Docetaxel and S-1 Combination Chemotherapy for Advanced Gastric Cancer.<br />
C. KUNISAKI, M. TAKAHASHI, Y. NAGAHORI, H. MAKINO, R. TAKAGAWA, T. SATO, T.<br />
OSHIMA, S. FUJII, T. KOSAKA, H.A. ONO, H. AKIYAMA, H. SHIMADA (Yokohama, Japan).............<br />
Microvessel Density (MVD) and Cyclooxygenase-2 (COX-2)/ ‚-Catenin Interaction Are Associated with<br />
Relapse in Patients with Transitional Carcinoma Receiving Adjuvant Chemotherapy with<br />
Paclitaxel/Carboplatin: A Hellenic Cooperative Oncology Group (HECOG) Study. A. BAMIAS, F.<br />
KYRIAKOU, M. CHORTI, N. KAVANTZAS, A. NONI, A. KYROUDI-VOULGARI, D.<br />
RONTOYIANNI, E. KASTRITIS, N. XIROS, E.S. PATSOURIS, S. MURRAY, N. TAMVAKIS, M.A.<br />
DIMOPOULOS (Athens, Greece) ...............................................................................................................................<br />
Development of a Nomogram for Predicting High-grade Prostate Cancer on Biopsy: the Significance of<br />
Serum Testosterone Levels. H. IDE, M. YASUDA, K. NISHIO, K. SAITO, S. ISOTANI, Y. KAMIYAMA,<br />
S. MUTO, S. HORIE (Tokyo, Japan).........................................................................................................................<br />
Expression of NLRP7 (PYPAF3, NALP7) Protein in Endometrial Cancer Tissues. S. OHNO, T.<br />
KINOSHITA, Y. OHNO, T. MINAMOTO, N. SUZUKI, M. INOUE, T. SUDA (Ishikawa, Japan).............<br />
Nutrient Patterns and Risk of Squamous Cell Carcinoma of the Esophagus: a Factor Analysis in Uruguay.<br />
E. DE STEFANI, P. BOFFETTA, R.B. FAGUNDES, H. DENEO-PELLEGRINI, A.L. RONCO, G.<br />
ACOSTA, M. MENDILAHARSU (Montevideo, Uruguay; Lyon, France; Porto Alegre, Brazil) ........................<br />
Micronuclei and Broken Eggs in Human Liver Carcinogenesis. M. GUIDO, M. FASSAN, L. GIACOMELLI,<br />
U. CILLO, F. FARINATI, P. BURRA, S. FAGIUOLI, M. RUGGE (Padova; Bergamo, Italy)............................<br />
2417<br />
2421<br />
2433<br />
2437<br />
2443<br />
2447<br />
2453<br />
2459<br />
2469<br />
2473<br />
2479<br />
2487<br />
2493<br />
2499<br />
2507<br />
4207
Adjuvant Treatment for Elderly Patients with Colon Cancer. An Observational Study. L.M. PASETTO,<br />
C. FALCI, U. BASSO, G. GASPARINI, M. D’ANDREA, P. BONGINELLI, E. BAJETTA, M. PLATANIA,<br />
O. ALABISO, S. MIRAGLIA, E. BERTONA, F. ONIGA, R. BIASON, M.C. CHETRÌ, P. FEDELE,<br />
G. MASSARA, I. ROMANIELLO, M.E. NEGRU, G. LUCHENA, M. GIORDANO, F. BUZZI,<br />
R. RICOTTA, S. SIENA, S. MONFARDINI (Rome; Novara; Venice; Borgomanero; Milan, Italy)...................<br />
Paclitaxel and Pegylated Liposomal Doxorubicin in Recurrent Head and Neck Cancer: Clinical and Unexpected<br />
Pharmacokinetic Interactions. M. AIROLDI, L. CATTEL, P. MILLA, F. PEDANI, M. GARZARO,<br />
F. DOSIO (Turin, Italy) ...........................................................................................................................................................<br />
*<br />
Reviews (pages 2333, 2421)<br />
Number 5A<br />
Experimental Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Use of an Extracellular Matrix Material as a Vaccine Carrier and Adjuvant. M.A. SUCKOW, P. HALL,<br />
W. WOLTER, V. SAILES, M.C. HILES (Notre Dame; West Lafayette, IN, USA) .............................................<br />
Expression of P16, P53 and Ki-67 Proteins in the Progression of Epithelial Dysplasia of the Oral Cavity.<br />
F. ANGIERO, A. BERENZI, A. BENETTI, E. ROSSI, R. DEL SORDO, A. SIDONI, M. STEFANI,<br />
E. DESSY (Milan; Brescia; Perugia, Italy)..................................................................................................................<br />
Human Tumor Growth in Nude Mice Is Associated with Decreased Plasma Cysteine and Homocysteine.<br />
F. AL-AWADI, M. YANG, Y. TAN, Q. HAN, S. LI, R.M. HOFFMAN (Kuwait; San Diego, CA, USA) .....<br />
Chemopreventive Effects of Heat-processed Panax quinquefolius Root on Human Breast Cancer Cells.<br />
C.-Z. WANG, H.H. AUNG, B. ZHANG, S. SUN, X.-L. LI, H. HE, J.-T. XIE, T.-C. HE, W. DU, C.-S.<br />
YUAN (Chicago, IL, USA)...........................................................................................................................................<br />
Conserved CPEs in the P53 3’ Untranslated Region Influence mRNA Stability and Protein Synthesis.<br />
M.W. ROSENSTIERNE, J. VINTHER, G. MITTLER, L. LARSEN, M. MANN, B. NORRILD<br />
(Copenhagen, Denmark; Freiburg; Martinsried, Germany) ........................................................................................<br />
[ 18 F]FDG and [ 18 F]FLT PET-CT and MR Imaging of Human Neuroblastomas in a SCID Mouse Xenograft<br />
Model. U. VALENTINER, C. HAANE, K. PELDSCHUS, H. GUSTKE, W. BRENNER, F. WILKE,<br />
A. POMMERT, M. OWSIJEWITSCH, U. SCHUMACHER, S. KLUTMANN (Hamburg; Heidelberg,<br />
Germany) .........................................................................................................................................................................<br />
Persistent Adenovirus-mediated Thymidine Kinase Gene Expression in Ovarian Cancer Cells Increases Cell<br />
Killing Efficacy Over Time. D.G. KIEBACK, B. DELVOUX, A. ROMANO, S. OLLIG, D.C. FISCHER<br />
(Aue, Germany; Maastricht, The Netherlands)............................................................................................................<br />
Tumor-specific Cytotoxicity and Type of Cell Death Induced by Sodium 5,6-Benzylidene-L-ascorbate.<br />
K. KISHINO, K. HASHIMOTO, O. AMANO, M. KOCHI, WK LIU, H. SAKAGAMI (Saitama; Chiba,<br />
Japan; Hong Kong PRC)................................................................................................................................................<br />
Molecular Mechanisms and Gene Regulation of Melphalan- and Hyperthermia-induced Apoptosis in Ewing<br />
Sarcoma Cells. C. KRAUSE, K. KLÜTTERMANN, C. MAUZ-KÖRHOLZ (Halle; Leipzig, Germany) ......<br />
Bax Expression in Untreated Breast Cancer: An Immunocytometric Study of 255 Cases. F. MARTÍNEZ-<br />
ARRIBAS, E. MARTÍN-GARABATO, I. ZAPARDIEL, J. S∞NCHEZ, A.R. LUCAS, A. TEJERINA,<br />
J. SCHNEIDER (Madrid, Spain) ................................................................................................................................<br />
4208<br />
2513<br />
2519<br />
2529<br />
2535<br />
2541<br />
2545<br />
2553<br />
2561<br />
2569<br />
2577<br />
2585<br />
2595
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Dephosphorylation of Cancer Protein by Tyrosine Phosphatases in Response to Analogs of Luteinizing<br />
Hormone-releasing Hormone and Somatostatin. L.-T. LEE, A.V. SCHALLY, C. LIEBOW, P.-P. LEE,<br />
P.-H. LEE, M.-T. LEE (Chia-Yi; Taipei, Taiwan, ROC; Miami, FL; Buffalo, NY, USA)....................................<br />
Antitumor Effects of Desmopressin in Combination with Chemotherapeutic Agents in a Mouse Model of<br />
Breast Cancer. G.V. RIPOLL, S. GIRON, M.J. KRZYMUSKI, G.A. HERMO, D.E. GOMEZ, D.F. ALONSO<br />
(Buenos Aires, Argentina).........................................................................................................................................................<br />
*<br />
Vitamin D and Wnt/‚-catenin Pathway in Colon Cancer: Role and Regulation of DICKKOPF Genes.<br />
N. PENDÁS-FRANCO, Ó. AGUILERA, F. PEREIRA, J.M. GONZÁLEZ-SANCHO, A. MUÑOZ<br />
(Madrid, Spain; Porto, Portugal)...................................................................................................................................<br />
The PARP Inhibitor, ABT-888 Potentiates Temozolomide: Correlation with Drug Levels and Reduction<br />
in PARP Activity In Vivo. J.P. PALMA, L.E. RODRIGUEZ, V.D. BONTCHEVA-DIAZ, J.J. BOUSKA,<br />
G. BUKOFZER, M. COLON-LOPEZ, R. GUAN, K. JARVIS, E.F. JOHNSON, V. KLINGHOFER,<br />
X. LIU, A. OLSON, M.J. SALTARELLI, Y. SHI, J.A. STAVROPOULOS, G.-D. ZHU, T.D. PENNING, Y.<br />
LUO, V.L. GIRANDA, S.H. ROSENBERG, D.J. FROST, C.K. DONAWHO (Abbott Park, IL, USA) ............<br />
Dys-synchronous Regulation of XPC and XPA in Trigeminal Ganglion Neurons following Cisplatin<br />
Treatment Cycles. O.W. GUTHRIE (Pittsburgh, PA; Durham, NC, USA)...........................................................<br />
Growth Inhibition of Human MDA-MB-231 Breast Cancer Cells by ‰-Tocotrienol Is Associated with Loss of<br />
Cyclin D1/CDK4 Expression and Accompanying Changes in the State of Phosphorylation of the Retinoblastoma<br />
Tumor Suppressor Gene Product. S. ELANGOVAN, T.-C. HSIEH, J.M. WU (Valhalla, NY, USA)........................<br />
Characterization of Amino Acid Transport System L in HTB-41 Human Salivary Gland Epidermoid<br />
Carcinoma Cells. N.-S. PARK, S.-G. KIM, H.-K. KIM, S.-Y. MOON, C.S. KIM, S.-H. CHO, Y. KANAI,<br />
H. ENDOU, D.K. KIM (Gwangju; South Korea; Osaka; Tokyo, Japan) ...............................................................<br />
Inhibition of LPS-stimulated NO Production in Mouse Macrophage-like Cells by Benzocycloheptoxazines.<br />
K. MIYAHARA, H. MURAYAMA, H. WAKABAYASHI, T. KURIHARA, K. HASHIMOTO,<br />
K.SATOH, N. MOTOHASHI, H. SAKAGAMI (Saitama; Tokyo, Japan)...........................................................<br />
Increased Glutathione Level Is not Involved in Enhanced Bleomycin Sensitivity in Cisplatin-resistant 2780 CP<br />
Cells. T. TANAKA, H. KUROKAWA, K. MATSUNO, S. MATSUMOTO, Y. HAYASHIDA (Kitakyushu;<br />
Oita; Miyazaki, Japan) ...................................................................................................................................................<br />
Up-regulated p27 Kip1 Reduces Matrix Metalloproteinase-9 and Inhibits Invasion of Human Breast Cancer<br />
Cells. M. MIZUMA, Y. KATAYOSE, K. YAMAMOTO, S. SHIRASO, T. SASAKI, S. YABUUCHI, A.<br />
ODA, K. MASUDA, T. RIKIYAMA, T. ONOGAWA, H. OHTSUKA, F. MOTOI, S. EGAWA, M. UNNO<br />
(Sendai, Japan) ...............................................................................................................................................................<br />
Enhanced Suppression of Melanoma Tumor Growth and Metastasis by Combined Therapy with Anti-VEGF<br />
Receptor and Anti-TYRP-1/gp75 Monoclonal Antibodies. D. PATEL, R. BASSI, A.T. HOOPER, H. SUN,<br />
J. HUBER, D.J. HICKLIN, X. KANG (New York, NY , USA)..............................................................................<br />
Variations in Sensitivity to Ionizing Radiation in Relation to p53 Mutation Point. K. OKAICHI, M. IDE-<br />
KANEMATSU, N. IZUMI, N. MORITA, Y. OKUMURA, M. IHARA (Nagasaki, Japan)............................<br />
Inotodiol, a Lanostane Triterpenoid, from Inonotus obliquus Inhibits Cell Proliferation through Caspase-<br />
3-dependent Apoptosis. M. NOMURA, T. TAKAHASHI, A. UESUGI, R. TANAKA, S. KOBAYASHI<br />
(Ishikawa; Osaka, Japan) ..............................................................................................................................................<br />
PGP9.5 Methylation as a Marker for Metastatic Colorectal Cancer. H. MIZUKAMI, A. SHIRAHATA,<br />
T. GOTO, M. SAKATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI<br />
(Yokohama, Japan) ........................................................................................................................................................<br />
2599<br />
2607<br />
2613<br />
2625<br />
2637<br />
2641<br />
2649<br />
2657<br />
2663<br />
2669<br />
2679<br />
2687<br />
2691<br />
2697<br />
4209
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Promotion of the Self-renewal Capacity of Human Acute Leukemia Cells by Wnt3A. N. KAWAGUCHI-<br />
IHARA, I. MUROHASHI, N. NARA, S. TOHDA (Tokyo; Saitama, Japan).....................................................<br />
<strong>Anticancer</strong> Activity of Novel Extracts from Cautleya gracilis (Smith) Dandy: Apoptosis in Human Medullary<br />
Thyroid Carcinoma Cells. Z. LI, S. STURM, B. SVEJDA, H. HÖGER, E. SCHRAML, E. INGOLIC,<br />
V. SIEGL, H. STUPPNER, R. PFRAGNER (Graz; Innsbruck; Himberg, Austria; Shanghai, China) .............<br />
High Serum TIMP-1 is Associated with Adverse Prognosis in Endometrial Carcinoma. M. HONKAVUORI,<br />
A. TALVENSAARI-MATTILA, U. PUISTOLA, T. TURPEENNIEMI-HUJANEN, M. SANTALA (Oulu,<br />
Finland) ...........................................................................................................................................................................<br />
Human Anti-mouse IgM and IgG Responses in Ovarian Cancer Patients after Radioimmunotherapy with<br />
90 Y-muHMFG1. A.L.M. OEI, F.C.G.J. SWEEP, A. GEURTS-MOESPOT, D. VAN TIENOVEN, S. VON<br />
MENSDORFF-POUILLY, C.M.G. THOMAS, L.F.A.G. MASSUGER (Nijmegen; Amsterdam, The<br />
Netherlands) ....................................................................................................................................................................<br />
*<br />
Altered Deoxyribonuclease Activity in Cancer Cells and its Role in Non Toxic Adjuvant Cancer Therapy<br />
with Mixed Vitamins C and K3. H.S. TAPER (Brussels, Belgium).........................................................................<br />
siRNA Inhibition of ER-· Expression Reduces KGF-induced Proliferation of Breast Cancer Cells. X.-P.<br />
ZANG, J.T. PENTO (Oklahoma City, OK, USA).....................................................................................................<br />
Antitumour Properties of Acridone Alkaloids on a Murine Lymphoma Cell Line. B. RÉTHY,<br />
J. HOHMANN, R. MINORICS, A. VARGA, I. OCSOVSZKI, J. MOLNÁR, K. JUHÁSZ, G. FALKAY,<br />
I. ZUPKÓ (Szeged, Hungary; Berlin, Germany) .........................................................................................................<br />
Molecular Analysis of PDGFRA and PDGFRB Genes by Rapid Single-strand Conformation Polymorphism<br />
(SSCP) in Patients with Core-binding Factor Leukaemias with KIT or FLT3 Mutation. A. TROJANI,<br />
C.B. RIPAMONTI, S. PENCO, A. BEGHINI, G. NADALI, E. DI BONA, A. VIOLA, C. CASTAGNOLA,<br />
P. COLAPIETRO, G. GRILLO, L. PEZZETTI, E. RAVELLI, M.C. PATROSSO, A. MAROCCHI,<br />
A. CUNEO, F. FERRARA, M. LAZZARINO, G. PIZZOLO, R. CAIROLI, E. MORRA (Milan; Verona;<br />
Vicenza; Naples; Pavia; Ferrara, Italy) .........................................................................................................................<br />
Cell Cycle Arrest and Apoptosis Responses of Human Breast Epithelial Cells to the Synthetic Organosulfur<br />
Compound p-Methoxyphenyl p-Toluenesulfonate. L. CYR, R. LANGLER, C. LAVIGNE (Moncton;<br />
Sackville, New Brunswick, Canada) .............................................................................................................................<br />
Mepacrine Antagonises Tumour Cell Growth Induced by Natural Polyamines. T. ROSSI, A. COPPI,<br />
E. BRUNI, A. RUBERTO, S. GIUDICE, G. BAGGIO (Modena, Italy) ............................................................<br />
Continuous Administration of the Somatostatin Structural Derivative /TT-232/ by Subcutaneously Implanted<br />
Osmotic Pump Improves the Efficacy and Potency of Antitumor Therapy in Different Mouse and Human<br />
Tumor Models. M. TEJEDA, D. GAAL, L. HULLÁN, O. CSUKA, R. SCHWAB, O. SZOKOLOCZI, G.Y.<br />
KÉRI (Budapest, Hungary)......................................................................................................................................................<br />
Albendazole-Cyclodextrin Complex: Enhanced Cytotoxicity in Ovarian Cancer Cells. M.H. POURGHOLAMI,<br />
K.T. WANGOO, D.L. MORRIS (Sydney, NSW, Australia) ............................................................................................<br />
Cytotoxicity of a Series of Ferrocene-containing ‚-Diketones. J.C. SWARTS, T.G. VOSLOO, S.J. CRONJE,<br />
W.C. (INA) DU PLESSIS, C.E.J. VAN RENSBURG, E. KREFT, J.E. VAN LIER (Bloemfontein; Pretoria,<br />
South Africa; Sherbrooke, QC, Canada)......................................................................................................................<br />
Immunogene Therapy by Adenovirus Vector Expressing CD40 Ligand for Metastatic Liver Cancer in Rats.<br />
K. HANYU, T. IIDA, H. SHIBA, T. OHASHI, Y. ETO, K. YANAGA (Tokyo, Japan)..................................<br />
4210<br />
2701<br />
2705<br />
2715<br />
2721<br />
2727<br />
2733<br />
2737<br />
2745<br />
2753<br />
2765<br />
2769<br />
2775<br />
2781<br />
2785
Diallyl Disulfide (DADS) Induces Apoptosis in Human Cervical Cancer Ca Ski Cells via Reactive Oxygen<br />
Species and Ca 2+ -dependent Mitochondria-dependent Pathway. Y.-T. LIN, J.-S. YANG, S.-Y. LIN, T.-W.<br />
TAN, C.-C. HO, T.-C. HSIA, T.-H. CHIU, C.-S. YU, H.-F. LU, Y.-S. WENG, J.-G. CHUNG (Miaoli;<br />
Taichung; Taipei, Taiwan, ROC)..................................................................................................................................<br />
A Liposomal Delivery Vehicle for the <strong>Anticancer</strong> Agent Gossypol. G. ZHAI, J. WU, X. ZHAO, B. YU,<br />
H. LI, Y. LU, W. YE, Y.C. LIN, R.J. LEE (Jinan, China; Columbus, OH, USA) ..............................................<br />
Methylenetetrahydrofolate Reductase (MTHFR) and Methionine Synthase Reductase (MTRR) Gene<br />
Polymorphisms as Risk Factors for Hepatocellular Carcinoma in a Korean Population. S.Y. KWAK, U.K.<br />
KIM, H.J. CHO, H.K. LEE, H.J. KIM, N.K. KIM, S.G. HWANG (Seongnam; Daegu, South Korea) ............<br />
Overexpression of the Angiogenic Tetrapeptide AcSDKP in Human Malignant Tumors. J.-M. LIU,<br />
M. KUSINSKI, V. ILIC, J. BIGNON, N. HAJEM, J. KOMOROWSKI, K. KUZDAK, H. STEPIEN,<br />
J. WDZIECZAK-BAKALA (Gif-sur-Yvette, France; Lodz, Poland)......................................................................<br />
Chemopreventive Effects of Anastrozole in a Premenopausal Breast Cancer Model. P. KUBATKA,<br />
V. SADLOŇOVÁ, K. KAJO, G. NOSÁ�OVÁ, D. OSTATÍ¡KOVÁ, K. ADAMICOVÁ (Martin; Bratislava,<br />
Slovak Republic) .............................................................................................................................................................<br />
Suprabasal BCL-2 Expression Does Not Sensitize to Chemically-induced Skin Cancer in Transgenic Mice. J.<br />
SCHENKEL, H. WEIHER, G. FÜRSTENBERGER, R. JÄGER (Heidelberg; Rheinbach; Bonn, Germany)......<br />
Impact of Antigen-unloaded Immature Dendritic Cells on Antileukemic T-Cell Cytotoxicity.<br />
U. HARNACK, G. PECHER (Berlin, Germany) .....................................................................................................<br />
Soy Extract Is More Potent than Genistein on Tumor Growth Inhibition. H.-A KIM, K.-S. JEONG, Y.K.<br />
KIM (Mokpo; Daegu, South Korea).............................................................................................................................<br />
* Reviews (pages 2613, 2727)<br />
Number 5B<br />
Clinical Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
*<br />
Interferon Á, a Possible Therapeutic Approach for Late-stage Prostate Cancer? C. HASTIE (Portsmouth,<br />
Hampshire, UK) ..............................................................................................................................................................<br />
Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced<br />
Non-small Cell Lung Cancer. R. TELL, C. SEDERHOLM, C. KLINTENBERG, L. FRANKSSON,<br />
E. BRANDÉN, G. HILLERDAL, U. LÖNN, C.-J. LINDÉN, S.-B. EWERS, K. LAMBERG, E. MRAZEK,<br />
B. LÖDÉN, A. SJÖGREN, T. LINNÉ, S. FRIESLAND, F. SIRZÉN (Stockholm; Linköping; Gävle; Lund;<br />
Västerå s; Karlstad; Bromma, Sweden) .........................................................................................................................<br />
A New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer.<br />
C. MATHELIN, S. SALVADOR, V. BEKAERT, S. CROCE, N. ANDRIAMISANDRATSOA,<br />
P. LIÉGEOIS, E. PRADOS, J.-L. GUYONNET, D. GRUCKER, D. BRASSE (Strasbourg, France) ...........<br />
Bladder and Rectal Toxicity of BeamCath ® Application in Radiotherapy of Prostate Cancer. S. HANSSEN,<br />
J. NORUM (Tromsø, Norway).....................................................................................................................................<br />
Low-grade Endometrial Stromal Sarcoma of the Uterus: Review of 10 Cases. V. LANDRÉAT,<br />
N. PAILLOCHER, L. CATALA, F. FOUCHER, P. DESCAMPS, J. LEVÊQUE (Rennes; Angers, France).....<br />
2791<br />
2801<br />
2807<br />
2813<br />
2819<br />
2825<br />
2831<br />
2837<br />
2843<br />
2851<br />
2859<br />
2865<br />
2869<br />
4211
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Clinical Significance of Total Gastrectomy for Proximal Gastric Cancer. A. OOKI, K. YAMASHITA,<br />
S. KIKUCHI, S. SAKURAMOTO, N. KATADA, N. HUTAWATARI, M. WATANABE (Kanagawa,<br />
Japan) ....................................................................................................................................................................<br />
Surgical Treatment of Intrathyroid Metastases: Preliminary Results of a Multicentric Study. F. CALZOLARI,<br />
P.V. SARTORI, C. TALARICO, D. PARMEGGIANI, E. BERETTA, L. PEZZULLO, G. BOVO,<br />
P. SPERLONGANO, M. MONACELLI, R. LUCCHINI, C. MISSO, A. GURRADO, M. D’AJELLO,<br />
F. UGGERI, E. PUXEDDU, P. NASI, M. TESTINI, L. ROSATO, A. BARBARISI, N. AVENIA (Perugia;<br />
Milan; Catanzaro; Naples; Bari; Turin; Ivrea, Italy).............................................................................................................<br />
Laparoscopic Resection of a Retroperitoneal Ancient Schwannoma: A Case Report and Review of the Literature.<br />
T. YOSHINO, K. YONEDA (Hiroshima, Japan) ....................................................................................................................<br />
*<br />
Morphological and Molecular Profiles and Pathways in Bladder Neoplasms. A. LOPEZ-BELTRAN, L. CHENG,<br />
R. MAZZUCCHELLI, M. BIANCONI, A. BLANCA, M. SCARPELLI, R. MONTIRONI (Cordoba, Spain;<br />
Indianapolis, IN, USA; Ancona, Italy)...........................................................................................................................................<br />
Biweekly Oxaliplatin and Irinotecan Chemotherapy in Advanced Gastric Cancer. A First-line Multicenter Phase<br />
II Trial of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). E. WÖLL, T. KÜHR,<br />
W. EISTERER, K. GATTRINGER, R. GREIL, A. ZABERNIGG, W. HILBE, J. THALER (Zams; Wels;<br />
Innsbruck; Kufstein; Salzburg, Austria)..........................................................................................................................................<br />
A New Diagnostic Method for Early Gastric Cancer: Volume Measurement by 3-Dimensional Endoscopic<br />
Ultrasonography in Early Gastric Cancer and Its Clinical Significance. N. FUTAWATARI, S. KIKUCHI,<br />
S. SAKURAMOTO, M. KIDA, M. WATANABE (Kanagawa, Japan) .............................................................................<br />
Myelotoxicity as a Prognostic Factor in Patients with Advanced Breast Cancer Treated with Chemotherapy:<br />
A Pooled Analysis of Two Randomised Trials Conducted by The Hellenic Cooperative Oncology Group.<br />
A.K. KOUTRAS, G. FOUNTZILAS, U. DAFNI, M.A. DIMOPOULOS, D. PECTASIDES, G. KLOUVAS,<br />
P. PAPAKOSTAS, P. KOSMIDIS, E. SAMANTAS, H. GOGAS, E. BRIASOULIS, G. VOURLI, T. PETSAS,<br />
N. XIROS, H.P. KALOFONOS; HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCoG) (Patras;<br />
Athens; Thessaloniki; Ioannina, Greece).......................................................................................................................................<br />
Antitumor Activity and Some Immunological Properties of Á‰ T-Cells from Patients with Gastrointestinal<br />
Carcinomas. M. MURAYAMA, Y. TANAKA, J. YAGI, T. UCHIYAMA, K. OGAWA (Tokyo; Kyoto, Japan)..<br />
Phase I Study of Irinotecan Combined with Mitomycin-C and 5-Fluorouracil for Gynecological Malignancies: The<br />
JGOG study. K. KOKAWA, N. UMESAKI, K. YAMAMOTO, K. TAKIZAWA, I. KONISHI, K. HASEGAWA<br />
(Wakayama; Sakai; Tokyo; Matsumoto; Hyogo, Japan) ............................................................................................................<br />
Polymorphisms of the DNA Repair Genes XRCC1 and XRCC3 and Risk of Lung and Colorectal Cancer: A Case-<br />
Control Study in a Southern Italian Population. G. IMPROTA, A. SGAMBATO, G. BIANCHINO, A. ZUPA,<br />
V. GRIECO, G. LA TORRE, A. TRAFICANTE, A. CITTADINI (Potenza; Rome, Italy).........................................<br />
Clinical Utility of a Combination of Tumour Markers in the Diagnosis of Malignant Pleural Effusions.<br />
M.J. GASPAR, J. DE MIGUEL, J.D. GARCÍA DÍAZ, M. DÍEZ (Madrid, Spain) ......................................................<br />
Report of Two Cases of Quintuple Primary Malignancies and Review of the Literature. M.C. CERCATO,<br />
E. COLELLA, V. FERRARESI, M.G. DIODORO, R. TONACHELLA (Rome, Italy) ............................................<br />
Immunohistochemical Evaluation of Metallothionein, Mcm-2 and Ki-67 Antigen Expression in Tumors of<br />
the Adrenal Cortex. A. SZAJERKA, P. DZIEGIEL, T. SZAJERKA, M. ZABEL, J. WINOWSKI,<br />
Z. GRZEBIENIAK (Wroclaw; Poznan, Poland).......................................................................................................<br />
4212<br />
2875<br />
2885<br />
2889<br />
2893<br />
2901<br />
2907<br />
2913<br />
2921<br />
2933<br />
2941<br />
2947<br />
2953<br />
2959
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Positive Correlation between Cyclooxygenase 2 and the Expression of ABC Transporters in Non-small Cell Lung<br />
Cancer. P. SUROWIAK, K. PAWEŁCZYK, A. MACIEJCZYK, M. PUDEŁKO, J. KOŁODZIEJ, M. ZABEL,<br />
D. MURAWA, M. DRAG, T. GANSUKH, M. DIETEL, H. LAGE (Berlin, Germany; Wrocław; Poznań, Poland;<br />
Ulan Bator, Mongolia; La Jolla, CA, USA) ..................................................................................................................................<br />
Activated p38-MAPK and Gemcitabine Sensitivity in Recurrent Ovarian Cancer. R. KLOTZ, A.G. ZEIMET,<br />
D. REIMER, E. MÜLLER-HOLZNER, M. CHAMSON, C. MARTH (Innsbruck, Austria).....................................<br />
TUNEL as a Tumor Marker of Tongue Cancer. O. BEN-IZHAK, Z. LASTER, S. AKRISH, G. COHEN,<br />
R.M. NAGLER (Haifa; Poriya, Tiberias, Israel)........................................................................................................................<br />
Oxaliplatin-eluting Microspheres for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Report.<br />
G. POGGI, P. QUARETTI, C. MINOIA, I. PALUMBO, L. VILLANI, A. AMATU, C. TERAGNI, M. SCELSI,<br />
F. ZAPPOLI, G. BERNARDO (Pavia, Italy) ...........................................................................................................................<br />
Expression and Prognostic Significance of PDCD4 in Human Epithelial Ovarian Carcinoma. X. WANG, Z. WEI,<br />
F. GAO, X. ZHANG, C. ZHOU, F. ZHU, Q. WANG, Q. GAO, C. MA, W. SUN, B. KONG, L. ZHANG (Jinan,<br />
Shandong, P. R. China)....................................................................................................................................................................<br />
*<br />
The Role of Podoplanin in Tumor Progression and Metastasis. M. RAICA, A.M. CIMPEAN, D. RIBATTI<br />
(Timisoara, Romania; Bari, Italy)...................................................................................................................................................<br />
Occult Prostate Cancer Effects the Results of Case-Control Studies Due to Verification Bias. T. IGUCHI,<br />
C.Y. WANG, N.B. DELONGCHAMPS, R. SUNHEIMER, T. NAKATANI, G. DE LA ROZA, G.P. HAAS<br />
(Syracuse, NY, USA; Osaka, Japan)...............................................................................................................................................<br />
Pleomorphic Adenoma of Salivary Glands Does Not Appear to Be a BRCA-1-dependent Tumour in a Polish<br />
Cohort. J. LUBIŃSKI, C. TARNOWSKA, E. JAWOROWSKA, T. BYRSKI, A. JAKUBOWSKA, B. GÓRSKI,<br />
S. BIEŃ, J. SYGUT, S. GÓŹDŹ, M. SIOŁEK, M. SULIKOWSKI, J. LUBIŃSKI (Szczecin; Kielce, Poland)..........<br />
Validation of the Graded Prognostic Assessment <strong>Index</strong> for Surgically Treated Patients with Brain Metastases.<br />
C. NIEDER, H. GEINITZ, M. MOLLS (Bodø; Tromsø, Norway; Munich, Germany)...................................................<br />
Gefitinib in Combination with Gemcitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pre-treated<br />
with Taxane and Anthracycline Chemotherapy: A Phase I/II Trial. I. GIOULBASANIS, Z. SARIDAKI,<br />
A. KALYKAKI, L. VAMVAKAS, K. KALBAKIS, M. IGNATIADIS, K. AMARANTIDIS, S. KAKOLYRIS,<br />
V. GEORGOULIAS, D. MAVROUDIS (Heraklion, Alexandroupolis, Greece) ..............................................................<br />
ProGRP and NSE in Therapy Monitoring in Patients with Small Cell Lung Cancer. E. WÓJCIK, J.K. KULPA,<br />
B. SAS-KORCZYŃSKA, S. KORZENIOWSKI, J. JAKUBOWICZ (Cracow, Poland)...............................................<br />
Hypofractionated Accelerated Radiotherapy, Cytoprotection and Capecitabine in the Treatment of Rectal Cancer:<br />
A Feasibility Study. M.I. KOUKOURAKIS, C. SIMOPOULOS, M. PITIAKOUDIS, N. LYRATZOPOULOS,<br />
K. ROMANIDIS, A. GIATROMANOLAKI, A. POLYCHRONIDIS, G. KOUKLAKIS, E. SIVRIDIS,<br />
G. MINOPOULOS, K. MANOLAS (Alexandroupolis, Greece)............................................................................................<br />
Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced<br />
and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature. I. ASMANE,<br />
V. LITIQUE, S. HEYMANN, L. MARCELLIN, A.-C. MÉTIVIER, B. DUCLOS, J.-P. BERGERAT,<br />
J.-E. KURTZ (Strasbourg, France) ...............................................................................................................................................<br />
Breast Metastasis 56 Months before the Diagnosis of Primary Ovarian Cancer: A Case Study. S.E. SCHNEUBER,<br />
H.S. SCHOLZ, P. REGITNIG, E. PETRU, R. WINTER (Graz, Austria) .......................................................................<br />
2967<br />
2975<br />
2981<br />
2987<br />
2991<br />
2997<br />
3007<br />
3011<br />
3015<br />
3019<br />
3027<br />
3035<br />
3041<br />
3047<br />
4213
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Toxic Encephalopathy and Delayed MTX Clearance after High-dose Methotrexate Therapy in a Child<br />
Homozygous for the MTHFR C677T Polymorphism. J. MÜLLER, J. KRALOVÁNSZKY, V. ADLEFF, É. PAP,<br />
K. NÉMETH, V. KOMLÓSI, G. KOVÁCS (Budapest, Hungary) .......................................................................................<br />
Gemcitabine and Protracted 5-Fluorouracil Infusion as Third-line Chemotherapy in Refractory Colorectal Cancer<br />
Patients. R. BITOSSI, C.M. SCULLI, M. TAMPELLINI, I. ALABISO, M.P. BRIZZI, A. FERRERO,<br />
A. OTTONE, E. BELLINI, G. GORZEGNO, A. BERRUTI, L. DOGLIOTTI (Orbassano, Torino, Italy) ...........<br />
Procalcitonin as a Useful Marker of Infection in Hemato-oncological Patients with Fever. M.T. SANDRI,<br />
R. PASSERINI, M.E. LEON, F.A. PECCATORI, L. ZORZINO, M. SALVATICI, D. RIGGIO,<br />
C. CASSATELLA, S. CINIERI, G. MARTINELLI (Milan; Brindisi, Italy) .....................................................................<br />
Evaluation of a Manual ELISA Kit for Determination of HER2/neu in Serum of Breast Cancer Patients. ANNE-<br />
SOPHIE GAUCHEZ, NADIA RAVANEL, DANIÈLE VILLEMAIN, FRAN∏OIS-XAVIER BRAND,<br />
DOMINIQUE PASQUIER, RAOUL PAYAN, MIREILLE MOUSSEAU (Grenoble; Saint-Martin d’Hères,<br />
France).................................................................................................................................................................................................<br />
Evaluation of Fixed Dosing of New <strong>Anticancer</strong> Agents in Phase I Studies. D. LEVÊQUE (Strasbourg, France)....<br />
Association Between Genetic Polymorphisms and Ovarian Cancer Risk. L. DELORT, N. CHALABI, S. SATIH,<br />
N. RABIAU, F. KWIATKOWSKI, Y.-J. BIGNON, D.J BERNARD-GALLON (Clermont-Ferrand; France).......<br />
Primary Uterine Leiomyosarcoma and Primary Atypical Meningioma Diagnosed during Pregnancy. B. BODNER-<br />
ADLER, P. LOZANO, K. BODNER, H. ZEISLER (Vienna, Austria).............................................................................<br />
Bevacizumab Added to the Irinotecan and Capecitabine Combination for Advanced Colorectal Cancer: A Welltolerated,<br />
Active and Convenient Regimen. A. ARDAVANIS, P. KOUNTOURAKIS, I. MANTZARIS,<br />
S. MALLIOU, D. DOUFEXIS, D. SYKOUTRI, I. FRAGOS, G. RIGATOS (Athens, Greece)................................<br />
Neoadjuvant Chemotherapy with Vinorelbine-containing Regimens in Elderly Patients with Locally Advanced<br />
Breast Cancer. C.-D. MA, C.-M. CHEN, X.-S. CHEN, G.-Y. LIU, G.-H. DI, J. WU, J.-S. LU, W.-T. YANG,<br />
J.-Y. CHEN, Z.-M. SHAO, Z.-Z. SHEN, K.-W. SHEN (Shanghai, P.R. China) .............................................................<br />
Safety of Nab-paclitaxel plus Sunitinib: Analysis of Three Cases. A.Z. DUDEK, S. NGUYEN (Minneapolis, MN,<br />
USA).....................................................................................................................................................................................................<br />
Von Recklinghausen’s Disease Associated with Malignant Peripheral Nerve Sheath Tumor Presenting with<br />
Constipation and Urinary Retention: A Case Report and Review of the Literature. P. KARATZOGLOU,<br />
A. KARAGIANNIDIS, J. KOUNTOURAS, C.V. CHRISTOFIRIDIS, M. KARAVALAKI, C. ZAVOS,<br />
E. GAVALAS, K. PATSIAOURA, N. VOUGIOUKLIS (Thessaloniki, Greece)............................................................<br />
Fatal Thrombocytopenia after Oxaliplatin-based Chemotherapy. Y.-Y. SHAO, R.-L. HONG (Taipei, Taiwan,<br />
ROC)....................................................................................................................................................................................................<br />
Protective Effect of Cox-2 Allelic Variants on Risk of Colorectal Adenoma Development in African Americans.<br />
H. ASHKTORAB, S. TSANG, B. LUKE, Z. SUN, L. ADAM-CAMPBELL, J. KWAGYAN, R. POIRIER,<br />
S. AKTER, A. AKHGAR, D. SMOOT, D.J. MUNROE, I.U. ALI (Washington, DC; Frederick, MD; Bethesda,<br />
MD, USA) ...........................................................................................................................................................................................<br />
Telomerase Activity in Head and Neck Cancer. Z. KUNICKÁ, I. MUCHA, J. FAJKUS (Brno, Czech Republic) .....<br />
Endocervical Cytobrush for the Detection of Cervical Dysplasia Before Large Loop Excision of the<br />
Transformation Zone (LLETZ). C. TEMPFER, S. POLTERAUER, C. GRIMM, E.-K. BENTZ,<br />
A. REINTHALLER, L.A. HEFLER (Vienna, Austria)..........................................................................................................<br />
4214<br />
3051<br />
3055<br />
3061<br />
3067<br />
3075<br />
3079<br />
3083<br />
3087<br />
3093<br />
3099<br />
3107<br />
3115<br />
3119<br />
3125<br />
3131
*<br />
Ovarian Cancer Detection and Treatment: Current Situation and Future Prospects. M. ARGENTO,<br />
P. HOFFMAN, A.-S. GAUCHEZ (Grenoble; La Tronche, France)....................................................................................<br />
High-dose Chemotherapy with Autologous Stem Cell Rescue in Stage IIIB Inflammatory Breast Cancer.<br />
K. YALAMANCHILI, J. LALMUANPUII, F. WAHEED, S. FARJAMI, R. KANCHERLA, Z. QURESHI,<br />
A. HOANG, Y. KHALED, D. LAKE, C. PUCCIO, H.G. CHUN, K. SEITER, T. AHMED (Valhalla; New York;<br />
Poughkeepsie, NY; Washington, DC, USA) ..................................................................................................................................<br />
Concurrent Radiotherapy, Paclitaxel and Dose Escalating Carboplatin in the Treatment of Cervical Cancer –<br />
A Phase I Study. D. ADDEO, S. BLANK, F. MUGGIA, S. FORMENTI (New York, NY, USA)..............................<br />
Invasive Breast Cancer Treated with Taxol and Epirubicin Neo-adjuvant Chemotherapy: The Role in the Outcome<br />
of the “Crosstalk” between Erb Receptors and p53. D. SARID, I.G. RON, L. SHOSHAN, I. BARNEA,<br />
S. SHINA, M. BARATZ, J. GREENBERG, O. MERIMSKY, R. BEN-YOSEF, S. LEV-ARI, Y. KEIDAR,<br />
N. YAAL-HAHOSHEN (Tel Aviv; Petach Tikva, Israel)........................................................................................................<br />
Diagnostic Procedures for Small Pulmonary Nodules Detected by Mass-screening. K. KANEMOTO, H. SATOH,<br />
H. ISHIKAWA, K. KAGOHASHI, K. KURISHIMA, K. SEKIZAWA (Tsukuba, Ibaraki, Japan)...........................<br />
* Reviews (pages 2843, 2893, 2997, 3135)<br />
Number 5C<br />
Abstracts of the Eighth International Conference of <strong>Anticancer</strong> <strong>Research</strong><br />
October 17-22, 2008, Kos, Greece<br />
Number 6A<br />
Experimental Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
The Impact of Enzymatic Degradation on the Uptake of Differently Sized Therapeutic Molecules.<br />
A. ERIKSON, I. TUFTO, A.B. BJØNNUM, Ø.S. BRULAND, C. DE LANGE DAVIES (Trondheim; Oslo,<br />
Norway) ...................................................................................................................................................................<br />
Alpha-folate Receptor Expression in Epithelial Ovarian Carcinoma and Non-neoplastic Ovarian Tissue.<br />
S. MARKERT, S. LASSMANN, B. GABRIEL, M. KLAR, M. WERNER, G. GITSCH, F. KRATZ,<br />
A. HASENBURG (Freiburg, Germany) ................................................................................................................<br />
*<br />
Identification of Parental Chromosomes Involved in Translocations BCR-ABL, t(9;22) and PML-RARA,<br />
t(15;17). J.P. CHAUDHURI, S. KARAMANOV, P. PAULRAJ, J.R. MCGILL, J.-U. WALTHER (München,<br />
Germany; Phoenix, AZ , USA)................................................................................................................................<br />
Role of Caspases in 5-FU and Selenium-induced Growth Inhibition of Colorectal Cancer Cells. A.A. THANT, Y.<br />
WU, J. LEE, D.K. MISHRA, H. GARCIA, H.P. KOEFFLER, J.V. VADGAMA (Los Angeles, CA, USA) ...........<br />
Pioglitazone, a Ligand for Peroxisome Proliferator-activated Receptor-γ Acts as an Inhibitor of Colon Cancer<br />
Liver Metastasis. S. TAKANO, T. KUBOTA, H. NISHIBORI, H. HASEGAWA, Y. ISHII, N. NITORI,<br />
H. OCHIAI, K. OKABAYASHI, Y. KITAGAWA, M. WATANABE, M. KITAJIMA (Tokyo, Japan) ...............<br />
3135<br />
3139<br />
3143<br />
3147<br />
3153<br />
3157<br />
3557<br />
3567<br />
3573<br />
3579<br />
3593<br />
4215
*<br />
*<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Radioprotection of Murine Gastrointestinal Epithelium by Interleukin-1α Involves Down-regulation of the<br />
Apoptotic Response. R.M. JOHNKE, E.S. SMITH, M.J. CARIVEAU, M.J. EVANS, J.M. KILBURN, N.T.G.<br />
BAKKEN, G.N. NANGAMI (Greenville, NC, USA)............................................................................................<br />
Genomic Profile of Colon Cancer Metastases. G. ZEITOUN, N. MOURRA, H. BLANCHÉ-KOCH, G. THOMAS,<br />
S. OLSCHWANG (Mantes-la-Jolie; Paris; Marseille, France; Gaithersburg, MD, USA)...........................................<br />
PTEN Mutation: Many Birds with One Stone in Tumorigenesis. W. LIU, Y. ZHOU, S.N. RESKE, C. SHEN<br />
(Huaihua, China; Heidelberg; Ulm, Germany; Memphis, TN, USA) ...................................................................<br />
Exploitation of the Notch Signaling Pathway as a Novel Target for Cancer Therapy. Z. WANG, Y. LI,<br />
S. BANERJEE, F.H. SARKAR (Detroit, MI, USA)..............................................................................................<br />
Dietary Sphingomyelin Inhibits Colonic Tumorigenesis with an Up-regulation of Alkaline Sphingomyelinase<br />
Expression in ICR Mice. P. ZHANG, B. LI, S. GAO, R.-D. DUAN (Harbin, China; Lund, Sweden) .............<br />
Combined Oncolytic Virotherapy with Herpes Simplex Virus for Oral Squamous Cell Carcinoma. F. OGAWA,<br />
H. TAKAOKA, S. IWAI, K. AOTA, Y. YURA (Osaka, Japan) ...........................................................................<br />
*<br />
The Guggul for Chronic Diseases: Ancient Medicine, Modern Targets. S. SHISHODIA, K.B. HARIKUMAR,<br />
S. DASS, K.G. RAMAWAT, B.B. AGGARWAL (Houston, TX, USA; Udaipur, India) .....................................<br />
New Method for Separation of Subpopulations from a Heterogeneous Colon Cancer Cell Line. Y. TAKAYA,<br />
K. TANAKA, C. HIRAKAWA, Y. TAGAWA, M. NIWA (Nagasaki, Japan)......................................................<br />
Green Tea Catechin Inhibits Fatty Acid Synthase without Stimulating Carnitine Palmitoyltransferase-1 or<br />
Inducing Weight Loss in Experimental Animals. T. PUIG, J. RELAT, P.F. MARRERO, D. HARO,<br />
J. BRUNET, R. COLOMER (Girona; Barcelona; Madrid, Spain) ......................................................................<br />
Antiproliferative Property and Apoptotic Effect of Xanthorrhizol on MDA-MB-231 Breast Cancer Cells.<br />
Y.H. CHEAH, F.J. NORDIN, T.T. TEE, H.L.P. AZIMAHTOL, N.R. ABDULLAH, Z. ISMAIL (Kuala<br />
Lumpur; Bangi, Selangor, Malaysia) .....................................................................................................................<br />
Radioiodinated Methylene Blue – A Promising Agent for Melanoma Scintigraphy: Labelling, Stability and In<br />
Vitro Uptake by Melanoma Cells. G. SOBAL, M. RODRIGUES, H. SINZINGER (Vienna, Austria) .............<br />
Association of Polymorphisms of NOD2, TLR4 and CD14 Genes with Susceptibility to Gastric Mucosaassociated<br />
Lymphoid Tissue Lymphoma. F. TÜRE-ÖZDEMIR, M. GAZOULI, M. TZIVRAS, C. PANAGOS,<br />
N. BOVARETOS, K. PETRAKI, A. GIANNAKOPOULOS, P. KORKOLOPOULOU, G.J. MANTZARIS<br />
(Istanbul, Turkey; Athens; Karditsa, Greece).........................................................................................................<br />
Noscapine Inhibits Human Prostate Cancer Progression and Metastasis in a Mouse Model. I. BARKEN,<br />
J. GELLER, M. ROGOSNITZKY (La Mesa; San Diego, CA, USA; Telz Stone, Israel) ....................................<br />
Zapotin Prevents Mouse Skin Tumorigenesis During the Stages of Initiation and Promotion. M. CUENDET, C.P.<br />
OTEHAM, A. MAITI, B.A. CRAIG, M. CUSHMAN, R.C. MOON, J.M. PEZZUTO (West Lafayette, IN, USA)...<br />
Lack of Involvement of the GNAS1 T393C Polymorphism in Prostate Cancer Risk in a Japanese Population.<br />
M. WATANABE, Y. HIROKAWA, M. TSUJI, M. YANAGAWA, T. MURATA, H. SUZUKI, T. ICHIKAWA,<br />
T. KATOH, Y. SUGIMURA, T. SHIRAISHI (Tsu;Yokohama; Kumamoto; Matsusaka; Suzuka; Chiba, Japan)......<br />
Omega-3 Fatty Acids Suppress Growth of SW620 Human Colon Cancer Xenografts in Nude Mice.<br />
T.F. BATHEN, K. HOLMGREN, A.G. LUNDEMO, M.H. HJELSTUEN, H.E. KROKAN, I.S. GRIBBESTAD,<br />
S.A. SCHØNBERG (Trondheim; Stavanger, Norway)..........................................................................................<br />
Epidermal Growth Factor Receptor Pathway Gene Expressions and Biological Response of Glioblastoma<br />
Multiforme Cell Lines to Erlotinib. M.-E. HALATSCH, S. LÖW, T. HIELSCHER, U. SCHMIDT,<br />
A. UNTERBERG, V.I. VOUGIOUKAS (Heidelberg; Freiburg, Germany) ........................................................<br />
4216<br />
3601<br />
3609<br />
3613<br />
3621<br />
3631<br />
3637<br />
3647<br />
3665<br />
3671<br />
3677<br />
3691<br />
3697<br />
3701<br />
3705<br />
3711<br />
3717<br />
3725
*<br />
Pathogenetic Pathways Leading to Glioblastoma Multiforme: Association between Gene Expressions and<br />
Resistance to Erlotinib. S. LÖW, V.I. VOUGIOUKAS, T. HIELSCHER, U. SCHMIDT, A. UNTERBERG,<br />
M.-E. HALATSCH (Heidelberg; Freiburg, Germany)..........................................................................................<br />
Genotypic Determination by PCR-RFLP of Human Papillomavirus in Normal Oral Mucosa, Oral Leukoplakia<br />
and Oral Squamous Cell Carcinoma Samples in Madrid (Spain). S. LLAMAS-MARTÍNEZ, G. ESPARZA-<br />
GÓMEZ, J. CAMPO-TRAPERO, P. CANCELA-RODRÍGUEZ, A. BASCONES-MARTÍNEZ, L.A. MORENO-<br />
LÓPEZ, J.A. GARCÍA-NÚÑEZ, R. CERERO-LAPIEDRA (Madrid, Spain) ...........................................................<br />
The Endocannabinoid Anandamide Neither Impairs In Vitro T-Cell Function Nor Induces Regulatory T-Cell<br />
Generation. P. LISSONI, A. TINTORI, L. FUMAGALLI, F. BRIVIO, G. MESSINA, D. PAROLINI,<br />
A. BIONDI, A. BALESTRA, G. D’AMICO (Monza, Italy) ................................................................................<br />
SUMO-1 Overexpression Increases RbAp46 Protein Stability and Suppresses Cell Growth. R. GIRI, H.-H. YEH,<br />
C.-H. WU, H.-S. LIU (Tainan, Taiwan, ROC) ...............................................................................................................<br />
Inhibition of Hepatocellular Cancer by EB1089: In Vitro and In Vivo Study. Z. GHOUS, J. AKHTER, M.H.<br />
POURGHOLAMI, D.L. MORRIS (Sydney, NSW, Australia)...............................................................................<br />
Expression of Mcm7 and Cdc6 in Oral Squamous Cell Carcinoma and Precancerous Lesions. C.-J. FENG,<br />
H.-J. LI, J.-N. LI, Y.-J. LU, G.-Q. LIAO (Guangzhou, China) ...........................................................................<br />
Correspondence between Flat Aberrant Crypt Foci and Mucin-depleted Foci in Rodent Colon Carcinogenesis. A.P.<br />
FEMIA, J.E. PAULSEN, P. DOLARA, J. ALEXANDER, G. CADERNI (Florence, Italy; Oslo, Norway) .............<br />
Berberine Inhibits Human Neuroblastoma Cell Growth through Induction of p53-dependent Apoptosis. M.S.<br />
CHOI, D.Y. YUK, J.H. OH, H.Y. JUNG, S.B. HAN, D.C. MOON, J.T. HONG (Chungbuk, South Korea) ..........<br />
Effects of 5-Fluorouracil on Human Mitogen-activated Peripheral Blood Lymphocytes from Healthy<br />
Individuals. A. EISENTHAL, K. EYTAN, E. BRAZOWSKI, B.-Z. KATZ, I. SHIRAZI, Y. SKORNICK (Tel<br />
Aviv, Israel) ..............................................................................................................................................................<br />
p53, p16 and Fhit Proteins Expressions in Chronic Esophagitis and Chagas Disease. M.F. BELLINI,<br />
K. RAMOS M. LEITE, P.M. CURY, A.E. SILVA (São José do Rio Preto; São Paulo, SP, Brazil) ..................<br />
mTOR Inhibition Sensitizes Gastric Cancer to Alkylating Chemotherapy In Vivo. D. CEJKA, M. PREUSSER,<br />
T. FUEREDER, W. SIEGHART, J. WERZOWA, S. STROMMER, V. WACHECK (Vienna, Austria) .............<br />
A Novel Approach for Gene Transduction with Adenovirus Vector and the Fibrin Glue System.<br />
M. SAKURAI, T. MISAWA, H. SHIBA, T. IIDA, T. OHASHI, K. YANAGA (Tokyo, Japan) .........................<br />
The E-Cadherin Adhesion Molecule and Colorectal Cancer. A Global Literature Approach. E. TSANOU, D.<br />
PESCHOS, A. BATISTATOU, A. CHARALABOPOULOS, K. CHARALABOPOULOS (Ioannina, Greece) ......<br />
p38α-Selective MAP Kinase Inhibitor Reduces Tumor Growth in Mouse Xenograft Models of Multiple<br />
Myeloma. S. MEDICHERLA, M. REDDY, J.Y. MA, T.A. NAVAS, L. LI, A.N. NGUYEN, I. KERR,<br />
N. HANJARAPPA, A.A. PROTTER, L.S. HIGGINS (Fremont, CA, USA) ........................................................<br />
*<br />
Reviews (pages 3573, 3613, 3621, 3647, 3815)<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
3729<br />
3733<br />
3743<br />
3749<br />
3757<br />
3763<br />
3771<br />
3777<br />
3785<br />
3793<br />
3801<br />
3809<br />
3815<br />
3827<br />
4217
Number 6B<br />
Clinical Studies<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Transhepatic Arterial Chemoembolization with Oxaliplatin-eluting Microspheres (OEM-TACE) for Unresectable<br />
Hepatic Tumors. G. POGGI, P. QUARETTI, C. MINOIA, G. BERNARDO, M.R. BONORA, R. GAGGERI, A.<br />
RONCHI, C.M. SALUZZO, A. AZZARETTI, G. RODOLICO, M. MONTAGNA, A. AMATU, C. TERAGNI,<br />
I. PALUMBO, E. TRAVERSO, S. TONINI, L. VILLANI, M. SCELSI, P. BAIARDI, M.G. FELISI, F.<br />
SOTTOTETTI, B. TAGLIAFERRI, A. RICCARDI (Pavia, Italy) ............................................................................<br />
Evaluation of a Powered Intraosseous Device for Bone Marrow Sampling. S.C. COHEN, J.M. GORE (San<br />
Antonio, TX, USA)...................................................................................................................................................<br />
Ameloblastic Carcinoma of the Maxillary Sinus. F. ANGIERO, R. BORLONI, M. MACCHI, M. STEFANI<br />
(Monza; Milan, Italy) ..............................................................................................................................................<br />
Efficacy of Amrubicin for Non-small Cell Lung Cancer after Failure of Two or More Prior Chemotherapy<br />
Regimens. S. IGAWA, T. TAKAHASHI, Y. NAKAMURA, A. TSUYA, A. ONO, T. SHUKUYA, H.<br />
MURAKAMI, M. ENDO, N. YAMAMOTO (Shizuoka, Japan)..........................................................................<br />
Prognostic Significance of Dysadherin and E-cadherin Expression in Patients with Head and Neck Cancer<br />
Treated by Radiation Therapy. H. MURAMATSU, T. AKIMOTO, K. MAEBAYASHI, M. KITA, N.<br />
MITSUHASHI (Tokyo; Kiryu; Huchu, Japan) ......................................................................................................<br />
VEGF-1 Expression in Colorectal Cancer is Associated with Disease Localization, Stage, and Long-term<br />
Disease-specific Survival. R. BENDARDAF, A. BUHMEIDA, M. HILSKA, M. LAATO, S. SYRJÄNEN, K.<br />
SYRJÄNEN, Y. COLLAN, S. PYRHÖNEN (Turku, Finland) ............................................................................<br />
CO 2 Laser Cylindrical Excision or Standard Re-conization for Persistent-recurrent High-grade Cervical<br />
Intraepithelial Neoplasia (HG-CIN) in Women of Fertile Age. M. FAMBRINI, C. PENNA, A. PIERALLI, M.G.<br />
FALLANI, K.L. ANDERSSON, V. LOZZA, G. SCARSELLI, M. MARCHIONNI (Florence, Italy)......................<br />
*<br />
High Hydrostatic Pressure, a Novel Approach in Orthopedic Surgical Oncology to Disinfect Bone, Tendons<br />
and Cartilage. P. DIEHL, J. SCHAUWECKER, W. MITTELMEIER, M. SCHMITT (Rostock; Muenchen,<br />
Germany) .................................................................................................................................................................<br />
Perioperative High-dose Rate Brachytherapy Using a Bendy Applicator (Flab): Treatment Results of 74<br />
Patients. T. BÖLLING, P. SCHÜLLER, B. DISTELMAIER, A. SCHUCK, I. ERNST, G. GOSHEGER, W.<br />
WINKELMANN, U. DIRKSEN, H. JÜRGENS, H.-L. KRONHOLZ, N. WILLICH, S. KÖNEMANN<br />
(Münster, Germany) ................................................................................................................................................<br />
Prostate Cancer – Are Ethnic Minorities Disadvantaged? D.S. LAMB, O. BUPHA-INTR, P. BETHWAITE,<br />
J. MURRAY, J. NACEY, G. RUSSELL, B. DELAHUNT (Wellington, New Zealand) ......................................<br />
Serological Thymidine Kinase 1 (STK1) Indicates an Elevated Risk for the Development of Malignant<br />
Tumours. Z. CHEN, H. ZHOU, S. LI, E. HE, J. HU, J. ZHOU, S. SKOG (ChangSha; Shenzhen, P.R. China;<br />
Stockholm, Sweden).................................................................................................................................................<br />
Autopsy Evaluation of a Prostate Cancer Case Treated with Brachytherapy. A. SHAPIRO, O. SHAPIRO,<br />
N.B. DELONGCHAMPS, J.A. BOGART, G.P. HAAS, G. DE LA ROSA (Syracuse, NY, USA; Paris,<br />
France) ...........................................................................................................................................................<br />
Reduction of Irradiation Volume and Toxicities with 3-D Radiotherapy Planning over Conventional<br />
Radiotherapy for Prostate Cancer Treated with Long-term Hormonal Therapy. H. YAMAZAKI, K.<br />
NISHIYAMA, E. TANAKA, O. MAEDA, N. MEGURO, T. KINOUCHI, M. USAMI, K. KAKIMOTO, Y.<br />
ONO, T. NISHIMURA (Kyoto; Osaka, Japan).....................................................................................................<br />
4218<br />
3835<br />
3843<br />
3847<br />
3855<br />
3859<br />
3865<br />
3871<br />
3877<br />
3885<br />
3891<br />
3897<br />
3909<br />
3913
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
ABCB1 Gene Polymorphisms and Expression of P-glycoprotein and Long-term Prognosis in Colorectal<br />
Cancer. S. DE IUDICIBUS, A. DE PELLEGRIN, G. STOCCO, F. BARTOLI, R. BUSSANI, G. DECORTI<br />
(Trieste, Italy) ..........................................................................................................................................................<br />
Value of High-dose Radiation Therapy for Isolated Osseous Metastasis in Breast Cancer in Terms of Oligorecurrence.<br />
Y. NIIBE, M. KURANAMI, K. MATSUNAGA, M. TAKAYA, S. KAKITA, T. HARA, K.<br />
SEKIGUCHI, M. WATANABE, K. HAYAKAWA (Kanagawa; Tokyo, Japan)...................................................<br />
ERC/Mesothelin as a Marker for Chemotherapeutic Response in Patients with Mesothelioma. K. TAJIMA, M.<br />
HIRAMA, K. SHIOMI, T. ISHIWATA, M. YOSHIOKA, A. IWASE, S. IWAKAMI, M. YAMAZAKI, M.<br />
TOBA, K. TOBINO, K. SUGANO, M. ICHIKAWA, Y. HAGIWARA, K. TAKAHASHI, O. HINO (Tokyo;<br />
Shizuoka; Gunma, Japan) .......................................................................................................................................<br />
Enzyme Replacement Therapy for Gaucher’s Disease in Patient Treated for Non-small Cell Lung Cancer.<br />
J.P. LEONE, A.Z. DUDEK (Minneapolis, MN, USA) ..........................................................................................<br />
Conservative Approach to Preneoplastic Cervical Lesions in Postmenopause. G. VETRANO, V. ALEANDRI,<br />
P. CIOLLI, P. SCARDAMAGLIA, A. PACCHIAROTTI, M. VERRICO, S. CARBONI, R. COROSU (Rome,<br />
Italy).........................................................................................................................................................................<br />
*<br />
Circulating Tumor Cells in Colorectal Cancer: Detection Methods and Clinical Significance. A. TSOUMA, C.<br />
AGGELI, N. PISSIMISSIS, P. LEMBESSIS, G.N. ZOGRAFOS, M. KOUTSILIERIS (Athens, Greece).............<br />
First Safety and Response Results of a Randomized Phase III Study with Liposomal Platin in the Treatment of<br />
Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). C.F. JEHN, T. BOULIKAS, A.<br />
KOURVETARIS, G. KOFLA, K. POSSINGER, D. LÜFTNER (Berlin, Germany; Mt. View, CA, USA) ..............<br />
Prediction of Prognosis Regarding Fractionation Schedule and Survival in Patients with Whole-brain<br />
Radiotherapy for Metastatic Disease. A. MEYER, D. STEINMANN, L. MALAIMARE, J.H. KARSTENS,<br />
M. BREMER (Hannover, Germany) ......................................................................................................................<br />
Weekly Low-dose Paclitaxel and Carboplatin Therapy in Gynecological Cancer Patients with Venous<br />
Thrombosis. T. TABATA, K. TANIDA, T. UMEKAWA, T. SHIOZAKI, E. KONDO, K. NAGAO, T.<br />
OKUGAWA, N. SAGAWA (Mie, Japan) ..............................................................................................................<br />
Erythropoetin β Twice Weekly Versus Standard Therapy in Patients with Gynaecological Malignancies – A<br />
Randomised Austrian AGO Trial. B. VOLGGER, E. PETRU, L. ANGLEITNER-BOUBENIZEK, M.<br />
WEIGERT, A. REINTHALLER, H. LASS, A. STEMPFL, C. GAMPER, M. DEIBL, C. MARTH (Innsbruck;<br />
Graz; Linz; Lainz; Vienna; Salzburg; Wr. Neustadt, Austria) ................................................................................<br />
Nuclear Morphometry in FNABs of Breast Disease in Libyans. F. ABDALLA, J. BODER, A. BUHMEIDA, H.<br />
HASHMI, AD. ELZAGHEID, Y. COLLAN (Turku, Finland; Sabratha; Benghazi, Libya)......................................<br />
Neuroimaging Abnormalities in Adult Medulloblastoma. Undergoing Intensified Therapy. S. SECONDINO,<br />
A. CITTERIO, P. PEDRAZZOLI, C. FUNAIOLI, G.G. SCIALFA, S. SIENA (Milan, Italy) ..........................<br />
Docetaxel for Metastatic Breast Cancer: Two Consecutive Phase II Trials. E. CAMPORA, G. COLLOCA,<br />
R. RATTI, G. ADDAMO, Z. COCCORULLO, A. VENTURINO, D. GUARNERI (Sanremo, Italy) ..............<br />
Prospective Study of Chemotherapy in Combination with Cytokine-induced Killer Cells in Patients Suffering<br />
from Advanced Non-small Cell Lung Cancer. C. WU, J. JIANG, L. SHI, N. XU (Changzhou, P.R. China;<br />
Lund, Sweden) .........................................................................................................................................................<br />
Skin Aging from Ultraviolet Irradiance and Smoking Reduces Risk of Melanoma: Epidemiological Evidence.<br />
W.B. GRANT (San Francisco, CA, USA) .............................................................................................................<br />
3921<br />
3929<br />
3933<br />
3937<br />
3941<br />
3945<br />
3961<br />
3965<br />
3971<br />
3977<br />
3985<br />
3991<br />
3993<br />
3997<br />
4003<br />
4219
Abstracts of the 14th International Hamburg Symposium on Tumor Markers, 7-9 December, 2008 Hamburg,<br />
Germany...................................................................................................................................................................<br />
The Accuracy of Intraoperative Frozen Section of the Inguinal Sentinel Lymph Node in Vulvar Cancer. A.H.<br />
BRUNNER, S. POLTERAUER, C. TEMPFER, E. JOURA, A. REINTHALLER, R. HORVAT, L. HEFLER<br />
(Vienna, Austria) .....................................................................................................................................................<br />
Neoadjuvant Chemoradiotherapy with 5-Fluorouracil by Bolus. L.M. PASETTO, G. SINIGAGLIA, U.<br />
BASSO, S. COCCHIO, A. COMPOSTELLA, S. PUCCIARELLI, M.L. FRISO, M. RUGGE, P. TOPPAN,<br />
M. AGOSTINI, S. MONFARDINI (Padova; Aviano, Italy) .................................................................................<br />
The Combination of 5-Fluorouracil, Leukovorin, Etoposide, and Cisplatin (FLEP) in Patients with Metastatic<br />
Esophageal Cancer. A Single-institution Experience. C. JONAK, M. RADERER, J. ZACHERL, G. PRAGER, M.<br />
TROCH, A. BA-SSALAMAH, M. HEJNA (Vienna, Austria; Kuala Lumpur, Malaysia).........................................<br />
Osteopontin Expression Profiles Predict Pathological and Clinical Outcome in Breast Cancer. N. PATANI,<br />
F. JOUHRA, W. JIANG, K. MOKBEL (Cardiff, Wales; London, UK) ...............................................................<br />
Treatment with Cetuximab, Bevacizumab and Irinotecan in Heavily Pretreated Patients with Metastasized<br />
Colorectal Cancer. N. HALAMA, C. HERRMANN, D. JAEGER, T. HERRMANN (Heidelberg, Germany) ......<br />
Giant Cell Tumor of the Sternum: A Case Report and Review of the Literature. H. FUTANI, Y. OKUMURA,<br />
Y. FUKUDA, S. FUKUNAGA, S. HASEGAWA, S. YOSHIYA (Hyogo, Japan) ...............................................<br />
Three-times Daily Radiotherapy after Chemotherapy in Stage III Non-small Cell Lung Cancer. Singleinstitution<br />
Prospective Study. G. CATALANO, T. DE PAS, L. SPAGGIARI, S. GANDINI, B.A. JERECZEK-<br />
FOSSA, F. DE BRAUD, F. LEO, G. VERONESI, R. ORECCHIA (Milan, Italy) .............................................<br />
Role of Neoadjuvant Treatment in cT3N0M0 Rectal Cancer. L.M. PASETTO, M.L. FRISO, S.<br />
PUCCIARELLI, U. BASSO, M. RUGGE, G. SINIGAGLIA, E. ROSSI, A. COMPOSTELLA, P. TOPPAN,<br />
M. AGOSTINI, S. MONFARDINI (Padova; Aviano, Italy) .................................................................................<br />
Epirubicin and Cyclophosphamide Followed by Docetaxel as Primary Systemic Chemotherapy in Locally<br />
Advanced Breast Cancer. A. HIRANO, T. SHIMIZU, O. WATANABE, J. KINOSHITA, K. KIMURA, M.<br />
KAMIMURA, K. DOMOTO, M. AIBA, K. OGAWA (Tokyo, Japan) ................................................................<br />
A Comparative Study for Wide Excision of Malignant Tumors Distal to S2. S. OSAKA, H. MATSUZAKI, E.<br />
OSAKA, Y. YOSHIDA, J. RYU (Tokyo, Japan) ...................................................................................................<br />
Immunohistochemical Detection of Prostate-specific Antigen Expression in Primary Urothelial Carcinoma<br />
of the Urinary Bladder. J.-C. CHEN, C.-L. HO, H.-W. TSAI, T.-S. TZAI, H.-S. LIU, N.-H. CHOW, W.-H.<br />
YANG, H.-L. CHENG (Tainan, Taiwan, ROC) ....................................................................................................<br />
Appendix to <strong>Anticancer</strong> <strong>Research</strong> Vol. 28, No 5C, 2008, Abstracts of the 8th International Conference of<br />
<strong>Anticancer</strong> <strong>Research</strong>, 17-22 October 2008, Kos, Greece......................................................................................<br />
Book Reviews ..........................................................................................................................................................<br />
*<br />
Reviews (pages 3877, 3945)<br />
4220<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
4009<br />
4091<br />
4095<br />
4101<br />
4105<br />
4111<br />
4117<br />
4121<br />
4129<br />
4137<br />
4143<br />
4149<br />
4155<br />
4161
Subject <strong>Index</strong><br />
(Figures refer to page numbers)<br />
518A2Ι, radioiodinated methylene blue, melanoma imaging,<br />
SK-MEL 28, 3691<br />
A20 leukemia/lymphoma, immature dendritic cells,<br />
cytotoxic T lymphocytes, co-culture, syngeneic, GM-CSF,<br />
2831<br />
A431, MMP-2, MMP-9, FAK, Boyden chamber assay, 2109<br />
ABC transporters, non-small cell lung cancer, COX-2,<br />
chemotherapy, 2967<br />
ABCB1 gene, colon cancer, P-glycoprotein, polymorphisms,<br />
immunohistochemistry, 3921<br />
Abnormality, medulloblastoma, neuroimaging, 3991<br />
Absolute hardness, 3-formylchromone derivatives, QSAR,<br />
cytotoxicity, semiempirical molecular-orbital method, 277<br />
Absolute hardness, 5-trifluoromethyloxazole derivatives,<br />
QSAR, cytotoxicity, semiempirical molecular-orbital<br />
method, 997<br />
Acceleration, capecitabine, radiotherapy, surgery,<br />
hypofractionation, amifostine, rectal cancer, 3035<br />
Acceleration, non-small cell lung cancer, vinorelbine,<br />
liposomal doxorubicin, hypofractionation, amifostine,<br />
radiotherapy, 1349<br />
Accessibility, ethnic minority, Māori, Pacific Island,<br />
diagnosis, treatment, 3891<br />
Accuracy of diagnosis, prostate cancer, proton magnetic<br />
resonance spectroscopy, prostate biopsy, 1899<br />
Acne, steroid sulphatase, oestrogen, androgen, breast<br />
cancer, skin, hirsutism, sulphatase inhibitor, 1517<br />
AcSDKP, POP, marker, angiogenesis, thyroid tumor, cancer,<br />
2813<br />
ACT, prostate cancer, inflammation, promoter<br />
polymorphism, PSA levels, 395<br />
Activation, lymphocytes, 5-fluorouracil, 3785<br />
Acute leukemia, Wnt, β-catenin, self-renewal, Notch, 2701<br />
Acute myeloid leukemia, children, drug resistance, drug<br />
sensitivity, prognostic factors, 1927<br />
Acute myeloid leukemia, PDGFR, single-strand<br />
conformation polymorphism, core-binding factor, 2745<br />
Adenocarcinoma, Gaucher’s disease, hematological toxicity,<br />
non-small cell lung cancer, cytopenia, chemotherapy,<br />
3937<br />
Adenocarcinoma, metastatic brain tumor, MRI, mucin, 407<br />
Adenoma, polyp, primary culture, carcinogenesis, cell<br />
culture, 843<br />
Adenomas, paneth cells, stem cells, turnover, 1571<br />
Adenomatous polyposis coli, inherited cancer syndrome,<br />
HNPCC, BRCA1, BRCA2, MEN 2, review, 1341<br />
Adenovirus vector, gene therapy, CD40 ligand, rat,<br />
metastatic liver cancer, 2785<br />
Adenovirus vector, gene therapy, hepatocellular carcinoma,<br />
arterial injection, iodized oil, rat, 51<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Adenovirus, gene therapy, thymidine kinase, Coxackieadenovirus<br />
receptor, ovarian cancer, 2569<br />
Adenovirus, snail, E-cadherin, metastasis, 621<br />
Adhesion, hypoxia, spheroids, integrin, fibronectin, 1013<br />
Adhesion, megakaryocytic, erythroid, lineage shift,<br />
fibronectin, integrin, 261<br />
Adipose tissue, lipoprotein lipase, sarcoma, triacylglycerol,<br />
2081<br />
Adjuvant chemotherapy, advanced gastric cancer, palliative<br />
gastrectomy, 1309<br />
Adjuvant chemotherapy, elderly, colon cancer, 2513<br />
Adjuvant chemotherapy, endometrial cancer, grade 3 tumor,<br />
1785<br />
Adjuvant chemotherapy, rectal cancer, 1805<br />
Adjuvant chemotherapy, UFT, LV, micrometastasis, 2045<br />
Adjuvant tamoxifen, endometrial carcinoma, breast cancer,<br />
ultrasound, 1259<br />
Adjuvant therapy, DNAses, prognosis, vitamin C, vitamin<br />
K 3 , review, 2727<br />
Adjuvant therapy, lung cancer, immunotherapy, N2 disease,<br />
surgery, dendritic cell, regional lymph node, 1229<br />
Adjuvant therapy, VEGF-1 expression, colorectal cancer,<br />
prognosis, 3865<br />
Adjuvant, vaccine, cancer, resection, Lobund-Wistar rat,<br />
2529<br />
ADP ribose, PARP, temozolomide, preclinical efficacy,<br />
biomarker, 2625<br />
Adrenocortical, incidentaloma, proliferation markers,<br />
metallothioneins, minichromosome maintenance protein,<br />
Ki-67, 2959<br />
Advanced colorectal cancer, bevacizumab, irinotecan,<br />
capecitabine, 3087<br />
Advanced colorectal cancer, weekly irinotecan, protracted<br />
venous infusion fluorouracil, 2327<br />
Advanced gastric cancer, adjuvant chemotherapy, palliative<br />
gastrectomy, 1309<br />
Advanced gastric cancer, chemotherapy, phase I study,<br />
toxicity, 2473<br />
Advanced gastric cancer, gastrectomy, non-curative factor,<br />
prognostic factor, 2379<br />
Advanced non-small cell lung cancer, erlotinib,<br />
monotherapy, 2409<br />
Advanced pancreatic cancer, S-1, cisplatin, phase Ⅱ study,<br />
2373<br />
Advanced, myelotoxicity, chemotherapy, prognosis, breast<br />
cancer, 2913<br />
African Americans, Cox-2 polymorphisms, colorectal<br />
adenoma, 3119<br />
Age, radiotherapy, brain metastasis, prognostic factors,<br />
malignant melanoma, 1325<br />
Age-specific expression, cervical cancer, markers, p53, p27,<br />
COX-2, Ki-67, EGFR, E-cadherin, c-myc, VEGF, CD44,<br />
CD4, 1793<br />
4221
Aggrecan, versican, decorin, Western blotting, immunohistochemistry,<br />
RT-PCR, proteoglycan, 245<br />
Akt, prohibitin, transformation, 957<br />
AKT, PTEN, mTOR, p53, genome stability, cell cycle,<br />
review, 3613<br />
Albendazole, β-cyclodextrin, ovarian cancer, efficacy,<br />
toxicity, 2775<br />
Alcohol, cancer, risk, diet, iron, legumes, meat, smoking,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Alkaline sphingomyelinase, sphingomyelin, colon cancer,<br />
mouse, 3631<br />
Allele-specific PCR, epidermal growth factor receptor, gefitinib,<br />
mutation screening, non-small cell lung cancer, 2265<br />
Allelic discrimination, bladder cancer, single nucleotide<br />
polymorphism, ERCC2, XPC, XRCC1, XRCC3, 1853<br />
Alpha-folate receptor, ovarian carcinoma, folate receptor<br />
overexpression, targeted therapy, 3567<br />
Amelanotic melanoma, ovarian metastasis, 563<br />
Ameloblastic carcinoma, ameloblastoma, oral cavity, 3847<br />
Ameloblastoma, ameloblastic carcinoma, oral cavity, 3847<br />
Amifostine, capecitabine, radiotherapy, surgery,<br />
acceleration, hypofractionation, rectal cancer, 3035<br />
Amifostine, non-small cell lung cancer, vinorelbine,<br />
liposomal doxorubicin, hypofractionation, acceleration,<br />
radiotherapy, 1349<br />
Amino acid transport system L, LAT1, salivary gland<br />
carcinoma cells, essential amino acids, antitumor therapy,<br />
2649<br />
Amino acids, human tumors, nude mice, methionine<br />
metabolism, transulfuration, 2541<br />
Amplification, EGFR, EGFRvIII, glioblastoma, glioma,<br />
oligodendroglioma, 913<br />
Ampullary cancer, pancreatic cancer, MMPs, TIMPs, MVD,<br />
1875<br />
Amrubicin, NSCLC, chemotherapy failure, third-line<br />
treatment, 3855<br />
Anal canal carcinoma, radiotherapy, chemotherapy, 1335<br />
Anal canal, squamous carcinoma, intratumoral lymphocytes,<br />
2469<br />
Anandamide, anticancer immunity, cannabinoids,<br />
lymphocytes, regulatory T-cell, 3743<br />
Anaplastic astrocytoma, glioblastoma multiforme, high<br />
grade glioma, histone deacetylase inhibitor, pediatric,<br />
valproic acid, 2437<br />
Anaplastic large cell lymphoma, small animal PET, FDG,<br />
xenograft, NOD/SCID, 981<br />
Anastrozole, premenopausal, mammary carcinogenesis, rat,<br />
chemoprevention, aromatase inhibitors, 2819<br />
Androgen receptor, cannabinoids, breast cancer, estrogen<br />
receptor, 85<br />
Androgen receptor, prostate cancer, SRC1, TIF2, Her2/neu,<br />
prognosis, radical prostatectomy, 425<br />
4222<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Androgen, steroid sulphatase, oestrogen, breast cancer, skin,<br />
acne, hirsutism, sulphatase inhibitor, 1517<br />
Anemia, cancer, erythrocyte transfusion, cost-effectiveness,<br />
459<br />
Anemia, darbepoetin alfa, chemotherapy, supportive care, 1767<br />
Angiogenesis, AcSDKP, POP, marker, thyroid tumor,<br />
cancer, 2813<br />
Angiogenesis, angiotensinogen, oral cancer, polymorphism,<br />
1675<br />
Angiogenesis, anti-VEGFR, anti-TYRP-1/gp75, melanoma,<br />
antibody therapy, 2679<br />
Angiogenesis, autocrine signalling, breast cancer, Flt-1,<br />
VEGF, 1719<br />
Angiogenesis, bisphosphonates, RENCA, vessel density,<br />
VEGF, 933<br />
Angiogenesis, hop beta-acids, angioprevention, cell<br />
proliferation, chemotaxis, VEGF, matrigel plug, 289<br />
Angiogenesis, inflammation, MIF, IL-10, tamoxifen,<br />
aspirin, 2093<br />
Angiogenesis, interleukin-10, oral cancer, inflammation,<br />
thrombophilia, 309<br />
Angiogenesis, monocytes, tumour growth, cytokines, 187<br />
Angiogenesis, oral squamous cell carcinoma, HIF-1α,<br />
VEGF-C, lymphangiogenesis, 1659<br />
Angiogenesis, pancreatic ductal adenocarcinoma, INK4a,<br />
K-RAS, SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB,<br />
p27 Kip1 , cell cycle, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
Angiogenesis, stromal-derived factor-1, oral cancer,<br />
thrombophilia, polymorphism, 271<br />
Angiogenesis, vinorelbine, malignant pleural effusion, lung<br />
cancer, vascular endothelial growth factor (VEGF), 1633<br />
Angiogenesis, zoledronic acid, TNP-470, neuroblastoma,<br />
SH-SY5Y, 1551<br />
Angioprevention, hop beta-acids, angiogenesis, cell<br />
proliferation, chemotaxis, VEGF, matrigel plug, 289<br />
Angiosarcoma, polychemotherapy, first-line, 3041<br />
Angiotensinogen, oral cancer, polymorphism, angiogenesis,<br />
1675<br />
Animal model, breast cancer, green tea catechins, fatty acid<br />
synthase, weight loss, anti-cancer drug, 3671<br />
Animal model, radiofrequency, human breast cancer,<br />
metastasis, rats, 879<br />
Annexin, prostate, cancer, cytokine, gp96, review, 2843<br />
Annexin, thymax, MCF-7, apoptosis, caspases, 1603<br />
Anthocyanins, colon cancer, differentiation, peach, plum,<br />
phenolics, 2067<br />
Antiangiogenic therapy, vascular disrupting agents,<br />
combination therapy, renal cell carcinoma, 2027<br />
Antibodies, colorectal cancer, metastases, chemotherapy,<br />
treatment, 4111
Antibody arrays, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, diagnosis, prognosis,<br />
sCD26, EGF, sEGFR, ELISA, cytometric beads,<br />
clustering, bioinformatics, review, 2333<br />
Antibody therapy, anti-VEGFR, anti-TYRP-1/gp75,<br />
melanoma, angiogenesis, 2679<br />
<strong>Anticancer</strong> agents, phase I, fixed dose, body surface area,<br />
body weight, 3075<br />
<strong>Anticancer</strong> cytotoxin, parasporin-1Ab, preferential<br />
cytotoxicity, Bacillus thuringiensis, 91<br />
Anti-cancer drug, breast cancer, green tea catechins, fatty<br />
acid synthase, animal model, weight loss, 3671<br />
<strong>Anticancer</strong> immunity, anandamide, cannabinoids,<br />
lymphocytes, regulatory T-cell, 3743<br />
Anticonvulsant, clonazepam, chemotherapy-induced nausea<br />
and vomiting (CINV), antiemesis, benzodiazepines, 2433<br />
Antiemesis, clonazepam, chemotherapy-induced nausea<br />
and vomiting (CINV), benzodiazepines, anticonvulsant,<br />
2433<br />
Anti-initiation, zapotin, two-stage mouse skin<br />
carcinogenesis, anti-promotion, 3705<br />
Antioxidants, colon carcinoma, cell lines, multidrug<br />
resistance, P-glycoprotein, pO 2 , 55<br />
Antiproliferation, Panax quinquefolius L., heat-processing,<br />
human breast cancer, HPLC analysis, ginsenoside Rg3,<br />
apoptosis, cell cycle, 2545<br />
Antiproliferative property, apoptotic effect, xanthorrhizol,<br />
MDA-MB-231, 3677<br />
Anti-promotion, zapotin, two-stage mouse skin<br />
carcinogenesis, anti-initiation, 3705<br />
Antisense, translationally controlled tumor protein, liver<br />
regeneration, liver cancer, proliferation, cell cycle,<br />
apoptosis, 1575<br />
Antitumor activity, γδ T-cells, nonpeptide antigens,<br />
pyrophosphomonoester, cancer immunotherapy, 2921<br />
Antitumor effect, hybrid liposomes, lymphoma, apoptosis,<br />
chemotherapy, 1187<br />
Antitumor therapy, amino acid transport system L, LAT1,<br />
salivary gland carcinoma cells, essential amino acids,<br />
2649<br />
Antitumoral vaccine, ovarian cancer, early diagnosis, tumor<br />
markers, gonadotropins, review, 3135<br />
Anti-TYRP-1/gp75, anti-VEGFR, melanoma, angiogenesis,<br />
antibody therapy, 2679<br />
Anti-VEGFR, anti-TYRP-1/gp75, melanoma, angiogenesis,<br />
antibody therapy, 2679<br />
AP, renal cell carcinoma, P1NP, tumour marker, bone<br />
metastases, 2443<br />
Aplidium glabrum, 3-demethylubiquinone Q2, ascidian,<br />
MRT, cancer preventive and anticancer activities,<br />
apoptosis, 927<br />
Apo2L/TRAIL, valproic acid, histone deacetylase inhibitors,<br />
K562 erythroleukemia cells, apoptosis, 855<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Apolipoprotein D, breast cancer, immuno-electrophoresis in<br />
cytosol, immunohistochemistry, whole sections, tissue<br />
microarray, 1151<br />
Aponecrosis, mitogen-activated protein kinase, prenylation<br />
inhibitor, ras, NaPa, 1029<br />
Apoptosis, 3-demethylubiquinone Q2, ascidian, Aplidium<br />
glabrum, MRT, cancer preventive and anticancer<br />
activities, 927<br />
Apoptosis, 5’-deoxy-5-fluorouridine, paclitaxel, nude mice,<br />
gastric cancer, thymidine phosphorylase, 1593<br />
Apoptosis, 6-dimethylaminopurine, caspase, intracellular<br />
calcium ion, gene expression, genetic network, 609<br />
Apoptosis, Apo2L/TRAIL, valproic acid, histone<br />
deacetylase inhibitors, K562 erythroleukemia cells, 855<br />
Apoptosis, astrocytoma, proliferation markers, p53, 15<br />
Apoptosis, baicalein, GADD153, calcium, mitochondrial<br />
membrane potential, 1701<br />
Apoptosis, bee venom (BV), caspase, reactive oxygen<br />
species, cytoplasmic calcium (Ca 2+ ), mitochondria, 833<br />
Apoptosis, benzocycloheptoxazines, autophagy, caspase,<br />
DNA fragmentation, 1069<br />
Apoptosis, benzylidene ascorbate, tumor specificity, type of<br />
cell death, autophagy, 2577<br />
Apoptosis, berberine, p53, cell cycle arrest, neuroblastoma<br />
cells, 3777<br />
Apoptosis, bisphosphonate, osteosarcoma, synergism, 2147<br />
Apoptosis, Cautleya gracilis, bioactive agents, medullary<br />
thyroid carcinoma, chemoresistance, 2705<br />
Apoptosis, CD28, FAS, immune dysfunction,<br />
immunosurveillance, TCR-zeta, T-cell impairment, breast<br />
cancer, 779<br />
Apoptosis, cervical cancer, estrogen receptor, gene therapy,<br />
chemotherapy, cytotoxicity, MTT, caspase-3, CaSki, 2181<br />
Apoptosis, chondrosarcoma, suberoylanilide hydroxamic<br />
acid, SAHA, autophagy-associated cell death, 1585<br />
Apoptosis, Cl– channel, cancer, cell volume, cisplatin, drug<br />
resistance, review, 75<br />
Apoptosis, colorectal cancer, caspases, selenium, selenous<br />
acid, 5-FU, 3579<br />
Apoptosis, cyclopentenone, cytotoxicity, mitochondria, 315<br />
Apoptosis, DADS, caspase-3, cytochrome c, mitochondrial<br />
membrane potential (Δψm), 2791<br />
Apoptosis, EGCG, macrophage, autophagy, 1713<br />
Apoptosis, FAS, FASL, polymorphism, atrophy, intestinal<br />
metaplasia, 97<br />
Apoptosis, furanoacridones, multidrug resistance, 2737<br />
Apoptosis, germ-cell testicular tumor, differentiation,<br />
chemoresistance, p53, p21, 1641<br />
Apoptosis, glioblastoma, survivin, mitosis, 109<br />
Apoptosis, guggul, guggulsterone, cancer, hyperlipidemia,<br />
inflammation, review, 3647<br />
Apoptosis, hybrid liposomes, antitumor effect, lymphoma,<br />
chemotherapy, 1187<br />
4223
Apoptosis, inotodiol, lanostane triterpenoids, cell<br />
proliferation, caspase-3, 2691<br />
Apoptosis, interleukin 1, radioprotection, gastrointestinal<br />
epithelium, 3601<br />
Apoptosis, leukemia, cell cycle, drug resistance, p21, 965<br />
Apoptosis, melphalan, hyperthermia, caspases, gene<br />
regulation, Ewing sarcoma, 2585<br />
Apoptosis, neuroblastoma, curcumin, NfkappaB, 209<br />
Apoptosis, NFÎB, IÎBα, chemosensitivity, 601<br />
Apoptosis, noxa gene, BH3, 1667<br />
Apoptosis, PAI-1, PAI-2, colon cancer, 693<br />
Apoptosis, Panax quinquefolius L., heat-processing,<br />
antiproliferation, human breast cancer, HPLC analysis,<br />
ginsenoside Rg3, cell cycle, 2545<br />
Apoptosis, pancreatic ductal adenocarcinoma, INK4a,<br />
K-RAS, SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB,<br />
p27 Kip1 , cell cycle, angiogenesis, metastasis, proliferation,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
Apoptosis, pro-apoptotic genes, cell cycle, lung cancer,<br />
plumbagin, 785<br />
Apoptosis, RET, doxorubicin, medullary thyroid cancer,<br />
MAPK pathway, 2019<br />
Apoptosis, sodium butyrate, hyperthermia, cell death, HCT<br />
116 colorectal cancer cells, 1693<br />
Apoptosis, solanum lyratum extracts, cytotoxicity, colon<br />
adenocarcinoma cell lines, 1045<br />
Apoptosis, thymax, MCF-7, annexin, caspases, 1603<br />
Apoptosis, TNF, death receptor, tyrosine phosphatase,<br />
resistance, Fas, CHX, FLIP, 593<br />
Apoptosis, translationally controlled tumor protein, liver<br />
regeneration, liver cancer, antisense, proliferation, cell<br />
cycle, 1575<br />
Apoptosis, vitamin K 2 , prenylalcohol, cytotoxicity,<br />
autophagy, type of cell death, 151<br />
Apoptotic effect, antiproliferative property, xanthorrhizol,<br />
MDA-MB-231, 3677<br />
AR42J cells, somatostatin analogues, 111 In-DOTA-1-Nal 3 -<br />
octreotide, 111 In-DOTA-Tyr 3 -octreotate, tumour targeting,<br />
renal handling, biodistribution, OK cells, 2189<br />
ARA24, prostate, PSA, NCOA4, IL-6, PSCA, PEDF,<br />
matriptase, 1969<br />
Arg72Pro, p53 codon 72 polymorphism, sporadic colorectal<br />
adenocarcinoma, left colon cancer, 1039<br />
Aromatase inhibitors, low-grade endometrial stromal<br />
sarcoma, surgery, progestins, 2869<br />
Aromatase inhibitors, premenopausal, mammary<br />
carcinogenesis, rat, chemoprevention, anastrozole, 2819<br />
Aromatase, breast cancer, progesterone, MCF-7aro cells, 2129<br />
Arp, gastric carcinoma, pathogenesis, progression, 2225<br />
Arterial injection, gene therapy, hepatocellular carcinoma,<br />
adenovirus vector, iodized oil, rat, 51<br />
4224<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Arterial, 5-fluorouracil, infusion, cetuximab, colorectal,<br />
irinotecan, oxaliplatin, metastases, 2459<br />
Asbestos, calretinin, immunohistochemistry, mesothelioma,<br />
occupational cancer, orchidectomy, 1365<br />
Ascidian, 3-demethylubiquinone Q2, Aplidium glabrum,<br />
MRT, cancer preventive and anticancer activities,<br />
apoptosis, 927<br />
Aspiration, dysphagia, postoperative radiation,<br />
oropharyngeal cancer, 431<br />
Aspiration, intraosseous, bone marrow, 3843<br />
Aspirin, angiogenesis, inflammation, MIF, IL-10,<br />
tamoxifen, 2093<br />
Astrocytoma, proliferation markers, apoptosis, p53, 15<br />
Ataxia telangiectasia, ATM gene, molecular genetics, cancer<br />
susceptibility, review, 401<br />
ATM gene, ataxia telangiectasia, molecular genetics, cancer<br />
susceptibility, review, 401<br />
ATP, chemosensitivity, prediction, ovarian cancer, drug<br />
resistance, 949<br />
ATP6V0A1, POLR2F, PRNP, colorectal cancer, quantitative<br />
RT-PCR, 1221<br />
Atrophy, FAS, FASL, polymorphism, apoptosis, intestinal<br />
metaplasia, 97<br />
Atypical menigioma, cancer in pregnancy, uterine<br />
leiomyosarcoma, 3083<br />
Autocrine signalling, angiogenesis, breast cancer, Flt-1,<br />
VEGF, 1719<br />
Autologous stem cell transplant, inflammatory breast cancer,<br />
chemotherapy, thiotepa, mitoxantrone, carboplatin, 3139<br />
Autophagy, benzocycloheptoxazines, apoptosis, caspase,<br />
DNA fragmentation, 1069<br />
Autophagy, benzylidene ascorbate, tumor specificity, type of<br />
cell death, apoptosis, 2577<br />
Autophagy, EGCG, macrophage, apoptosis, 1713<br />
Autophagy, vitamin K 2 , prenylalcohol, cytotoxicity,<br />
apoptosis, type of cell death, 151<br />
Autophagy-associated cell death, chondrosarcoma,<br />
suberoylanilide hydroxamic acid, SAHA, apoptosis, 1585<br />
Autopsy, prostate cancer, brachytherapy, morphology, 3909<br />
Autopsy, prostate cancer, polymorphisms, occult cancer,<br />
prostate-specific antigen, 3007<br />
Axillary node metastases, rhinopharyngeal carcinoma,<br />
breast skin metastases, 419<br />
B16 melanoma, biphenylalkyl hydroquinone, cell cycle<br />
arrest, 1005<br />
B16, nanoparticles, BNCT, cancer, boron, 571<br />
Baboons, colon cancer, progression, 193<br />
Bacillus thuringiensis, parasporin-1Ab, anticancer<br />
cytotoxin, preferential cytotoxicity, 91<br />
Bacteria, high hydrostatic pressure, tumor cells, orthopedic<br />
surgery, viruses, review, 3877<br />
Baicalein, GADD153, calcium, apoptosis, mitochondrial<br />
membrane potential, 1701
Barrett's esophagus, photodynamic therapy, dysplasia, p53,<br />
485<br />
Bax, breast cancer, Nup88, immunocytometry, 2595<br />
BAY 11-7085, parthenolide, N-acetylcysteine, Lbuthionine-(S,R)-sulfoximine,<br />
PRIMA-1, Gemcitabine,<br />
MG-132, flavopiridol, 681<br />
BCL2, BCL2L1, BIRC4, siRNA, chemosensitization,<br />
inhibition of apoptosis, 2259<br />
Bcl-2, syndecan-1, tenascin-C, TATI, p53, p21,<br />
immunohistochemistry, flow cytometry, gastric cancer,<br />
prognosis, 2279<br />
Bcl-2, transgenic mice, skin cancer, sensitize, 2825<br />
BCL2L1, BCL2, BIRC4, siRNA, chemosensitization,<br />
inhibition of apoptosis, 2259<br />
BCR-ABL, intranuclear order, genomic karyotyping,<br />
t(9:22), PML-RARA, t(15;17), review, 3573<br />
Bee venom (BV), apoptosis, caspase, reactive oxygen<br />
species, cytoplasmic calcium (Ca 2+ ), mitochondria, 833<br />
Bendy applicator, HDR brachytherapy, perioperative, flab,<br />
sarcoma, 3885<br />
Benign, thymidine kinase 1, TK1, health screening, cancer,<br />
malignancy, tumour, fatty liver, inflammation, infection,<br />
virus, 3897<br />
Benzocycloheptoxazines, apoptosis, autophagy, caspase,<br />
DNA fragmentation, 1069<br />
Benzocycloheptoxazines, Raw 264.7 cells, NO, iNOS, ESR,<br />
radical, 2657<br />
Benzodiazepines, clonazepam, chemotherapy-induced<br />
nausea and vomiting (CINV), antiemesis, anticonvulsant,<br />
2433<br />
Benzopyrene, promoter methylation, smoke, coal, PAH,<br />
sputum, lung cancer, 2061<br />
Benzylidene ascorbate, tumor specificity, type of cell death,<br />
apoptosis, autophagy, 2577<br />
Berberine, p53, cell cycle arrest, apoptosis, neuroblastoma<br />
cells, 3777<br />
Bevacizumab, advanced colorectal cancer, irinotecan,<br />
capecitabine, 3087<br />
BH3, noxa gene, apoptosis, 1667<br />
Bioactive agents, Cautleya gracilis, medullary thyroid<br />
carcinoma, chemoresistance, apoptosis, 2705<br />
Bioactive substances. Uruguay, factor analysis, esophageal<br />
cancer, nutrients, 2499<br />
Biodistribution, somatostatin analogues, 111 In-DOTA-1-<br />
Nal 3 -octreotide, 111 In-DOTA-Tyr 3 -octreotate, tumour<br />
targeting, renal handling, AR42J cells, OK cells, 2189<br />
Bioinformatics, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, diagnosis, prognosis,<br />
sCD26, EGF, sEGFR, ELISA, cytometric beads, antibody<br />
arrays, clustering, review, 2333<br />
Biomarker, mesothelin, osteopontin, mesothelioma, 3933<br />
Biomarker, PARP, temozolomide, ADP ribose, preclinical<br />
efficacy, 2625<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Biomarkers, cancer, lung, colorectal, head and neck, serum,<br />
screening, diagnosis, prognosis, sCD26, EGF, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Biopsy, oral cancer, metastasis, bleomycin, 2253<br />
Biorheology, steep pulsed electric field (SPEF), hepatoma,<br />
proliferation, micropipette aspiration, 2245<br />
Biospecific column chromatography, RTPs, GSTP1, ER-β,<br />
resveratrol, glutathione sulfotransferase-π 29<br />
Biphenylalkyl hydroquinone, cell cycle arrest, B16<br />
melanoma, 1005<br />
BIRC4, BCL2, BCL2L1, siRNA, chemosensitization,<br />
inhibition of apoptosis, 2259<br />
BIRC5, tumor marker, survivin, gene expression, real-time<br />
RT-PCR, lung cancer, 1525<br />
Bisphosphonate, osteosarcoma, apoptosis, synergism, 2147<br />
Bisphosphonates, angiogenesis, RENCA, vessel density,<br />
VEGF, 933<br />
Bisphosphonates, zoledronic acid, bone metastases, nonsmall<br />
cell lung cancer, small cell lung cancer, 529<br />
Biweekly schedule, ovarian cancer, second-line therapy,<br />
pegylated liposomal doxorubicin, toxic skin reactions,<br />
palmar-plantar erythrodysesthesia, 1329<br />
BKV, colorectal cancer, DNA viruses, HPV, JVC, SV40,<br />
1405<br />
Bladder cancer, DNA content, image cytometry, review, 443<br />
Bladder cancer, MVD, CD105, COX-2, β-catenin, 2479<br />
Bladder cancer, single nucleotide polymorphism, allelic<br />
discrimination, ERCC2, XPC, XRCC1, XRCC3, 1853<br />
Bladder neoplasm classification, bladder neoplasms,<br />
molecular classification, profiling, review, 2893<br />
Bladder neoplasms, bladder neoplasm classification,<br />
molecular classification, profiling, review, 2893<br />
Bladder, maspin, papillary neoplasms, 471<br />
Bleomycin, cisplatin, glutathione, cell cycle, DNA<br />
synthesis, cisplatin resistance, 2663<br />
Bleomycin, oral cancer, metastasis, biopsy, 2253<br />
Blood-brain barrier, brain metastases, ovarian cancer,<br />
pegylated liposomal doxorubicin, 1943<br />
BLU, NPC, methylation, p16, DLEC1, E-cadherin, 2161<br />
BNCT, nanoparticles, cancer, B16, boron, 571<br />
Body surface area, phase I, anticancer agents, fixed dose,<br />
body weight, 3075<br />
Body weight, phase I, anticancer agents, fixed dose, body<br />
surface area, 3075<br />
Bolus 5-fluorouracil, neoadjuvant chemotherapy, rectal<br />
cancer, cardiotoxicity, 4095<br />
Bone marrow infiltration, metastatic breast cancer,<br />
capecitabine, 539<br />
Bone marrow metastasis, gastric cancer, disseminated<br />
intravascular coagulation, 5-fluorouracil infusional<br />
therapy, 1293<br />
Bone marrow, intraosseous, aspiration, 3843<br />
4225
Bone metastases, bisphosphonates, zoledronic acid, nonsmall<br />
cell lung cancer, small cell lung cancer, 529<br />
Bone metastases, renal cell carcinoma, P1NP, AP, tumour<br />
marker, 2443<br />
Bone scan, primary breast cancer, metastatic disease, X-ray,<br />
liver ultrasound, staging, 2397<br />
Boron, nanoparticles, BNCT, cancer, B16, 571<br />
Bortezomib, cetuximab, epidermal growth factor receptor,<br />
EGFR, squamous cell head and neck carcinoma cell lines<br />
(HNSCC), 2239<br />
Bortezomib, epidermal growth factor receptor, EGFR, head<br />
and neck squamous cell carcinoma cell lines, 687<br />
Boyden chamber assay, MMP-2, MMP-9, A431, FAK, 2109<br />
Brachytherapy, prostate cancer, autopsy, morphology, 3909<br />
BRAF, K-RAS, mutation, papillary, medullary, thyroid<br />
carcinoma, 305<br />
Brain metastases, blood-brain barrier, ovarian cancer,<br />
pegylated liposomal doxorubicin, 1943<br />
Brain metastases, palliative radiotherapy, whole-brain<br />
radiotherapy, survival prediction, 3965<br />
Brain metastases, radiotherapy, prognosis, surgery, 3015<br />
Brain metastasis, radiotherapy, prognostic factors, age,<br />
malignant melanoma, 1325<br />
Brain tumor, glioma, regulatory T cells (Treg), CD4 +<br />
CD25 + cells, glioblastoma multiforme, immune function,<br />
review, 1143<br />
Brain tumour, MRI, paediatrics, stem cell, 741<br />
BRCA1, inherited cancer syndrome, adenomatous polyposis<br />
coli, HNPCC, BRCA2, MEN 2, review, 1341<br />
BRCA-1, pleomorphic adenoma, salivary glands, mutation,<br />
3011<br />
BRCA2, inherited cancer syndrome, adenomatous polyposis<br />
coli, HNPCC, BRCA1, MEN 2, review, 1341<br />
BrdU, cell cycle, chemoresistance, 5-fluorouracil, 9<br />
Breast cancer cell motility, KGF, WT1, FAK, Grb2, Erk1,2,<br />
133<br />
Breast cancer, 2-methoxyestradiol, estrogen, sulfamate,<br />
STX140, 577<br />
Breast cancer, adjuvant tamoxifen, endometrial carcinoma,<br />
ultrasound, 1259<br />
Breast cancer, angiogenesis, autocrine signalling, Flt-1,<br />
VEGF, 1719<br />
Breast cancer, Apolipoprotein D, immuno-electrophoresis in<br />
cytosol, immunohistochemistry, whole sections, tissue<br />
microarray, 1151<br />
Breast cancer, apoptosis, CD28, FAS, immune dysfunction,<br />
immunosurveillance, TCR-zeta, T-cell impairment, 779<br />
Breast cancer, Bax, Nup88, immunocytometry, 2595<br />
Breast cancer, cannabinoids, androgen receptor, estrogen<br />
receptor, 85<br />
Breast cancer, CarolIReS, intraoperative gamma camera,<br />
lymphoscintigraphy, sentinel lymph node, 2859<br />
Breast cancer, cell-free DNA, plasma, serum, 921<br />
4226<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Breast cancer, chemoresponse, pathologic response,<br />
chemosensitivity assay, chemosensitivity resistance assay<br />
(CSRA), ChemoFx ® , 1733<br />
Breast cancer, complementary treatment, standardized<br />
mistletoe extract, quality of life, epidemiological cohort<br />
study, 523<br />
Breast cancer, cytology, fine-needle aspiration biopsy,<br />
nuclear morphometry, breast disease, fibroadenoma,<br />
fibrocystic disease, sampling, mean nuclear area, MNA,<br />
3985<br />
Breast cancer, desmopressin, vasopressin, peptide analog,<br />
chemotherapy, 2607<br />
Breast cancer, E2F, tumour suppressor, 2135<br />
Breast cancer, endothelial cell-derived microparticles,<br />
leukocyte-derived microparticles, CEA, CA15-3, 1107<br />
Breast cancer, erythropoetin, thrombosis, gynaecological<br />
cancer, 3977<br />
Breast cancer, estrogen receptor α, hedgehog signaling<br />
pathway, proliferation, sonic hedgehog, 731<br />
Breast cancer, green tea catechins, fatty acid synthase,<br />
animal model, weight loss, anti-cancer drug, 3671<br />
Breast cancer, mammaglobin, lipophilin B, secretoglobin,<br />
proliferation, 1493<br />
Breast cancer, MDA-MB-231 cells, δ-tocotrienol, cell<br />
cycle, retinoblastoma, cyclin D1, 2641<br />
Breast cancer, myelotoxicity, chemotherapy, prognosis,<br />
advanced, 2913<br />
Breast cancer, neoadjuvant chemotherapy, paclitaxel, Her2<br />
overexpression, 1239<br />
Breast cancer, oestrogen receptor, progesterone receptor,<br />
PST, 1797<br />
Breast cancer, osseous metastasis, oligo-recurrence,<br />
radiation therapy, 3929<br />
Breast cancer, osteopontin, mortality, survival, 4105<br />
Breast cancer, p27 kip1 , matrix metalloproteinase, invasion,<br />
2669<br />
Breast cancer, predictive markers, radiation pneumonitis,<br />
radiation therapy, review, 2421<br />
Breast cancer, pregnancy, hormonotherapy, patient outcome,<br />
child outcome, 2447<br />
Breast cancer, progesterone, aromatase, MCF-7aro cells, 2129<br />
Breast cancer, risk factors, oral contraceptives, estrogen<br />
receptor, progesterone receptor, 491<br />
Breast cancer, steroid sulphatase, oestrogen, androgen, skin,<br />
acne, hirsutism, sulphatase inhibitor, 1517<br />
Breast cancer, steroids, in vitro assay, MCF-7, tamoxifen,<br />
2213<br />
Breast cancer, STX140, 2-methoxyestradiol, ENMD-1198,<br />
myelotoxicity, 1483<br />
Breast cancer, sulfonate ester, cell growth inhibition, cell<br />
cycle arrest and apoptosis, p53 and Bcl-2 status, 2753<br />
Breast cancer, vinorelbine, gemcitabine, gefitinib, phase I/II<br />
study, 3019
Breast cancer, WT1, tumor suppressor, MCF10AT3B cells,<br />
proliferative breast disease, 2155<br />
Breast cancer, XRCC4, polymorphism, carcinogenesis, 267<br />
Breast carcinoma, chemotherapy, cyclophosphamide,<br />
doxorubicin, ferritin, iron, neopterin, paclitaxel, 2389<br />
Breast carcinoma, HER2/neu ECD, tumor marker,<br />
trastuzumab, HER2, 3067<br />
Breast disease, breast cancer, cytology, fine-needle<br />
aspiration biopsy, nuclear morphometry, fibroadenoma,<br />
fibrocystic disease, sampling, mean nuclear area, MNA,<br />
3985<br />
Breast metastasis, primary ovarian cancer, diagnosis, 3047<br />
Breast metastasis, squamous cell lung carcinoma,<br />
metastasis, 1299<br />
Breast skin metastases, rhinopharyngeal carcinoma, axillary<br />
node metastases, 419<br />
Breast, neoadjuvant chemotherapy, epirubicin, taxol, p53,<br />
Erb family, 3147<br />
Breast-conserving surgery, resection volume, locoregional<br />
recurrence, risk factors, 1207<br />
Broken eggs, hepatocarcinoma, micronuclei, liver dysplastic<br />
nodules, genotoxic damage, 2507<br />
Bronchoscopy, diagnosis, lung cancer, pulmonary nodule,<br />
mass-screening, video-assisted thoracoscopic surgery,<br />
3153<br />
Bystander effect, chloroethylnitrosoureas, melanoma,<br />
murine type, NMR spectroscopy, 21<br />
CA 125, CEA, CA 15.3, CA 19.9, TAG 72, pleural<br />
effusions, tumour markers, 2947<br />
CA 15.3, CEA, CA 125, CA 19.9, TAG 72, pleural<br />
effusions, tumour markers, 2947<br />
CA 19.9, CEA, CA 125, CA 15.3, TAG 72, pleural<br />
effusions, tumour markers, 2947<br />
CA15-3, breast cancer, endothelial cell-derived<br />
microparticles, leukocyte-derived microparticles, CEA,<br />
1107<br />
Caelyx, head and neck cancer, chemotherapy, Doxil, Taxol,<br />
pharmacokinetics, 2519<br />
Caffeine, cisplatin, combination therapy, osteosarcoma,<br />
1681<br />
Caffeine, osteosarcoma, chemotherapy, synergistic effect,<br />
cDNA array analysis, 645<br />
Caffeine, osteosarcoma, pegylated liposome, cisplatin, 1449<br />
Calcium, baicalein, GADD153, apoptosis, mitochondrial<br />
membrane potential, 1701<br />
Calretinin, asbestos, immunohistochemistry, mesothelioma,<br />
occupational cancer, orchidectomy, 1365<br />
Cancer chemoprevention, clinical trials, epidemiological<br />
data, review, 1857<br />
Cancer immunotherapy, IL-2, melatonin, neuroimmunomodulation,<br />
1377<br />
Cancer immunotherapy, γδ T-cells, nonpeptide antigens,<br />
pyrophosphomonoester, antitumor activity, 2921<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Cancer in pregnancy, uterine leiomyosarcoma, atypical<br />
menigioma, 3083<br />
Cancer of unknown primary site, CUP, chemoresistance,<br />
paclitaxel, tau, tubulin, tubulin III, 1161<br />
Cancer patients, viscum album, mistletoe, local reactions,<br />
peripheral lymphocytes, quality of life, 1893<br />
Cancer preventive and anticancer activities, 3demethylubiquinone<br />
Q2, ascidian, Aplidium glabrum,<br />
MRT, apoptosis, 927<br />
Cancer susceptibility, ataxia telangiectasia, ATM gene,<br />
molecular genetics, review, 401<br />
Cancer susceptibility, DNA-repair genes, genetic<br />
polymorphisms, 2941<br />
Cancer, AcSDKP, POP, marker, angiogenesis, thyroid tumor,<br />
2813<br />
Cancer, alcohol, risk, diet, iron, legumes, meat, smoking,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Cancer, anemia, erythrocyte transfusion, cost-effectiveness,<br />
459<br />
Cancer, caveolin-1, EGF receptor, MAP kinase signaling,<br />
PPARγ, rosiglitazone, 895<br />
Cancer, Cl– channel, cell volume, apoptosis, cisplatin, drug<br />
resistance, review, 75<br />
Cancer, colorectal, colon, E-cadherin, catenins, review, 3815<br />
Cancer, confocal microscopy, endomicroscopy, molecular<br />
imaging, ulcerative colitis, review, 353<br />
Cancer, glioma, protease, plasminogen activator inhibitor-1<br />
(PAI-1), serum marker, 415<br />
Cancer, guggul, guggulsterone, apoptosis, hyperlipidemia,<br />
inflammation, review, 3647<br />
Cancer, lung, colorectal, head and neck, biomarkers, serum,<br />
screening, diagnosis, prognosis, sCD26, EGF, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Cancer, MHC, class Ib, promoter, gene expression, gene<br />
therapy, 799<br />
Cancer, nanoparticles, BNCT, B16, boron, 571<br />
Cancer, notch, signal pathway, review, 3621<br />
Cancer, primary immunodeficiencies, review, 1263<br />
Cancer, prostate, annexin, cytokine, gp96, review, 2843<br />
Cancer, thymidine kinase 1, TK1, health screening, benign,<br />
malignancy, tumour, fatty liver, inflammation, infection,<br />
virus, 3897<br />
Cancer, type 2 diabetes mellitus, mortality, obesity, 1373<br />
Cancer, vaccine, adjuvant, resection, Lobund-Wistar rat,<br />
2529<br />
Cannabinoids, anandamide, anticancer immunity,<br />
lymphocytes, regulatory T-cell, 3743<br />
Cannabinoids, breast cancer, androgen receptor, estrogen<br />
receptor, 85<br />
Capecitabine, advanced colorectal cancer, bevacizumab,<br />
irinotecan, 3087<br />
4227
Capecitabine, colorectal cancer, irinotecan, first-line<br />
therapy, 1923<br />
Capecitabine, metastatic breast cancer, bone marrow<br />
infiltration, 539<br />
Capecitabine, radiotherapy, surgery, acceleration,<br />
hypofractionation, amifostine, rectal cancer, 3035<br />
Carboplatin, cervical cancer, paclitaxel, concurrent<br />
radiotherapy, 3143<br />
Carboplatin, elderly, head and neck cancer, oesophageal<br />
cancer, poor performance status, vinorelbine, 1383<br />
Carboplatin, inflammatory breast cancer, chemotherapy,<br />
autologous stem cell transplant, thiotepa, mitoxantrone,<br />
3139<br />
Carboplatin, non-small cell lung cancer, phase II study,<br />
induction chemotherapy, paclitaxel, chemoradiotherapy,<br />
2851<br />
Carcinogenesis, polyp, adenoma, primary culture, cell<br />
culture, 843<br />
Carcinogenesis, XRCC4, polymorphism, breast cancer, 267<br />
Carcinogenesis, XRCC4, polymorphism, oral cancer, 1687<br />
Carcinoma in situ, dysplasia, DNA, RNA, 2417<br />
Carcinoma, thyroid, metastases, surgery, neoplasm, 2885<br />
Cardiotoxicity, neoadjuvant chemotherapy, rectal cancer,<br />
bolus 5-fluorouracil, 4095<br />
CarolIReS, breast cancer, intraoperative gamma camera,<br />
lymphoscintigraphy, sentinel lymph node, 2859<br />
CaSki, cervical cancer, estrogen receptor, gene therapy,<br />
chemotherapy, cytotoxicity, apoptosis, MTT, caspase-3,<br />
2181<br />
Caspase, 6-dimethylaminopurine, apoptosis, intracellular<br />
calcium ion, gene expression, genetic network, 609<br />
Caspase, bee venom (BV), apoptosis, reactive oxygen<br />
species, cytoplasmic calcium (Ca 2+ ), mitochondria, 833<br />
Caspase, benzocycloheptoxazines, apoptosis, autophagy,<br />
DNA fragmentation, 1069<br />
Caspase-3, cervical cancer, estrogen receptor, gene therapy,<br />
chemotherapy, cytotoxicity, apoptosis, MTT, CaSki, 2181<br />
Caspase-3, DADS, apoptosis, cytochrome c, mitochondrial<br />
membrane potential (Δψm), 2791<br />
Caspase-3, inotodiol, lanostane triterpenoids, cell<br />
proliferation, apoptosis, 2691<br />
Caspases, colorectal cancer, selenium, selenous acid, 5-FU,<br />
apoptosis, 3579<br />
Caspases, melphalan, hyperthermia, apoptosis, gene<br />
regulation, Ewing sarcoma, 2585<br />
Caspases, thymax, MCF-7, apoptosis, annexin, 1603<br />
Caspases, α-santalol, p53, UVB radiation, skin cancer, 129<br />
Catenins, colorectal, colon, cancer, E-cadherin, review,<br />
3815<br />
Cathepsin B, prostate cancer, Gleason grade, tissue<br />
microarray, inhibitor stefin A, 2271<br />
Cautleya gracilis, bioactive agents, medullary thyroid<br />
carcinoma, chemoresistance, apoptosis, 2705<br />
4228<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Caveolin-1, cancer, EGF receptor, MAP kinase signaling,<br />
PPARγ, rosiglitazone, 895<br />
CCN2, mandibular bone destruction, osteoclast, 2343<br />
CD105, bladder cancer, MVD, COX-2, β-catenin, 2479<br />
CD105, laryngeal carcinoma, vascular endothelial growth<br />
factor receptor 2 (VEGFR2), recurrence, prognosis, 551<br />
CD105, lymphangiogenesis, small cell lung carcinoma,<br />
prognosis, immunohistochemistry, 343<br />
CD14, NOD2, TLR4, gene polymorphism, MALT<br />
lymphoma, Helicobacter pylori infection, 3697<br />
CD28, apoptosis, FAS, immune dysfunction,<br />
immunosurveillance, TCR-zeta, T-cell impairment, breast<br />
cancer, 779<br />
CD4, cervical cancer, markers, p53, p27, COX-2, Ki-67,<br />
EGFR, E-cadherin, c-myc, VEGF, CD44, age-specific<br />
expression, 1793<br />
CD4 + CD25 + cells, glioma, regulatory T cells (Treg), brain<br />
tumor, glioblastoma multiforme, immune function,<br />
review, 1143<br />
CD4 + CD25 + T-cell, Host immunity, soluble IL-2R, lowdose<br />
chemotherapy, colorectal cancer, 373<br />
CD40 ligand, gene therapy, adenovirus vector, rat,<br />
metastatic liver cancer, 2785<br />
CD44, cervical cancer, markers, p53, p27, COX-2, Ki-67,<br />
EGFR, E-cadherin, c-myc, VEGF, CD4, age-specific<br />
expression, 1793<br />
CD8highCD57+ lymphocytes, melanoma, interferon-·,<br />
survival, 1139<br />
CDC20, siRNA, pancreas, therapy, cytotoxicity,<br />
chemoradiation, 1559<br />
Cdc6, oral squamous cell carcinoma(OSCC), precancerous<br />
lesions, Mcm7, 3763<br />
CDDP-resistant cell line, gastric cancer, oxaliplatin,<br />
ERCC1, GST-π, MKN45, 2087<br />
CDNA array analysis, osteosarcoma, chemotherapy,<br />
caffeine, synergistic effect, 645<br />
CDNA array, plakoglobin (gamma-catenin), soft tissue<br />
sarcoma, pulmonary metastasis, orthotopic implantation<br />
model, 655<br />
CEA, breast cancer, endothelial cell-derived microparticles,<br />
leukocyte-derived microparticles, CA15-3, 1107<br />
CEA, CA 125, CA 15.3, CA 19.9, TAG 72, pleural<br />
effusions, tumour markers, 2947<br />
CEA, Dukes’ C, prognosis, colorectal cancer, 1933<br />
CEA, hemoglobin, non-small cell lung cancer, preoperative,<br />
survival, 1947<br />
Cell culture, polyp, adenoma, primary culture,<br />
carcinogenesis, 843<br />
Cell cycle arrest and apoptosis, sulfonate ester, breast<br />
cancer, cell growth inhibition, p53 and Bcl-2 status, 2753<br />
Cell cycle arrest, berberine, p53, apoptosis, neuroblastoma<br />
cells, 3777<br />
Cell cycle arrest, biphenylalkyl hydroquinone, B16
melanoma, 1005<br />
Cell cycle, apoptosis, pro-apoptotic genes, lung cancer,<br />
plumbagin, 785<br />
Cell cycle, bleomycin, cisplatin, glutathione, DNA<br />
synthesis, cisplatin resistance, 2663<br />
Cell cycle, breast cancer, MDA-MB-231 cells, δtocotrienol,<br />
retinoblastoma, cyclin D1, 2641<br />
Cell cycle, chemoresistance, 5-fluorouracil, BrdU, 9<br />
Cell cycle, Hodgkin's lymphoma, chemotherapy,<br />
roscovitine, interleukin-26, 887<br />
Cell cycle, irinotecan, CPT-11, colon cancer, HCT116,<br />
DNA damage checkpoint activation, endoreduplication,<br />
senescence, cell death, 583<br />
Cell cycle, leukemia, apoptosis, drug resistance, p21, 965<br />
Cell cycle, Panax quinquefolius L., heat-processing,<br />
antiproliferation, human breast cancer, HPLC analysis,<br />
ginsenoside Rg3, apoptosis, 2545<br />
Cell cycle, pancreatic ductal adenocarcinoma, INK4a,<br />
K-RAS, SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB,<br />
p27 Kip1 , angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
Cell cycle, PTEN, mTOR, p53, AKT, genome stability,<br />
review, 3613<br />
Cell cycle, translationally controlled tumor protein, liver<br />
regeneration, liver cancer, antisense, proliferation,<br />
apoptosis, 1575<br />
Cell death therapy, differentiation therapy, gene therapy,<br />
prostate cancer, radiosensitivity, tumor suppression,<br />
tyrosine kinases, 2141<br />
Cell death, irinotecan, CPT-11, colon cancer, HCT116, cell<br />
cycle, DNA damage checkpoint activation,<br />
endoreduplication, senescence, 583<br />
Cell death, sodium butyrate, hyperthermia, apoptosis, HCT<br />
116 colorectal cancer cells, 1693<br />
Cell differentiation, embryology, intermediate filaments,<br />
keratin, prostate, 237<br />
Cell growth inhibition, sulfonate ester, breast cancer, cell<br />
cycle arrest and apoptosis, p53 and Bcl-2 status, 2753<br />
Cell growth, RbAp46, small ubiquitin-like modifier<br />
(SUMO-1), protein stability, 3749<br />
Cell invasion and migration, gypenosides, NFÎB, MMP-2,<br />
MMP-9, 1093<br />
Cell line, murine osteosarcoma, transplantation, osteoblastic<br />
differentiation, endochondral ossification, 1627<br />
Cell lines, colon carcinoma, multidrug resistance, Pglycoprotein,<br />
pO 2 , antioxidants, 55<br />
Cell proliferation, hop beta-acids, angiogenesis,<br />
angioprevention, chemotaxis, VEGF, matrigel plug, 289<br />
Cell proliferation, inotodiol, lanostane triterpenoids,<br />
apoptosis, caspase-3, 2691<br />
Cell proliferation, KGF, ER, siRNA, MCF-7, 2733<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Cell proliferation, polyamines, mepacrine, MCF-7, Vero,<br />
2765<br />
Cell volume, Cl– channel, cancer, apoptosis, cisplatin, drug<br />
resistance, review, 75<br />
Cell-free DNA, plasma, serum, breast cancer, 921<br />
Cell-free mRNA, malignant effusion, real-time quantitative<br />
PCR, ERCC1, thymidylate synthase, 1085<br />
C-erbB-2 (HER-2), EGF (epidermal growth factor), EGFR<br />
(epidermal growth factor receptor), pancreatic ductal<br />
carcinoma, 1399<br />
Cervical cancer, carboplatin, paclitaxel, concurrent<br />
radiotherapy, 3143<br />
Cervical cancer, estrogen receptor, gene therapy,<br />
chemotherapy, cytotoxicity, apoptosis, MTT, caspase-3,<br />
CaSki, 2181<br />
Cervical cancer, feasibility, docetaxel, nedaplatin,<br />
chemotherapy, 2385<br />
Cervical cancer, lymph nodes, laparoscopic staging<br />
procedure, morbidity, 1849<br />
Cervical cancer, markers, p53, p27, COX-2, Ki-67, EGFR,<br />
E-cadherin, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
Cervical dysplasia, cervical intraepithelial neoplasia,<br />
colposcopy, 1763<br />
Cervical dysplasia, CIN, PAP smear, endocervical cytology,<br />
cytobrush, 3131<br />
Cervical dysplasia, colposcopy, negative histology, positive<br />
margin, LLETZ, 519<br />
Cervical intraepithelial neoplasia, cervical dysplasia,<br />
colposcopy, 1763<br />
Cetuximab, 5-fluorouracil, arterial, infusion, colorectal,<br />
irinotecan, oxaliplatin, metastases, 2459<br />
Cetuximab, bortezomib, epidermal growth factor receptor,<br />
EGFR, squamous cell head and neck carcinoma cell lines<br />
(HNSCC), 2239<br />
Chemical descriptors, curcumin, tetrahydrocurcumin, COX-<br />
2, NF-ÎB, lipopolysaccharide, Porphyromonas gingivalis<br />
fimbriae, 699<br />
ChemoFx ® , breast cancer, chemoresponse, pathologic<br />
response, chemosensitivity assay, chemosensitivity<br />
resistance assay (CSRA), 1733<br />
Chemokine receptors, Twist, lymph node metastasis, head<br />
and neck squamous cell carcinoma, 1355<br />
Chemoprevention, premenopausal, mammary<br />
carcinogenesis, rat, anastrozole, aromatase inhibitors,<br />
2819<br />
Chemoradiation, CDC20, siRNA, pancreas, therapy,<br />
cytotoxicity, 1559<br />
Chemoradiotherapy, non-small cell lung cancer, phase II<br />
study, induction chemotherapy, paclitaxel, carboplatin, 2851<br />
Chemoradiotherapy, pancreas, unresectable cancer, hyperfractionated<br />
accelerated radiotherapy, conformal<br />
radiotherapy, gemcitabine, 2369<br />
4229
Chemoresistance, cancer of unknown primary site, CUP,<br />
paclitaxel, tau, tubulin, tubulin III, 1161<br />
Chemoresistance, Cautleya gracilis, bioactive agents,<br />
medullary thyroid carcinoma, apoptosis, 2705<br />
Chemoresistance, cell cycle, 5-fluorouracil, BrdU, 9<br />
Chemoresistance, germ-cell testicular tumor, differentiation,<br />
apoptosis, p53, p21, 1641<br />
Chemoresistance, osteosarcoma, gene profiling, MG-63,<br />
673<br />
Chemoresistance, p38-MAPK, ovarian cancer, gemcitabine,<br />
2975<br />
Chemoresistant seminoma, chemotherapy, c-kit, imatinib,<br />
2317<br />
Chemoresponse, breast cancer, pathologic response,<br />
chemosensitivity assay, chemosensitivity resistance assay<br />
(CSRA), ChemoFx ® , 1733<br />
Chemosensitivity assay, breast cancer, chemoresponse,<br />
pathologic response, chemosensitivity resistance assay<br />
(CSRA), ChemoFx ® , 1733<br />
Chemosensitivity resistance assay (CSRA), breast cancer,<br />
chemoresponse, pathologic response, chemosensitivity<br />
assay, ChemoFx ® , 1733<br />
Chemosensitivity, ATP, prediction, ovarian cancer, drug<br />
resistance, 949<br />
Chemosensitivity, NFÎB, IÎBα, apoptosis, 601<br />
Chemosensitization, BCL2, BCL2L1, BIRC4, siRNA,<br />
inhibition of apoptosis, 2259<br />
Chemotaxis, hop beta-acids, angiogenesis, angioprevention,<br />
cell proliferation, VEGF, matrigel plug, 289<br />
Chemotaxis, pancreatic ductal adenocarcinoma, INK4a,<br />
K-RAS, SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB,<br />
p27 Kip1 , cell cycle, angiogenesis, metastasis, proliferation,<br />
apoptosis, epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, sonic hedgehog, review, 1541<br />
Chemotherapy failure, amrubicin, NSCLC, third-line<br />
treatment, 3855<br />
Chemotherapy, advanced gastric cancer, phase I study,<br />
toxicity, 2473<br />
Chemotherapy, anemia, darbepoetin alfa, supportive care,<br />
1767<br />
Chemotherapy, breast carcinoma, cyclophosphamide,<br />
doxorubicin, ferritin, iron, neopterin, paclitaxel, 2389<br />
Chemotherapy, cervical cancer, estrogen receptor, gene<br />
therapy, cytotoxicity, apoptosis, MTT, caspase-3, CaSki,<br />
2181<br />
Chemotherapy, chemoresistant seminoma, c-kit, imatinib,<br />
2317<br />
Chemotherapy, cisplatin, 5-fluorouracil, oral squamous cell<br />
carcinoma, 253<br />
Chemotherapy, colorectal cancer, metastases, antibodies,<br />
treatment, 4111<br />
Chemotherapy, desmopressin, vasopressin, peptide analog,<br />
breast cancer, 2607<br />
4230<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Chemotherapy, esophageal cancer, FLEP, fluorouracil,<br />
leukovorin, etoposide, cisplatin, 4101<br />
Chemotherapy, feasibility, cervical cancer, docetaxel,<br />
nedaplatin, 2385<br />
Chemotherapy, gastric cancer, oxaliplatin, irinotecan, 2901<br />
Chemotherapy, gastric cancer, review, 1213<br />
Chemotherapy, Gaucher’s disease, hematological toxicity,<br />
non-small cell lung cancer, adenocarcinoma, cytopenia,<br />
3937<br />
Chemotherapy, head and neck cancer, Doxil, Caelyx, Taxol,<br />
pharmacokinetics, 2519<br />
Chemotherapy, head and neck carcinoma, cisplatin,<br />
paclitaxel, radiotherapy, 1285<br />
Chemotherapy, Hodgkin's lymphoma, cell cycle,<br />
roscovitine, interleukin-26, 887<br />
Chemotherapy, hybrid liposomes, antitumor effect,<br />
lymphoma, apoptosis, 1187<br />
Chemotherapy, inflammatory breast cancer, autologous stem<br />
cell transplant, thiotepa, mitoxantrone, carboplatin, 3139<br />
Chemotherapy, loss of heterozygosity, TP53, RB, ovarian<br />
carcinoma, 989<br />
Chemotherapy, lung cancer, esophageal cancer, tyrosine<br />
kinase inhibitor, taxane, 3099<br />
Chemotherapy, metastatic breast cancer, docetaxel, 3993<br />
Chemotherapy, myelotoxicity, prognosis, advanced, breast<br />
cancer, 2913<br />
Chemotherapy, non-small cell lung cancer, COX-2, ABC<br />
transporters, 2967<br />
Chemotherapy, osteosarcoma, caffeine, synergistic effect,<br />
cDNA array analysis, 645<br />
Chemotherapy, pancreatic cancer, vitamin K 3 (menadione),<br />
endoscopic ultrasound-guided fine needle injection, drug<br />
delivery system, 45<br />
Chemotherapy, prognostic factors, pancreatic carcinoma,<br />
surgical therapy, survival, 543<br />
Chemotherapy, radiotherapy, anal canal carcinoma, 1335<br />
Chemotherapy, sclerosing rhabdomyosarcoma, metastasis,<br />
peripheral blood stem cell transplantation, 2361<br />
Chemotherapy, thrombosis, gynecological cancer, 3971<br />
Chemotherapy-induced nausea and vomiting (CINV),<br />
clonazepam, antiemesis, benzodiazepines, anticonvulsant,<br />
2433<br />
Child outcome, breast cancer, pregnancy, hormonotherapy,<br />
patient outcome, 2447<br />
Children, acute myeloid leukemia, drug resistance, drug<br />
sensitivity, prognostic factors, 1927<br />
Chk2, prostate cancer, high-intensity focused ultrasound,<br />
DNA damage, 639<br />
Chloroethylnitrosoureas, melanoma, bystander effect,<br />
murine type, NMR spectroscopy, 21<br />
Chondrosarcoma, suberoylanilide hydroxamic acid,<br />
SAHA, apoptosis, autophagy-associated cell death,<br />
1585
CHX, apoptosis, TNF, death receptor, tyrosine phosphatase,<br />
resistance, Fas, FLIP, 593<br />
Cidofovir, human papillomavirus 11, laryngeal neoplasms,<br />
polymerase chain reaction, 2169<br />
CIITA, MHC class II, MHC2TA, polymorphism, colorectal<br />
cancer, 1789<br />
CIN, cervical dysplasia, PAP smear, endocervical cytology,<br />
cytobrush, 3131<br />
Circulating hTERT DNA, hepatocellular carcinoma, PAI-1,<br />
t-PA, 223<br />
Circulating RNA, serum, renal cancer, diagnosis, 321<br />
Circulating tumor cells, colorectal cancer, molecular<br />
staging, polymerase chain reaction, peripheral blood,<br />
review, 3945<br />
Cisplatin resistance, bleomycin, cisplatin, glutathione, cell<br />
cycle, DNA synthesis, 2663<br />
Cisplatin, 5-fluorouracil, chemotherapy, oral squamous cell<br />
carcinoma, 253<br />
Cisplatin, 5-fluorouracil, recurrent cervical cancer,<br />
metastasis, 1887<br />
Cisplatin, bleomycin, glutathione, cell cycle, DNA<br />
synthesis, cisplatin resistance, 2663<br />
Cisplatin, caffeine, combination therapy, osteosarcoma,<br />
1681<br />
Cisplatin, Cl– channel, cancer, cell volume, apoptosis, drug<br />
resistance, review, 75<br />
Cisplatin, esophageal cancer, chemotherapy, FLEP,<br />
fluorouracil, leukovorin, etoposide, 4101<br />
Cisplatin, head and neck carcinoma, paclitaxel,<br />
chemotherapy, radiotherapy, 1285<br />
Cisplatin, neuropathy, valproate, neuroprotection, 335<br />
Cisplatin, osteosarcoma, pegylated liposome, caffeine, 1449<br />
Cisplatin, S-1, advanced pancreatic cancer, phase Ⅱ study,<br />
2373<br />
Cisplatin, trigeminal ganglion, nucleotide excision repair, 2637<br />
C-kit, chemoresistant seminoma, chemotherapy, imatinib,<br />
2317<br />
Cl– channel, cancer, cell volume, apoptosis, cisplatin, drug<br />
resistance, review, 75<br />
Class Ib, MHC, promoter, cancer, gene expression, gene<br />
therapy, 799<br />
Classification systems, gastrointestinal stromal tumors,<br />
prognosis, 367<br />
Claudin, separation, subpopulation, colon cancer,<br />
heterogeneity, ZO-1, 3665<br />
Clinical management, preoperative diagnosis, ultrasound,<br />
endometrial cancer, 2453<br />
Clinical trials, cancer chemoprevention, epidemiological<br />
data, review, 1857<br />
Clinicopathological factors, NLRP7, immunohistochemistry,<br />
endometrial cancer, prognosis, 2493<br />
Clonal expansion, colon cancer, metastasis, genomic<br />
profiling, dormancy, microsatellite stability, 3609<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Clonazepam, chemotherapy-induced nausea and vomiting<br />
(CINV), antiemesis, benzodiazepines, anticonvulsant,<br />
2433<br />
Clustering, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, diagnosis, prognosis,<br />
sCD26, EGF, sEGFR, ELISA, cytometric beads, antibody<br />
arrays, bioinformatics, review, 2333<br />
C-myc, cervical cancer, markers, p53, p27, COX-2, Ki-67,<br />
EGFR, E-cadherin, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
CO2 laser, persistent-recurrent CIN, conservative treatment,<br />
3871<br />
Coal, promoter methylation, smoke, PAH, benzopyrene,<br />
sputum, lung cancer, 2061<br />
Co-culture, immature dendritic cells, cytotoxic T<br />
lymphocytes, A20 leukemia/lymphoma, syngeneic,<br />
GM-CSF, 2831<br />
Collagenase, matrix metalloproteinase-9 (MMP-9),<br />
gelatinase A, survival, transitiocellular carcinoma, 1757<br />
CoLo 320DM, ferrocene, β-diketone, cytotoxicity,<br />
CorL23/CPR, 2781<br />
Colon adenocarcinoma cell lines, solanum lyratum extracts,<br />
cytotoxicity, apoptosis, 1045<br />
Colon cancer, baboons, progression, 193<br />
Colon cancer, differentiation, anthocyanins, peach, plum,<br />
phenolics, 2067<br />
Colon cancer, elderly, adjuvant chemotherapy, 2513<br />
Colon cancer, elderly, palliative chemotherapy, 1813<br />
Colon cancer, irinotecan, CPT-11, HCT116, cell cycle,<br />
DNA damage checkpoint activation, endoreduplication,<br />
senescence, cell death, 583<br />
Colon cancer, metastasis, genomic profiling, dormancy,<br />
clonal expansion, microsatellite stability, 3609<br />
Colon cancer, omega-3, omega-6, SW620, xenograft, lipids,<br />
3717<br />
Colon cancer, PAI-1, PAI-2, apoptosis, 693<br />
Colon cancer, P-glycoprotein, ABCB1 gene,<br />
polymorphisms, immunohistochemistry, 3921<br />
Colon cancer, pioglitazone, liver metastasis, 3593<br />
Colon cancer, polymorphism, VEGF, Korea, 1271<br />
Colon cancer, separation, subpopulation, heterogeneity,<br />
claudin, ZO-1, 3665<br />
Colon cancer, sphingomyelin, alkaline sphingomyelinase,<br />
mouse, 3631<br />
Colon cancer, vitamin D, Wnt, β-catenin, Dickkopf, review,<br />
2613<br />
Colon carcinogenesis, preneoplastic lesions, flat aberrant<br />
crypt foci, mucin-depleted foci, 3771<br />
Colon carcinoma, cell lines, multidrug resistance,<br />
P-glycoprotein, pO 2 , antioxidants, 55<br />
Colon, colorectal, cancer, E-cadherin, catenins, review, 3815<br />
Color Doppler ultrasonography, prostate cancer, resistance<br />
index, 1985<br />
4231
Colorectal adenoma, Cox-2 polymorphisms, African<br />
Americans, 3119<br />
Colorectal adenomas, CYP1A2 164 A➠C polymorphism,<br />
smoking, red meat, colorectal carcinomas, 2289<br />
Colorectal cancer liver metastasis, MMP expression, TIMP<br />
expression, 1459<br />
Colorectal cancer metastases, TS, matched primary tumours,<br />
1741<br />
Colorectal cancer, 5-fluorouracil, gemcitabine, metastatic<br />
disease, 3055<br />
Colorectal cancer, caspases, selenium, selenous acid, 5-FU,<br />
apoptosis, 3579<br />
Colorectal cancer, CEA, Dukes’ C, prognosis, 1933<br />
Colorectal cancer, DNA viruses, HPV, BKV, JVC, SV40,<br />
1405<br />
Colorectal cancer, GSTM1, GSTT1, p53, polymorphism,<br />
Dukes’ stage, survival, 1917<br />
Colorectal cancer, HACE1, quantitative methylation-specific<br />
PCR, 1581<br />
Colorectal cancer, Host immunity, CD4 + CD25 + T-cell,<br />
soluble IL-2R, low-dose chemotherapy, 373<br />
Colorectal cancer, hypersensitivity reaction, intracranial<br />
hemorrhage, oxaliplatin, thrombocytopenia, 3115<br />
Colorectal cancer, irinotecan, capecitabine, first-line<br />
therapy, 1923<br />
Colorectal cancer, Ki-67, PCNA, MCM2, 451<br />
Colorectal cancer, mass screening, SSCP analysis,<br />
exfoliated colonocytes, fecal DNA, 145<br />
Colorectal cancer, matrix metalloproteinases, thyroid<br />
neoplasm, review, 1389<br />
Colorectal cancer, metastases, chemotherapy, antibodies,<br />
treatment, 4111<br />
Colorectal cancer, metastasis, S-1, CPT-11, 1837<br />
Colorectal cancer, MHC class II, MHC2TA, CIITA,<br />
polymorphism, 1789<br />
Colorectal cancer, molecular staging, circulating tumor<br />
cells, polymerase chain reaction, peripheral blood, review,<br />
3945<br />
Colorectal cancer, PGP9.5, quantitative methylation-specific<br />
PCR, marker, 2697<br />
Colorectal cancer, POLR2F, PRNP, ATP6V0A1, quantitative<br />
RT-PCR, 1221<br />
Colorectal cancer, S-1, tegafur/uracil, oral leucovorin, 1779<br />
Colorectal cancer, tumor budding, prognosis,<br />
immunohistochemistry, D2-40, 1831<br />
Colorectal cancer, VEGF-1 expression, prognosis, adjuvant<br />
therapy, 3865<br />
Colorectal carcinoma, liver metastasis, S-1, COX-2<br />
inhibitor, 629<br />
Colorectal carcinomas, CYP1A2 164 A C polymorphism,<br />
smoking, red meat, colorectal adenomas, 2289<br />
Colorectal, 5-fluorouracil, arterial, infusion, cetuximab,<br />
irinotecan, oxaliplatin, metastases, 2459<br />
4232<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Colorectal, cancer, lung, head and neck, biomarkers, serum,<br />
screening, diagnosis, prognosis, sCD26, EGF, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Colorectal, colon, cancer, E-cadherin, catenins, review, 3815<br />
Colposcopy, cervical dysplasia, cervical intraepithelial<br />
neoplasia, 1763<br />
Colposcopy, cervical dysplasia, negative histology, positive<br />
margin, LLETZ, 519<br />
Combination chemotherapy, S-1, 5-fluorouracil,<br />
gemcitabine, human equilibrative nucleotide transporter,<br />
schedule-dependent effect, in vivo, pancreatic cancer, 179<br />
Combination chemotherapy, S-1, CPT-11, complete<br />
response, 559<br />
Combination therapy, antiangiogenic therapy, vascular<br />
disrupting agents, renal cell carcinoma, 2027<br />
Combination therapy, caffeine, cisplatin, osteosarcoma, 1681<br />
Combination therapy, S-1, low-dose cisplatin, gastric<br />
cancer, outpatient setting, 1433<br />
Combined PET/CT, oesophageal cancer, FDG-positron<br />
emission tomography, computed tomography, software<br />
fusion, 1867<br />
Complementary treatment, breast cancer, standardized<br />
mistletoe extract, quality of life, epidemiological cohort<br />
study, 523<br />
Complete response, S-1, CPT-11, combination<br />
chemotherapy, 559<br />
Computed tomography, oesophageal cancer, FDG-positron<br />
emission tomography, combined PET/CT, software<br />
fusion, 1867<br />
Computed tomography, ovarian cancer, positron emission<br />
tomography, tumor marker, 2303<br />
Computed tomography, polyps, size, 1911<br />
Concurrent radiotherapy, cervical cancer, carboplatin,<br />
paclitaxel, 3143<br />
Confocal microscopy, endomicroscopy, molecular imaging,<br />
cancer, ulcerative colitis, review, 353<br />
Conformal radiotherapy, pancreas, unresectable cancer,<br />
chemoradiotherapy, hyper-fractionated accelerated<br />
radiotherapy, gemcitabine, 2369<br />
Conservative treatment, persistent-recurrent CIN, CO2 laser,<br />
3871<br />
Constipation, neurofibromatosis-1, von Recklinghausen’s<br />
disease, malignant peripheral nerve sheath tumor,<br />
sarcomas, 3107<br />
Core-binding factor, PDGFR, acute myeloid leukemia,<br />
single-strand conformation polymorphism, 2745<br />
CorL23/CPR, ferrocene, β-diketone, cytotoxicity, CoLo<br />
320DM, 2781<br />
Cost-effectiveness, anemia, cancer, erythrocyte transfusion,<br />
459<br />
COX-2 inhibitor, colorectal carcinoma, liver metastasis, S-<br />
1, 629
Cox-2 polymorphisms, colorectal adenoma, African<br />
Americans, 3119<br />
COX-2, bladder cancer, MVD, CD105, β-catenin, 2479<br />
COX-2, cervical cancer, markers, p53, p27, Ki-67, EGFR,<br />
E-cadherin, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
COX-2, curcumin, tetrahydrocurcumin, NF-ÎB, chemical<br />
descriptors, lipopolysaccharide, Porphyromonas gingivalis<br />
fimbriae, 699<br />
COX-2, non-small cell lung cancer, ABC transporters,<br />
chemotherapy, 2967<br />
Coxackie-adenovirus receptor, gene therapy, thymidine<br />
kinase, adenovirus, ovarian cancer, 2569<br />
CPT-11, colorectal cancer, metastasis, S-1, 1837<br />
CPT-11, irinotecan, colon cancer, HCT116, cell cycle, DNA<br />
damage checkpoint activation, endoreduplication,<br />
senescence, cell death, 583<br />
CPT-11, new combined chemotherapy, phase I study,<br />
gynecological malignancy, MMC, 5-FU, 2933<br />
CPT-11, S-1, complete response, combination<br />
chemotherapy, 559<br />
Craniofacial reconstruction, head and neck cancer, epithesis,<br />
self-perception, social reintegration, 2349<br />
C-reactive protein, procalcitonin, infection, leukopenia,<br />
3061<br />
CRNA microarrays, glioblastoma multiforme, epidermal<br />
growth factor receptor pathway, erlotinib, gene<br />
expression, 3725<br />
CRNA microarrays, glioblastoma multiforme, genetic<br />
pathways of pathogenesis, erlotinib, gene expression,<br />
3729<br />
C-src, vimentin, prostate cancer, invasion, E-cadherin/catenin,<br />
327<br />
CT3N0M0, neoadjuvant chemotherapy, rectal cancer, 4129<br />
CTL, pancreatic cancer, MUC1, dendritic cell,<br />
immunotherapy, 379<br />
CUP, cancer of unknown primary site, chemoresistance,<br />
paclitaxel, tau, tubulin, tubulin III, 1161<br />
Curcumin, neuroblastoma, apoptosis, NfkappaB, 209<br />
Curcumin, tetrahydrocurcumin, COX-2, NF-ÎB, chemical<br />
descriptors, lipopolysaccharide, Porphyromonas gingivalis<br />
fimbriae, 699<br />
Curettage, giant cell tumor, sternum,<br />
polymethylmethacrylate, 4117<br />
Cutaneous tumors, HER3, squamous cell carcinoma, nevus,<br />
PCR, 973<br />
Cyclin D1, breast cancer, MDA-MB-231 cells, δtocotrienol,<br />
cell cycle, retinoblastoma, 2641<br />
Cyclin dependent kinase, mesothelioma, p16 INK4a , 1<br />
Cyclooxygenase, extrahepatic cholangiocarcinoma,<br />
lipoxygenase, eicosanoid pathways, survival, 873<br />
Cyclopentenone, apoptosis, cytotoxicity, mitochondria,<br />
315<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Cyclophosphamide, breast carcinoma, chemotherapy,<br />
doxorubicin, ferritin, iron, neopterin, paclitaxel, 2389<br />
Cyclophosphamide, mTOR, everolimus, rapamycin,<br />
sensitization, 3801<br />
Cyclosporine, immunosuppression, experimental model,<br />
HT29 cells, 105<br />
CYP1A1, oral cancer, susceptibility genes, GSTM1, GSTT1,<br />
1023<br />
CYP1A2 164 A C polymorphism, smoking, red meat,<br />
colorectal adenomas, colorectal carcinomas, 2289<br />
CYP27B1, prostate, tumor suppressor, vitamin D, 25hydroxyvitamin<br />
D-1 alpha-hydroxylase, 2015<br />
Cyp27b1, vitamin D hydroxylase, histone deacetylase<br />
inhibitor, prostate cancer, 2009<br />
Cytobrush, cervical dysplasia, CIN, PAP smear,<br />
endocervical cytology, 3131<br />
Cytochrome c, DADS, apoptosis, caspase-3, mitochondrial<br />
membrane potential (Δψm), 2791<br />
Cytogenetics, single-walled carbon nanotubes, multi-walled<br />
carbon nanotubes, genotoxicity, Salmonella Ames test,<br />
349<br />
Cytokine, prostate, cancer, annexin, gp96, review, 2843<br />
Cytokine-induced killer cells, non-small cell lung cancer,<br />
immunotherapy, 3997<br />
Cytokines, monocytes, tumour growth, angiogenesis, 187<br />
Cytology, breast cancer, fine-needle aspiration biopsy,<br />
nuclear morphometry, breast disease, fibroadenoma,<br />
fibrocystic disease, sampling, mean nuclear area, MNA,<br />
3985<br />
Cytometric beads, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, diagnosis, prognosis,<br />
sCD26, EGF, sEGFR, ELISA, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Cytopenia, Gaucher’s disease, hematological toxicity, nonsmall<br />
cell lung cancer, adenocarcinoma, chemotherapy,<br />
3937<br />
Cytoplasmic calcium (Ca 2+ ), bee venom (BV), apoptosis,<br />
caspase, reactive oxygen species, mitochondria, 833<br />
Cytotoxic T lymphocytes, immature dendritic cells, A20<br />
leukemia/lymphoma, co-culture, syngeneic, GM-CSF,<br />
2831<br />
Cytotoxicity, 3-formylchromone derivatives, QSAR,<br />
semiempirical molecular-orbital method, absolute<br />
hardness, 277<br />
Cytotoxicity, 5-trifluoromethyloxazole derivatives, QSAR,<br />
semiempirical molecular-orbital method, absolute<br />
hardness, 997<br />
Cytotoxicity, CDC20, siRNA, pancreas, therapy,<br />
chemoradiation, 1559<br />
Cytotoxicity, cervical cancer, estrogen receptor, gene<br />
therapy, chemotherapy, apoptosis, MTT, caspase-3,<br />
CaSki, 2181<br />
Cytotoxicity, cyclopentenone, apoptosis, mitochondria, 315<br />
4233
Cytotoxicity, ferrocene, β-diketone, CoLo 320DM,<br />
CorL23/CPR, 2781<br />
Cytotoxicity, solanum lyratum extracts, apoptosis, colon<br />
adenocarcinoma cell lines, 1045<br />
Cytotoxicity, vitamin K 2 , prenylalcohol, apoptosis,<br />
autophagy, type of cell death, 151<br />
Β-Catenin, bladder cancer, MVD, CD105, COX-2, 2479<br />
Β-Catenin, invasive front, liver metastasis, 1821<br />
Β-Catenin, vitamin D, Wnt, Dickkopf, colon cancer, review,<br />
2613<br />
Β-Catenin, Wnt, acute leukemia, self-renewal, Notch,<br />
2701<br />
β-Cyclodextrin benzaldehyde inclusion compound, type of<br />
cell death, oral squamous cell carcinoma, 229<br />
Β-Cyclodextrin, albendazole, ovarian cancer, efficacy,<br />
toxicity, 2775<br />
3-Demethylubiquinone Q2, ascidian, Aplidium glabrum,<br />
MRT, cancer preventive and anticancer activities,<br />
apoptosis, 927<br />
5’-Deoxy-5-fluorouridine, paclitaxel, nude mice, gastric<br />
cancer, thymidine phosphorylase, apoptosis, 1593<br />
6-Dimethylaminopurine, apoptosis, caspase, intracellular<br />
calcium ion, gene expression, genetic network, 609<br />
D2-40, tumor budding, colorectal cancer, prognosis,<br />
immunohistochemistry, 1831<br />
Da Vinci, prostate cancer, robot, laparoscopic radical<br />
prostatectomy, 1989<br />
DADS, apoptosis, caspase-3, cytochrome c, mitochondrial<br />
membrane potential (Δψm), 2791<br />
Darbepoetin alfa, anemia, chemotherapy, supportive care,<br />
1767<br />
DBM, rectal cancer, rectosigmoid cancer, prognostic factor,<br />
1773<br />
Death receptor, apoptosis, TNF, tyrosine phosphatase,<br />
resistance, Fas, CHX, FLIP, 593<br />
Decorin, aggrecan, versican, Western blotting, immunohistochemistry,<br />
RT-PCR, proteoglycan, 245<br />
Dendritic cell, lung cancer, immunotherapy, N2 disease,<br />
adjuvant therapy, surgery, regional lymph node, 1229<br />
Dendritic cell, pancreatic cancer, MUC1, CTL,<br />
immunotherapy, 379<br />
Dendritic cells, interferon-gamma, maturation, T H 1<br />
polarisation, 1467<br />
Dendritic cells, regulatory T-cells, human FOXP3,<br />
immunotherapy, tumor immunity, survival, 2401<br />
Deoxycytidine kinase, gemcitabine resistance, pancreatic<br />
cancer, 2205<br />
Depsipeptide, p53 gene therapy, histone deacetylase<br />
inhibitor, FK228, esophageal squamous cell carcinoma,<br />
665<br />
Depsipeptide, transfection efficiency, polyethylenimine, Raji<br />
cells, KB cells, 793<br />
Desmoid tumor, fibromatosis, oral cavity, 1725<br />
4234<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Desmopressin, vasopressin, peptide analog, chemotherapy,<br />
breast cancer, 2607<br />
Des-γ-carboxyprothrombin, hepatocellular carcinoma,<br />
electrochemiluminescence immunoassay, 2219<br />
Dexamethasone, plasmacytoma, MAPK inhibitor, p38,<br />
SCIO-469, SD-282, RPMI-8226, H-929, HSP-27, 3827<br />
Diagnosis, breast metastasis, primary ovarian cancer, 3047<br />
Diagnosis, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, prognosis, sCD26, EGF,<br />
sEGFR, ELISA, cytometric beads, antibody arrays,<br />
clustering, bioinformatics, review, 2333<br />
Diagnosis, ethnic minority, Māori, Pacific Island, treatment,<br />
accessibility, 3891<br />
Diagnosis, lung cancer, pulmonary nodule, mass-screening,<br />
bronchoscopy, video-assisted thoracoscopic surgery, 3153<br />
Diagnosis, melanoma, imprint touch cytology,<br />
intraoperative, sentinel node, treatment,<br />
immunohistochemistry, 465<br />
Diagnosis, primary retroperitoneal mucinous cystadenoma,<br />
staging, treatment, 2309<br />
Diagnosis, serum, circulating RNA, renal cancer, 321<br />
Dickkopf, vitamin D, Wnt, β-catenin, colon cancer, review,<br />
2613<br />
Diet, alcohol, cancer, risk, iron, legumes, meat, smoking,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Differentiation therapy, cell death therapy, gene therapy,<br />
prostate cancer, radiosensitivity, tumor suppression,<br />
tyrosine kinases, 2141<br />
Differentiation, colon cancer, anthocyanins, peach, plum,<br />
phenolics, 2067<br />
Differentiation, germ-cell testicular tumor, chemoresistance,<br />
apoptosis, p53, p21, 1641<br />
Dihydropyrimidine dehydrogenase, thymidine synthase,<br />
thymidine phosphorylase, orotate phophoribosyl<br />
transferase, 389<br />
Dihydropyrimidine dehydrogenase, thymidine synthase,<br />
thymidine phosphorylase, orotate phosphoribosyl<br />
transferase, laser-captured microdissection, 1477<br />
Disseminated intravascular coagulation, gastric cancer, bone<br />
marrow metastasis, 5-fluorouracil infusional therapy,<br />
1293<br />
DLEC1, NPC, methylation, p16, BLU, E-cadherin, 2161<br />
DNA content, image cytometry, bladder cancer, review, 443<br />
DNA damage checkpoint activation, irinotecan, CPT-11,<br />
colon cancer, HCT116, cell cycle, endoreduplication,<br />
senescence, cell death, 583<br />
DNA damage, prostate cancer, high-intensity focused<br />
ultrasound, Chk2, 639<br />
DNA fragmentation, benzocycloheptoxazines, apoptosis,<br />
autophagy, caspase, 1069<br />
DNA repair, gastric cancer, oxidative DNA damage, 215<br />
DNA repair, pur-alpha, HIV-1 Tat, Rad51, 1441
DNA synthesis, bleomycin, cisplatin, glutathione, cell cycle,<br />
cisplatin resistance, 2663<br />
DNA viruses, colorectal cancer, HPV, BKV, JVC, SV40,<br />
1405<br />
DNA, dysplasia, carcinoma in situ, RNA, 2417<br />
DNA-repair genes, cancer susceptibility, genetic<br />
polymorphisms, 2941<br />
DNAses, prognosis, vitamin C, vitamin K 3 , adjuvant<br />
therapy, review, 2727<br />
Docetaxel, feasibility, cervical cancer, nedaplatin,<br />
chemotherapy, 2385<br />
Docetaxel, first-line chemotherapy, gemcitabine, HER-2,<br />
metastatic breast cancer, paclitaxel, taxane, review, 1245<br />
Docetaxel, metastatic breast cancer, chemotherapy, 3993<br />
Docetaxel, reast cancer, primary systemic chemotherapy,<br />
epirubicin, 4137<br />
Dormancy, colon cancer, metastasis, genomic profiling,<br />
clonal expansion, microsatellite stability, 3609<br />
Doxil, head and neck cancer, chemotherapy, Caelyx, Taxol,<br />
pharmacokinetics, 2519<br />
Doxorubicin, breast carcinoma, chemotherapy,<br />
cyclophosphamide, ferritin, iron, neopterin, paclitaxel,<br />
2389<br />
Doxorubicin, RET, apoptosis, medullary thyroid cancer,<br />
MAPK pathway, 2019<br />
Drug delivery system, pancreatic cancer, vitamin K 3<br />
(menadione), chemotherapy, endoscopic ultrasoundguided<br />
fine needle injection, 45<br />
Drug resistance, acute myeloid leukemia, children, drug<br />
sensitivity, prognostic factors, 1927<br />
Drug resistance, ATP, chemosensitivity, prediction, ovarian<br />
cancer, 949<br />
Drug resistance, Cl– channel, cancer, cell volume,<br />
apoptosis, cisplatin, review, 75<br />
Drug resistance, leukemia, cell cycle, apoptosis, p21, 965<br />
Drug resistance, silibinin, paclitaxel, invasion, Pglycoprotein,<br />
survivin, 1119<br />
Drug sensitivity, acute myeloid leukemia, children, drug<br />
resistance, prognostic factors, 1927<br />
Dukes’ C, CEA, prognosis, colorectal cancer, 1933<br />
Dukes’ stage, GSTM1, GSTT1, p53, polymorphism,<br />
colorectal cancer, survival, 1917<br />
Dysadherin, head and neck cancer, radiation therapy, Ecadherin,<br />
3859<br />
Dysphagia, aspiration, postoperative radiation,<br />
oropharyngeal cancer, 431<br />
Dysplasia, carcinoma in situ, DNA, RNA, 2417<br />
Dysplasia, photodynamic therapy, Barrett's esophagus, p53,<br />
485<br />
Β-Diketone, ferrocene, cytotoxicity, CoLo 320DM,<br />
CorL23/CPR, 2781<br />
3D endoscopic ultrasonography, early gastric cancer, tumor<br />
volumetry, lymph node metastasis, 2907<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
E2F, breast cancer, tumour suppressor, 2135<br />
Early diagnosis, ovarian cancer, tumor markers,<br />
gonadotropins, antitumoral vaccine, review, 3135<br />
Early gastric cancer, tumor volumetry, 3D endoscopic<br />
ultrasonography, lymph node metastasis, 2907<br />
E-cadherin, cervical cancer, markers, p53, p27, COX-2, Ki-<br />
67, EGFR, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
E-cadherin, colorectal, colon, cancer, catenins, review, 3815<br />
E-cadherin, head and neck cancer, radiation therapy,<br />
dysadherin, 3859<br />
E-cadherin, NPC, methylation, p16, DLEC1, BLU, 2161<br />
E-cadherin, snail, adenovirus, metastasis, 621<br />
E-cadherin/-catenin, vimentin, prostate cancer, invasion, Csrc,<br />
327<br />
Efficacy, albendazole, β-cyclodextrin, ovarian cancer,<br />
toxicity, 2775<br />
EGCG, macrophage, apoptosis, autophagy, 1713<br />
EGF (epidermal growth factor), EGFR (epidermal growth<br />
factor receptor), c-erbB-2 (HER-2), pancreatic ductal<br />
carcinoma, 1399<br />
EGF receptor, cancer, caveolin-1, MAP kinase signaling,<br />
PPARγ, rosiglitazone, 895<br />
EGF, cancer, lung, colorectal, head and neck, biomarkers,<br />
serum, screening, diagnosis, prognosis, sCD26, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
EGFR (epidermal growth factor receptor), EGF (epidermal<br />
growth factor), c-erbB-2 (HER-2), pancreatic ductal<br />
carcinoma, 1399<br />
EGFR, amplification, EGFRvIII, glioblastoma, glioma,<br />
oligodendroglioma, 913<br />
EGFR, bortezomib, cetuximab, epidermal growth factor<br />
receptor, squamous cell head and neck carcinoma cell<br />
lines (HNSCC), 2239<br />
EGFR, bortezomib, epidermal growth factor receptor, head<br />
and neck squamous cell carcinoma cell lines, 687<br />
EGFR, cervical cancer, markers, p53, p27, COX-2, Ki-67,<br />
E-cadherin, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
EGFRvIII, amplification, EGFR, glioblastoma, glioma,<br />
oligodendroglioma, 913<br />
Egg PC, liposome, microfluidics, ethanol injection, 943<br />
Eicosanoid pathways, extrahepatic cholangiocarcinoma,<br />
cyclooxygenase, lipoxygenase, survival, 873<br />
Elastosis, melanoma, skin cancer, smoking, ultraviolet,<br />
vitamin D, 4003<br />
Elderly, adjuvant chemotherapy, colon cancer, 2513<br />
Elderly, carboplatin, head and neck cancer, oesophageal<br />
cancer, poor performance status, vinorelbine, 1383<br />
Elderly, neoadjuvant chemotherapy, vinorelbine, locally<br />
advanced breast cancer, 3093<br />
Elderly, palliative chemotherapy, colon cancer, 1813<br />
4235
Electrochemiluminescence immunoassay, Des-γcarboxyprothrombin,<br />
hepatocellular carcinoma, 2219<br />
Electron microscopy, Krukenberg tumour, ovary, signet-ring<br />
cell carcinoma, stomach, immunohistochemistry, 1417<br />
ELISA, cancer, lung, colorectal, head and neck, biomarkers,<br />
serum, screening, diagnosis, prognosis, sCD26, EGF,<br />
sEGFR, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Embryology, cell differentiation, intermediate filaments,<br />
keratin, prostate, 237<br />
Embryonal carcinoma, gingival metastasis, germ cell tumor,<br />
testicular tumor, 1181<br />
EMMPRIN, invasion, oral SCC, TN-C, MMP, 2049<br />
Endocervical cytology, cervical dysplasia, CIN, PAP smear,<br />
cytobrush, 3131<br />
Endochondral ossification, murine osteosarcoma, cell line,<br />
transplantation, osteoblastic differentiation, 1627<br />
Endometrial cancer, grade 3 tumor, adjuvant chemotherapy,<br />
1785<br />
Endometrial cancer, hepsin, prognostic significance, 159<br />
Endometrial cancer, MMP-2, MMP-9, TIMP-1, TIMP-2,<br />
prognosis, 2715<br />
Endometrial cancer, NLRP7, immunohistochemistry,<br />
clinicopathological factors, prognosis, 2493<br />
Endometrial cancer, preoperative diagnosis, ultrasound,<br />
clinical management, 2453<br />
Endometrial carcinoma, adjuvant tamoxifen, breast cancer,<br />
ultrasound, 1259<br />
Endometrial carcinoma, imup-1, imup-2, up-regulation, 865<br />
Endomicroscopy, confocal microscopy, molecular imaging,<br />
cancer, ulcerative colitis, review, 353<br />
Endoplasmatic reticulum, hypericin, photodynamic therapy,<br />
glioma, intracellular localization, Golgi apparatus, 2033<br />
Endoreduplication, irinotecan, CPT-11, colon cancer,<br />
HCT116, cell cycle, DNA damage checkpoint activation,<br />
senescence, cell death, 583<br />
Endoscopic ultrasound-guided fine needle injection,<br />
pancreatic cancer, vitamin K 3 (menadione),<br />
chemotherapy, drug delivery system, 45<br />
Endothelial cell-derived microparticles, breast cancer,<br />
leukocyte-derived microparticles, CEA, CA15-3, 1107<br />
Endothelial cells, tumor angiogenesis, marrow-derived stem<br />
cells, origin, 771<br />
ENMD-1198, STX140, breast cancer, 2-methoxyestradiol,<br />
myelotoxicity, 1483<br />
Enzymes, nitrobutadiene derivatives, toxicity, liver, kidney,<br />
813<br />
EpCAM, urothelial cancer, renal pelvis, 125<br />
EphB receptors, ephrin-B, rhabdomyosarcoma, 763<br />
Ephrin-B, EphB receptors, rhabdomyosarcoma, 763<br />
Epidemiological cohort study, breast cancer, complementary<br />
treatment, standardized mistletoe extract, quality of life,<br />
523<br />
4236<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Epidemiological data, cancer chemoprevention, clinical<br />
trials, review, 1857<br />
Epidermal growth factor receptor pathway, glioblastoma<br />
multiforme, erlotinib, gene expression, cRNA<br />
microarrays, 3725<br />
Epidermal growth factor receptor, allele-specific PCR,<br />
gefitinib, mutation screening, non-small cell lung cancer,<br />
2265<br />
Epidermal growth factor receptor, bortezomib, cetuximab,<br />
EGFR, squamous cell head and neck carcinoma cell lines<br />
(HNSCC), 2239<br />
Epidermal growth factor receptor, bortezomib, EGFR, head<br />
and neck squamous cell carcinoma cell lines, 687<br />
Epidermal growth factor receptor, fluorescence activated<br />
cell sorter, mesothelin, N-cadherin, SV40, ultrastructure,<br />
197<br />
Epigenetic gene regulation, pancreatic ductal<br />
adenocarcinoma, INK4a, K-RAS, SMAD4, TP53, NF-ÎB,<br />
PI3K, SKP2, RB, p27 Kip1 , cell cycle, angiogenesis,<br />
metastasis, proliferation, apoptosis, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
Epirubicin, neoadjuvant chemotherapy, breast, taxol, p53,<br />
Erb family, 3147<br />
Epirubicin, reast cancer, primary systemic chemotherapy,<br />
docetaxel, 4137<br />
Epithelial-mesenchymal transition, pancreatic ductal<br />
adenocarcinoma, INK4a, K-RAS, SMAD4, TP53, NF-ÎB,<br />
PI3K, SKP2, RB, p27 Kip1 , cell cycle, angiogenesis,<br />
metastasis, proliferation, apoptosis, epigenetic gene<br />
regulation, miRNA, chemotaxis, sonic hedgehog, review,<br />
1541<br />
Epithesis, head and neck cancer, craniofacial reconstruction,<br />
self-perception, social reintegration, 2349<br />
ER, KGF, siRNA, MCF-7, cell proliferation, 2733<br />
ER-β, biospecific column chromatography, RTPs, GSTP1,<br />
resveratrol, glutathione sulfotransferase-π, 29<br />
ER-α36, estrogen receptor, ER-negative breast cancer, ERα66,<br />
479<br />
ER-α66, estrogen receptor, ER-α36, ER-negative breast<br />
cancer, 479<br />
Erb family, neoadjuvant chemotherapy, breast, epirubicin,<br />
taxol, p53, 3147<br />
ERCC1, gastric cancer, CDDP-resistant cell line,<br />
oxaliplatin, GST-π, MKN45, 2087<br />
ERCC1, malignant effusion, cell-free mRNA, real-time<br />
quantitative PCR, thymidylate synthase, 1085<br />
ERCC2, bladder cancer, single nucleotide polymorphism,<br />
allelic discrimination, XPC, XRCC1, XRCC3, 1853<br />
Erk1,2, KGF, WT1, FAK, Grb2, breast cancer cell motility,<br />
133<br />
Erlotinib, advanced non-small cell lung cancer,<br />
monotherapy, 2409
Erlotinib, glioblastoma multiforme, epidermal growth factor<br />
receptor pathway, gene expression, cRNA microarrays,<br />
3725<br />
Erlotinib, glioblastoma multiforme, genetic pathways of<br />
pathogenesis, gene expression, cRNA microarrays, 3729<br />
ER-negative breast cancer, estrogen receptor, ER-α36, ERα66,<br />
479<br />
Erythrocyte transfusion, anemia, cancer, cost-effectiveness,<br />
459<br />
Erythroid, megakaryocytic, lineage shift, adhesion,<br />
fibronectin, integrin, 261<br />
Erythropoetin, thrombosis, gynaecological cancer, breast<br />
cancer, 3977<br />
Esophageal cancer, chemotherapy, FLEP, fluorouracil,<br />
leukovorin, etoposide, cisplatin, 4101<br />
Esophageal cancer, chemotherapy, lung cancer, tyrosine<br />
kinase inhibitor, taxane, 3099<br />
Esophageal cancer, factor analysis, nutrients, bioactive<br />
substances. Uruguay, 2499<br />
Esophageal cancer, neoadjuvant chemotherapy, FAP, 2321<br />
Esophageal cancer, occult lung cancer, gastric cancer, 1841<br />
Esophageal cancer, VEGF-C, serum, lymph node<br />
metastasis, prognosis, recurrence, 165<br />
Esophageal carcinoma, p53, p16, Fhit protein, esophagitis,<br />
megaesophagus, 3793<br />
Esophageal squamous cell carcinoma, p53 gene therapy,<br />
histone deacetylase inhibitor, FK228, depsipeptide, 665<br />
Esophagitis, p53, p16, Fhit protein, megaesophagus,<br />
esophageal carcinoma, 3793<br />
ESR, benzocycloheptoxazines, Raw 264.7 cells, NO, iNOS,<br />
radical, 2657<br />
ESR, trihaloacetylazulenes, Raw 264.7 cells, NO, iNOS,<br />
radical, 171<br />
Essential amino acids, amino acid transport system L,<br />
LAT1, salivary gland carcinoma cells, antitumor therapy,<br />
2649<br />
Estrogen and xenobiotic metabolism, ovarian cancer,<br />
polymorphisms, 3079<br />
Estrogen receptor α, breast cancer, hedgehog signaling<br />
pathway, proliferation, sonic hedgehog, 731<br />
Estrogen receptor β, genistein, p21, prostate cancer, 709<br />
Estrogen receptor, breast cancer, risk factors, oral<br />
contraceptives, progesterone receptor, 491<br />
Estrogen receptor, cannabinoids, breast cancer, androgen<br />
receptor, 85<br />
Estrogen receptor, cervical cancer, gene therapy,<br />
chemotherapy, cytotoxicity, apoptosis, MTT, caspase-3,<br />
CaSki, 2181<br />
Estrogen receptor, ER-α36, ER-negative breast cancer, ERα66,<br />
479<br />
Estrogen, 2-methoxyestradiol, sulfamate, breast cancer,<br />
STX140, 577<br />
Ethanol injection, liposome, microfluidics, egg PC, 943<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Ethnic minority, Māori, Pacific Island, diagnosis, treatment,<br />
accessibility, 3891<br />
Etoposide, esophageal cancer, chemotherapy, FLEP,<br />
fluorouracil, leukovorin, cisplatin, 4101<br />
Everolimus, mTOR, rapamycin, sensitization,<br />
cyclophosphamide, 3801<br />
Ewing sarcoma, melphalan, hyperthermia, apoptosis,<br />
caspases, gene regulation, 2585<br />
Exfoliated colonocytes, colorectal cancer, mass screening,<br />
SSCP analysis, fecal DNA, 145<br />
Experimental lung tumor, surgical stress, growth rate, 1129<br />
Experimental model, immunosuppression, HT29 cells,<br />
cyclosporine, 105<br />
Expression profiling, miRNA, FFPE, 119<br />
Expression, programmed cell death 4 (PDCD4), ovarian<br />
cancer, prognosis, 2991<br />
Extrahepatic cholangiocarcinoma, cyclooxygenase,<br />
lipoxygenase, eicosanoid pathways, survival, 873<br />
Factor analysis, esophageal cancer, nutrients, bioactive<br />
substances. Uruguay, 2499<br />
FAK, KGF, WT1, Grb2, Erk1,2, breast cancer cell motility,<br />
133<br />
FAK, MMP-2, MMP-9, A431, Boyden chamber assay, 2109<br />
FAP, esophageal cancer, neoadjuvant chemotherapy, 2321<br />
FAS, apoptosis, CD28, immune dysfunction,<br />
immunosurveillance, TCR-zeta, T-cell impairment, breast<br />
cancer, 779<br />
Fas, apoptosis, TNF, death receptor, tyrosine phosphatase,<br />
resistance, CHX, FLIP, 593<br />
FAS, FASL, polymorphism, apoptosis, atrophy, intestinal<br />
metaplasia, 97<br />
Fascin, Ki-67, immunohistochemistry, serous ovarian<br />
cancer, prognosis, 1905<br />
FASL, FAS, polymorphism, apoptosis, atrophy, intestinal<br />
metaplasia, 97<br />
Fatty acid synthase, breast cancer, green tea catechins,<br />
animal model, weight loss, anti-cancer drug, 3671<br />
Fatty liver, thymidine kinase 1, TK1, health screening,<br />
benign, cancer, malignancy, tumour, inflammation,<br />
infection, virus, 3897<br />
FDG, anaplastic large cell lymphoma, small animal PET,<br />
xenograft, NOD/SCID, 981<br />
FDG, FLT, neuroblastoma, MRT, PET-CT, SCID mouse,<br />
2561<br />
FDG-positron emission tomography, oesophageal cancer,<br />
computed tomography, combined PET/CT, software<br />
fusion, 1867<br />
Feasibility, cervical cancer, docetaxel, nedaplatin,<br />
chemotherapy, 2385<br />
Fecal DNA, colorectal cancer, mass screening, SSCP<br />
analysis, exfoliated colonocytes, 145<br />
Ferritin, breast carcinoma, chemotherapy, cyclophosphamide,<br />
doxorubicin, iron, neopterin, paclitaxel, 2389<br />
4237
Ferrocene, β-diketone, cytotoxicity, CoLo 320DM,<br />
CorL23/CPR, 2781<br />
FFPE, miRNA, expression profiling, 119<br />
Fhit protein, p53, p16, esophagitis, megaesophagus,<br />
esophageal carcinoma, 3793<br />
Fibrin glue, gene transfer, gene therapy, 3809<br />
Fibroadenoma, breast cancer, cytology, fine-needle<br />
aspiration biopsy, nuclear morphometry, breast disease,<br />
fibrocystic disease, sampling, mean nuclear area, MNA,<br />
3985<br />
Fibrocystic disease, breast cancer, cytology, fine-needle<br />
aspiration biopsy, nuclear morphometry, breast disease,<br />
fibroadenoma, sampling, mean nuclear area, MNA, 3985<br />
Fibromatosis, desmoid tumor, oral cavity, 1725<br />
Fibronectin, hypoxia, spheroids, adhesion, integrin, 1013<br />
Fibronectin, megakaryocytic, erythroid, lineage shift,<br />
adhesion, integrin, 261<br />
Fine-needle aspiration biopsy, breast cancer, cytology,<br />
nuclear morphometry, breast disease, fibroadenoma,<br />
fibrocystic disease, sampling, mean nuclear area, MNA,<br />
3985<br />
First-line chemotherapy, docetaxel, gemcitabine, HER-2,<br />
metastatic breast cancer, paclitaxel, taxane, review, 1245<br />
First-line therapy, colorectal cancer, irinotecan,<br />
capecitabine, 1923<br />
First-line, polychemotherapy, angiosarcoma, 3041<br />
Fixed dose, phase I, anticancer agents, body surface area,<br />
body weight, 3075<br />
FK228, p53 gene therapy, histone deacetylase inhibitor,<br />
depsipeptide, esophageal squamous cell carcinoma, 665<br />
Flab, HDR brachytherapy, perioperative, bendy applicator,<br />
sarcoma, 3885<br />
Flat aberrant crypt foci, preneoplastic lesions, mucindepleted<br />
foci, colon carcinogenesis, 3771<br />
Flavopiridol, parthenolide, BAY 11-7085, N-acetylcysteine,<br />
L-buthionine-(S,R)-sulfoximine, PRIMA-1, Gemcitabine,<br />
MG-132, 681<br />
FLEP, esophageal cancer, chemotherapy, fluorouracil,<br />
leukovorin, etoposide, cisplatin, 4101<br />
FLIP, apoptosis, TNF, death receptor, tyrosine phosphatase,<br />
resistance, Fas, CHX, 593<br />
Flow cytometry, neuroblastoma, rhabdomyosarcoma,<br />
immunophenotyping, 1565<br />
Flow cytometry, syndecan-1, tenascin-C, TATI, p53, p21,<br />
bcl-2, immunohistochemistry, gastric cancer, prognosis,<br />
2279<br />
FLT, FDG, neuroblastoma, MRT, PET-CT, SCID mouse,<br />
2561<br />
Flt-1, angiogenesis, autocrine signalling, breast cancer,<br />
VEGF, 1719<br />
Fluorescence activated cell sorter, epidermal growth factor<br />
receptor, mesothelin, N-cadherin, SV40, ultrastructure,<br />
197<br />
4238<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
5-Fluorouracil infusional therapy, gastric cancer,<br />
disseminated intravascular coagulation, bone marrow<br />
metastasis, 1293<br />
5-Fluorouracil, arterial, infusion, cetuximab, colorectal,<br />
irinotecan, oxaliplatin, metastases, 2459<br />
5-Fluorouracil, cell cycle, chemoresistance, BrdU, 9<br />
5-Fluorouracil, cisplatin, chemotherapy, oral squamous cell<br />
carcinoma, 253<br />
5-Fluorouracil, cisplatin, recurrent cervical cancer,<br />
metastasis, 1887<br />
5-Fluorouracil, colorectal cancer, gemcitabine, metastatic<br />
disease, 3055<br />
5-Fluorouracil, liposomal cisplatin, lipoplatin, head and<br />
neck cancer, 3961<br />
5-Fluorouracil, lymphocytes, activation, 3785<br />
5-Fluorouracil, S-1, gemcitabine, human equilibrative<br />
nucleotide transporter, schedule-dependent effect,<br />
combination chemotherapy, in vivo, pancreatic cancer,<br />
179<br />
Fluorouracil, esophageal cancer, chemotherapy, FLEP,<br />
leukovorin, etoposide, cisplatin, 4101<br />
Folate receptor overexpression, ovarian carcinoma, alphafolate<br />
receptor, targeted therapy, 3567<br />
3-Formylchromone derivatives, QSAR, cytotoxicity,<br />
semiempirical molecular-orbital method, absolute<br />
hardness, 277<br />
Fresh frozen plasma, hepatocellular carcinoma,<br />
hepatectomy, 1749<br />
Frozen section analysis, vulvar cancer, sentinel lymph node<br />
dissection, 4091<br />
5-FU, colorectal cancer, caspases, selenium, selenous acid,<br />
apoptosis, 3579<br />
5-FU, new combined chemotherapy, phase I study,<br />
gynecological malignancy, CPT-11, MMC, 2933<br />
5-FU, thymidylate synthase, resistance, 5-FUdR,<br />
mycoplasma, 2175<br />
5-FUdR, thymidylate synthase, resistance, 5-FU,<br />
mycoplasma, 2175<br />
Furanoacridones, multidrug resistance, apoptosis, 2737<br />
Fusion genes, lipoma, HMGA2, 535<br />
GADD153, baicalein, calcium, apoptosis, mitochondrial<br />
membrane potential, 1701<br />
Gastrectomy, non-curative factor, prognostic factor,<br />
advanced gastric cancer, 2379<br />
Gastric cancer, 5’-deoxy-5-fluorouridine, paclitaxel, nude<br />
mice, thymidine phosphorylase, apoptosis, 1593<br />
Gastric cancer, CDDP-resistant cell line, oxaliplatin,<br />
ERCC1, GST-π, MKN45, 2087<br />
Gastric cancer, chemotherapy, oxaliplatin, irinotecan, 2901<br />
Gastric cancer, chemotherapy, review, 1213<br />
Gastric cancer, disseminated intravascular coagulation, bone<br />
marrow metastasis, 5-fluorouracil infusional therapy,<br />
1293
Gastric cancer, DNA repair, oxidative DNA damage, 215<br />
Gastric cancer, interleukin-12, immunohistochemistry,<br />
prognosis, 1277<br />
Gastric cancer, microRNAs (miRNAs), miR-21, prognosis,<br />
907<br />
Gastric cancer, myeloperoxidase, polymorphism,<br />
Helicobacter pylori, neutrophil, gastritis, 1317<br />
Gastric cancer, ND-factor, prognosis, non-curative factor, 435<br />
Gastric cancer, occult lung cancer, esophageal cancer, 1841<br />
Gastric cancer, P15, SMAD4, immunohistochemistry, 1079<br />
Gastric cancer, protease activated receptor-1 (PAR-1),<br />
matrix metalloproteinase-1 (MMP-1),<br />
immunohistochemistry, prognostic factor, 847<br />
Gastric cancer, RegIV, peritoneal metastasis, RT-PCR, 1169<br />
Gastric cancer, S-1, low-dose cisplatin, combination<br />
therapy, outpatient setting, 1433<br />
Gastric cancer, stomach, NOD-2, polymorphisms, 757<br />
Gastric cancer, syndecan-1, tenascin-C, TATI, p53, p21,<br />
bcl-2, immunohistochemistry, flow cytometry, prognosis,<br />
2279<br />
Gastric carcinoma, Arp, pathogenesis, progression, 2225<br />
Gastric carcinoma, MUC-1, pathobiological behavior,<br />
prognosis, 1061<br />
Gastritis, gastric cancer, myeloperoxidase, polymorphism,<br />
Helicobacter pylori, neutrophil, 1317<br />
Gastrointestinal epithelium, interleukin 1, radioprotection,<br />
apoptosis, 3601<br />
Gastrointestinal stromal tumors, classification systems,<br />
prognosis, 367<br />
Gaucher’s disease, hematological toxicity, non-small cell<br />
lung cancer, adenocarcinoma, cytopenia, chemotherapy,<br />
3937<br />
Gefitinib, allele-specific PCR, epidermal growth factor<br />
receptor, mutation screening, non-small cell lung cancer,<br />
2265<br />
Gefitinib, breast cancer, vinorelbine, gemcitabine, phase I/II<br />
study, 3019<br />
Gelatinase A, matrix metalloproteinase-9 (MMP-9),<br />
Collagenase, survival, transitiocellular carcinoma, 1757<br />
Gemcitabine resistance, pancreatic cancer, deoxycytidine<br />
kinase, 2205<br />
Gemcitabine, breast cancer, vinorelbine, gefitinib, phase I/II<br />
study, 3019<br />
Gemcitabine, colorectal cancer, 5-fluorouracil, metastatic<br />
disease, 3055<br />
Gemcitabine, docetaxel, first-line chemotherapy, HER-2,<br />
metastatic breast cancer, paclitaxel, taxane, review, 1245<br />
Gemcitabine, oxaliplatin, phase II, ovarian cancer, 495<br />
Gemcitabine, p38-MAPK, ovarian cancer, chemoresistance,<br />
2975<br />
Gemcitabine, pancreas, unresectable cancer,<br />
chemoradiotherapy, hyper-fractionated accelerated<br />
radiotherapy, conformal radiotherapy, 2369<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Gemcitabine, parthenolide, BAY 11-7085, N-acetylcysteine,<br />
L-buthionine-(S,R)-sulfoximine, PRIMA-1, MG-132,<br />
flavopiridol, 681<br />
Gemcitabine, S-1, 5-fluorouracil, human equilibrative<br />
nucleotide transporter, schedule-dependent effect,<br />
combination chemotherapy, in vivo, pancreatic cancer,<br />
179<br />
Gene expression analysis, lung cancer, HOXB2, invasion<br />
assay, microarray, 2121<br />
Gene expression, 6-dimethylaminopurine, apoptosis,<br />
caspase, intracellular calcium ion, genetic network, 609<br />
Gene expression, glioblastoma multiforme, epidermal<br />
growth factor receptor pathway, erlotinib, cRNA<br />
microarrays, 3725<br />
Gene expression, glioblastoma multiforme, genetic<br />
pathways of pathogenesis, erlotinib, cRNA microarrays,<br />
3729<br />
Gene expression, MHC, class Ib, promoter, cancer, gene<br />
therapy, 799<br />
Gene expression, TGFβ, Smads, Sp1/KLF-like transcription<br />
factors, review, 1531<br />
Gene expression, tumor marker, survivin, BIRC5, real-time<br />
RT-PCR, lung cancer, 1525<br />
Gene polymorphism, NOD2, TLR4, CD14, MALT<br />
lymphoma, Helicobacter pylori infection, 3697<br />
Gene profiling, osteosarcoma, chemoresistance, MG-63,<br />
673<br />
Gene regulation, melphalan, hyperthermia, apoptosis,<br />
caspases, Ewing sarcoma, 2585<br />
Gene therapy, adenovirus vector, CD40 ligand, rat,<br />
metastatic liver cancer, 2785<br />
Gene therapy, cell death therapy, differentiation therapy,<br />
prostate cancer, radiosensitivity, tumor suppression,<br />
tyrosine kinases, 2141<br />
Gene therapy, cervical cancer, estrogen receptor,<br />
chemotherapy, cytotoxicity, apoptosis, MTT, caspase-3,<br />
CaSki, 2181<br />
Gene therapy, gene transfer, fibrin glue, 3809<br />
Gene therapy, hepatocellular carcinoma, adenovirus vector,<br />
arterial injection, iodized oil, rat, 51<br />
Gene therapy, MHC, class Ib, promoter, cancer, gene<br />
expression, 799<br />
Gene therapy, thymidine kinase, adenovirus, Coxackieadenovirus<br />
receptor, ovarian cancer, 2569<br />
Gene transfer, gene therapy, fibrin glue, 3809<br />
Genetic network, 6-dimethylaminopurine, apoptosis,<br />
caspase, intracellular calcium ion, gene expression, 609<br />
Genetic pathways of pathogenesis, glioblastoma multiforme,<br />
erlotinib, gene expression, cRNA microarrays, 3729<br />
Genetic polymorphisms, DNA-repair genes, cancer<br />
susceptibility, 2941<br />
Genetic polymorphisms, oral leukoplakia, p53, 1101<br />
Genistein, estrogen receptor β, p21, prostate cancer, 709<br />
4239
Genistein, soy extract, MDA-MB-231 cell, nude mice,<br />
tumor growth, 2837<br />
Genome stability, PTEN, mTOR, p53, AKT, cell cycle,<br />
review, 3613<br />
Genomic karyotyping, intranuclear order, BCR-ABL,<br />
t(9:22), PML-RARA, t(15;17), review, 3573<br />
Genomic profiling, colon cancer, metastasis, dormancy,<br />
clonal expansion, microsatellite stability, 3609<br />
Genotoxic damage, hepatocarcinoma, micronuclei, broken<br />
eggs, liver dysplastic nodules, 2507<br />
Genotoxicity, single-walled carbon nanotubes, multi-walled<br />
carbon nanotubes, Salmonella Ames test, cytogenetics,<br />
349<br />
Germ cell tumor, gingival metastasis, testicular tumor,<br />
embryonal carcinoma, 1181<br />
Germ-cell testicular tumor, differentiation, chemoresistance,<br />
apoptosis, p53, p21, 1641<br />
Giant cell tumor, sternum, polymethylmethacrylate,<br />
curettage, 4117<br />
Gingival metastasis, germ cell tumor, testicular tumor,<br />
embryonal carcinoma, 1181<br />
Ginsenoside Rg3, Panax quinquefolius L., heat-processing,<br />
antiproliferation, human breast cancer, HPLC analysis,<br />
apoptosis, cell cycle, 2545<br />
Gleason grade, prostate cancer, tissue microarray, cathepsin<br />
B, inhibitor stefin A, 2271<br />
Glioblastoma multiforme, anaplastic astrocytoma, high<br />
grade glioma, histone deacetylase inhibitor, pediatric,<br />
valproic acid, 2437<br />
Glioblastoma multiforme, epidermal growth factor receptor<br />
pathway, erlotinib, gene expression, cRNA microarrays,<br />
3725<br />
Glioblastoma multiforme, genetic pathways of pathogenesis,<br />
erlotinib, gene expression, cRNA microarrays, 3729<br />
Glioblastoma multiforme, glioma, regulatory T cells (Treg),<br />
brain tumor, CD4 + CD25 + cells, immune function,<br />
review, 1143<br />
Glioblastoma multiforme, insulin like growth factor,<br />
migration, proliferation, 1055<br />
Glioblastoma, amplification, EGFR, EGFRvIII, glioma,<br />
oligodendroglioma, 913<br />
Glioblastoma, survivin, apoptosis, mitosis, 109<br />
Glioma, amplification, EGFR, EGFRvIII, glioblastoma,<br />
oligodendroglioma, 913<br />
Glioma, cancer, protease, plasminogen activator inhibitor-1<br />
(PAI-1), serum marker, 415<br />
Glioma, hypericin, photodynamic therapy, intracellular<br />
localization, endoplasmatic reticulum, Golgi apparatus, 2033<br />
Glioma, regulatory T cells (Treg), brain tumor, CD4 +<br />
CD25 + cells, glioblastoma multiforme, immune function,<br />
review, 1143<br />
Glutathione sulfotransferase-π, biospecific column<br />
chromatography, RTPs, GSTP1, ER-β, resveratrol, 29<br />
4240<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Glutathione, bleomycin, cisplatin, cell cycle, DNA<br />
synthesis, cisplatin resistance, 2663<br />
GM-CSF, immature dendritic cells, cytotoxic T<br />
lymphocytes, A20 leukemia/lymphoma, co-culture,<br />
syngeneic, 2831<br />
GNAS1, polymorphism, prostate cancer, 3711<br />
Golgi apparatus, hypericin, photodynamic therapy, glioma,<br />
intracellular localization, endoplasmatic reticulum, 2033<br />
Gonadotropins, ovarian cancer, early diagnosis, tumor<br />
markers, antitumoral vaccine, review, 3135<br />
Gossypol, liposome, PEG-DSPE, TPGS, 2801<br />
Gp96, prostate, cancer, annexin, cytokine, review, 2843<br />
Grade 3 tumor, endometrial cancer, adjuvant chemotherapy,<br />
1785<br />
Granulosa cell tumors, surgery, platinum-based<br />
chemotherapy, 1421<br />
Grb2, KGF, WT1, FAK, Erk1,2, breast cancer cell motility,<br />
133<br />
Greek population, HPV detection, HPV typing, 2233<br />
Green tea catechins, breast cancer, fatty acid synthase,<br />
animal model, weight loss, anti-cancer drug, 3671<br />
Growth inhibition, human monoclonal antibody, hybridoma,<br />
specificity to cancer cell, 1651<br />
Growth rate, surgical stress, experimental lung tumor, 1129<br />
GSTM1, GSTT1, p53, polymorphism, colorectal cancer,<br />
Dukes’ stage, survival, 1917<br />
GSTM1, oral cancer, susceptibility genes, CYP1A1, GSTT1,<br />
1023<br />
GSTP1, biospecific column chromatography, RTPs, ER-β,<br />
resveratrol, glutathione sulfotransferase-π 29<br />
GSTT1, GSTM1, p53, polymorphism, colorectal cancer,<br />
Dukes’ stage, survival, 1917<br />
GSTT1, oral cancer, susceptibility genes, CYP1A1, GSTM1,<br />
1023<br />
GST-π, gastric cancer, CDDP-resistant cell line, oxaliplatin,<br />
ERCC1, MKN45, 2087<br />
GTPase, renal cell carcinoma, real-time PCR,<br />
immunohistochemistry, 2039<br />
Guggul, guggulsterone, cancer, apoptosis, hyperlipidemia,<br />
inflammation, review, 3647<br />
Guggulsterone, guggul, cancer, apoptosis, hyperlipidemia,<br />
inflammation, review, 3647<br />
Gynaecological cancer, erythropoetin, thrombosis, breast<br />
cancer, 3977<br />
Gynecological cancer, thrombosis, chemotherapy, 3971<br />
Gynecological malignancy, new combined chemotherapy,<br />
phase I study, CPT-11, MMC, 5-FU, 2933<br />
Gypenosides, cell invasion and migration, NFÎB, MMP-2,<br />
MMP-9, 1093<br />
25-Hydroxyvitamin D-1 alpha-hydroxylase, prostate, tumor<br />
suppressor, vitamin D, CYP27B1, 2015<br />
H-929, plasmacytoma, dexamethasone, MAPK inhibitor,<br />
p38, SCIO-469, SD-282, RPMI-8226, HSP-27, 3827
HACE1, quantitative methylation-specific PCR, colorectal<br />
cancer, 1581<br />
HAMA, HMFG1, IgG, IgM, intraperitoneal, ovarian cancer,<br />
2721<br />
HCC, MTHFR, MTRR, polymorphism, risk factors, 2807<br />
HCT 116 colorectal cancer cells, sodium butyrate,<br />
hyperthermia, cell death, apoptosis, 1693<br />
HCT116, irinotecan, CPT-11, colon cancer, cell cycle, DNA<br />
damage checkpoint activation, endoreduplication,<br />
senescence, cell death, 583<br />
HDR brachytherapy, perioperative, flab, bendy applicator,<br />
sarcoma, 3885<br />
Head and neck cancer, carboplatin, elderly, oesophageal<br />
cancer, poor performance status, vinorelbine, 1383<br />
Head and neck cancer, chemotherapy, Doxil, Caelyx, Taxol,<br />
pharmacokinetics, 2519<br />
Head and neck cancer, craniofacial reconstruction, epithesis,<br />
self-perception, social reintegration, 2349<br />
Head and neck cancer, liposomal cisplatin, lipoplatin, 5fluorouracil,<br />
3961<br />
Head and neck cancer, radiation therapy, E-cadherin,<br />
dysadherin, 3859<br />
Head and neck cancer, telomerase activity, real-time TRAP,<br />
prognosis, marker, 3125<br />
Head and neck cancer, tonsillar cancer, HPV, review, 1133<br />
Head and neck carcinoma, cisplatin, paclitaxel,<br />
chemotherapy, radiotherapy, 1285<br />
Head and neck squamous cell carcinoma cell lines,<br />
bortezomib, epidermal growth factor receptor, EGFR,<br />
687<br />
Head and neck squamous cell carcinoma, chemokine<br />
receptors, Twist, lymph node metastasis, 1355<br />
Head and neck, cancer, lung, colorectal, biomarkers, serum,<br />
screening, diagnosis, prognosis, sCD26, EGF, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Health screening, thymidine kinase 1, TK1, benign, cancer,<br />
malignancy, tumour, fatty liver, inflammation, infection,<br />
virus, 3897<br />
Heat shock proteins, NSCLC, immunohistochemistry,<br />
prognosis, 501<br />
Heat-processing, Panax quinquefolius L., antiproliferation,<br />
human breast cancer, HPLC analysis, ginsenoside Rg3,<br />
apoptosis, cell cycle, 2545<br />
Hedgehog signaling pathway, breast cancer, estrogen<br />
receptor α, proliferation, sonic hedgehog, 731<br />
Helicobacter pylori infection, NOD2, TLR4, CD14, gene<br />
polymorphism, MALT lymphoma, 3697<br />
Helicobacter pylori, gastric cancer, myeloperoxidase,<br />
polymorphism, neutrophil, gastritis, 1317<br />
Hematological toxicity, Gaucher’s disease, non-small cell<br />
lung cancer, adenocarcinoma, cytopenia, chemotherapy,<br />
3937<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Hemoglobin, CEA, non-small cell lung cancer, preoperative,<br />
survival, 1947<br />
Heparanase, TUNEL, p53, tumor marker, tongue cancer,<br />
oral cancer, 2981<br />
Hepatectomy, hepatocellular carcinoma, fresh frozen<br />
plasma, 1749<br />
Hepatocarcinoma, micronuclei, broken eggs, liver dysplastic<br />
nodules, genotoxic damage, 2507<br />
Hepatocellular cancer, nude mice, seocalcitol, SKHEP-1,<br />
3757<br />
Hepatocellular carcinoma, circulating hTERT DNA, PAI-1,<br />
t-PA, 223<br />
Hepatocellular carcinoma, Des-γ-carboxyprothrombin,<br />
electrochemiluminescence immunoassay, 2219<br />
Hepatocellular carcinoma, fresh frozen plasma,<br />
hepatectomy, 1749<br />
Hepatocellular carcinoma, gene therapy, adenovirus vector,<br />
arterial injection, iodized oil, rat, 51<br />
Hepatoma, steep pulsed electric field (SPEF), proliferation,<br />
biorheology, micropipette aspiration, 2245<br />
Hepsin, endometrial cancer, prognostic significance, 159<br />
Her2 overexpression, neoadjuvant chemotherapy, paclitaxel,<br />
breast cancer, 1239<br />
HER-2, docetaxel, first-line chemotherapy, gemcitabine,<br />
metastatic breast cancer, paclitaxel, taxane, review, 1245<br />
HER2, HER2/neu ECD, breast carcinoma, tumor marker,<br />
trastuzumab, 3067<br />
HER2/neu ECD, breast carcinoma, tumor marker,<br />
trastuzumab, HER2, 3067<br />
Her2/neu, prostate cancer, androgen receptor, SRC1, TIF2,<br />
prognosis, radical prostatectomy, 425<br />
HER3, cutaneous tumors, squamous cell carcinoma, nevus,<br />
PCR, 973<br />
Herpes simplex virus, oncolytic virotherapy, oral squamous<br />
cell carcinoma, syncytial formation, 3637<br />
Heterogeneity, separation, subpopulation, colon cancer,<br />
claudin, ZO-1, 3665<br />
HIF-1α, oral squamous cell carcinoma, VEGF-C,<br />
lymphangiogenesis, angiogenesis, 1659<br />
High grade glioma, anaplastic astrocytoma, glioblastoma<br />
multiforme, histone deacetylase inhibitor, pediatric,<br />
valproic acid, 2437<br />
High hydrostatic pressure, tumor cells, orthopedic surgery,<br />
viruses, bacteria, review, 3877<br />
High-intensity focused ultrasound, prostate cancer, Chk2,<br />
DNA damage, 639<br />
Hirsutism, steroid sulphatase, oestrogen, androgen, breast<br />
cancer, skin, acne, sulphatase inhibitor, 1517<br />
Histone deacetylase inhibitor, anaplastic astrocytoma,<br />
glioblastoma multiforme, high grade glioma, pediatric,<br />
valproic acid, 2437<br />
Histone deacetylase inhibitor, p53 gene therapy, FK228,<br />
depsipeptide, esophageal squamous cell carcinoma, 665<br />
4241
Histone deacetylase inhibitor, vitamin D hydroxylase,<br />
prostate cancer, Cyp27b1, 2009<br />
Histone deacetylase inhibitors, Apo2L/TRAIL, valproic<br />
acid, K562 erythroleukemia cells, apoptosis, 855<br />
HIV-1 Tat, pur-alpha, Rad51, DNA repair, 1441<br />
HMFG1, HAMA, IgG, IgM, intraperitoneal, ovarian cancer,<br />
2721<br />
HMGA2, lipoma, fusion genes, 535<br />
HNPCC, inherited cancer syndrome, adenomatous polyposis<br />
coli, BRCA1, BRCA2, MEN 2, review, 1341<br />
Hodgkin's lymphoma, chemotherapy, cell cycle, roscovitine,<br />
interleukin-26, 887<br />
Hop beta-acids, angiogenesis, angioprevention, cell<br />
proliferation, chemotaxis, VEGF, matrigel plug, 289<br />
Hormonal therapy, prostate cancer, 3-D planning, sideeffect,<br />
3913<br />
Hormonotherapy, breast cancer, pregnancy, patient outcome,<br />
child outcome, 2447<br />
Host immunity, CD4 + CD25 + T-cell, soluble IL-2R, lowdose<br />
chemotherapy, colorectal cancer, 373<br />
HOXB2, lung cancer, invasion assay, microarray, gene<br />
expression analysis, 2121<br />
HPLC analysis, Panax quinquefolius L., heat-processing,<br />
antiproliferation, human breast cancer, ginsenoside Rg3,<br />
apoptosis, cell cycle, 2545<br />
HPV detection, HPV typing, Greek population, 2233<br />
HPV typing, HPV detection, Greek population, 2233<br />
HPV, colorectal cancer, DNA viruses, BKV, JVC, SV40,<br />
1405<br />
HPV, tonsillar cancer, head and neck cancer, review, 1133<br />
HPV, tonsillar cancer, oral cancer, oropharyngeal cancer,<br />
2077<br />
HSP-27, plasmacytoma, dexamethasone, MAPK inhibitor,<br />
p38, SCIO-469, SD-282, RPMI-8226, H-929, 3827<br />
HT29 cells, immunosuppression, experimental model,<br />
cyclosporine, 105<br />
Human breast cancer, animal model, radiofrequency,<br />
metastasis, rats, 879<br />
Human breast cancer, Panax quinquefolius L., heatprocessing,<br />
antiproliferation, HPLC analysis, ginsenoside<br />
Rg3, apoptosis, cell cycle, 2545<br />
Human equilibrative nucleotide transporter, S-1, 5fluorouracil,<br />
gemcitabine, schedule-dependent effect,<br />
combination chemotherapy, in vivo, pancreatic cancer,<br />
179<br />
Human FOXP3, regulatory T-cells, immunotherapy, tumor<br />
immunity, dendritic cells, survival, 2401<br />
Human monoclonal antibody, hybridoma, specificity to<br />
cancer cell, growth inhibition, 1651<br />
Human papillomavirus 11, cidofovir, laryngeal neoplasms,<br />
polymerase chain reaction, 2169<br />
Human papillomavirus, oral leukoplakia, oral cancer,<br />
3733<br />
4242<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Human tumors, amino acids, nude mice, methionine<br />
metabolism, transulfuration, 2541<br />
Hybrid liposomes, antitumor effect, lymphoma, apoptosis,<br />
chemotherapy, 1187<br />
Hybridoma, human monoclonal antibody, specificity to<br />
cancer cell, growth inhibition, 1651<br />
Hyper-fractionated accelerated radiotherapy, pancreas,<br />
unresectable cancer, chemoradiotherapy, conformal<br />
radiotherapy, gemcitabine, 2369<br />
Hyperfractionated radiotherapy, non-small cell lung cancer,<br />
three-times daily radiotherapy, induction chemotherapy,<br />
integrated treatments, 4121<br />
Hypericin, photodynamic therapy, glioma, intracellular<br />
localization, endoplasmatic reticulum, Golgi apparatus, 2033<br />
Hyperlipidemia, guggul, guggulsterone, cancer, apoptosis,<br />
inflammation, review, 3647<br />
Hypersensitivity reaction, colorectal cancer, intracranial<br />
hemorrhage, oxaliplatin, thrombocytopenia, 3115<br />
Hyperthermia, melphalan, apoptosis, caspases, gene<br />
regulation, Ewing sarcoma, 2585<br />
Hyperthermia, sodium butyrate, cell death, apoptosis, HCT<br />
116 colorectal cancer cells, 1693<br />
Hyperthermia, thermotherapy, induction heating, 69<br />
Hypofractionation, capecitabine, radiotherapy, surgery,<br />
acceleration, amifostine, rectal cancer, 3035<br />
Hypofractionation, non-small cell lung cancer, vinorelbine,<br />
liposomal doxorubicin, acceleration, amifostine,<br />
radiotherapy, 1349<br />
Hypoxia, spheroids, adhesion, integrin, fibronectin, 1013<br />
IGF-I receptor, MYC-N, mTOR, neuroblastoma, rapamycin,<br />
temsirolimus, 1509<br />
IGF-I, prostate cancer, prostate stroma, TGF-β, tumor<br />
growth, 721<br />
IgG, HMFG1, HAMA, IgM, intraperitoneal, ovarian cancer,<br />
2721<br />
IgM, HMFG1, HAMA, IgG, intraperitoneal, ovarian cancer,<br />
2721<br />
IL-10, angiogenesis, inflammation, MIF, tamoxifen, aspirin,<br />
2093<br />
IL-2, cancer immunotherapy, melatonin, neuroimmunomodulation,<br />
1377<br />
IL-6, prostate, PSA, ARA24, NCOA4, PSCA, PEDF,<br />
matriptase, 1969<br />
Image cytometry, DNA content, bladder cancer, review, 443<br />
Image DNA analysis, immunohistochemistry, Wilms’<br />
tumour, p53, p57 kip2 , Ki-67, 751<br />
Imatinib, chemoresistant seminoma, chemotherapy, c-kit,<br />
2317<br />
Immature dendritic cells, cytotoxic T lymphocytes, A20<br />
leukemia/lymphoma, co-culture, syngeneic, GM-CSF, 2831<br />
Immune dysfunction, apoptosis, CD28, FAS,<br />
immunosurveillance, TCR-zeta, T-cell impairment, breast<br />
cancer, 779
Immune function, glioma, regulatory T cells (Treg), brain<br />
tumor, CD4 + CD25 + cells, glioblastoma multiforme,<br />
review, 1143<br />
Immunocytometry, breast cancer, Bax, Nup88, 2595<br />
Immuno-electrophoresis in cytosol, breast cancer,<br />
Apolipoprotein D, immunohistochemistry, whole sections,<br />
tissue microarray, 1151<br />
Immuno-histochemistry, aggrecan, versican, decorin,<br />
Western blotting, RT-PCR, proteoglycan, 245<br />
Immunohistochemistry, asbestos, calretinin, mesothelioma,<br />
occupational cancer, orchidectomy, 1365<br />
Immunohistochemistry, breast cancer, Apolipoprotein D,<br />
immuno-electrophoresis in cytosol, whole sections, tissue<br />
microarray, 1151<br />
Immunohistochemistry, colon cancer, P-glycoprotein,<br />
ABCB1 gene, polymorphisms, 3921<br />
Immunohistochemistry, fascin, Ki-67, serous ovarian cancer,<br />
prognosis, 1905<br />
Immunohistochemistry, gastric cancer, protease activated<br />
receptor-1 (PAR-1), matrix metalloproteinase-1 (MMP-<br />
1), prognostic factor, 847<br />
Immunohistochemistry, GTPase, renal cell carcinoma, realtime<br />
PCR, 2039<br />
Immunohistochemistry, image DNA analysis, Wilms’<br />
tumour, p53, p57 kip2 , Ki-67, 751<br />
Immunohistochemistry, interleukin-12, gastric cancer,<br />
prognosis, 1277<br />
Immunohistochemistry, Krukenberg tumour, ovary, signetring<br />
cell carcinoma, stomach, electron microscopy, 1417<br />
Immunohistochemistry, lymphangiogenesis, CD105, small<br />
cell lung carcinoma, prognosis, 343<br />
Immunohistochemistry, melanoma, imprint touch cytology,<br />
intraoperative, sentinel node, diagnosis, treatment, 465<br />
Immunohistochemistry, NLRP7, endometrial cancer,<br />
clinicopathological factors, prognosis, 2493<br />
Immunohistochemistry, NSCLC, heat shock proteins,<br />
prognosis, 501<br />
Immunohistochemistry, P15, SMAD4, gastric cancer, 1079<br />
Immunohistochemistry, syndecan-1, tenascin-C, TATI, p53,<br />
p21, bcl-2, flow cytometry, gastric cancer, prognosis,<br />
2279<br />
Immunohistochemistry, tumor budding, colorectal cancer,<br />
prognosis, D2-40, 1831<br />
Immunophenotyping, neuroblastoma, rhabdomyosarcoma,<br />
flow cytometry, 1565<br />
Immunosuppression, experimental model, HT29 cells,<br />
cyclosporine, 105<br />
Immunosurgery, immunotherapy, interleukin-2,<br />
lymphocytopenia, pancreatic cancer, 1951<br />
Immunosurveillance, apoptosis, CD28, FAS, immune<br />
dysfunction, TCR-zeta, T-cell impairment, breast cancer, 779<br />
Immunotherapy, immunosurgery, interleukin-2,<br />
lymphocytopenia, pancreatic cancer, 1951<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Immunotherapy, lung cancer, N2 disease, adjuvant therapy,<br />
surgery, dendritic cell, regional lymph node, 1229<br />
Immunotherapy, non-small cell lung cancer, cytokineinduced<br />
killer cells, 3997<br />
Immunotherapy, pancreatic cancer, MUC1, dendritic cell,<br />
CTL, 379<br />
Immunotherapy, regulatory T-cells, human FOXP3, tumor<br />
immunity, dendritic cells, survival, 2401<br />
Implanted pump, TT-232, somatostatin analog, rodent and<br />
human tumor models, 2769<br />
Imprint touch cytology, melanoma, intraoperative, sentinel<br />
node, diagnosis, treatment, immunohistochemistry, 465<br />
Imup-1, endometrial carcinoma, imup-2, up-regulation, 865<br />
Imup-2, endometrial carcinoma, imup-1, up-regulation, 865<br />
111 In-DOTA-1-Nal 3 -octreotide, somatostatin analogues,<br />
111 In-DOTA-Tyr 3 -octreotate, tumour targeting, renal<br />
handling, biodistribution, AR42J cells, OK cells, 2189<br />
111 In-DOTA-Tyr 3 -octreotate, somatostatin analogues, 111 In-<br />
DOTA-1-Nal 3 -octreotide, tumour targeting, renal<br />
handling, biodistribution, AR42J cells, OK cells, 2189<br />
In vitro assay, breast cancer, steroids, MCF-7, tamoxifen,<br />
2213<br />
In vivo, S-1, 5-fluorouracil, gemcitabine, human<br />
equilibrative nucleotide transporter, schedule-dependent<br />
effect, combination chemotherapy, pancreatic cancer, 179<br />
Incidentaloma, adrenocortical, proliferation markers,<br />
metallothioneins, minichromosome maintenance protein,<br />
Ki-67, 2959<br />
Induction chemotherapy, non-small cell lung cancer,<br />
hyperfractionated radiotherapy, three-times daily<br />
radiotherapy, integrated treatments, 4121<br />
Induction chemotherapy, non-small cell lung cancer, phase<br />
II study, paclitaxel, carboplatin, chemoradiotherapy, 2851<br />
Induction heating, hyperthermia, thermotherapy, 69<br />
Infection, procalcitonin, C-reactive protein, leukopenia,<br />
3061<br />
Infection, thymidine kinase 1, TK1, health screening,<br />
benign, cancer, malignancy, tumour, fatty liver,<br />
inflammation, virus, 3897<br />
Inflammation, angiogenesis, MIF, IL-10, tamoxifen, aspirin,<br />
2093<br />
Inflammation, guggul, guggulsterone, cancer, apoptosis,<br />
hyperlipidemia, review, 3647<br />
Inflammation, interleukin-10, oral cancer, angiogenesis,<br />
thrombophilia, 309<br />
Inflammation, methylation, p53, iNOS, LPS, 2101<br />
Inflammation, prostate cancer, ACT, promoter<br />
polymorphism, PSA levels, 395<br />
Inflammation, thymidine kinase 1, TK1, health screening,<br />
benign, cancer, malignancy, tumour, fatty liver, infection,<br />
virus, 3897<br />
Inflammatory breast cancer, chemotherapy, autologous stem<br />
cell transplant, thiotepa, mitoxantrone, carboplatin, 3139<br />
4243
Infusion, 5-fluorouracil, arterial, cetuximab, colorectal,<br />
irinotecan, oxaliplatin, metastases, 2459<br />
Inherited cancer syndrome, adenomatous polyposis coli,<br />
HNPCC, BRCA1, BRCA2, MEN 2, review, 1341<br />
Inhibition of apoptosis, BCL2, BCL2L1, BIRC4, siRNA,<br />
chemosensitization, 2259<br />
Inhibitor stefin A, prostate cancer, Gleason grade, tissue<br />
microarray, cathepsin B, 2271<br />
INK4a, pancreatic ductal adenocarcinoma, K-RAS, SMAD4,<br />
TP53, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
INOS, benzocycloheptoxazines, Raw 264.7 cells, NO, ESR,<br />
radical, 2657<br />
INOS, methylation, inflammation, p53, LPS, 2101<br />
INOS, trihaloacetylazulenes, Raw 264.7 cells, NO, ESR,<br />
radical, 171<br />
Inotodiol, lanostane triterpenoids, cell proliferation,<br />
apoptosis, caspase-3, 2691<br />
Insulin like growth factor, glioblastoma multiforme,<br />
migration, proliferation, 1055<br />
Integrated treatments, non-small cell lung cancer,<br />
hyperfractionated radiotherapy, three-times daily<br />
radiotherapy, induction chemotherapy, 4121<br />
Integrin, hypoxia, spheroids, adhesion, fibronectin, 1013<br />
Integrin, megakaryocytic, erythroid, lineage shift, adhesion,<br />
fibronectin, 261<br />
Interferon-·, melanoma, CD8highCD57+ lymphocytes,<br />
survival, 1139<br />
Interferon-alpha combination therapy, pancreatic cancer,<br />
multidrug resistance, 1499<br />
Interferon-gamma, dendritic cells, maturation, T H 1<br />
polarisation, 1467<br />
Interleukin 1, radioprotection, gastrointestinal epithelium,<br />
apoptosis, 3601<br />
Interleukin-10, oral cancer, inflammation, angiogenesis,<br />
thrombophilia, 309<br />
Interleukin-12, gastric cancer, immunohistochemistry,<br />
prognosis, 1277<br />
Interleukin-2, immunosurgery, immunotherapy,<br />
lymphocytopenia, pancreatic cancer, 1951<br />
Interleukin-26, Hodgkin's lymphoma, chemotherapy, cell<br />
cycle, roscovitine, 887<br />
Intermediate filaments, embryology, cell differentiation,<br />
keratin, prostate, 237<br />
Intestinal metaplasia, FAS, FASL, polymorphism, apoptosis,<br />
atrophy, 97<br />
Intracellular calcium ion, 6-dimethylaminopurine, apoptosis,<br />
caspase, gene expression, genetic network, 609<br />
Intracellular localization, hypericin, photodynamic therapy,<br />
glioma, endoplasmatic reticulum, Golgi apparatus, 2033<br />
4244<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Intracranial hemorrhage, colorectal cancer, hypersensitivity<br />
reaction, oxaliplatin, thrombocytopenia, 3115<br />
Intrahepatic cholangiocarcinoma, oxaliplatin, microspheres,<br />
TACE, 2987<br />
Intrahepatic cholangiocarcinoma, R0 resection, lymph node<br />
dissection, poor prognostic factors, 2353<br />
Intranuclear order, genomic karyotyping, BCR-ABL,<br />
t(9:22), PML-RARA, t(15;17), review, 3573<br />
Intraoperative gamma camera, breast cancer, CarolIReS,<br />
lymphoscintigraphy, sentinel lymph node, 2859<br />
Intraoperative, melanoma, imprint touch cytology, sentinel<br />
node, diagnosis, treatment, immunohistochemistry, 465<br />
Intraosseous, bone marrow, aspiration, 3843<br />
Intraperitoneal, HMFG1, HAMA, IgG, IgM, ovarian cancer,<br />
2721<br />
Intratumoral lymphocytes, squamous carcinoma, anal canal,<br />
2469<br />
Invasion assay, lung cancer, HOXB2, microarray, gene<br />
expression analysis, 2121<br />
Invasion, EMMPRIN, oral SCC, TN-C, MMP, 2049<br />
Invasion, p27 kip1 , matrix metalloproteinase, breast cancer,<br />
2669<br />
Invasion, prostate-specific antigen, urothelial carcinoma,<br />
prognosis, PSA, 4149<br />
Invasion, silibinin, paclitaxel, drug resistance, Pglycoprotein,<br />
survivin, 1119<br />
Invasion, vimentin, prostate cancer, C-src, E-cadherin/catenin,<br />
327<br />
Invasive front, β-catenin, liver metastasis, 1821<br />
Iodized oil, gene therapy, hepatocellular carcinoma,<br />
adenovirus vector, arterial injection, rat, 51<br />
Ionizing radiation, mutant p53, radiosensitivity, Saos-2,<br />
2687<br />
Irinotecan, 5-fluorouracil, arterial, infusion, cetuximab,<br />
colorectal, oxaliplatin, metastases, 2459<br />
Irinotecan, advanced colorectal cancer, bevacizumab,<br />
capecitabine, 3087<br />
Irinotecan, colorectal cancer, capecitabine, first-line therapy,<br />
1923<br />
Irinotecan, CPT-11, colon cancer, HCT116, cell cycle, DNA<br />
damage checkpoint activation, endoreduplication,<br />
senescence, cell death, 583<br />
Irinotecan, gastric cancer, chemotherapy, oxaliplatin, 2901<br />
Iron, alcohol, cancer, risk, diet, legumes, meat, smoking,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Iron, breast carcinoma, chemotherapy, cyclophosphamide,<br />
doxorubicin, ferritin, neopterin, paclitaxel, 2389<br />
IÎBα, NFÎB, chemosensitivity, apoptosis, 601<br />
JVC, colorectal cancer, DNA viruses, HPV, BKV, SV40,<br />
1405<br />
K562 erythroleukemia cells, Apo2L/TRAIL, valproic acid,<br />
histone deacetylase inhibitors, apoptosis, 855
KB cells, transfection efficiency, polyethylenimine,<br />
depsipeptide, Raji cells, 793<br />
Keratin, embryology, cell differentiation, intermediate<br />
filaments, prostate, 237<br />
KGF, ER, siRNA, MCF-7, cell proliferation, 2733<br />
KGF, WT1, FAK, Grb2, Erk1,2, breast cancer cell motility,<br />
133<br />
Ki-67 antigen, non-Hodgkin’s lymphoma, prognosis, 1113<br />
Ki-67, cervical cancer, markers, p53, p27, COX-2, EGFR,<br />
E-cadherin, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
Ki-67, fascin, immunohistochemistry, serous ovarian cancer,<br />
prognosis, 1905<br />
Ki-67, image DNA analysis, immunohistochemistry, Wilms’<br />
tumour, p53, p57 kip2 , 751<br />
Ki-67, incidentaloma, adrenocortical, proliferation markers,<br />
metallothioneins, minichromosome maintenance protein,<br />
2959<br />
Ki-67, p16, p53, oral dysplasia, oral carcinoma, 2535<br />
Ki-67, PCNA, MCM2, colorectal cancer, 451<br />
Kidney, nitrobutadiene derivatives, toxicity, liver, enzymes,<br />
813<br />
Korea, colon cancer, polymorphism, VEGF, 1271<br />
K-RAS, BRAF, mutation, papillary, medullary, thyroid<br />
carcinoma, 305<br />
K-RAS, pancreatic ductal adenocarcinoma, INK4a, SMAD4,<br />
TP53, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
Krukenberg tumour, ovary, signet-ring cell carcinoma,<br />
stomach, electron microscopy, immunohistochemistry, 1417<br />
Lanostane triterpenoids, inotodiol, cell proliferation,<br />
apoptosis, caspase-3, 2691<br />
Laparoscopic radical prostatectomy, prostate cancer, robot,<br />
da Vinci, 1989<br />
Laparoscopic staging procedure, cervical cancer, lymph<br />
nodes, morbidity, 1849<br />
Laparoscopic surgery, Schwannoma, retroperitoneum, S-100<br />
protein, 2889<br />
Large cell neuroendocrine carcinoma, neuroendocrine<br />
tumour, neuroendocrine carcinoma, urinary bladder<br />
tumour, neuroendocrine marker, 1369<br />
Laryngeal carcinoma, CD105, vascular endothelial growth<br />
factor receptor 2 (VEGFR2), recurrence, prognosis, 551<br />
Laryngeal neoplasms, human papillomavirus 11, cidofovir,<br />
polymerase chain reaction, 2169<br />
Laser conization, postmenopause, preneoplastic cervical<br />
lesions, 3941<br />
Laser-captured microdissection, thymidine synthase,<br />
dihydropyrimidine dehydrogenase, thymidine<br />
phosphorylase, orotate phosphoribosyl transferase, 1477<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
LAT1, amino acid transport system L, salivary gland<br />
carcinoma cells, essential amino acids, antitumor therapy,<br />
2649<br />
L-Buthionine-(S,R)-sulfoximine, parthenolide, BAY 11-<br />
7085, N-acetylcysteine, PRIMA-1, Gemcitabine, MG-<br />
132, flavopiridol, 681<br />
Left colon cancer, p53 codon 72 polymorphism, Arg72Pro,<br />
sporadic colorectal adenocarcinoma, 1039<br />
Legumes, alcohol, cancer, risk, diet, iron, meat, smoking,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Leukemia cells, retinoids, valproic acid, RA-resistance, 283<br />
Leukemia, cell cycle, apoptosis, drug resistance, p21, 965<br />
Leukocyte-derived microparticles, breast cancer, endothelial<br />
cell-derived microparticles, CEA, CA15-3, 1107<br />
Leukopenia, procalcitonin, C-reactive protein, infection, 3061<br />
Leukovorin, esophageal cancer, chemotherapy, FLEP,<br />
fluorouracil, etoposide, cisplatin, 4101<br />
LHRH, somatostatin, protein tyrosine kinase, protein<br />
tyrosine phosphatase, receptor, 2599<br />
Lineage shift, megakaryocytic, erythroid, adhesion,<br />
fibronectin, integrin, 261<br />
Lipids, omega-3, omega-6, colon cancer, SW620, xenograft,<br />
3717<br />
Lipoma, fusion genes, HMGA2, 535<br />
Lipophilin B, mammaglobin, secretoglobin, breast cancer,<br />
proliferation, 1493<br />
Lipoplatin, liposomal cisplatin, 5-fluorouracil, head and<br />
neck cancer, 3961<br />
Lipopolysaccharide, curcumin, tetrahydrocurcumin, COX-2,<br />
NF-ÎB, chemical descriptors, Porphyromonas gingivalis<br />
fimbriae, 699<br />
Lipoprotein lipase, sarcoma, adipose tissue, triacylglycerol,<br />
2081<br />
Liposomal cisplatin, lipoplatin, 5-fluorouracil, head and<br />
neck cancer, 3961<br />
Liposomal doxorubicin, non-small cell lung cancer,<br />
vinorelbine, hypofractionation, acceleration, amifostine,<br />
radiotherapy, 1349<br />
Liposome, gossypol, PEG-DSPE, TPGS, 2801<br />
Liposome, microfluidics, ethanol injection, egg PC, 943<br />
Lipoxygenase, extrahepatic cholangiocarcinoma,<br />
cyclooxygenase, eicosanoid pathways, survival, 873<br />
Liver cancer, translationally controlled tumor protein, liver<br />
regeneration, antisense, proliferation, cell cycle,<br />
apoptosis, 1575<br />
Liver dysplastic nodules, hepatocarcinoma, micronuclei,<br />
broken eggs, genotoxic damage, 2507<br />
Liver interventional procedures, liver neoplasms,<br />
radiofrequency (RF) ablation, transhepatic arterial<br />
chemoembolization (TACE), 3835<br />
Liver metastasis, colorectal carcinoma, S-1, COX-2<br />
inhibitor, 629<br />
4245
Liver metastasis, pioglitazone, colon cancer, 3593<br />
Liver metastasis, β-catenin, invasive front, 1821<br />
Liver neoplasms, liver interventional procedures,<br />
radiofrequency (RF) ablation, transhepatic arterial<br />
chemoembolization (TACE), 3835<br />
Liver regeneration, translationally controlled tumor protein,<br />
liver cancer, antisense, proliferation, cell cycle, apoptosis,<br />
1575<br />
Liver ultrasound, primary breast cancer, metastatic disease,<br />
X-ray, bone scan, staging, 2397<br />
Liver, nitrobutadiene derivatives, toxicity, kidney, enzymes,<br />
813<br />
LLETZ, cervical dysplasia, colposcopy, negative histology,<br />
positive margin, 519<br />
Lobund-Wistar rat, vaccine, adjuvant, cancer, resection,<br />
2529<br />
Local reactions, viscum album, mistletoe, cancer patients,<br />
peripheral lymphocytes, quality of life, 1893<br />
Localized, N-linked oligosaccharide chains, matrix<br />
metalloproteinase-2, metastatic cancer, 715<br />
Locally advanced breast cancer, neoadjuvant chemotherapy,<br />
vinorelbine, elderly, 3093<br />
Locoregional recurrence, breast-conserving surgery,<br />
resection volume, risk factors, 1207<br />
Long-term survival, melanoma, metastatic disease, 1429<br />
Loss of heterozygosity, TP53, RB, ovarian carcinoma,<br />
chemotherapy, 989<br />
Low-dose chemotherapy, Host immunity, CD4 + CD25 +<br />
T-cell, soluble IL-2R, colorectal cancer, 373<br />
Low-dose cisplatin, S-1, gastric cancer, combination<br />
therapy, outpatient setting, 1433<br />
Low-grade endometrial stromal sarcoma, surgery,<br />
progestins, aromatase inhibitors, 2869<br />
LPS, methylation, inflammation, p53, iNOS, 2101<br />
Lung cancer, apoptosis, pro-apoptotic genes, cell cycle,<br />
plumbagin, 785<br />
Lung cancer, chemotherapy, esophageal cancer, tyrosine<br />
kinase inhibitor, taxane, 3099<br />
Lung cancer, diagnosis, pulmonary nodule, massscreening,<br />
bronchoscopy, video-assisted thoracoscopic<br />
surgery, 3153<br />
Lung cancer, HOXB2, invasion assay, microarray, gene<br />
expression analysis, 2121<br />
Lung cancer, immunotherapy, N2 disease, adjuvant therapy,<br />
surgery, dendritic cell, regional lymph node, 1229<br />
Lung cancer, promoter methylation, smoke, coal, PAH,<br />
benzopyrene, sputum, 2061<br />
Lung cancer, tumor marker, survivin, BIRC5, gene<br />
expression, real-time RT-PCR, 1525<br />
Lung cancer, vinorelbine, malignant pleural effusion,<br />
vascular endothelial growth factor (VEGF), angiogenesis,<br />
1633<br />
Lung metastasis, s-TREM-1, prognostic marker, 1411<br />
4246<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Lung, cancer, colorectal, head and neck, biomarkers, serum,<br />
screening, diagnosis, prognosis, sCD26, EGF, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
LV, UFT, adjuvant chemotherapy, micrometastasis, 2045<br />
Lymph node dissection, intrahepatic cholangiocarcinoma,<br />
R0 resection, poor prognostic factors, 2353<br />
Lymph node metastasis, chemokine receptors, Twist, head<br />
and neck squamous cell carcinoma, 1355<br />
Lymph node metastasis, early gastric cancer, tumor<br />
volumetry, 3D endoscopic ultrasonography, 2907<br />
Lymph node metastasis, VEGF-C, serum, prognosis,<br />
recurrence, esophageal cancer, 165<br />
Lymph node metastatic density, proximal gastric cancer,<br />
prognosis, 2875<br />
Lymph nodes, cervical cancer, laparoscopic staging<br />
procedure, morbidity, 1849<br />
Lymphangiogenesis, CD105, small cell lung carcinoma,<br />
prognosis, immunohistochemistry, 343<br />
Lymphangiogenesis, oral squamous cell carcinoma, HIF-1α,<br />
VEGF-C, angiogenesis, 1659<br />
Lymphatic vessels, metastasis, podoplanin, tumor growth,<br />
review, 2997<br />
Lymphocytes, activation, 5-fluorouracil, 3785<br />
Lymphocytes, anandamide, anticancer immunity,<br />
cannabinoids, regulatory T-cell, 3743<br />
Lymphocytopenia, immunosurgery, immunotherapy,<br />
interleukin-2, pancreatic cancer, 1951<br />
Lymphoma, hybrid liposomes, antitumor effect, apoptosis,<br />
chemotherapy, 1187<br />
Lymphoscintigraphy, breast cancer, CarolIReS,<br />
intraoperative gamma camera, sentinel lymph node, 2859<br />
Macrophage, EGCG, apoptosis, autophagy, 1713<br />
Malignancy, thymidine kinase 1, TK1, health screening,<br />
benign, cancer, tumour, fatty liver, inflammation,<br />
infection, virus, 3897<br />
Malignant effusion, cell-free mRNA, real-time quantitative<br />
PCR, ERCC1, thymidylate synthase, 1085<br />
Malignant fibrous histiocytoma (MFH), PKC412, PKCα,<br />
molecular targeting therapy, sarcoma, osteosarcoma, 825<br />
Malignant melanoma, radiotherapy, brain metastasis,<br />
prognostic factors, age, 1325<br />
Malignant peripheral nerve sheath tumor,<br />
neurofibromatosis-1, von Recklinghausen’s disease,<br />
constipation, sarcomas, 3107<br />
Malignant pleural effusion, vinorelbine, lung cancer,<br />
vascular endothelial growth factor (VEGF), angiogenesis,<br />
1633<br />
Malignant sacral tumors, tumor distal to S2, modified<br />
threadwire saw, sacral canal osteotomy, wide margin,<br />
4143<br />
MALT lymphoma, NOD2, TLR4, CD14, gene<br />
polymorphism, Helicobacter pylori infection, 3697
Mammaglobin, lipophilin B, secretoglobin, breast cancer,<br />
proliferation, 1493<br />
Mammary carcinogenesis, premenopausal, rat,<br />
chemoprevention, anastrozole, aromatase inhibitors, 2819<br />
Mandibular bone destruction, CCN2, osteoclast, 2343<br />
Māori, ethnic minority, Pacific Island, diagnosis, treatment,<br />
accessibility, 3891<br />
MAP kinase signaling, cancer, caveolin-1, EGF receptor,<br />
PPARγ, rosiglitazone, 895<br />
MAPK inhibitor, plasmacytoma, dexamethasone, p38,<br />
SCIO-469, SD-282, RPMI-8226, H-929, HSP-27, 3827<br />
MAPK pathway, RET, apoptosis, doxorubicin, medullary<br />
thyroid cancer, 2019<br />
Marker, AcSDKP, POP, angiogenesis, thyroid tumor, cancer,<br />
2813<br />
Marker, PGP9.5, quantitative methylation-specific PCR,<br />
colorectal cancer, 2697<br />
Marker, telomerase activity, head and neck cancer, real-time<br />
TRAP, prognosis, 3125<br />
Markers, cervical cancer, p53, p27, COX-2, Ki-67, EGFR,<br />
E-cadherin, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
Marrow-derived stem cells, tumor angiogenesis, endothelial<br />
cells, origin, 771<br />
Maspin, bladder, papillary neoplasms, 471<br />
Mass screening, colorectal cancer, SSCP analysis, exfoliated<br />
colonocytes, fecal DNA, 145<br />
Mass-screening, diagnosis, lung cancer, pulmonary nodule,<br />
bronchoscopy, video-assisted thoracoscopic surgery, 3153<br />
Matched primary tumours, TS, colorectal cancer metastases,<br />
1741<br />
Matrigel plug, hop beta-acids, angiogenesis,<br />
angioprevention, cell proliferation, chemotaxis, VEGF,<br />
289<br />
Matriptase, prostate, metastasis, PC-3, proliferation,<br />
tumorigenesis, 1977<br />
Matriptase, prostate, metastasis, PC-3, proliferation,<br />
tumorigenicity, N-acetylglucosaminyltransferase V, 1993<br />
Matriptase, prostate, PSA, ARA24, NCOA4, IL-6, PSCA,<br />
PEDF, 1969<br />
Matrix metalloproteinase, p27 kip1 , invasion, breast cancer,<br />
2669<br />
Matrix metalloproteinase-1 (MMP-1), gastric cancer,<br />
protease activated receptor-1 (PAR-1),<br />
immunohistochemistry, prognostic factor, 847<br />
Matrix metalloproteinase-2, N-linked oligosaccharide<br />
chains, localized, metastatic cancer, 715<br />
Matrix metalloproteinase-9 (MMP-9), gelatinase A,<br />
Collagenase, survival, transitiocellular carcinoma, 1757<br />
Matrix metalloproteinases, colorectal cancer, thyroid<br />
neoplasm, review, 1389<br />
Maturation, dendritic cells, interferon-gamma, T H 1<br />
polarisation, 1467<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
MCF10AT3B cells, WT1, tumor suppressor, proliferative<br />
breast disease, breast cancer, 2155<br />
MCF-7, breast cancer, steroids, in vitro assay, tamoxifen,<br />
2213<br />
MCF-7, KGF, ER, siRNA, cell proliferation, 2733<br />
MCF-7, polyamines, mepacrine, Vero, cell proliferation,<br />
2765<br />
MCF-7, thymax, apoptosis, annexin, caspases, 1603<br />
MCF-7aro cells, breast cancer, progesterone, aromatase,<br />
2129<br />
MCM2, Ki-67, PCNA, colorectal cancer, 451<br />
Mcm7, oral squamous cell carcinoma(OSCC), precancerous<br />
lesions, Cdc6, 3763<br />
MDA-MB-231 cell, genistein, soy extract, nude mice, tumor<br />
growth, 2837<br />
MDA-MB-231 cells, breast cancer, δ-tocotrienol, cell cycle,<br />
retinoblastoma, cyclin D1, 2641<br />
MDA-MB-231, antiproliferative property, apoptotic effect,<br />
xanthorrhizol, 3677<br />
Mean nuclear area, breast cancer, cytology, fine-needle<br />
aspiration biopsy, nuclear morphometry, breast disease,<br />
fibroadenoma, fibrocystic disease, sampling, MNA, 3985<br />
Meat, alcohol, cancer, risk, diet, iron, legumes, smoking,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Medullary thyroid cancer, RET, apoptosis, doxorubicin,<br />
MAPK pathway, 2019<br />
Medullary thyroid carcinoma, Cautleya gracilis, bioactive<br />
agents, chemoresistance, apoptosis, 2705<br />
Medullary, BRAF, K-RAS, mutation, papillary, thyroid<br />
carcinoma, 305<br />
Medulloblastoma, neuroimaging, abnormality, 3991<br />
Megaesophagus, p53, p16, Fhit protein, esophagitis,<br />
esophageal carcinoma, 3793<br />
Megakaryocytic, erythroid, lineage shift, adhesion,<br />
fibronectin, integrin, 261<br />
Melanoma imaging, radioiodinated methylene blue,<br />
SK-MEL 28, 518A2, 3691<br />
Melanoma, anti-VEGFR, anti-TYRP-1/gp75, angiogenesis,<br />
antibody therapy, 2679<br />
Melanoma, chloroethylnitrosoureas, bystander effect,<br />
murine type, NMR spectroscopy, 21<br />
Melanoma, elastosis, skin cancer, smoking, ultraviolet,<br />
vitamin D, 4003<br />
Melanoma, imprint touch cytology, intraoperative, sentinel<br />
node, diagnosis, treatment, immunohistochemistry, 465<br />
Melanoma, interferon-·, CD8highCD57+ lymphocytes,<br />
survival, 1139<br />
Melanoma, metastatic disease, long-term survival, 1429<br />
Melanoma, S-100B, stage IIIB/C, relapse, survival,<br />
prediction, 2297<br />
Melatonin, cancer immunotherapy, IL-2, neuroimmunomodulation,<br />
1377<br />
4247
Melphalan, hyperthermia, apoptosis, caspases, gene<br />
regulation, Ewing sarcoma, 2585<br />
MEN 2, inherited cancer syndrome, adenomatous polyposis<br />
coli, HNPCC, BRCA1, BRCA2, review, 1341<br />
Mepacrine, polyamines, MCF-7, Vero, cell proliferation,<br />
2765<br />
Merkel cell tumor, metastasis, urinary bladder, therapy,<br />
prognosis, 1361<br />
Mesothelin, biomarker, osteopontin, mesothelioma, 3933<br />
Mesothelin, epidermal growth factor receptor, fluorescence<br />
activated cell sorter, N-cadherin, SV40, ultrastructure,<br />
197<br />
Mesothelioma, asbestos, calretinin, immunohistochemistry,<br />
occupational cancer, orchidectomy, 1365<br />
Mesothelioma, biomarker, mesothelin, osteopontin, 3933<br />
Mesothelioma, p16 INK4a , cyclin dependent kinase, 1<br />
Metallothioneins, incidentaloma, adrenocortical,<br />
proliferation markers, minichromosome maintenance<br />
protein, Ki-67, 2959<br />
Metastases, 5-fluorouracil, arterial, infusion, cetuximab,<br />
colorectal, irinotecan, oxaliplatin, 2459<br />
Metastases, colorectal cancer, chemotherapy, antibodies,<br />
treatment, 4111<br />
Metastases, renal cell carcinoma, pancreatic resection,<br />
pancreatectomy, 361<br />
Metastases, thyroid, surgery, carcinoma, neoplasm, 2885<br />
Metastasis, animal model, radiofrequency, human breast<br />
cancer, rats, 879<br />
Metastasis, cisplatin, 5-fluorouracil, recurrent cervical<br />
cancer, 1887<br />
Metastasis, colon cancer, genomic profiling, dormancy,<br />
clonal expansion, microsatellite stability, 3609<br />
Metastasis, colorectal cancer, S-1, CPT-11, 1837<br />
Metastasis, lymphatic vessels, podoplanin, tumor growth,<br />
review, 2997<br />
Metastasis, merkel cell tumor, urinary bladder, therapy,<br />
prognosis, 1361<br />
Metastasis, oral cancer, biopsy, bleomycin, 2253<br />
Metastasis, pancreatic ductal adenocarcinoma, INK4a,<br />
K-RAS, SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB,<br />
p27 Kip1 , cell cycle, angiogenesis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
Metastasis, prostate, PC-3, proliferation, tumorigenesis,<br />
matriptase, 1977<br />
Metastasis, prostate, PC-3, proliferation, tumorigenicity,<br />
matriptase, N-acetylglucosaminyltransferase V, 1993<br />
Metastasis, sclerosing rhabdomyosarcoma, peripheral blood<br />
stem cell transplantation, chemotherapy, 2361<br />
Metastasis, snail, E-cadherin, adenovirus, 621<br />
Metastasis, squamous cell lung carcinoma, breast<br />
metastasis, 1299<br />
4248<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Metastatic brain tumor, adenocarcinoma, MRI, mucin, 407<br />
Metastatic breast cancer, bone marrow infiltration,<br />
capecitabine, 539<br />
Metastatic breast cancer, chemotherapy, docetaxel, 3993<br />
Metastatic breast cancer, docetaxel, first-line chemotherapy,<br />
gemcitabine, HER-2, paclitaxel, taxane, review, 1245<br />
Metastatic cancer, N-linked oligosaccharide chains, matrix<br />
metalloproteinase-2, localized, 715<br />
Metastatic disease, colorectal cancer, 5-fluorouracil,<br />
gemcitabine, 3055<br />
Metastatic disease, melanoma, long-term survival, 1429<br />
Metastatic disease, primary breast cancer, X-ray, bone scan,<br />
liver ultrasound, staging, 2397<br />
Metastatic liver cancer, gene therapy, adenovirus vector,<br />
CD40 ligand, rat, 2785<br />
Methionine metabolism, amino acids, human tumors, nude<br />
mice, transulfuration, 2541<br />
Methotrexate, toxicity, MTHFR, polymorphism,<br />
osteosarcoma, 3051<br />
2-Methoxyestradiol, estrogen, sulfamate, breast cancer,<br />
STX140, 577<br />
2-Methoxyestradiol, STX140, breast cancer, ENMD-1198,<br />
myelotoxicity, 1483<br />
Methylation, inflammation, p53, iNOS, LPS, 2101<br />
Methylation, NPC, p16, DLEC1, BLU, E-cadherin, 2161<br />
MG-132, parthenolide, BAY 11-7085, N-acetylcysteine, Lbuthionine-(S,R)-sulfoximine,<br />
PRIMA-1, Gemcitabine,<br />
flavopiridol, 681<br />
MG-63, osteosarcoma, chemoresistance, gene profiling, 673<br />
MHC class II, MHC2TA, CIITA, polymorphism, colorectal<br />
cancer, 1789<br />
MHC, class Ib, promoter, cancer, gene expression, gene<br />
therapy, 799<br />
MHC2TA, MHC class II, CIITA, polymorphism, colorectal<br />
cancer, 1789<br />
Microarray, lung cancer, HOXB2, invasion assay, gene<br />
expression analysis, 2121<br />
Microfluidics, liposome, ethanol injection, egg PC, 943<br />
Micrometastasis, UFT, LV, adjuvant chemotherapy, 2045<br />
Micronuclei, hepatocarcinoma, broken eggs, liver dysplastic<br />
nodules, genotoxic damage, 2507<br />
Micropipette aspiration, steep pulsed electric field (SPEF),<br />
hepatoma, proliferation, biorheology, 2245<br />
MicroRNAs (miRNAs), miR-21, gastric cancer, prognosis,<br />
907<br />
Microsatellite stability, colon cancer, metastasis, genomic<br />
profiling, dormancy, clonal expansion, 3609<br />
Microspheres, intrahepatic cholangiocarcinoma, oxaliplatin,<br />
TACE, 2987<br />
MIF, angiogenesis, inflammation, IL-10, tamoxifen, aspirin,<br />
2093<br />
Migration, glioblastoma multiforme, insulin like growth<br />
factor, proliferation, 1055
Minichromosome maintenance protein, incidentaloma,<br />
adrenocortical, proliferation markers, metallothioneins,<br />
Ki-67, 2959<br />
MiR-21, microRNAs (miRNAs), gastric cancer, prognosis,<br />
907<br />
MiRNA, FFPE, expression profiling, 119<br />
MiRNA, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 , cell<br />
cycle, angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, epithelial-mesenchymal<br />
transition, chemotaxis, sonic hedgehog, review, 1541<br />
Mistletoe, viscum album, cancer patients, local reactions,<br />
peripheral lymphocytes, quality of life, 1893<br />
Mitochondria, bee venom (BV), apoptosis, caspase, reactive<br />
oxygen species, cytoplasmic calcium (Ca 2+ ), 833<br />
Mitochondria, cyclopentenone, apoptosis, cytotoxicity, 315<br />
Mitochondrial membrane potential (Δψm), DADS,<br />
apoptosis, caspase-3, cytochrome c, 2791<br />
Mitochondrial membrane potential, baicalein, GADD153,<br />
calcium, apoptosis, 1701<br />
Mitogen-activated protein kinase, aponecrosis, prenylation<br />
inhibitor, ras, NaPa, 1029<br />
Mitosis, glioblastoma, survivin, apoptosis, 109<br />
Mitotic spindle assembly checkpoint, thyroid carcinoma,<br />
tumor aggressiveness, 139<br />
Mitoxantrone, inflammatory breast cancer, chemotherapy,<br />
autologous stem cell transplant, thiotepa, carboplatin,<br />
3139<br />
MKN45, gastric cancer, CDDP-resistant cell line,<br />
oxaliplatin, ERCC1, GST-π, 2087<br />
MMC, new combined chemotherapy, phase I study,<br />
gynecological malignancy, CPT-11, 5-FU, 2933<br />
MMP expression, colorectal cancer liver metastasis, TIMP<br />
expression, 1459<br />
MMP, EMMPRIN, invasion, oral SCC, TN-C, 2049<br />
MMP-2, endometrial cancer, MMP-9, TIMP-1, TIMP-2,<br />
prognosis, 2715<br />
MMP-2, gypenosides, cell invasion and migration, NFÎB,<br />
MMP-9, 1093<br />
MMP-2, MMP-9, A431, FAK, Boyden chamber assay, 2109<br />
MMP-9, endometrial cancer, MMP-2, TIMP-1, TIMP-2,<br />
prognosis, 2715<br />
MMP-9, gypenosides, cell invasion and migration, NFÎB,<br />
MMP-2, 1093<br />
MMP-9, MMP-2, A431, FAK, Boyden chamber assay, 2109<br />
MMPs, pancreatic cancer, ampullary cancer, TIMPs, MVD,<br />
1875<br />
MNA, breast cancer, cytology, fine-needle aspiration biopsy,<br />
nuclear morphometry, breast disease, fibroadenoma,<br />
fibrocystic disease, sampling, mean nuclear area, 3985<br />
Modified threadwire saw, malignant sacral tumors, tumor<br />
distal to S2, sacral canal osteotomy, wide margin,<br />
4143<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Molecular classification, bladder neoplasms, bladder<br />
neoplasm classification, profiling, review, 2893<br />
Molecular genetics, ataxia telangiectasia, ATM gene, cancer<br />
susceptibility, review, 401<br />
Molecular imaging, confocal microscopy, endomicroscopy,<br />
cancer, ulcerative colitis, review, 353<br />
Molecular markers, molecular pathology, oncogenes, oral<br />
squamous carcinoma, tumour suppressor genes, review,<br />
1197<br />
Molecular pathology, molecular markers, oncogenes, oral<br />
squamous carcinoma, tumour suppressor genes, review,<br />
1197<br />
Molecular staging, colorectal cancer, circulating tumor cells,<br />
polymerase chain reaction, peripheral blood, review, 3945<br />
Molecular targeting therapy, PKC412, PKCα, sarcoma,<br />
osteosarcoma, malignant fibrous histiocytoma (MFH),<br />
825<br />
Monitoring of therapy, small cell lung cancer, ProGRP,<br />
NSE, 3027<br />
Monocytes, tumour growth, cytokines, angiogenesis, 187<br />
Monotherapy, advanced non-small cell lung cancer,<br />
erlotinib, 2409<br />
Morbidity, cervical cancer, lymph nodes, laparoscopic<br />
staging procedure, 1849<br />
Morphology, prostate cancer, brachytherapy, autopsy, 3909<br />
Mortality, breast cancer, osteopontin, survival, 4105<br />
Mortality, type 2 diabetes mellitus, cancer, obesity, 1373<br />
Mouse, sphingomyelin, alkaline sphingomyelinase, colon<br />
cancer, 3631<br />
MRI, adenocarcinoma, metastatic brain tumor, mucin, 407<br />
MRI, brain tumour, paediatrics, stem cell, 741<br />
MRT, 3-demethylubiquinone Q2, ascidian, Aplidium<br />
glabrum, cancer preventive and anticancer activities,<br />
apoptosis, 927<br />
MRT, FDG, FLT, neuroblastoma, PET-CT, SCID mouse,<br />
2561<br />
MTHFR, methotrexate, toxicity, polymorphism,<br />
osteosarcoma, 3051<br />
MTHFR, MTRR, polymorphism, risk factors, HCC, 2807<br />
MTOR, everolimus, rapamycin, sensitization,<br />
cyclophosphamide, 3801<br />
MTOR, IGF-I receptor, MYC-N, neuroblastoma,<br />
rapamycin, temsirolimus, 1509<br />
MTOR, PTEN, p53, AKT, genome stability, cell cycle,<br />
review, 3613<br />
MTRR, MTHFR, polymorphism, risk factors, HCC, 2807<br />
MTT, cervical cancer, estrogen receptor, gene therapy,<br />
chemotherapy, cytotoxicity, apoptosis, caspase-3, CaSki,<br />
2181<br />
MUC-1, gastric carcinoma, pathobiological behavior,<br />
prognosis, 1061<br />
MUC1, pancreatic cancer, dendritic cell, CTL,<br />
immunotherapy, 379<br />
4249
Mucin, adenocarcinoma, metastatic brain tumor, MRI, 407<br />
Mucin-depleted foci, preneoplastic lesions, flat aberrant<br />
crypt foci, colon carcinogenesis, 3771<br />
Multidrug resistance, colon carcinoma, cell lines, Pglycoprotein,<br />
pO 2 , antioxidants, 55<br />
Multidrug resistance, furanoacridones, apoptosis, 2737<br />
Multidrug resistance, pancreatic cancer, interferon-alpha<br />
combination therapy, 1499<br />
Multiple myeloma, PI3-kinase, necrosis, 37<br />
Multiple primary, neoplasm, second primary, 2953<br />
Multi-walled carbon nanotubes, single-walled carbon<br />
nanotubes, genotoxicity, Salmonella Ames test,<br />
cytogenetics, 349<br />
Murine osteosarcoma, cell line, transplantation, osteoblastic<br />
differentiation, endochondral ossification, 1627<br />
Murine type, chloroethylnitrosoureas, melanoma, bystander<br />
effect, NMR spectroscopy, 21<br />
Mutant p53, ionizing radiation, radiosensitivity, Saos-2, 2687<br />
Mutation screening, allele-specific PCR, epidermal growth<br />
factor receptor, gefitinib, non-small cell lung cancer, 2265<br />
Mutation, BRAF, K-RAS, papillary, medullary, thyroid<br />
carcinoma, 305<br />
Mutation, pleomorphic adenoma, salivary glands, BRCA-1,<br />
3011<br />
MVD, bladder cancer, CD105, COX-2, β-catenin, 2479<br />
MVD, pancreatic cancer, ampullary cancer, MMPs, TIMPs,<br />
1875<br />
MYC-N, IGF-I receptor, mTOR, neuroblastoma, rapamycin,<br />
temsirolimus, 1509<br />
Mycoplasma, thymidylate synthase, resistance, 5-FU, 5-<br />
FUdR, 2175<br />
Myeloperoxidase, gastric cancer, polymorphism,<br />
Helicobacter pylori, neutrophil, gastritis, 1317<br />
Myelotoxicity, chemotherapy, prognosis, advanced, breast<br />
cancer, 2913<br />
Myelotoxicity, STX140, breast cancer, 2-methoxyestradiol,<br />
ENMD-1198, 1483<br />
N2 disease, lung cancer, immunotherapy, adjuvant therapy,<br />
surgery, dendritic cell, regional lymph node, 1229<br />
N-acetylcysteine, parthenolide, BAY 11-7085, Lbuthionine-(S,R)-sulfoximine,<br />
PRIMA-1, Gemcitabine,<br />
MG-132, flavopiridol, 681<br />
N-acetylglucosaminyltransferase V, prostate, metastasis, PC-<br />
3, proliferation, tumorigenicity, matriptase, 1993<br />
Nanoparticles, BNCT, cancer, B16, boron, 571<br />
NaPa, aponecrosis, mitogen-activated protein kinase,<br />
prenylation inhibitor, ras, 1029<br />
N-cadherin, epidermal growth factor receptor, fluorescence<br />
activated cell sorter, mesothelin, SV40, ultrastructure, 197<br />
NCOA4, prostate, PSA, ARA24, IL-6, PSCA, PEDF,<br />
matriptase, 1969<br />
ND-factor, gastric cancer, prognosis, non-curative factor,<br />
435<br />
4250<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Necrosis, multiple myeloma, PI3-kinase, 37<br />
Nedaplatin, feasibility, cervical cancer, docetaxel,<br />
chemotherapy, 2385<br />
Negative histology, cervical dysplasia, colposcopy, positive<br />
margin, LLETZ, 519<br />
Neoadjuvant chemotherapy, breast, epirubicin, taxol, p53,<br />
Erb family, 3147<br />
Neoadjuvant chemotherapy, cT3N0M0, rectal cancer, 4129<br />
Neoadjuvant chemotherapy, esophageal cancer, FAP, 2321<br />
Neoadjuvant chemotherapy, paclitaxel, breast cancer, Her2<br />
overexpression, 1239<br />
Neoadjuvant chemotherapy, rectal cancer, bolus 5fluorouracil,<br />
cardiotoxicity, 4095<br />
Neoadjuvant chemotherapy, vinorelbine, elderly, locally<br />
advanced breast cancer, 3093<br />
Neoplasm, multiple primary, second primary, 2953<br />
Neoplasm, thyroid, metastases, surgery, carcinoma, 2885<br />
Neopterin, breast carcinoma, chemotherapy,<br />
cyclophosphamide, doxorubicin, ferritin, iron, paclitaxel,<br />
2389<br />
Neural growth factor receptors, thymus, neuroendocrine<br />
differentiation, tubulin, 295<br />
Neuroblastoma cells, berberine, p53, cell cycle arrest,<br />
apoptosis, 3777<br />
Neuroblastoma, angiogenesis, zoledronic acid, TNP-470,<br />
SH-SY5Y, 1551<br />
Neuroblastoma, curcumin, apoptosis, NfkappaB, 209<br />
Neuroblastoma, FDG, FLT, MRT, PET-CT, SCID mouse,<br />
2561<br />
Neuroblastoma, IGF-I receptor, MYC-N, mTOR,<br />
rapamycin, temsirolimus, 1509<br />
Neuroblastoma, rhabdomyosarcoma, flow cytometry,<br />
immunophenotyping, 1565<br />
Neuroendocrine carcinoma, neuroendocrine tumour, urinary<br />
bladder tumour, large cell neuroendocrine carcinoma,<br />
neuroendocrine marker, 1369<br />
Neuroendocrine differentiation, thymus, neural growth<br />
factor receptors, tubulin, 295<br />
Neuroendocrine marker, neuroendocrine tumour,<br />
neuroendocrine carcinoma, urinary bladder tumour, large<br />
cell neuroendocrine carcinoma, 1369<br />
Neuroendocrine tumour, neuroendocrine carcinoma, urinary<br />
bladder tumour, large cell neuroendocrine carcinoma,<br />
neuroendocrine marker, 1369<br />
Neurofibromatosis-1, von Recklinghausen’s disease,<br />
constipation, malignant peripheral nerve sheath tumor,<br />
sarcomas, 3107<br />
Neuroimaging, medulloblastoma, abnormality, 3991<br />
Neuro-immunomodulation, cancer immunotherapy, IL-2,<br />
melatonin, 1377<br />
Neuron-specific enolase, Non-small cell lung cancer, NSE,<br />
predictive factor, prognostic factor, 507<br />
Neuropathy, cisplatin, valproate, neuroprotection, 335
Neuroprotection, cisplatin, neuropathy, valproate, 335<br />
Neutrophil, gastric cancer, myeloperoxidase, polymorphism,<br />
Helicobacter pylori, gastritis, 1317<br />
Nevus, HER3, cutaneous tumors, squamous cell carcinoma,<br />
PCR, 973<br />
New combined chemotherapy, phase I study, gynecological<br />
malignancy, CPT-11, MMC, 5-FU, 2933<br />
NF-ÎB, curcumin, tetrahydrocurcumin, COX-2, chemical<br />
descriptors, lipopolysaccharide, Porphyromonas gingivalis<br />
fimbriae, 699<br />
NFÎB, gypenosides, cell invasion and migration, MMP-2,<br />
MMP-9, 1093<br />
NfkappaB, neuroblastoma, curcumin, apoptosis, 209<br />
NFÎB, IÎBα, chemosensitivity, apoptosis, 601<br />
NF-ÎB, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, TP53, PI3K, SKP2, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis, epigenetic<br />
gene regulation, miRNA, epithelial-mesenchymal transition,<br />
chemotaxis, sonic hedgehog, review, 1541<br />
Nitrobutadiene derivatives, toxicity, liver, kidney, enzymes,<br />
813<br />
N-linked oligosaccharide chains, matrix metalloproteinase-<br />
2, localized, metastatic cancer, 715<br />
NLRP7, immunohistochemistry, endometrial cancer,<br />
clinicopathological factors, prognosis, 2493<br />
NMR spectroscopy, chloroethylnitrosoureas, melanoma,<br />
bystander effect, murine type, 21<br />
NO, benzocycloheptoxazines, Raw 264.7 cells, iNOS, ESR,<br />
radical, 2657<br />
NO, trihaloacetylazulenes, Raw 264.7 cells, iNOS, ESR,<br />
radical, 171<br />
NOD/SCID, anaplastic large cell lymphoma, small animal<br />
PET, FDG, xenograft, 981<br />
NOD-2, gastric cancer, stomach, polymorphisms, 757<br />
NOD2, TLR4, CD14, gene polymorphism, MALT<br />
lymphoma, Helicobacter pylori infection, 3697<br />
Nomogram, prostate cancer, testosterone, prostate- specific<br />
antigen, prostate biopsy, 2487<br />
Non-curative factor, gastrectomy, prognostic factor,<br />
advanced gastric cancer, 2379<br />
Non-curative factor, gastric cancer, ND-factor, prognosis,<br />
435<br />
Non-Hodgkin’s lymphoma, Ki-67 antigen, prognosis, 1113<br />
Nonpeptide antigens, γδ T-cells, pyrophosphomonoester,<br />
antitumor activity, cancer immunotherapy, 2921<br />
Non-small cell lung cancer, allele-specific PCR, epidermal<br />
growth factor receptor, gefitinib, mutation screening, 2265<br />
Non-small cell lung cancer, bisphosphonates, zoledronic<br />
acid, bone metastases, small cell lung cancer, 529<br />
Non-small cell lung cancer, COX-2, ABC transporters,<br />
chemotherapy, 2967<br />
Non-small cell lung cancer, cytokine-induced killer cells,<br />
immunotherapy, 3997<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Non-small cell lung cancer, Gaucher’s disease,<br />
hematological toxicity, adenocarcinoma, cytopenia,<br />
chemotherapy, 3937<br />
Non-small cell lung cancer, hemoglobin, CEA, preoperative,<br />
survival, 1947<br />
Non-small cell lung cancer, hyperfractionated radiotherapy,<br />
three-times daily radiotherapy, induction chemotherapy,<br />
integrated treatments, 4121<br />
Non-small cell lung cancer, neuron-specific enolase, NSE,<br />
predictive factor, prognostic factor, 507<br />
Non-small cell lung cancer, phase II study, induction<br />
chemotherapy, paclitaxel, carboplatin, chemoradiotherapy,<br />
2851<br />
Non-small cell lung cancer, vinorelbine, liposomal<br />
doxorubicin, hypofractionation, acceleration, amifostine,<br />
radiotherapy, 1349<br />
Noscapine, prostate cancer therapy, tumour inhibition, 3701<br />
Notch, cancer, signal pathway, review, 3621<br />
Notch, Wnt, β-catenin, acute leukemia, self-renewal, 2701<br />
Noxa gene, BH3, apoptosis, 1667<br />
NPC, methylation, p16, DLEC1, BLU, E-cadherin, 2161<br />
NSCLC, amrubicin, chemotherapy failure, third-line<br />
treatment, 3855<br />
NSCLC, heat shock proteins, immunohistochemistry,<br />
prognosis, 501<br />
NSE, Non-small cell lung cancer, neuron-specific enolase,<br />
predictive factor, prognostic factor, 507<br />
NSE, small cell lung cancer, ProGRP, monitoring of<br />
therapy, 3027<br />
Nuclear morphometry, breast cancer, cytology, fine-needle<br />
aspiration biopsy, breast disease, fibroadenoma,<br />
fibrocystic disease, sampling, mean nuclear area, MNA,<br />
3985<br />
Nucleotide excision repair, cisplatin, trigeminal ganglion,<br />
2637<br />
Nude mice, 5’-deoxy-5-fluorouridine, paclitaxel, gastric<br />
cancer, thymidine phosphorylase, apoptosis, 1593<br />
Nude mice, amino acids, human tumors, methionine<br />
metabolism, transulfuration, 2541<br />
Nude mice, genistein, soy extract, MDA-MB-231 cell,<br />
tumor growth, 2837<br />
Nude mice, hepatocellular cancer, seocalcitol, SKHEP-1,<br />
3757<br />
Nup88, breast cancer, Bax, immunocytometry, 2595<br />
Nutrients, factor analysis, esophageal cancer, bioactive<br />
substances. Uruguay, 2499<br />
Obesity, type 2 diabetes mellitus, mortality, cancer, 1373<br />
Occult cancer, prostate cancer, polymorphisms, autopsy,<br />
prostate-specific antigen, 3007<br />
Occult lung cancer, esophageal cancer, gastric cancer, 1841<br />
Occupational cancer, asbestos, calretinin,<br />
immunohistochemistry, mesothelioma, orchidectomy,<br />
1365<br />
4251
Oesophageal cancer, carboplatin, elderly, head and neck<br />
cancer, poor performance status, vinorelbine, 1383<br />
Oesophageal cancer, FDG-positron emission tomography,<br />
computed tomography, combined PET/CT, software<br />
fusion, 1867<br />
Oestrogen receptor, breast cancer, progesterone receptor,<br />
PST, 1797<br />
Oestrogen, steroid sulphatase, androgen, breast cancer, skin,<br />
acne, hirsutism, sulphatase inhibitor, 1517<br />
OK cells, somatostatin analogues, 111 In-DOTA-1-Nal 3 -<br />
octreotide, 111 In-DOTA-Tyr 3 -octreotate, tumour targeting,<br />
renal handling, biodistribution, AR42J cells, 2189<br />
Oligodendroglioma, amplification, EGFR, EGFRvIII,<br />
glioblastoma, glioma, 913<br />
Oligo-recurrence, breast cancer, osseous metastasis,<br />
radiation therapy, 3929<br />
Omega-3, omega-6, colon cancer, SW620, xenograft, lipids,<br />
3717<br />
Omega-6, omega-3, colon cancer, SW620, xenograft, lipids,<br />
3717<br />
Oncogenes, molecular markers, molecular pathology, oral<br />
squamous carcinoma, tumour suppressor genes, review,<br />
1197<br />
Oncolytic virotherapy, herpes simplex virus, oral squamous<br />
cell carcinoma, syncytial formation, 3637<br />
Oral cancer, angiotensinogen, polymorphism, angiogenesis,<br />
1675<br />
Oral cancer, HPV, tonsillar cancer, oropharyngeal cancer,<br />
2077<br />
Oral cancer, human papillomavirus, oral leukoplakia, 3733<br />
Oral cancer, interleukin-10, inflammation, angiogenesis,<br />
thrombophilia, 309<br />
Oral cancer, metastasis, biopsy, bleomycin, 2253<br />
Oral cancer, stromal-derived factor-1, angiogenesis,<br />
thrombophilia, polymorphism, 271<br />
Oral cancer, susceptibility genes, CYP1A1, GSTM1, GSTT1,<br />
1023<br />
Oral cancer, TUNEL, p53, heparanase, tumor marker,<br />
tongue cancer, 2981<br />
Oral cancer, XRCC4, polymorphism, carcinogenesis, 1687<br />
Oral carcinoma, p16, p53, Ki-67, oral dysplasia, 2535<br />
Oral cavity, ameloblastic carcinoma, ameloblastoma, 3847<br />
Oral cavity, fibromatosis, desmoid tumor, 1725<br />
Oral contraceptives, breast cancer, risk factors, estrogen<br />
receptor, progesterone receptor, 491<br />
Oral dysplasia, p16, p53, Ki-67, oral carcinoma, 2535<br />
Oral leucovorin, S-1, tegafur/uracil, colorectal cancer, 1779<br />
Oral leukoplakia, genetic polymorphisms, p53, 1101<br />
Oral leukoplakia, human papillomavirus, oral cancer, 3733<br />
Oral SCC, EMMPRIN, invasion, TN-C, MMP, 2049<br />
Oral squamous carcinoma, molecular markers, molecular<br />
pathology, oncogenes, tumour suppressor genes, review,<br />
1197<br />
4252<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Oral squamous cell carcinoma(OSCC), precancerous<br />
lesions, Mcm7, Cdc6, 3763<br />
Oral squamous cell carcinoma, cisplatin, 5-fluorouracil,<br />
chemotherapy, 253<br />
Oral squamous cell carcinoma, herpes simplex virus,<br />
oncolytic virotherapy, syncytial formation, 3637<br />
Oral squamous cell carcinoma, HIF-1α, VEGF-C,<br />
lymphangiogenesis, angiogenesis, 1659<br />
Oral squamous cell carcinoma, peplomycin, type of cell<br />
death, 2197<br />
Oral squamous cell carcinoma, β-cyclodextrin benzaldehyde<br />
inclusion compound, type of cell death, 229<br />
Orchidectomy, asbestos, calretinin, immunohistochemistry,<br />
mesothelioma, occupational cancer, 1365<br />
Origin, tumor angiogenesis, marrow-derived stem cells,<br />
endothelial cells, 771<br />
Oropharyngeal cancer, dysphagia, aspiration, postoperative<br />
radiation, 431<br />
Oropharyngeal cancer, HPV, tonsillar cancer, oral cancer,<br />
2077<br />
Orotate phophoribosyl transferase, thymidine synthase,<br />
dihydropyrimidine dehydrogenase, thymidine<br />
phosphorylase, 389<br />
Orotate phosphoribosyl transferase, thymidine synthase,<br />
dihydropyrimidine dehydrogenase, thymidine<br />
phosphorylase, laser-captured microdissection, 1477<br />
Orthopedic surgery, high hydrostatic pressure, tumor cells,<br />
viruses, bacteria, review, 3877<br />
Orthotopic implantation model, plakoglobin (gammacatenin),<br />
soft tissue sarcoma, pulmonary metastasis,<br />
cDNA array, 655<br />
Osseous metastasis, breast cancer, oligo-recurrence,<br />
radiation therapy, 3929<br />
Osteoblastic differentiation, murine osteosarcoma, cell line,<br />
transplantation, endochondral ossification, 1627<br />
Osteoclast, mandibular bone destruction, CCN2, 2343<br />
Osteopontin, biomarker, mesothelin, mesothelioma, 3933<br />
Osteopontin, breast cancer, mortality, survival, 4105<br />
Osteosarcoma, bisphosphonate, apoptosis, synergism, 2147<br />
Osteosarcoma, caffeine, cisplatin, combination therapy,<br />
1681<br />
Osteosarcoma, chemoresistance, gene profiling, MG-63,<br />
673<br />
Osteosarcoma, chemotherapy, caffeine, synergistic effect,<br />
cDNA array analysis, 645<br />
Osteosarcoma, methotrexate, toxicity, MTHFR,<br />
polymorphism, 3051<br />
Osteosarcoma, pegylated liposome, cisplatin, caffeine, 1449<br />
Osteosarcoma, PKC412, PKCα, molecular targeting<br />
therapy, sarcoma, malignant fibrous histiocytoma (MFH),<br />
825<br />
Outpatient setting, S-1, low-dose cisplatin, gastric cancer,<br />
combination therapy, 1433
Ovarian cancer, albendazole, β-cyclodextrin, efficacy,<br />
toxicity, 2775<br />
Ovarian cancer, ATP, chemosensitivity, prediction, drug<br />
resistance, 949<br />
Ovarian cancer, blood-brain barrier, brain metastases,<br />
pegylated liposomal doxorubicin, 1943<br />
Ovarian cancer, early diagnosis, tumor markers,<br />
gonadotropins, antitumoral vaccine, review, 3135<br />
Ovarian cancer, gemcitabine, oxaliplatin, phase II, 495<br />
Ovarian cancer, gene therapy, thymidine kinase, adenovirus,<br />
Coxackie-adenovirus receptor, 2569<br />
Ovarian cancer, HMFG1, HAMA, IgG, IgM,<br />
intraperitoneal, 2721<br />
Ovarian cancer, p38-MAPK, gemcitabine, chemoresistance,<br />
2975<br />
Ovarian cancer, polymorphisms, estrogen and xenobiotic<br />
metabolism, 3079<br />
Ovarian cancer, positron emission tomography, computed<br />
tomography, tumor marker, 2303<br />
Ovarian cancer, programmed cell death 4 (PDCD4),<br />
expression, prognosis, 2991<br />
Ovarian cancer, second-line therapy, pegylated liposomal<br />
doxorubicin, biweekly schedule, toxic skin reactions,<br />
palmar-plantar erythrodysesthesia, 1329<br />
Ovarian carcinoma, alpha-folate receptor, folate receptor<br />
overexpression, targeted therapy, 3567<br />
Ovarian carcinoma, loss of heterozygosity, TP53, RB,<br />
chemotherapy, 989<br />
Ovarian metastasis, amelanotic melanoma, 563<br />
Ovary, Krukenberg tumour, signet-ring cell carcinoma,<br />
stomach, electron microscopy, immunohistochemistry,<br />
1417<br />
Oxaliplatin, 5-fluorouracil, arterial, infusion, cetuximab,<br />
colorectal, irinotecan, metastases, 2459<br />
Oxaliplatin, colorectal cancer, hypersensitivity reaction,<br />
intracranial hemorrhage, thrombocytopenia, 3115<br />
Oxaliplatin, gastric cancer, CDDP-resistant cell line,<br />
ERCC1, GST-π, MKN45, 2087<br />
Oxaliplatin, gastric cancer, chemotherapy, irinotecan, 2901<br />
Oxaliplatin, gemcitabine, phase II, ovarian cancer, 495<br />
Oxaliplatin, intrahepatic cholangiocarcinoma, microspheres,<br />
TACE, 2987<br />
Oxidative DNA damage, gastric cancer, DNA repair, 215<br />
3-D planning, prostate cancer, side-effect, hormonal<br />
therapy, 3913<br />
P15, SMAD4, gastric cancer, immunohistochemistry, 1079<br />
P16, NPC, methylation, DLEC1, BLU, E-cadherin, 2161<br />
P16, p53, Fhit protein, esophagitis, megaesophagus,<br />
esophageal carcinoma, 3793<br />
P16, p53, Ki-67, oral dysplasia, oral carcinoma, 2535<br />
P16 INK4a , mesothelioma, cyclin dependent kinase, 1<br />
P1NP, renal cell carcinoma, AP, tumour marker, bone<br />
metastases, 2443<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
P21, genistein, estrogen receptor β, prostate cancer, 709<br />
P21, germ-cell testicular tumor, differentiation,<br />
chemoresistance, apoptosis, p53, 1641<br />
P21, leukemia, cell cycle, apoptosis, drug resistance, 965<br />
P21, syndecan-1, tenascin-C, TATI, p53, bcl-2,<br />
immunohistochemistry, flow cytometry, gastric cancer,<br />
prognosis, 2279<br />
P27, cervical cancer, markers, p53, COX-2, Ki-67, EGFR,<br />
E-cadherin, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
P27 kip1 , matrix metalloproteinase, invasion, breast cancer,<br />
2669<br />
P27 Kip1 , pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB, cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
P38, plasmacytoma, dexamethasone, MAPK inhibitor,<br />
SCIO-469, SD-282, RPMI-8226, H-929, HSP-27, 3827<br />
P38-MAPK, ovarian cancer, gemcitabine, chemoresistance,<br />
2975<br />
P53 and Bcl-2 status, sulfonate ester, breast cancer, cell<br />
growth inhibition, cell cycle arrest and apoptosis, 2753<br />
P53 codon 72 polymorphism, Arg72Pro, sporadic colorectal<br />
adenocarcinoma, left colon cancer, 1039<br />
P53 gene therapy, histone deacetylase inhibitor, FK228,<br />
depsipeptide, esophageal squamous cell carcinoma, 665<br />
P53, astrocytoma, proliferation markers, apoptosis, 15<br />
P53, berberine, cell cycle arrest, apoptosis, neuroblastoma<br />
cells, 3777<br />
P53, cervical cancer, markers, p27, COX-2, Ki-67, EGFR,<br />
E-cadherin, c-myc, VEGF, CD44, CD4, age-specific<br />
expression, 1793<br />
P53, germ-cell testicular tumor, differentiation,<br />
chemoresistance, apoptosis, p21, 1641<br />
P53, GSTM1, GSTT1, polymorphism, colorectal cancer,<br />
Dukes’ stage, survival, 1917<br />
P53, image DNA analysis, immunohistochemistry, Wilms’<br />
tumour, p57 kip2 , Ki-67, 751<br />
P53, methylation, inflammation, iNOS, LPS, 2101<br />
P53, neoadjuvant chemotherapy, breast, epirubicin, taxol,<br />
Erb family, 3147<br />
P53, oral leukoplakia, genetic polymorphisms, 1101<br />
P53, p16, Fhit protein, esophagitis, megaesophagus,<br />
esophageal carcinoma, 3793<br />
P53, p16, Ki-67, oral dysplasia, oral carcinoma, 2535<br />
P53, photodynamic therapy, Barrett's esophagus, dysplasia,<br />
485<br />
P53, PTEN, mTOR, AKT, genome stability, cell cycle,<br />
review, 3613<br />
P53, regulation, protein synthesis, post-transcriptional<br />
regulation, 2553<br />
4253
P53, syndecan-1, tenascin-C, TATI, p21, bcl-2,<br />
immunohistochemistry, flow cytometry, gastric cancer,<br />
prognosis, 2279<br />
P53, TUNEL, heparanase, tumor marker, tongue cancer,<br />
oral cancer, 2981<br />
P53, α-santalol, caspases, UVB radiation, skin cancer, 129<br />
P57 kip2 , image DNA analysis, immunohistochemistry,<br />
Wilms’ tumour, p53, Ki-67, 751<br />
Pacific Island, ethnic minority, Māori, diagnosis, treatment,<br />
accessibility, 3891<br />
Paclitaxel, 5’-deoxy-5-fluorouridine, nude mice, gastric<br />
cancer, thymidine phosphorylase, apoptosis, 1593<br />
Paclitaxel, breast carcinoma, chemotherapy,<br />
cyclophosphamide, doxorubicin, ferritin, iron, neopterin,<br />
2389<br />
Paclitaxel, cancer of unknown primary site, CUP,<br />
chemoresistance, tau, tubulin, tubulin III, 1161<br />
Paclitaxel, cervical cancer, carboplatin, concurrent<br />
radiotherapy, 3143<br />
Paclitaxel, docetaxel, first-line chemotherapy, gemcitabine,<br />
HER-2, metastatic breast cancer, taxane, review, 1245<br />
Paclitaxel, head and neck carcinoma, cisplatin,<br />
chemotherapy, radiotherapy, 1285<br />
Paclitaxel, neoadjuvant chemotherapy, breast cancer, Her2<br />
overexpression, 1239<br />
Paclitaxel, non-small cell lung cancer, phase II study,<br />
induction chemotherapy, carboplatin, chemoradiotherapy,<br />
2851<br />
Paclitaxel, silibinin, drug resistance, invasion, Pglycoprotein,<br />
survivin, 1119<br />
Paediatrics, brain tumour, MRI, stem cell, 741<br />
PAH, promoter methylation, smoke, coal, benzopyrene,<br />
sputum, lung cancer, 2061<br />
PAI-1, hepatocellular carcinoma, circulating hTERT DNA,<br />
t-PA, 223<br />
PAI-1, PAI-2, apoptosis, colon cancer, 693<br />
PAI-2, PAI-1, apoptosis, colon cancer, 693<br />
Palliative chemotherapy, elderly, colon cancer, 1813<br />
Palliative gastrectomy, adjuvant chemotherapy, advanced<br />
gastric cancer, 1309<br />
Palliative radiotherapy, whole-brain radiotherapy, brain<br />
metastases, survival prediction, 3965<br />
Palmar-plantar erythrodysesthesia, ovarian cancer, secondline<br />
therapy, pegylated liposomal doxorubicin, biweekly<br />
schedule, toxic skin reactions, 1329<br />
Panax quinquefolius L., heat-processing, antiproliferation,<br />
human breast cancer, HPLC analysis, ginsenoside Rg3,<br />
apoptosis, cell cycle, 2545<br />
Pancreas, CDC20, siRNA, therapy, cytotoxicity,<br />
chemoradiation, 1559<br />
Pancreas, unresectable cancer, chemoradiotherapy, hyperfractionated<br />
accelerated radiotherapy, conformal<br />
radiotherapy, gemcitabine, 2369<br />
4254<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Pancreatectomy, renal cell carcinoma, metastases, pancreatic<br />
resection, 361<br />
Pancreatic cancer, ampullary cancer, MMPs, TIMPs, MVD,<br />
1875<br />
Pancreatic cancer status, review, 1303<br />
Pancreatic cancer, gemcitabine resistance, deoxycytidine<br />
kinase, 2205<br />
Pancreatic cancer, immunosurgery, immunotherapy,<br />
interleukin-2, lymphocytopenia, 1951<br />
Pancreatic cancer, MUC1, dendritic cell, CTL,<br />
immunotherapy, 379<br />
Pancreatic cancer, multidrug resistance, interferon-alpha<br />
combination therapy, 1499<br />
Pancreatic cancer, S-1, 5-fluorouracil, gemcitabine, human<br />
equilibrative nucleotide transporter, schedule-dependent<br />
effect, combination chemotherapy, in vivo, 179<br />
Pancreatic cancer, vitamin K 3 (menadione), chemotherapy,<br />
endoscopic ultrasound-guided fine needle injection, drug<br />
delivery system, 45<br />
Pancreatic carcinoma, prognostic factors, chemotherapy,<br />
surgical therapy, survival, 543<br />
Pancreatic ductal adenocarcinoma, INK4a, K-RAS, SMAD4,<br />
TP53, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
Pancreatic ductal carcinoma, EGF (epidermal growth<br />
factor), EGFR (epidermal growth factor receptor), cerbB-2<br />
(HER-2), 1399<br />
Pancreatic resection, renal cell carcinoma, metastases,<br />
pancreatectomy, 361<br />
Paneth cells, stem cells, turnover, adenomas, 1571<br />
PAP smear, cervical dysplasia, CIN, endocervical cytology,<br />
cytobrush, 3131<br />
Papillary neoplasms, maspin, bladder, 471<br />
Papillary, BRAF, K-RAS, mutation, medullary, thyroid<br />
carcinoma, 305<br />
Parasporin-1Ab, anticancer cytotoxin, preferential<br />
cytotoxicity, Bacillus thuringiensis, 91<br />
PARP, temozolomide, ADP ribose, preclinical efficacy,<br />
biomarker, 2625<br />
Parthenolide, BAY 11-7085, N-acetylcysteine, Lbuthionine-(S,R)-sulfoximine,<br />
PRIMA-1, Gemcitabine,<br />
MG-132, flavopiridol, 681<br />
Pathobiological behavior, gastric carcinoma, MUC-1,<br />
prognosis, 1061<br />
Pathogenesis, gastric carcinoma, Arp, progression, 2225<br />
Pathologic response, breast cancer, chemoresponse,<br />
chemosensitivity assay, chemosensitivity resistance assay<br />
(CSRA), ChemoFx ® , 1733<br />
Patient outcome, breast cancer, pregnancy, hormonotherapy,<br />
child outcome, 2447
PC-3, prostate, metastasis, proliferation, tumorigenesis,<br />
matriptase, 1977<br />
PC-3, prostate, metastasis, proliferation, tumorigenicity,<br />
matriptase, N-acetylglucosaminyltransferase V, 1993<br />
PCNA, Ki-67, MCM2, colorectal cancer, 451<br />
PCR, HER3, cutaneous tumors, squamous cell carcinoma,<br />
nevus, 973<br />
PCR-ELISA, solid-phase PCR, quantitative DNA<br />
methylation analysis, promoter hypermethylation,<br />
quantitative PCR, 2055<br />
PCR-RFLP, restriction enzyme, SNP genotyping, primer<br />
design, software, review, 2001<br />
PDGFR, acute myeloid leukemia, single-strand<br />
conformation polymorphism, core-binding factor, 2745<br />
Peach, colon cancer, differentiation, anthocyanins, plum,<br />
phenolics, 2067<br />
PEDF, prostate, PSA, ARA24, NCOA4, IL-6, PSCA,<br />
matriptase, 1969<br />
Pediatric, anaplastic astrocytoma, glioblastoma multiforme,<br />
high grade glioma, histone deacetylase inhibitor, valproic<br />
acid, 2437<br />
PEG-DSPE, gossypol, liposome, TPGS, 2801<br />
Pegylated liposomal doxorubicin, blood-brain barrier, brain<br />
metastases, ovarian cancer, 1943<br />
Pegylated liposomal doxorubicin, ovarian cancer, secondline<br />
therapy, biweekly schedule, toxic skin reactions,<br />
palmar-plantar erythrodysesthesia, 1329<br />
Pegylated liposome, osteosarcoma, cisplatin, caffeine, 1449<br />
Peplomycin, type of cell death, oral squamous cell<br />
carcinoma, 2197<br />
Peptide analog, desmopressin, vasopressin, chemotherapy,<br />
breast cancer, 2607<br />
Perioperative, HDR brachytherapy, flab, bendy applicator,<br />
sarcoma, 3885<br />
Peripheral blood stem cell transplantation, sclerosing<br />
rhabdomyosarcoma, metastasis, chemotherapy, 2361<br />
Peripheral blood, colorectal cancer, molecular staging,<br />
circulating tumor cells, polymerase chain reaction, review,<br />
3945<br />
Peripheral lymphocytes, viscum album, mistletoe, cancer<br />
patients, local reactions, quality of life, 1893<br />
Peritoneal metastasis, RegIV, gastric cancer, RT-PCR, 1169<br />
Persistent-recurrent CIN, CO2 laser, conservative treatment,<br />
3871<br />
PET-CT, FDG, FLT, neuroblastoma, MRT, SCID mouse, 2561<br />
P-glycoprotein, colon cancer, ABCB1 gene, polymorphisms,<br />
immunohistochemistry, 3921<br />
P-glycoprotein, colon carcinoma, cell lines, multidrug<br />
resistance, pO 2 , antioxidants, 55<br />
P-glycoprotein, silibinin, paclitaxel, drug resistance,<br />
invasion, survivin, 1119<br />
PGP9.5, quantitative methylation-specific PCR, colorectal<br />
cancer, marker, 2697<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Pharmacokinetics, head and neck cancer, chemotherapy,<br />
Doxil, Caelyx, Taxol, 2519<br />
Phase Ⅱ study, S-1, cisplatin, advanced pancreatic cancer,<br />
2373<br />
Phase I study, advanced gastric cancer, chemotherapy,<br />
toxicity, 2473<br />
Phase I study, new combined chemotherapy, gynecological<br />
malignancy, CPT-11, MMC, 5-FU, 2933<br />
Phase I, anticancer agents, fixed dose, body surface area,<br />
body weight, 3075<br />
Phase I/II study, breast cancer, vinorelbine, gemcitabine,<br />
gefitinib, 3019<br />
Phase II study, non-small cell lung cancer, induction<br />
chemotherapy, paclitaxel, carboplatin, chemoradiotherapy,<br />
2851<br />
Phase II, gemcitabine, oxaliplatin, ovarian cancer, 495<br />
Phenolics, colon cancer, differentiation, anthocyanins,<br />
peach, plum, 2067<br />
Photodynamic therapy, Barrett's esophagus, dysplasia, p53,<br />
485<br />
Photodynamic therapy, hypericin, glioma, intracellular<br />
localization, endoplasmatic reticulum, Golgi apparatus,<br />
2033<br />
PI3K, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, TP53, NF-ÎB, SKP2, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
PI3-kinase, multiple myeloma, necrosis, 37<br />
Pioglitazone, colon cancer, liver metastasis, 3593<br />
PKC412, PKCα, molecular targeting therapy, sarcoma,<br />
osteosarcoma, malignant fibrous histiocytoma (MFH),<br />
825<br />
PKCα, PKC412, molecular targeting therapy, sarcoma,<br />
osteosarcoma, malignant fibrous histiocytoma (MFH),<br />
825<br />
Plakoglobin (gamma-catenin), soft tissue sarcoma,<br />
pulmonary metastasis, orthotopic implantation model,<br />
cDNA array, 655<br />
Plasma, cell-free DNA, serum, breast cancer, 921<br />
Plasmacytoma, dexamethasone, MAPK inhibitor, p38,<br />
SCIO-469, SD-282, RPMI-8226, H-929, HSP-27, 3827<br />
Plasminogen activator inhibitor-1 (PAI-1), glioma, cancer,<br />
protease, serum marker, 415<br />
Platinum-based chemotherapy, granulosa cell tumors,<br />
surgery, 1421<br />
Pleomorphic adenoma, salivary glands, BRCA-1, mutation,<br />
3011<br />
Pleural effusions, CEA, CA 125, CA 15.3, CA 19.9, TAG<br />
72, tumour markers, 2947<br />
Plum, colon cancer, differentiation, anthocyanins, peach,<br />
phenolics, 2067<br />
4255
Plumbagin, apoptosis, pro-apoptotic genes, cell cycle, lung<br />
cancer, 785<br />
PML-RARA, intranuclear order, genomic karyotyping,<br />
BCR-ABL, t(9:22), t(15;17), review, 3573<br />
PO 2 , colon carcinoma, cell lines, multidrug resistance, Pglycoprotein,<br />
antioxidants, 55<br />
Podoplanin, lymphatic vessels, metastasis, tumor growth,<br />
review, 2997<br />
POLR2F, PRNP, ATP6V0A1, colorectal cancer, quantitative<br />
RT-PCR, 1221<br />
Polyamines, mepacrine, MCF-7, Vero, cell proliferation,<br />
2765<br />
Polychemotherapy, angiosarcoma, first-line, 3041<br />
Polyethylenimine, transfection efficiency, depsipeptide, Raji<br />
cells, KB cells, 793<br />
Polymerase chain reaction, colorectal cancer, molecular<br />
staging, circulating tumor cells, peripheral blood, review,<br />
3945<br />
Polymerase chain reaction, human papillomavirus 11,<br />
cidofovir, laryngeal neoplasms, 2169<br />
Polymethylmethacrylate, giant cell tumor, sternum,<br />
curettage, 4117<br />
Polymorphism, angiotensinogen, oral cancer, angiogenesis,<br />
1675<br />
Polymorphism, colon cancer, VEGF, Korea, 1271<br />
Polymorphism, FAS, FASL, apoptosis, atrophy, intestinal<br />
metaplasia, 97<br />
Polymorphism, gastric cancer, myeloperoxidase,<br />
Helicobacter pylori, neutrophil, gastritis, 1317<br />
Polymorphism, GNAS1, prostate cancer, 3711<br />
Polymorphism, GSTM1, GSTT1, p53, colorectal cancer,<br />
Dukes’ stage, survival, 1917<br />
Polymorphism, methotrexate, toxicity, MTHFR,<br />
osteosarcoma, 3051<br />
Polymorphism, MHC class II, MHC2TA, CIITA, colorectal<br />
cancer, 1789<br />
Polymorphism, MTHFR, MTRR, risk factors, HCC, 2807<br />
Polymorphism, stromal-derived factor-1, oral cancer,<br />
angiogenesis, thrombophilia, 271<br />
Polymorphism, XRCC4, breast cancer, carcinogenesis, 267<br />
Polymorphism, XRCC4, oral cancer, carcinogenesis, 1687<br />
Polymorphisms, colon cancer, P-glycoprotein, ABCB1 gene,<br />
immunohistochemistry, 3921<br />
Polymorphisms, gastric cancer, stomach, NOD-2, 757<br />
Polymorphisms, ovarian cancer, estrogen and xenobiotic<br />
metabolism, 3079<br />
Polymorphisms, prostate cancer, autopsy, occult cancer,<br />
prostate-specific antigen, 3007<br />
Polyp, adenoma, primary culture, carcinogenesis, cell<br />
culture, 843<br />
Polyps, size, computed tomography, 1911<br />
Poor performance status, carboplatin, elderly, head and neck<br />
cancer, oesophageal cancer, vinorelbine, 1383<br />
4256<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Poor prognostic factors, intrahepatic cholangiocarcinoma,<br />
R0 resection, lymph node dissection, 2353<br />
POP, AcSDKP, marker, angiogenesis, thyroid tumor, cancer,<br />
2813<br />
Porphyromonas gingivalis fimbriae, curcumin,<br />
tetrahydrocurcumin, COX-2, NF-ÎB, chemical<br />
descriptors, lipopolysaccharide, 699<br />
Positive margin, cervical dysplasia, colposcopy, negative<br />
histology, LLETZ, 519<br />
Positron emission tomography, ovarian cancer, computed<br />
tomography, tumor marker, 2303<br />
Postmenopause, preneoplastic cervical lesions, laser<br />
conization, 3941<br />
Postoperative morbidity, vulvar cancer, sentinel, prognosis, 515<br />
Postoperative radiation, dysphagia, aspiration,<br />
oropharyngeal cancer, 431<br />
Post-transcriptional regulation, p53, regulation, protein<br />
synthesis, 2553<br />
PPARγ, cancer, caveolin-1, EGF receptor, MAP kinase<br />
signaling, rosiglitazone, 895<br />
Precancerous lesions, oral squamous cell<br />
carcinoma(OSCC), Mcm7, Cdc6, 3763<br />
Preclinical efficacy, PARP, temozolomide, ADP ribose,<br />
biomarker, 2625<br />
Prediction, ATP, chemosensitivity, ovarian cancer, drug<br />
resistance, 949<br />
Prediction, S-100B, melanoma, stage IIIB/C, relapse,<br />
survival, 2297<br />
Predictive factor, Non-small cell lung cancer, neuronspecific<br />
enolase, NSE, prognostic factor, 507<br />
Predictive markers, radiation pneumonitis, breast cancer,<br />
radiation therapy, review, 2421<br />
Preferential cytotoxicity, parasporin-1Ab, anticancer<br />
cytotoxin, Bacillus thuringiensis, 91<br />
Pregnancy, breast cancer, hormonotherapy, patient outcome,<br />
child outcome, 2447<br />
Premenopausal, mammary carcinogenesis, rat,<br />
chemoprevention, anastrozole, aromatase inhibitors, 2819<br />
Preneoplastic cervical lesions, postmenopause, laser<br />
conization, 3941<br />
Preneoplastic lesions, flat aberrant crypt foci, mucindepleted<br />
foci, colon carcinogenesis, 3771<br />
Prenylalcohol, vitamin K 2 , cytotoxicity, apoptosis,<br />
autophagy, type of cell death, 151<br />
Prenylation inhibitor, aponecrosis, mitogen-activated protein<br />
kinase, ras, NaPa, 1029<br />
Preoperative diagnosis, ultrasound, endometrial cancer,<br />
clinical management, 2453<br />
Preoperative, hemoglobin, CEA, non-small cell lung cancer,<br />
survival, 1947<br />
PRIMA-1, parthenolide, BAY 11-7085, N-acetylcysteine,<br />
L-buthionine-(S,R)-sulfoximine, Gemcitabine, MG-<br />
132, flavopiridol, 681
Primary breast cancer, metastatic disease, X-ray, bone scan,<br />
liver ultrasound, staging, 2397<br />
Primary culture, polyp, adenoma, carcinogenesis, cell<br />
culture, 843<br />
Primary immunodeficiencies, cancer, review, 1263<br />
Primary ovarian cancer, breast metastasis, diagnosis, 3047<br />
Primary retroperitoneal mucinous cystadenoma, diagnosis,<br />
staging, treatment, 2309<br />
Primary systemic chemotherapy, reast cancer, epirubicin,<br />
docetaxel, 4137<br />
Primer design, restriction enzyme, SNP genotyping, PCR-<br />
RFLP, software, review, 2001<br />
PRNP, POLR2F, ATP6V0A1, colorectal cancer, quantitative<br />
RT-PCR, 1221<br />
Pro-apoptotic genes, apoptosis, cell cycle, lung cancer,<br />
plumbagin, 785<br />
Procalcitonin, C-reactive protein, infection, leukopenia,<br />
3061<br />
Profiling, bladder neoplasms, bladder neoplasm<br />
classification, molecular classification, review, 2893<br />
Progesterone receptor, breast cancer, oestrogen receptor,<br />
PST, 1797<br />
Progesterone receptor, breast cancer, risk factors, oral<br />
contraceptives, estrogen receptor, 491<br />
Progesterone, breast cancer, aromatase, MCF-7aro cells,<br />
2129<br />
Progestins, low-grade endometrial stromal sarcoma, surgery,<br />
aromatase inhibitors, 2869<br />
Prognosis, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, diagnosis, sCD26, EGF,<br />
sEGFR, ELISA, cytometric beads, antibody arrays,<br />
clustering, bioinformatics, review, 2333<br />
Prognosis, CEA, Dukes’ C, colorectal cancer, 1933<br />
Prognosis, DNAses, vitamin C, vitamin K 3 , adjuvant<br />
therapy, review, 2727<br />
Prognosis, endometrial cancer, MMP-2, MMP-9, TIMP-1,<br />
TIMP-2, 2715<br />
Prognosis, fascin, Ki-67, immunohistochemistry, serous<br />
ovarian cancer, 1905<br />
Prognosis, gastric cancer, ND-factor, non-curative factor,<br />
435<br />
Prognosis, gastric carcinoma, MUC-1, pathobiological<br />
behavior, 1061<br />
Prognosis, gastrointestinal stromal tumors, classification<br />
systems, 367<br />
Prognosis, interleukin-12, gastric cancer,<br />
immunohistochemistry, 1277<br />
Prognosis, Ki-67 antigen, non-Hodgkin’s lymphoma, 1113<br />
Prognosis, laryngeal carcinoma, CD105, vascular<br />
endothelial growth factor receptor 2 (VEGFR2),<br />
recurrence, 551<br />
Prognosis, lymphangiogenesis, CD105, small cell lung<br />
carcinoma, immunohistochemistry, 343<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Prognosis, merkel cell tumor, metastasis, urinary bladder,<br />
therapy, 1361<br />
Prognosis, microRNAs (miRNAs), miR-21, gastric cancer,<br />
907<br />
Prognosis, myelotoxicity, chemotherapy, advanced, breast<br />
cancer, 2913<br />
Prognosis, NLRP7, immunohistochemistry, endometrial<br />
cancer, clinicopathological factors, 2493<br />
Prognosis, NSCLC, heat shock proteins,<br />
immunohistochemistry, 501<br />
Prognosis, programmed cell death 4 (PDCD4), expression,<br />
ovarian cancer, 2991<br />
Prognosis, prostate cancer, androgen receptor, SRC1, TIF2,<br />
Her2/neu, radical prostatectomy, 425<br />
Prognosis, prostate-specific antigen, urothelial carcinoma,<br />
invasion, PSA, 4149<br />
Prognosis, proximal gastric cancer, lymph node metastatic<br />
density, 2875<br />
Prognosis, radiotherapy, brain metastases, surgery, 3015<br />
Prognosis, syndecan-1, tenascin-C, TATI, p53, p21, bcl-2,<br />
immunohistochemistry, flow cytometry, gastric cancer,<br />
2279<br />
Prognosis, telomerase activity, head and neck cancer, realtime<br />
TRAP, marker, 3125<br />
Prognosis, tumor budding, colorectal cancer,<br />
immunohistochemistry, D2-40, 1831<br />
Prognosis, VEGF-1 expression, colorectal cancer, adjuvant<br />
therapy, 3865<br />
Prognosis, VEGF-C, serum, lymph node metastasis,<br />
recurrence, esophageal cancer, 165<br />
Prognosis, vulvar cancer, sentinel, postoperative morbidity,<br />
515<br />
Prognostic factor, DBM, rectal cancer, rectosigmoid cancer,<br />
1773<br />
Prognostic factor, gastrectomy, non-curative factor,<br />
advanced gastric cancer, 2379<br />
Prognostic factor, gastric cancer, protease activated<br />
receptor-1 (PAR-1), matrix metalloproteinase-1 (MMP-<br />
1), immunohistochemistry, 847<br />
Prognostic factor, Non-small cell lung cancer, neuronspecific<br />
enolase, NSE, predictive factor, 507<br />
Prognostic factors, acute myeloid leukemia, children, drug<br />
resistance, drug sensitivity, 1927<br />
Prognostic factors, pancreatic carcinoma, chemotherapy,<br />
surgical therapy, survival, 543<br />
Prognostic factors, radiotherapy, brain metastasis, age,<br />
malignant melanoma, 1325<br />
Prognostic marker, s-TREM-1, lung metastasis, 1411<br />
Prognostic significance, hepsin, endometrial cancer, 159<br />
Programmed cell death 4 (PDCD4), expression, ovarian<br />
cancer, prognosis, 2991<br />
Progression, baboons, colon cancer, 193<br />
Progression, gastric carcinoma, Arp, pathogenesis, 2225<br />
4257
ProGRP, small cell lung cancer, NSE, monitoring of<br />
therapy, 3027<br />
Prohibitin, Akt, transformation, 957<br />
Proliferation markers, astrocytoma, apoptosis, p53, 15<br />
Proliferation markers, incidentaloma, adrenocortical,<br />
metallothioneins, minichromosome maintenance protein,<br />
Ki-67, 2959<br />
Proliferation, glioblastoma multiforme, insulin like growth<br />
factor, migration, 1055<br />
Proliferation, mammaglobin, lipophilin B, secretoglobin,<br />
breast cancer, 1493<br />
Proliferation, pancreatic ductal adenocarcinoma, INK4a,<br />
K-RAS, SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 ,<br />
cell cycle, angiogenesis, metastasis, apoptosis, epigenetic<br />
gene regulation, miRNA, epithelial-mesenchymal<br />
transition, chemotaxis, sonic hedgehog, review, 1541<br />
Proliferation, prostate, metastasis, PC-3, tumorigenesis,<br />
matriptase, 1977<br />
Proliferation, prostate, metastasis, PC-3, tumorigenicity,<br />
matriptase, N-acetylglucosaminyltransferase V, 1993<br />
Proliferation, steep pulsed electric field (SPEF), hepatoma,<br />
biorheology, micropipette aspiration, 2245<br />
Proliferation, translationally controlled tumor protein, liver<br />
regeneration, liver cancer, antisense, cell cycle, apoptosis,<br />
1575<br />
Proliferation, breast cancer, estrogen receptor α, hedgehog<br />
signaling pathway, sonic hedgehog, 731<br />
Proliferative breast disease, WT1, tumor suppressor,<br />
MCF10AT3B cells, breast cancer, 2155<br />
Promoter hypermethylation, solid-phase PCR, PCR-ELISA,<br />
quantitative DNA methylation analysis, quantitative PCR,<br />
2055<br />
Promoter methylation, smoke, coal, PAH, benzopyrene,<br />
sputum, lung cancer, 2061<br />
Promoter polymorphism, prostate cancer, inflammation,<br />
ACT, PSA levels, 395<br />
Promoter, MHC, class Ib, cancer, gene expression, gene<br />
therapy, 799<br />
Prostate biopsy, prostate cancer, nomogram, testosterone,<br />
prostate- specific antigen, 2487<br />
Prostate biopsy, prostate cancer, proton magnetic resonance<br />
spectroscopy, accuracy of diagnosis, 1899<br />
Prostate cancer therapy, noscapine, tumour inhibition, 3701<br />
Prostate cancer, 3-D planning, side-effect, hormonal<br />
therapy, 3913<br />
Prostate cancer, androgen receptor, SRC1, TIF2, Her2/neu,<br />
prognosis, radical prostatectomy, 425<br />
Prostate cancer, brachytherapy, autopsy, morphology, 3909<br />
Prostate cancer, cell death therapy, differentiation therapy,<br />
gene therapy, radiosensitivity, tumor suppression, tyrosine<br />
kinases, 2141<br />
Prostate cancer, color Doppler ultrasonography, resistance<br />
index, 1985<br />
4258<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Prostate cancer, genistein, estrogen receptor β, p21, 709<br />
Prostate cancer, Gleason grade, tissue microarray, cathepsin<br />
B, inhibitor stefin A, 2271<br />
Prostate cancer, GNAS1, polymorphism, 3711<br />
Prostate cancer, high-intensity focused ultrasound, Chk2,<br />
DNA damage, 639<br />
Prostate cancer, inflammation, ACT, promoter<br />
polymorphism, PSA levels, 395<br />
Prostate cancer, nomogram, testosterone, prostate- specific<br />
antigen, prostate biopsy, 2487<br />
Prostate cancer, polymorphisms, autopsy, occult cancer,<br />
prostate-specific antigen, 3007<br />
Prostate cancer, prostate stroma, TGF-β, IGF-I, tumor<br />
growth, 721<br />
Prostate cancer, proton magnetic resonance spectroscopy,<br />
prostate biopsy, accuracy of diagnosis, 1899<br />
Prostate cancer, radiotherapy, toxicity, 2865<br />
Prostate cancer, robot, da Vinci, laparoscopic radical<br />
prostatectomy, 1989<br />
Prostate cancer, vimentin, invasion, C-src, E-cadherin/catenin,<br />
327<br />
Prostate cancer, vitamin D hydroxylase, histone deacetylase<br />
inhibitor, Cyp27b1, 2009<br />
Prostate carcinoma, ultrasound, prostatic biopsy, transrectal<br />
ultrasound, RULES, 1883<br />
Prostate- specific antigen, prostate cancer, nomogram,<br />
testosterone, prostate biopsy, 2487<br />
Prostate stroma, prostate cancer, TGF-β, IGF-I, tumor<br />
growth, 721<br />
Prostate, cancer, annexin, cytokine, gp96, review, 2843<br />
Prostate, embryology, cell differentiation, intermediate<br />
filaments, keratin, 237<br />
Prostate, metastasis, PC-3, proliferation, tumorigenesis,<br />
matriptase, 1977<br />
Prostate, metastasis, PC-3, proliferation, tumorigenicity,<br />
matriptase, N-acetylglucosaminyltransferase V, 1993<br />
Prostate, PSA, ARA24, NCOA4, IL-6, PSCA, PEDF,<br />
matriptase, 1969<br />
Prostate, tumor suppressor, vitamin D, 25-hydroxyvitamin<br />
D-1 alpha-hydroxylase, CYP27B1, 2015<br />
Prostate-specific antigen, prostate cancer, polymorphisms,<br />
autopsy, occult cancer, 3007<br />
Prostate-specific antigen, urothelial carcinoma, invasion,<br />
prognosis, PSA, 4149<br />
Prostatic biopsy, ultrasound, prostate carcinoma, transrectal<br />
ultrasound, RULES, 1883<br />
Protease activated receptor-1 (PAR-1), gastric cancer,<br />
matrix metalloproteinase-1 (MMP-1),<br />
immunohistochemistry, prognostic factor, 847<br />
Protease, glioma, cancer, plasminogen activator inhibitor-1<br />
(PAI-1), serum marker, 415<br />
Protein stability, RbAp46, small ubiquitin-like modifier<br />
(SUMO-1), cell growth, 3749
Protein synthesis, p53, regulation, post-transcriptional<br />
regulation, 2553<br />
Protein tyrosine kinase, LHRH, somatostatin, protein<br />
tyrosine phosphatase, receptor, 2599<br />
Protein tyrosine phosphatase, LHRH, somatostatin, protein<br />
tyrosine kinase, receptor, 2599<br />
Proteoglycan, aggrecan, versican, decorin, Western blotting,<br />
immuno-histochemistry, RT-PCR, 245<br />
Proton magnetic resonance spectroscopy, prostate cancer,<br />
prostate biopsy, accuracy of diagnosis, 1899<br />
Protracted venous infusion fluorouracil, advanced colorectal<br />
cancer, weekly irinotecan, 2327<br />
Proximal gastric cancer, lymph node metastatic density,<br />
prognosis, 2875<br />
PSA levels, prostate cancer, inflammation, ACT, promoter<br />
polymorphism, 395<br />
PSA, prostate, ARA24, NCOA4, IL-6, PSCA, PEDF,<br />
matriptase, 1969<br />
PSA, prostate-specific antigen, urothelial carcinoma,<br />
invasion, prognosis, 4149<br />
PSCA, prostate, PSA, ARA24, NCOA4, IL-6, PEDF,<br />
matriptase, 1969<br />
PST, breast cancer, oestrogen receptor, progesterone<br />
receptor, 1797<br />
PTEN, mTOR, p53, AKT, genome stability, cell cycle,<br />
review, 3613<br />
Pulmonary metastasis, plakoglobin (gamma-catenin), soft<br />
tissue sarcoma, orthotopic implantation model, cDNA<br />
array, 655<br />
Pulmonary nodule, diagnosis, lung cancer, massscreening,<br />
bronchoscopy, video-assisted thoracoscopic<br />
surgery, 3153<br />
Pur-alpha, HIV-1 Tat, Rad51, DNA repair, 1441<br />
Pyrophosphomonoester, γδ T-cells, nonpeptide antigens,<br />
antitumor activity, cancer immunotherapy, 2921<br />
QSAR, 3-formylchromone derivatives, cytotoxicity,<br />
semiempirical molecular-orbital method, absolute<br />
hardness, 277<br />
QSAR, 5-trifluoromethyloxazole derivatives, cytotoxicity,<br />
semiempirical molecular-orbital method, absolute<br />
hardness, 997<br />
Quality of life, breast cancer, complementary treatment,<br />
standardized mistletoe extract, epidemiological cohort<br />
study, 523<br />
Quality of life, viscum album, mistletoe, cancer patients,<br />
local reactions, peripheral lymphocytes, 1893<br />
Quantitative DNA methylation analysis, solid-phase PCR,<br />
PCR-ELISA, promoter hypermethylation, quantitative<br />
PCR, 2055<br />
Quantitative methylation-specific PCR, HACE1, colorectal<br />
cancer, 1581<br />
Quantitative methylation-specific PCR, PGP9.5, colorectal<br />
cancer, marker, 2697<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Quantitative PCR, solid-phase PCR, PCR-ELISA,<br />
quantitative DNA methylation analysis, promoter<br />
hypermethylation, 2055<br />
Quantitative RT-PCR, POLR2F, PRNP, ATP6V0A1,<br />
colorectal cancer, 1221<br />
R0 resection, intrahepatic cholangiocarcinoma, lymph node<br />
dissection, poor prognostic factors, 2353<br />
Rad51, pur-alpha, HIV-1 Tat, DNA repair, 1441<br />
Radiation pneumonitis, predictive markers, breast cancer,<br />
radiation therapy, review, 2421<br />
Radiation therapy, breast cancer, osseous metastasis, oligorecurrence,<br />
3929<br />
Radiation therapy, head and neck cancer, E-cadherin,<br />
dysadherin, 3859<br />
Radiation therapy, predictive markers, radiation<br />
pneumonitis, breast cancer, review, 2421<br />
Radical prostatectomy, prostate cancer, androgen receptor,<br />
SRC1, TIF2, Her2/neu, prognosis, 425<br />
Radical, benzocycloheptoxazines, Raw 264.7 cells, NO,<br />
iNOS, ESR, 2657<br />
Radical, trihaloacetylazulenes, Raw 264.7 cells, NO, iNOS,<br />
ESR, 171<br />
Radiofrequency (RF) ablation, liver neoplasms, liver<br />
interventional procedures, transhepatic arterial<br />
chemoembolization (TACE), 3835<br />
Radiofrequency, animal model, human breast cancer,<br />
metastasis, rats, 879<br />
Radioiodinated methylene blue, melanoma imaging, SK-<br />
MEL 28, 518A2, 3691<br />
Radioprotection, interleukin 1, gastrointestinal epithelium,<br />
apoptosis, 3601<br />
Radiosensitivity, cell death therapy, differentiation therapy,<br />
gene therapy, prostate cancer, tumor suppression, tyrosine<br />
kinases, 2141<br />
Radiosensitivity, ionizing radiation, mutant p53, Saos-2, 2687<br />
Radiotherapy, anal canal carcinoma, chemotherapy, 1335<br />
Radiotherapy, brain metastases, prognosis, surgery, 3015<br />
Radiotherapy, brain metastasis, prognostic factors, age,<br />
malignant melanoma, 1325<br />
Radiotherapy, capecitabine, surgery, acceleration,<br />
hypofractionation, amifostine, rectal cancer, 3035<br />
Radiotherapy, head and neck carcinoma, cisplatin,<br />
paclitaxel, chemotherapy, 1285<br />
Radiotherapy, non-small cell lung cancer, vinorelbine,<br />
liposomal doxorubicin, hypofractionation, acceleration,<br />
amifostine, 1349<br />
Radiotherapy, prostate cancer, toxicity, 2865<br />
Raji cells, transfection efficiency, polyethylenimine,<br />
depsipeptide, KB cells, 793<br />
Rapamycin, IGF-I receptor, MYC-N, mTOR,<br />
neuroblastoma, temsirolimus, 1509<br />
Rapamycin, mTOR, everolimus, sensitization,<br />
cyclophosphamide, 3801<br />
4259
RA-resistance, leukemia cells, retinoids, valproic acid, 283<br />
Ras, aponecrosis, mitogen-activated protein kinase,<br />
prenylation inhibitor, NaPa, 1029<br />
Rat, gene therapy, adenovirus vector, CD40 ligand,<br />
metastatic liver cancer, 2785<br />
Rat, gene therapy, hepatocellular carcinoma, adenovirus<br />
vector, arterial injection, iodized oil, 51<br />
Rat, premenopausal, mammary carcinogenesis,<br />
chemoprevention, anastrozole, aromatase inhibitors, 2819<br />
Rats, animal model, radiofrequency, human breast cancer,<br />
metastasis, 879<br />
Raw 264.7 cells, benzocycloheptoxazines, NO, iNOS, ESR,<br />
radical, 2657<br />
Raw 264.7 cells, trihaloacetylazulenes, NO, iNOS, ESR,<br />
radical, 171<br />
RB, loss of heterozygosity, TP53, ovarian carcinoma,<br />
chemotherapy, 989<br />
RB, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, TP53, NF-ÎB, PI3K, SKP2, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
RbAp46, small ubiquitin-like modifier (SUMO-1), protein<br />
stability, cell growth, 3749<br />
Reactive oxygen species, bee venom (BV), apoptosis,<br />
caspase, cytoplasmic calcium (Ca 2+ ), mitochondria, 833<br />
Real-time PCR, GTPase, renal cell carcinoma,<br />
immunohistochemistry, 2039<br />
Real-time quantitative PCR, malignant effusion, cell-free<br />
mRNA, ERCC1, thymidylate synthase, 1085<br />
Real-time RT-PCR, tumor marker, survivin, BIRC5, gene<br />
expression, lung cancer, 1525<br />
Real-time TRAP, telomerase activity, head and neck cancer,<br />
prognosis, marker, 3125<br />
Reast cancer, primary systemic chemotherapy, epirubicin,<br />
docetaxel, 4137<br />
Receptor, LHRH, somatostatin, protein tyrosine kinase,<br />
protein tyrosine phosphatase, 2599<br />
Rectal cancer, adjuvant chemotherapy, 1805<br />
Rectal cancer, capecitabine, radiotherapy, surgery,<br />
acceleration, hypofractionation, amifostine, 3035<br />
Rectal cancer, cT3N0M0, neoadjuvant chemotherapy,<br />
4129<br />
Rectal cancer, DBM, rectosigmoid cancer, prognostic factor,<br />
1773<br />
Rectal cancer, neoadjuvant chemotherapy, bolus 5fluorouracil,<br />
cardiotoxicity, 4095<br />
Rectosigmoid cancer, DBM, rectal cancer, prognostic factor,<br />
1773<br />
Recurrence, laryngeal carcinoma, CD105, vascular<br />
endothelial growth factor receptor 2 (VEGFR2),<br />
prognosis, 551<br />
4260<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Recurrence, VEGF-C, serum, lymph node metastasis,<br />
prognosis, esophageal cancer, 165<br />
Recurrent cervical cancer, cisplatin, 5-fluorouracil,<br />
metastasis, 1887<br />
Red meat, CYP1A2 164 A C polymorphism, smoking,<br />
colorectal adenomas, colorectal carcinomas, 2289<br />
Regional lymph node, lung cancer, immunotherapy, N2<br />
disease, adjuvant therapy, surgery, dendritic cell, 1229<br />
RegIV, gastric cancer, peritoneal metastasis, RT-PCR, 1169<br />
Regulation, p53, protein synthesis, post-transcriptional<br />
regulation, 2553<br />
Regulatory T cells (Treg), glioma, brain tumor, CD4 +<br />
CD25 + cells, glioblastoma multiforme, immune function,<br />
review, 1143<br />
Regulatory T-cell, anandamide, anticancer immunity,<br />
cannabinoids, lymphocytes, 3743<br />
Regulatory T-cells, human FOXP3, immunotherapy, tumor<br />
immunity, dendritic cells, survival, 2401<br />
Relapse, S-100B, melanoma, stage IIIB/C, survival,<br />
prediction, 2297<br />
Renal cancer, serum, circulating RNA, diagnosis, 321<br />
Renal cell carcinoma, antiangiogenic therapy, vascular<br />
disrupting agents, combination therapy, 2027<br />
Renal cell carcinoma, GTPase, real-time PCR,<br />
immunohistochemistry, 2039<br />
Renal cell carcinoma, metastases, pancreatic resection,<br />
pancreatectomy, 361<br />
Renal cell carcinoma, P1NP, AP, tumour marker, bone<br />
metastases, 2443<br />
Renal handling, somatostatin analogues, 111 In-DOTA-1-<br />
Nal 3 -octreotide, 111 In-DOTA-Tyr 3 -octreotate, tumour<br />
targeting, biodistribution, AR42J cells, OK cells, 2189<br />
Renal pelvis, EpCAM, urothelial cancer, 125<br />
RENCA, bisphosphonates, angiogenesis, vessel density,<br />
VEGF, 933<br />
Resection volume, breast-conserving surgery, locoregional<br />
recurrence, risk factors, 1207<br />
Resection, vaccine, adjuvant, cancer, Lobund-Wistar rat,<br />
2529<br />
Resistance index, prostate cancer, color Doppler<br />
ultrasonography, 1985<br />
Resistance, apoptosis, TNF, death receptor, tyrosine<br />
phosphatase, Fas, CHX, FLIP, 593<br />
Resistance, thymidylate synthase, 5-FU, 5-FUdR,<br />
mycoplasma, 2175<br />
Restriction enzyme, SNP genotyping, primer design, PCR-<br />
RFLP, software, review, 2001<br />
Resveratrol, biospecific column chromatography, RTPs,<br />
GSTP1, ER-β, glutathione sulfotransferase-π, 29<br />
RET, apoptosis, doxorubicin, medullary thyroid cancer,<br />
MAPK pathway, 2019<br />
Retinoblastoma, breast cancer, MDA-MB-231 cells, δtocotrienol,<br />
cell cycle, cyclin D1, 2641
Retinoids, leukemia cells, valproic acid, RA-resistance, 283<br />
Retroperitoneum, Schwannoma, laparoscopic surgery, S-<br />
100 protein, 2889<br />
Review, ataxia telangiectasia, ATM gene, molecular<br />
genetics, cancer susceptibility, 401<br />
Review, bladder neoplasms, bladder neoplasm<br />
classification, molecular classification, profiling, 2893<br />
Review, cancer chemoprevention, clinical trials,<br />
epidemiological data, 1857<br />
Review, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, diagnosis, prognosis,<br />
sCD26, EGF, sEGFR, ELISA, cytometric beads, antibody<br />
arrays, clustering, bioinformatics, 2333<br />
Review, cancer, primary immunodeficiencies, 1263<br />
Review, Cl– channel, cancer, cell volume, apoptosis,<br />
cisplatin, drug resistance, 75<br />
Review, colorectal cancer, molecular staging, circulating<br />
tumor cells, polymerase chain reaction, peripheral blood,<br />
3945<br />
Review, colorectal, colon, cancer, E-cadherin, catenins,<br />
3815<br />
Review, confocal microscopy, endomicroscopy, molecular<br />
imaging, cancer, ulcerative colitis, 353<br />
Review, DNA content, image cytometry, bladder cancer,<br />
443<br />
Review, DNAses, prognosis, vitamin C, vitamin K 3 ,<br />
adjuvant therapy, 2727<br />
Review, docetaxel, first-line chemotherapy, gemcitabine,<br />
HER-2, metastatic breast cancer, paclitaxel, taxane,<br />
1245<br />
Review, gastric cancer, chemotherapy, 1213<br />
Review, glioma, regulatory T cells (Treg), brain tumor,<br />
CD4 + CD25 + cells, glioblastoma multiforme, immune<br />
function, 1143<br />
Review, guggul, guggulsterone, cancer, apoptosis,<br />
hyperlipidemia, inflammation, 3647<br />
Review, high hydrostatic pressure, tumor cells, orthopedic<br />
surgery, viruses, bacteria, 3877<br />
Review, inherited cancer syndrome, adenomatous polyposis<br />
coli, HNPCC, BRCA1, BRCA2, MEN 2, 1341<br />
Review, intranuclear order, genomic karyotyping, BCR-<br />
ABL, t(9:22), PML-RARA, t(15;17), 3573<br />
Review, lymphatic vessels, metastasis, podoplanin, tumor<br />
growth, 2997<br />
Review, matrix metalloproteinases, colorectal cancer,<br />
thyroid neoplasm, 1389<br />
Review, molecular markers, molecular pathology,<br />
oncogenes, oral squamous carcinoma, tumour suppressor<br />
genes, 1197<br />
Review, notch, cancer, signal pathway, 3621<br />
Review, ovarian cancer, early diagnosis, tumor markers,<br />
gonadotropins, antitumoral vaccine, 3135<br />
Review, pancreatic cancer status, 1303<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Review, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 , cell<br />
cycle, angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
1541<br />
Review, predictive markers, radiation pneumonitis, breast<br />
cancer, radiation therapy, 2421<br />
Review, prostate, cancer, annexin, cytokine, gp96, 2843<br />
Review, PTEN, mTOR, p53, AKT, genome stability, cell<br />
cycle, 3613<br />
Review, restriction enzyme, SNP genotyping, primer<br />
design, PCR-RFLP, software, 2001<br />
Review, TGFβ, Smads, Sp1/KLF-like transcription factors,<br />
gene expression, 1531<br />
Review, tonsillar cancer, head and neck cancer, HPV, 1133<br />
Review, vitamin D, Wnt, β-catenin, Dickkopf, colon cancer,<br />
2613<br />
Rhabdomyosarcoma, ephrin-B, EphB receptors, 763<br />
Rhabdomyosarcoma, neuroblastoma, flow cytometry,<br />
immunophenotyping, 1565<br />
Rhinopharyngeal carcinoma, breast skin metastases, axillary<br />
node metastases, 419<br />
Risk factors, breast cancer, oral contraceptives, estrogen<br />
receptor, progesterone receptor, 491<br />
Risk factors, breast-conserving surgery, resection volume,<br />
locoregional recurrence, 1207<br />
Risk factors, MTHFR, MTRR, polymorphism, HCC, 2807<br />
Risk, alcohol, cancer, diet, iron, legumes, meat, smoking,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
RNA, dysplasia, carcinoma in situ, DNA, 2417<br />
Robot, prostate cancer, da Vinci, laparoscopic radical<br />
prostatectomy, 1989<br />
Rodent and human tumor models, TT-232, somatostatin<br />
analog, implanted pump, 2769<br />
Roscovitine, Hodgkin's lymphoma, chemotherapy, cell<br />
cycle, interleukin-26, 887<br />
Rosiglitazone, cancer, caveolin-1, EGF receptor, MAP<br />
kinase signaling, PPARγ, 895<br />
RPMI-8226, plasmacytoma, dexamethasone, MAPK<br />
inhibitor, p38, SCIO-469, SD-282, H-929, HSP-27, 3827<br />
RT-PCR, aggrecan, versican, decorin, Western blotting,<br />
immuno-histochemistry, proteoglycan, 245<br />
RT-PCR, RegIV, gastric cancer, peritoneal metastasis, 1169<br />
RTPs, biospecific column chromatography, GSTP1, ER-β,<br />
resveratrol, glutathione sulfotransferase-π, 29<br />
RULES, ultrasound, prostatic biopsy, prostate carcinoma,<br />
transrectal ultrasound, 1883<br />
S-1, 5-fluorouracil, gemcitabine, human equilibrative<br />
nucleotide transporter, schedule-dependent effect,<br />
combination chemotherapy, in vivo, pancreatic cancer,<br />
179<br />
4261
S-1, cisplatin, advanced pancreatic cancer, phase Ⅱ study,<br />
2373<br />
S-1, colorectal cancer, metastasis, CPT-11, 1837<br />
S-1, colorectal carcinoma, liver metastasis, COX-2<br />
inhibitor, 629<br />
S-1, CPT-11, complete response, combination<br />
chemotherapy, 559<br />
S-1, low-dose cisplatin, gastric cancer, combination therapy,<br />
outpatient setting, 1433<br />
S-1, tegafur/uracil, oral leucovorin, colorectal cancer, 1779<br />
S-100 protein, Schwannoma, laparoscopic surgery,<br />
retroperitoneum, 2889<br />
S-100B, melanoma, stage IIIB/C, relapse, survival,<br />
prediction, 2297<br />
Sacral canal osteotomy, malignant sacral tumors, tumor<br />
distal to S2, modified threadwire saw, wide margin, 4143<br />
SAHA, chondrosarcoma, suberoylanilide hydroxamic acid,<br />
apoptosis, autophagy-associated cell death, 1585<br />
Salivary gland carcinoma cells, amino acid transport system<br />
L, LAT1, essential amino acids, antitumor therapy, 2649<br />
Salivary glands, pleomorphic adenoma, BRCA-1, mutation,<br />
3011<br />
Salmonella Ames test, single-walled carbon nanotubes,<br />
multi-walled carbon nanotubes, genotoxicity,<br />
cytogenetics, 349<br />
Sampling, breast cancer, cytology, fine-needle aspiration<br />
biopsy, nuclear morphometry, breast disease,<br />
fibroadenoma, fibrocystic disease, mean nuclear area,<br />
MNA, 3985<br />
Saos-2, ionizing radiation, mutant p53, radiosensitivity,<br />
2687<br />
Sarcoma, HDR brachytherapy, perioperative, flab, bendy<br />
applicator, 3885<br />
Sarcoma, lipoprotein lipase, adipose tissue, triacylglycerol,<br />
2081<br />
Sarcoma, PKC412, PKCα, molecular targeting therapy,<br />
osteosarcoma, malignant fibrous histiocytoma (MFH),<br />
825<br />
Sarcomas, neurofibromatosis-1, von Recklinghausen’s<br />
disease, constipation, malignant peripheral nerve sheath<br />
tumor, 3107<br />
SCD26, cancer, lung, colorectal, head and neck, biomarkers,<br />
serum, screening, diagnosis, prognosis, EGF, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Schedule-dependent effect, S-1, 5-fluorouracil, gemcitabine,<br />
human equilibrative nucleotide transporter, combination<br />
chemotherapy, in vivo, pancreatic cancer, 179<br />
Schwannoma, laparoscopic surgery, retroperitoneum, S-100<br />
protein, 2889<br />
SCID mouse, FDG, FLT, neuroblastoma, MRT, PET-CT, 2561<br />
SCIO-469, plasmacytoma, dexamethasone, MAPK inhibitor,<br />
p38, SD-282, RPMI-8226, H-929, HSP-27, 3827<br />
4262<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Sclerosing rhabdomyosarcoma, metastasis, peripheral blood<br />
stem cell transplantation, chemotherapy, 2361<br />
Screening, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, diagnosis, prognosis, sCD26, EGF,<br />
sEGFR, ELISA, cytometric beads, antibody arrays,<br />
clustering, bioinformatics, review, 2333<br />
SD-282, plasmacytoma, dexamethasone, MAPK inhibitor,<br />
p38, SCIO-469, RPMI-8226, H-929, HSP-27, 3827<br />
Second primary, neoplasm, multiple primary, 2953<br />
Second-line therapy, ovarian cancer, pegylated liposomal<br />
doxorubicin, biweekly schedule, toxic skin reactions,<br />
palmar-plantar erythrodysesthesia, 1329<br />
Secretoglobin, mammaglobin, lipophilin B, breast cancer,<br />
proliferation, 1493<br />
SEGFR, cancer, lung, colorectal, head and neck,<br />
biomarkers, serum, screening, diagnosis, prognosis,<br />
sCD26, EGF, ELISA, cytometric beads, antibody arrays,<br />
clustering, bioinformatics, review, 2333<br />
Selenium, colorectal cancer, caspases, selenous acid, 5-FU,<br />
apoptosis, 3579<br />
Selenous acid, colorectal cancer, caspases, selenium, 5-FU,<br />
apoptosis, 3579<br />
Self-perception, head and neck cancer, craniofacial<br />
reconstruction, epithesis, social reintegration, 2349<br />
Self-renewal, Wnt, β-catenin, acute leukemia, Notch, 2701<br />
Semiempirical molecular-orbital method, 3-formylchromone<br />
derivatives, QSAR, cytotoxicity, absolute hardness, 277<br />
Semiempirical molecular-orbital method, 5trifluoromethyloxazole<br />
derivatives, QSAR, cytotoxicity,<br />
absolute hardness, 997<br />
Senescence, irinotecan, CPT-11, colon cancer, HCT116, cell<br />
cycle, DNA damage checkpoint activation,<br />
endoreduplication, cell death, 583<br />
Sensitization, mTOR, everolimus, rapamycin,<br />
cyclophosphamide, 3801<br />
Sensitize, transgenic mice, skin cancer, Bcl-2, 2825<br />
Sentinel lymph node dissection, vulvar cancer, frozen<br />
section analysis, 4091<br />
Sentinel lymph node, breast cancer, CarolIReS,<br />
intraoperative gamma camera, lymphoscintigraphy, 2859<br />
Sentinel node, melanoma, imprint touch cytology,<br />
intraoperative, diagnosis, treatment,<br />
immunohistochemistry, 465<br />
Sentinel, vulvar cancer, postoperative morbidity, prognosis,<br />
515<br />
Seocalcitol, hepatocellular cancer, nude mice, SKHEP-1,<br />
3757<br />
Separation, subpopulation, colon cancer, heterogeneity,<br />
claudin, ZO-1, 3665<br />
Serous ovarian cancer, fascin, Ki-67,<br />
immunohistochemistry, prognosis, 1905<br />
Serum marker, glioma, cancer, protease, plasminogen<br />
activator inhibitor-1 (PAI-1), 415
Serum, cancer, lung, colorectal, head and neck, biomarkers,<br />
screening, diagnosis, prognosis, sCD26, EGF, sEGFR,<br />
ELISA, cytometric beads, antibody arrays, clustering,<br />
bioinformatics, review, 2333<br />
Serum, cell-free DNA, plasma, breast cancer, 921<br />
Serum, circulating RNA, renal cancer, diagnosis, 321<br />
Serum, VEGF-C, lymph node metastasis, prognosis,<br />
recurrence, esophageal cancer, 165<br />
SH-SY5Y, angiogenesis, zoledronic acid, TNP-470,<br />
neuroblastoma, 1551<br />
Side-effect, prostate cancer, 3-D planning, hormonal<br />
therapy, 3913<br />
Signal pathway, notch, cancer, review, 3621<br />
Signet-ring cell carcinoma, Krukenberg tumour, ovary,<br />
stomach, electron microscopy, immunohistochemistry, 1417<br />
Silibinin, paclitaxel, drug resistance, invasion, Pglycoprotein,<br />
survivin, 1119<br />
Single nucleotide polymorphism, bladder cancer, allelic<br />
discrimination, ERCC2, XPC, XRCC1, XRCC3, 1853<br />
Single-strand conformation polymorphism, PDGFR, acute<br />
myeloid leukemia, core-binding factor, 2745<br />
Single-walled carbon nanotubes, multi-walled carbon<br />
nanotubes, genotoxicity, Salmonella Ames test,<br />
cytogenetics, 349<br />
SiRNA, BCL2, BCL2L1, BIRC4, chemosensitization,<br />
inhibition of apoptosis, 2259<br />
SiRNA, CDC20, pancreas, therapy, cytotoxicity,<br />
chemoradiation, 1559<br />
SiRNA, KGF, ER, MCF-7, cell proliferation, 2733<br />
Size, polyps, computed tomography, 1911<br />
SKHEP-1, hepatocellular cancer, nude mice, seocalcitol, 3757<br />
Skin cancer, elastosis, melanoma, smoking, ultraviolet,<br />
vitamin D, 4003<br />
Skin cancer, transgenic mice, Bcl-2, sensitize, 2825<br />
Skin cancer, α-santalol, caspases, p53, UVB radiation, 129<br />
Skin, steroid sulphatase, oestrogen, androgen, breast cancer,<br />
acne, hirsutism, sulphatase inhibitor, 1517<br />
SK-MEL 28, radioiodinated methylene blue, melanoma<br />
imaging, 518A2, 3691<br />
SKP2, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, TP53, NF-ÎB, PI3K, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis,<br />
epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, sonic hedgehog,<br />
review, 1541<br />
SMAD4, P15, gastric cancer, immunohistochemistry, 1079<br />
SMAD4, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
TP53, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis, epigenetic<br />
gene regulation, miRNA, epithelial-mesenchymal transition,<br />
chemotaxis, sonic hedgehog, review, 1541<br />
Smads, TGFβ, Sp1/KLF-like transcription factors, gene<br />
expression, review, 1531<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Small animal PET, anaplastic large cell lymphoma, FDG,<br />
xenograft, NOD/SCID, 981<br />
Small cell lung cancer, bisphosphonates, zoledronic acid,<br />
bone metastases, non-small cell lung cancer, 529<br />
Small cell lung cancer, ProGRP, NSE, monitoring of<br />
therapy, 3027<br />
Small cell lung carcinoma, lymphangiogenesis, CD105,<br />
prognosis, immunohistochemistry, 343<br />
Small ubiquitin-like modifier (SUMO-1), RbAp46, protein<br />
stability, cell growth, 3749<br />
Smoke, promoter methylation, coal, PAH, benzopyrene,<br />
sputum, lung cancer, 2061<br />
Smoking, alcohol, cancer, risk, diet, iron, legumes, meat,<br />
supplements, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Smoking, CYP1A2 164 A C polymorphism, red meat,<br />
colorectal adenomas, colorectal carcinomas, 2289<br />
Smoking, elastosis, melanoma, skin cancer, ultraviolet,<br />
vitamin D, 4003<br />
Snail, E-cadherin, adenovirus, metastasis, 621<br />
SNP genotyping, restriction enzyme, primer design,<br />
PCR-RFLP, software, review, 2001<br />
Social reintegration, head and neck cancer, craniofacial<br />
reconstruction, epithesis, self-perception, 2349<br />
Sodium butyrate, hyperthermia, cell death, apoptosis,<br />
HCT 116 colorectal cancer cells, 1693<br />
Soft tissue sarcoma, plakoglobin (gamma-catenin),<br />
pulmonary metastasis, orthotopic implantation model,<br />
cDNA array, 655<br />
Software fusion, oesophageal cancer, FDG-positron<br />
emission tomography, computed tomography, combined<br />
PET/CT, 1867<br />
Software, restriction enzyme, SNP genotyping, primer<br />
design, PCR-RFLP, review, 2001<br />
Solanum lyratum extracts, cytotoxicity, apoptosis, colon<br />
adenocarcinoma cell lines, 1045<br />
Solid-phase PCR, PCR-ELISA, quantitative DNA<br />
methylation analysis, promoter hypermethylation,<br />
quantitative PCR, 2055<br />
Soluble IL-2R, Host immunity, CD4 + CD25 + T-cell, lowdose<br />
chemotherapy, colorectal cancer, 373<br />
Somatostatin analog, TT-232, rodent and human tumor<br />
models, implanted pump, 2769<br />
Somatostatin analogues, 111 In-DOTA-1-Nal 3 -octreotide,<br />
111 In-DOTA-Tyr 3 -octreotate, tumour targeting, renal<br />
handling, biodistribution, AR42J cells, OK cells, 2189<br />
Somatostatin, LHRH, protein tyrosine kinase, protein<br />
tyrosine phosphatase, receptor, 2599<br />
Sonic hedgehog, pancreatic ductal adenocarcinoma, INK4a,<br />
K-RAS, SMAD4, TP53, NF-ÎB, PI3K, SKP2, RB,<br />
p27 Kip1 , cell cycle, angiogenesis, metastasis, proliferation,<br />
apoptosis, epigenetic gene regulation, miRNA, epithelialmesenchymal<br />
transition, chemotaxis, review, 1541<br />
4263
Sonic hedgehog, breast cancer, estrogen receptor α,<br />
hedgehog signaling pathway, proliferation, 731<br />
Soy extract, genistein, MDA-MB-231 cell, nude mice,<br />
tumor growth, 2837<br />
Sp1/KLF-like transcription factors, TGFβ, Smads, gene<br />
expression, review, 1531<br />
Specificity to cancer cell, human monoclonal antibody,<br />
hybridoma, growth inhibition, 1651<br />
Spheroids, hypoxia, adhesion, integrin, fibronectin, 1013<br />
Sphingomyelin, alkaline sphingomyelinase, colon cancer,<br />
mouse, 3631<br />
Sporadic colorectal adenocarcinoma, p53 codon 72<br />
polymorphism, Arg72Pro, left colon cancer, 1039<br />
Sputum, promoter methylation, smoke, coal, PAH,<br />
benzopyrene, lung cancer, 2061<br />
Squamous carcinoma, anal canal, intratumoral lymphocytes,<br />
2469<br />
Squamous cell carcinoma, HER3, cutaneous tumors, nevus,<br />
PCR, 973<br />
Squamous cell head and neck carcinoma cell lines<br />
(HNSCC), bortezomib, cetuximab, epidermal growth<br />
factor receptor, EGFR, 2239<br />
Squamous cell lung carcinoma, metastasis, breast<br />
metastasis, 1299<br />
SRC1, prostate cancer, androgen receptor, TIF2, Her2/neu,<br />
prognosis, radical prostatectomy, 425<br />
SSCP analysis, colorectal cancer, mass screening, exfoliated<br />
colonocytes, fecal DNA, 145<br />
Stage IIIB/C, S-100B, melanoma, relapse, survival,<br />
prediction, 2297<br />
Staging, primary breast cancer, metastatic disease, X-ray,<br />
bone scan, liver ultrasound, 2397<br />
Staging, primary retroperitoneal mucinous cystadenoma,<br />
diagnosis, treatment, 2309<br />
Standardized mistletoe extract, breast cancer,<br />
complementary treatment, quality of life, epidemiological<br />
cohort study, 523<br />
Steep pulsed electric field (SPEF), hepatoma, proliferation,<br />
biorheology, micropipette aspiration, 2245<br />
Stem cell, brain tumour, MRI, paediatrics, 741<br />
Stem cells, paneth cells, turnover, adenomas, 1571<br />
Sternum, giant cell tumor, polymethylmethacrylate,<br />
curettage, 4117<br />
Steroid sulphatase, oestrogen, androgen, breast cancer, skin,<br />
acne, hirsutism, sulphatase inhibitor, 1517<br />
Steroids, breast cancer, in vitro assay, MCF-7, tamoxifen, 2213<br />
Stomach, gastric cancer, NOD-2, polymorphisms, 757<br />
Stomach, Krukenberg tumour, ovary, signet-ring cell<br />
carcinoma, electron microscopy, immunohistochemistry,<br />
1417<br />
S-TREM-1, prognostic marker, lung metastasis, 1411<br />
Stromal-derived factor-1, oral cancer, angiogenesis,<br />
thrombophilia, polymorphism, 271<br />
4264<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
STX140, 2-methoxyestradiol, estrogen, sulfamate, breast<br />
cancer, 577<br />
STX140, breast cancer, 2-methoxyestradiol, ENMD-1198,<br />
myelotoxicity, 1483<br />
Suberoylanilide hydroxamic acid, chondrosarcoma, SAHA,<br />
apoptosis, autophagy-associated cell death, 1585<br />
Subpopulation, separation, colon cancer, heterogeneity,<br />
claudin, ZO-1, 3665<br />
Sulfamate, 2-methoxyestradiol, estrogen, breast cancer,<br />
STX140, 577<br />
Sulfonate ester, breast cancer, cell growth inhibition, cell<br />
cycle arrest and apoptosis, p53 and Bcl-2 status, 2753<br />
Sulphatase inhibitor, steroid sulphatase, oestrogen,<br />
androgen, breast cancer, skin, acne, hirsutism, 1517<br />
Supplements, alcohol, cancer, risk, diet, iron, legumes,<br />
meat, smoking, urban, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Supportive care, anemia, darbepoetin alfa, chemotherapy,<br />
1767<br />
Surgery, capecitabine, radiotherapy, acceleration,<br />
hypofractionation, amifostine, rectal cancer, 3035<br />
Surgery, granulosa cell tumors, platinum-based<br />
chemotherapy, 1421<br />
Surgery, low-grade endometrial stromal sarcoma,<br />
progestins, aromatase inhibitors, 2869<br />
Surgery, lung cancer, immunotherapy, N2 disease, adjuvant<br />
therapy, dendritic cell, regional lymph node, 1229<br />
Surgery, radiotherapy, brain metastases, prognosis, 3015<br />
Surgery, thyroid, metastases, carcinoma, neoplasm, 2885<br />
Surgical stress, growth rate, experimental lung tumor,<br />
1129<br />
Surgical therapy, prognostic factors, pancreatic carcinoma,<br />
chemotherapy, survival, 543<br />
Survival prediction, palliative radiotherapy, whole-brain<br />
radiotherapy, brain metastases, 3965<br />
Survival, breast cancer, osteopontin, mortality, 4105<br />
Survival, extrahepatic cholangiocarcinoma, cyclooxygenase,<br />
lipoxygenase, eicosanoid pathways, 873<br />
Survival, GSTM1, GSTT1, p53, polymorphism, colorectal<br />
cancer, Dukes’ stage, 1917<br />
Survival, hemoglobin, CEA, non-small cell lung cancer,<br />
preoperative, 1947<br />
Survival, matrix metalloproteinase-9 (MMP-9), gelatinase<br />
A, Collagenase, transitiocellular carcinoma, 1757<br />
Survival, melanoma, interferon-·, CD8highCD57+<br />
lymphocytes, 1139<br />
Survival, prognostic factors, pancreatic carcinoma,<br />
chemotherapy, surgical therapy, 543<br />
Survival, regulatory T-cells, human FOXP3,<br />
immunotherapy, tumor immunity, dendritic cells, 2401<br />
Survival, S-100B, melanoma, stage IIIB/C, relapse,<br />
prediction, 2297<br />
Survivin, glioblastoma, apoptosis, mitosis, 109
Survivin, silibinin, paclitaxel, drug resistance, invasion, Pglycoprotein,<br />
1119<br />
Survivin, tumor marker, BIRC5, gene expression, real-time<br />
RT-PCR, lung cancer, 1525<br />
Susceptibility genes, oral cancer, CYP1A1, GSTM1, GSTT1,<br />
1023<br />
SV40, colorectal cancer, DNA viruses, HPV, BKV, JVC,<br />
1405<br />
SV40, epidermal growth factor receptor, fluorescence<br />
activated cell sorter, mesothelin, N-cadherin,<br />
ultrastructure, 197<br />
SW620, omega-3, omega-6, colon cancer, xenograft, lipids,<br />
3717<br />
Syncytial formation, herpes simplex virus, oncolytic<br />
virotherapy, oral squamous cell carcinoma, 3637<br />
Syndecan-1, tenascin-C, TATI, p53, p21, bcl-2,<br />
immunohistochemistry, flow cytometry, gastric cancer,<br />
prognosis, 2279<br />
Synergism, bisphosphonate, osteosarcoma, apoptosis, 2147<br />
Synergistic effect, osteosarcoma, chemotherapy, caffeine,<br />
cDNA array analysis, 645<br />
Syngeneic, immature dendritic cells, cytotoxic T<br />
lymphocytes, A20 leukemia/lymphoma, co-culture, GM-<br />
CSF, 2831<br />
α-Santalol, caspases, p53, UVB radiation, skin cancer, 129<br />
5-Trifluoromethyloxazole derivatives, QSAR, cytotoxicity,<br />
semiempirical molecular-orbital method, absolute<br />
hardness, 997<br />
T(15;17), intranuclear order, genomic karyotyping, BCR-<br />
ABL, t(9:22), PML-RARA, review, 3573<br />
T(9:22), intranuclear order, genomic karyotyping, BCR-<br />
ABL, PML-RARA, t(15;17), review, 3573<br />
TACE, intrahepatic cholangiocarcinoma, oxaliplatin,<br />
microspheres, 2987<br />
TAG 72, CEA, CA 125, CA 15.3, CA 19.9, pleural<br />
effusions, tumour markers, 2947<br />
Tamoxifen, angiogenesis, inflammation, MIF, IL-10,<br />
aspirin, 2093<br />
Tamoxifen, breast cancer, steroids, in vitro assay, MCF-7,<br />
2213<br />
Targeted therapy, ovarian carcinoma, alpha-folate receptor,<br />
folate receptor overexpression, 3567<br />
TATI, syndecan-1, tenascin-C, p53, p21, bcl-2,<br />
immunohistochemistry, flow cytometry, gastric cancer,<br />
prognosis, 2279<br />
Tau, cancer of unknown primary site, CUP,<br />
chemoresistance, paclitaxel, tubulin, tubulin III, 1161<br />
Taxane, chemotherapy, lung cancer, esophageal cancer,<br />
tyrosine kinase inhibitor, 3099<br />
Taxane, docetaxel, first-line chemotherapy, gemcitabine,<br />
HER-2, metastatic breast cancer, paclitaxel, review, 1245<br />
Taxol, head and neck cancer, chemotherapy, Doxil, Caelyx,<br />
pharmacokinetics, 2519<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Taxol, neoadjuvant chemotherapy, breast, epirubicin, p53,<br />
Erb family, 3147<br />
T-cell impairment, apoptosis, CD28, FAS, immune<br />
dysfunction, immunosurveillance, TCR-zeta, breast<br />
cancer, 779<br />
Γδ T-cells, nonpeptide antigens, pyrophosphomonoester,<br />
antitumor activity, cancer immunotherapy, 2921<br />
TCR-zeta, apoptosis, CD28, FAS, immune dysfunction,<br />
immunosurveillance, T-cell impairment, breast cancer, 779<br />
Tegafur/uracil, S-1, oral leucovorin, colorectal cancer, 1779<br />
Telomerase activity, head and neck cancer, real-time TRAP,<br />
prognosis, marker, 3125<br />
Temozolomide, PARP, ADP ribose, preclinical efficacy,<br />
biomarker, 2625<br />
Temsirolimus, IGF-I receptor, MYC-N, mTOR,<br />
neuroblastoma, rapamycin, 1509<br />
Tenascin-C, syndecan-1, TATI, p53, p21, bcl-2,<br />
immunohistochemistry, flow cytometry, gastric cancer,<br />
prognosis, 2279<br />
Testicular tumor, gingival metastasis, germ cell tumor,<br />
embryonal carcinoma, 1181<br />
Testosterone, prostate cancer, nomogram, prostate- specific<br />
antigen, prostate biopsy, 2487<br />
Tetrahydrocurcumin, curcumin, COX-2, NF-ÎB, chemical<br />
descriptors, lipopolysaccharide, Porphyromonas gingivalis<br />
fimbriae, 699<br />
TGF-β, prostate cancer, prostate stroma, IGF-I, tumor<br />
growth, 721<br />
TGFβ, Smads, Sp1/KLF-like transcription factors, gene<br />
expression, review, 1531<br />
T H 1 polarisation, dendritic cells, interferon-gamma,<br />
maturation, 1467<br />
Therapy, CDC20, siRNA, pancreas, cytotoxicity,<br />
chemoradiation, 1559<br />
Therapy, merkel cell tumor, metastasis, urinary bladder,<br />
prognosis, 1361<br />
Thermotherapy, hyperthermia, induction heating, 69<br />
Thiotepa, inflammatory breast cancer, chemotherapy,<br />
autologous stem cell transplant, mitoxantrone,<br />
carboplatin, 3139<br />
Third-line treatment, amrubicin, NSCLC, chemotherapy<br />
failure, 3855<br />
Three-times daily radiotherapy, non-small cell lung cancer,<br />
hyperfractionated radiotherapy, induction chemotherapy,<br />
integrated treatments, 4121<br />
Thrombocytopenia, colorectal cancer, hypersensitivity<br />
reaction, intracranial hemorrhage, oxaliplatin, 3115<br />
Thrombophilia, interleukin-10, oral cancer, inflammation,<br />
angiogenesis, 309<br />
Thrombophilia, stromal-derived factor-1, oral cancer,<br />
angiogenesis, polymorphism, 271<br />
Thrombosis, erythropoetin, gynaecological cancer, breast<br />
cancer, 3977<br />
4265
Thrombosis, gynecological cancer, chemotherapy, 3971<br />
Thymax, MCF-7, apoptosis, annexin, caspases, 1603<br />
Thymidine kinase 1, TK1, health screening, benign, cancer,<br />
malignancy, tumour, fatty liver, inflammation, infection,<br />
virus, 3897<br />
Thymidine kinase, gene therapy, adenovirus, Coxackieadenovirus<br />
receptor, ovarian cancer, 2569<br />
Thymidine phosphorylase, 5’-deoxy-5-fluorouridine,<br />
paclitaxel, nude mice, gastric cancer, apoptosis, 1593<br />
Thymidine phosphorylase, thymidine synthase,<br />
dihydropyrimidine dehydrogenase, orotate phophoribosyl<br />
transferase, 389<br />
Thymidine phosphorylase, thymidine synthase,<br />
dihydropyrimidine dehydrogenase, orotate<br />
phosphoribosyl transferase, laser-captured<br />
microdissection, 1477<br />
Thymidine synthase, dihydropyrimidine dehydrogenase,<br />
thymidine phosphorylase, orotate phophoribosyl<br />
transferase, 389<br />
Thymidine synthase, dihydropyrimidine dehydrogenase,<br />
thymidine phosphorylase, orotate phosphoribosyl<br />
transferase, laser-captured microdissection, 1477<br />
Thymidylate synthase, malignant effusion, cell-free mRNA,<br />
real-time quantitative PCR, ERCC1, 1085<br />
Thymidylate synthase, resistance, 5-FU, 5-FUdR,<br />
mycoplasma, 2175<br />
Thymus, neuroendocrine differentiation, neural growth<br />
factor receptors, tubulin, 295<br />
Thyroid carcinoma, BRAF, K-RAS, mutation, papillary,<br />
medullary, 305<br />
Thyroid carcinoma, Mitotic spindle assembly checkpoint,<br />
tumor aggressiveness, 139<br />
Thyroid neoplasm, matrix metalloproteinases, colorectal<br />
cancer, review, 1389<br />
Thyroid tumor, AcSDKP, POP, marker, angiogenesis,<br />
cancer, 2813<br />
Thyroid, metastases, surgery, carcinoma, neoplasm,<br />
2885<br />
TIF2, prostate cancer, androgen receptor, SRC1, Her2/neu,<br />
prognosis, radical prostatectomy, 425<br />
TIMP expression, colorectal cancer liver metastasis, MMP<br />
expression, 1459<br />
TIMP-1, endometrial cancer, MMP-2, MMP-9, TIMP-2,<br />
prognosis, 2715<br />
TIMP-2, endometrial cancer, MMP-2, MMP-9, TIMP-1,<br />
prognosis, 2715<br />
TIMPs, pancreatic cancer, ampullary cancer, MMPs, MVD,<br />
1875<br />
Tissue microarray, breast cancer, Apolipoprotein D,<br />
immuno-electrophoresis in cytosol,<br />
immunohistochemistry, whole sections, 1151<br />
Tissue microarray, prostate cancer, Gleason grade, cathepsin<br />
B, inhibitor stefin A, 2271<br />
4266<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
TK1, thymidine kinase 1, health screening, benign, cancer,<br />
malignancy, tumour, fatty liver, inflammation, infection,<br />
virus, 3897<br />
TLR4, NOD2, CD14, gene polymorphism, MALT<br />
lymphoma, Helicobacter pylori infection, 3697<br />
TN-C, EMMPRIN, invasion, oral SCC, MMP, 2049<br />
TNF, apoptosis, death receptor, tyrosine phosphatase,<br />
resistance, Fas, CHX, FLIP, 593<br />
TNP-470, angiogenesis, zoledronic acid, neuroblastoma,<br />
SH-SY5Y, 1551<br />
Δ-Tocotrienol, breast cancer, MDA-MB-231 cells, cell<br />
cycle, retinoblastoma, cyclin D1, 2641<br />
Δ-Tocotrienol, breast cancer, MDA-MB-231 cells, cell<br />
cycle, retinoblastoma, cyclin D1, 2641<br />
Tongue cancer, TUNEL, p53, heparanase, tumor marker,<br />
oral cancer, 2981<br />
Tonsillar cancer, head and neck cancer, HPV, review, 1133<br />
Tonsillar cancer, HPV, oral cancer, oropharyngeal cancer,<br />
2077<br />
Toxic skin reactions, ovarian cancer, second-line therapy,<br />
pegylated liposomal doxorubicin, biweekly schedule,<br />
palmar-plantar erythrodysesthesia, 1329<br />
Toxicity, advanced gastric cancer, chemotherapy, phase I<br />
study, 2473<br />
Toxicity, albendazole, β-cyclodextrin, ovarian cancer,<br />
efficacy, 2775<br />
Toxicity, methotrexate, MTHFR, polymorphism,<br />
osteosarcoma, 3051<br />
Toxicity, nitrobutadiene derivatives, liver, kidney, enzymes,<br />
813<br />
Toxicity, prostate cancer, radiotherapy, 2865<br />
TP53, loss of heterozygosity, RB, ovarian carcinoma,<br />
chemotherapy, 989<br />
TP53, pancreatic ductal adenocarcinoma, INK4a, K-RAS,<br />
SMAD4, NF-ÎB, PI3K, SKP2, RB, p27 Kip1 , cell cycle,<br />
angiogenesis, metastasis, proliferation, apoptosis, epigenetic<br />
gene regulation, miRNA, epithelial-mesenchymal transition,<br />
chemotaxis, sonic hedgehog, review, 1541<br />
T-PA, hepatocellular carcinoma, circulating hTERT DNA,<br />
PAI-1, 223<br />
TPGS, gossypol, liposome, PEG-DSPE, 2801<br />
Transfection efficiency, polyethylenimine, depsipeptide,<br />
Raji cells, KB cells, 793<br />
Transformation, Akt, prohibitin, 957<br />
Transgenic mice, skin cancer, Bcl-2, sensitize, 2825<br />
Transhepatic arterial chemoembolization (TACE), liver<br />
neoplasms, liver interventional procedures,<br />
radiofrequency (RF) ablation, 3835<br />
Transitiocellular carcinoma, matrix metalloproteinase-9<br />
(MMP-9), gelatinase A, Collagenase, survival, 1757<br />
Translationally controlled tumor protein, liver regeneration,<br />
liver cancer, antisense, proliferation, cell cycle, apoptosis,<br />
1575
Transplantation, murine osteosarcoma, cell line, osteoblastic<br />
differentiation, endochondral ossification, 1627<br />
Transrectal ultrasound, ultrasound, prostatic biopsy, prostate<br />
carcinoma, RULES, 1883<br />
Transulfuration, amino acids, human tumors, nude mice,<br />
methionine metabolism, 2541<br />
Trastuzumab, HER2/neu ECD, breast carcinoma, tumor<br />
marker, HER2, 3067<br />
Treatment, colorectal cancer, metastases, chemotherapy,<br />
antibodies, 4111<br />
Treatment, ethnic minority, Māori, Pacific Island, diagnosis,<br />
accessibility, 3891<br />
Treatment, melanoma, imprint touch cytology,<br />
intraoperative, sentinel node, diagnosis,<br />
immunohistochemistry, 465<br />
Treatment, primary retroperitoneal mucinous cystadenoma,<br />
diagnosis, staging, 2309<br />
Triacylglycerol, lipoprotein lipase, sarcoma, adipose tissue,<br />
2081<br />
Trigeminal ganglion, cisplatin, nucleotide excision repair,<br />
2637<br />
Trihaloacetylazulenes, Raw 264.7 cells, NO, iNOS, ESR,<br />
radical, 171<br />
TS, colorectal cancer metastases, matched primary tumours,<br />
1741<br />
TT-232, somatostatin analog, rodent and human tumor<br />
models, implanted pump, 2769<br />
Tubulin III, cancer of unknown primary site, CUP,<br />
chemoresistance, paclitaxel, tau, tubulin, 1161<br />
Tubulin, cancer of unknown primary site, CUP,<br />
chemoresistance, paclitaxel, tau, tubulin III, 1161<br />
Tubulin, thymus, neuroendocrine differentiation, neural<br />
growth factor receptors, 295<br />
Tumor aggressiveness, Mitotic spindle assembly checkpoint,<br />
thyroid carcinoma, 139<br />
Tumor angiogenesis, marrow-derived stem cells, endothelial<br />
cells, origin, 771<br />
Tumor budding, colorectal cancer, prognosis,<br />
immunohistochemistry, D2-40, 1831<br />
Tumor cells, high hydrostatic pressure, orthopedic surgery,<br />
viruses, bacteria, review, 3877<br />
Tumor distal to S2, malignant sacral tumors, modified<br />
threadwire saw, sacral canal osteotomy, wide margin, 4143<br />
Tumor growth, genistein, soy extract, MDA-MB-231 cell,<br />
nude mice, 2837<br />
Tumor growth, lymphatic vessels, metastasis, podoplanin,<br />
review, 2997<br />
Tumor growth, prostate cancer, prostate stroma, TGF-β,<br />
IGF-I, 721<br />
Tumor immunity, regulatory T-cells, human FOXP3,<br />
immunotherapy, dendritic cells, survival, 2401<br />
Tumor marker, HER2/neu ECD, breast carcinoma,<br />
trastuzumab, HER2, 3067<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Tumor marker, ovarian cancer, positron emission<br />
tomography, computed tomography, 2303<br />
Tumor marker, survivin, BIRC5, gene expression, real-time<br />
RT-PCR, lung cancer, 1525<br />
Tumor marker, TUNEL, p53, heparanase, tongue cancer,<br />
oral cancer, 2981<br />
Tumor markers, ovarian cancer, early diagnosis,<br />
gonadotropins, antitumoral vaccine, review, 3135<br />
Tumor specificity, benzylidene ascorbate, type of cell death,<br />
apoptosis, autophagy, 2577<br />
Tumor suppression, cell death therapy, differentiation<br />
therapy, gene therapy, prostate cancer, radiosensitivity,<br />
tyrosine kinases, 2141<br />
Tumor suppressor, prostate, vitamin D, 25-hydroxyvitamin<br />
D-1 alpha-hydroxylase, CYP27B1, 2015<br />
Tumor suppressor, WT1, MCF10AT3B cells, proliferative<br />
breast disease, breast cancer, 2155<br />
Tumor volumetry, early gastric cancer, 3D endoscopic<br />
ultrasonography, lymph node metastasis, 2907<br />
Tumorigenesis, prostate, metastasis, PC-3, proliferation,<br />
matriptase, 1977<br />
Tumorigenicity, prostate, metastasis, PC-3, proliferation,<br />
matriptase, N-acetylglucosaminyltransferase V, 1993<br />
Tumour growth, monocytes, cytokines, angiogenesis, 187<br />
Tumour inhibition, prostate cancer therapy, noscapine, 3701<br />
Tumour marker, renal cell carcinoma, P1NP, AP, bone<br />
metastases, 2443<br />
Tumour markers, CEA, CA 125, CA 15.3, CA 19.9, TAG<br />
72, pleural effusions, 2947<br />
Tumour suppressor genes, molecular markers, molecular<br />
pathology, oncogenes, oral squamous carcinoma, review,<br />
1197<br />
Tumour suppressor, E2F, breast cancer, 2135<br />
Tumour targeting, somatostatin analogues, 111 In-DOTA-1-<br />
Nal 3 -octreotide, 111 In-DOTA-Tyr 3 -octreotate, renal<br />
handling, biodistribution, AR42J cells, OK cells, 2189<br />
Tumour, thymidine kinase 1, TK1, health screening, benign,<br />
cancer, malignancy, fatty liver, inflammation, infection,<br />
virus, 3897<br />
TUNEL, p53, heparanase, tumor marker, tongue cancer, oral<br />
cancer, 2981<br />
Turnover, paneth cells, stem cells, adenomas, 1571<br />
Twist, chemokine receptors, lymph node metastasis, head<br />
and neck squamous cell carcinoma, 1355<br />
Two-stage mouse skin carcinogenesis, zapotin, antiinitiation,<br />
anti-promotion, 3705<br />
Type 2 diabetes mellitus, mortality, cancer, obesity, 1373<br />
Type of cell death, benzylidene ascorbate, tumor specificity,<br />
apoptosis, autophagy, 2577<br />
Type of cell death, peplomycin, oral squamous cell<br />
carcinoma, 2197<br />
Type of cell death, vitamin K 2 , prenylalcohol, cytotoxicity,<br />
apoptosis, autophagy, 151<br />
4267
Type of cell death, β-cyclodextrin benzaldehyde inclusion<br />
compound, oral squamous cell carcinoma, 229<br />
Tyrosine kinase inhibitor, chemotherapy, lung cancer,<br />
esophageal cancer, taxane, 3099<br />
Tyrosine kinases, cell death therapy, differentiation therapy,<br />
gene therapy, prostate cancer, radiosensitivity, tumor<br />
suppression, 2141<br />
Tyrosine phosphatase, apoptosis, TNF, death receptor,<br />
resistance, Fas, CHX, FLIP, 593<br />
UFT, LV, adjuvant chemotherapy, micrometastasis, 2045<br />
Ulcerative colitis, confocal microscopy, endomicroscopy,<br />
molecular imaging, cancer, review, 353<br />
Ultrasound, adjuvant tamoxifen, endometrial carcinoma,<br />
breast cancer, 1259<br />
Ultrasound, preoperative diagnosis, endometrial cancer,<br />
clinical management, 2453<br />
Ultrasound, prostatic biopsy, prostate carcinoma, transrectal<br />
ultrasound, RULES, 1883<br />
Ultrastructure, epidermal growth factor receptor,<br />
fluorescence activated cell sorter, mesothelin, N-cadherin,<br />
SV40, 197<br />
Ultraviolet, elastosis, melanoma, skin cancer, smoking,<br />
vitamin D, 4003<br />
Ultraviolet-B, alcohol, cancer, risk, diet, iron, legumes,<br />
meat, smoking, supplements, urban, vitamin D, whole<br />
grains, zinc, 1955<br />
Unresectable cancer, pancreas, chemoradiotherapy, hyperfractionated<br />
accelerated radiotherapy, conformal<br />
radiotherapy, gemcitabine, 2369<br />
Up-regulation, endometrial carcinoma, imup-1, imup-2, 865<br />
Urban, alcohol, cancer, risk, diet, iron, legumes, meat,<br />
smoking, supplements, ultraviolet-B, vitamin D, whole<br />
grains, zinc, 1955<br />
Urinary bladder tumour, neuroendocrine tumour,<br />
neuroendocrine carcinoma, large cell neuroendocrine<br />
carcinoma, neuroendocrine marker, 1369<br />
Urinary bladder, merkel cell tumor, metastasis, therapy,<br />
prognosis, 1361<br />
Urothelial cancer, EpCAM, renal pelvis, 125<br />
Urothelial carcinoma, prostate-specific antigen, invasion,<br />
prognosis, PSA, 4149<br />
Uterine leiomyosarcoma, cancer in pregnancy, atypical<br />
menigioma, 3083<br />
UVB radiation, α-santalol, caspases, p53, skin cancer, 129<br />
Vaccine, adjuvant, cancer, resection, Lobund-Wistar rat,<br />
2529<br />
Valproate, cisplatin, neuropathy, neuroprotection, 335<br />
Valproic acid, anaplastic astrocytoma, glioblastoma<br />
multiforme, high grade glioma, histone deacetylase<br />
inhibitor, pediatric, 2437<br />
Valproic acid, Apo2L/TRAIL, histone deacetylase<br />
inhibitors, K562 erythroleukemia cells, apoptosis, 855<br />
Valproic acid, leukemia cells, retinoids, RA-resistance, 283<br />
4268<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Vascular disrupting agents, antiangiogenic therapy,<br />
combination therapy, renal cell carcinoma, 2027<br />
Vascular endothelial growth factor (VEGF), vinorelbine,<br />
malignant pleural effusion, lung cancer, angiogenesis,<br />
1633<br />
Vascular endothelial growth factor receptor 2 (VEGFR2),<br />
laryngeal carcinoma, CD105, recurrence, prognosis, 551<br />
Vasopressin, desmopressin, peptide analog, chemotherapy,<br />
breast cancer, 2607<br />
VEGF, angiogenesis, autocrine signalling, breast cancer,<br />
Flt-1, 1719<br />
VEGF, bisphosphonates, angiogenesis, RENCA, vessel<br />
density, 933<br />
VEGF, cervical cancer, markers, p53, p27, COX-2, Ki-67,<br />
EGFR, E-cadherin, c-myc, CD44, CD4, age-specific<br />
expression, 1793<br />
VEGF, colon cancer, polymorphism, Korea, 1271<br />
VEGF, hop beta-acids, angiogenesis, angioprevention, cell<br />
proliferation, chemotaxis, matrigel plug, 289<br />
VEGF-1 expression, colorectal cancer, prognosis, adjuvant<br />
therapy, 3865<br />
VEGF-C, oral squamous cell carcinoma, HIF-1α,<br />
lymphangiogenesis, angiogenesis, 1659<br />
VEGF-C, serum, lymph node metastasis, prognosis,<br />
recurrence, esophageal cancer, 165<br />
Vero, polyamines, mepacrine, MCF-7, cell proliferation,<br />
2765<br />
Versican, aggrecan, decorin, Western blotting, immunohistochemistry,<br />
RT-PCR, proteoglycan, 245<br />
Vessel density, bisphosphonates, angiogenesis, RENCA,<br />
VEGF, 933<br />
Video-assisted thoracoscopic surgery, diagnosis, lung<br />
cancer, pulmonary nodule, mass-screening, bronchoscopy,<br />
3153<br />
Vimentin, prostate cancer, invasion, C-src, E-cadherin/catenin,<br />
327<br />
Vinorelbine, breast cancer, gemcitabine, gefitinib, phase I/II<br />
study, 3019<br />
Vinorelbine, carboplatin, elderly, head and neck cancer,<br />
oesophageal cancer, poor performance status, 1383<br />
Vinorelbine, malignant pleural effusion, lung cancer,<br />
vascular endothelial growth factor (VEGF), angiogenesis,<br />
1633<br />
Vinorelbine, neoadjuvant chemotherapy, elderly, locally<br />
advanced breast cancer, 3093<br />
Vinorelbine, non-small cell lung cancer, liposomal<br />
doxorubicin, hypofractionation, acceleration, amifostine,<br />
radiotherapy, 1349<br />
Virus, thymidine kinase 1, TK1, health screening, benign,<br />
cancer, malignancy, tumour, fatty liver, inflammation,<br />
infection, 3897<br />
Viruses, high hydrostatic pressure, tumor cells, orthopedic<br />
surgery, bacteria, review, 3877
Viscum album, mistletoe, cancer patients, local reactions,<br />
peripheral lymphocytes, quality of life, 1893<br />
Vitamin C, DNAses, prognosis, vitamin K 3 , adjuvant<br />
therapy, review, 2727<br />
Vitamin D hydroxylase, histone deacetylase inhibitor,<br />
prostate cancer, Cyp27b1, 2009<br />
Vitamin D, alcohol, cancer, risk, diet, iron, legumes, meat,<br />
smoking, supplements, urban, ultraviolet-B, whole grains,<br />
zinc, 1955<br />
Vitamin D, elastosis, melanoma, skin cancer, smoking,<br />
ultraviolet, 4003<br />
Vitamin D, prostate, tumor suppressor, 25-hydroxyvitamin<br />
D-1 alpha-hydroxylase, CYP27B1, 2015<br />
Vitamin D, Wnt, β-catenin, Dickkopf, colon cancer, review,<br />
2613<br />
Vitamin K 2 , prenylalcohol, cytotoxicity, apoptosis,<br />
autophagy, type of cell death, 151<br />
Vitamin K 3 (menadione), pancreatic cancer, chemotherapy,<br />
endoscopic ultrasound-guided fine needle injection, drug<br />
delivery system, 45<br />
Vitamin K 3 , DNAses, prognosis, vitamin C, adjuvant<br />
therapy, review, 2727<br />
Von Recklinghausen’s disease, neurofibromatosis-1,<br />
constipation, malignant peripheral nerve sheath tumor,<br />
sarcomas, 3107<br />
Vulvar cancer, sentinel lymph node dissection, frozen<br />
section analysis, 4091<br />
Vulvar cancer, sentinel, postoperative morbidity, prognosis,<br />
515<br />
Weekly irinotecan, advanced colorectal cancer, protracted<br />
venous infusion fluorouracil, 2327<br />
Weight loss, breast cancer, green tea catechins, fatty acid<br />
synthase, animal model, anti-cancer drug, 3671<br />
Western blotting, aggrecan, versican, decorin, immunohistochemistry,<br />
RT-PCR, proteoglycan, 245<br />
Whole grains, alcohol, cancer, risk, diet, iron, legumes,<br />
meat, smoking, supplements, urban, ultraviolet-B, vitamin<br />
D, zinc, 1955<br />
Whole sections, breast cancer, Apolipoprotein D, immunoelectrophoresis<br />
in cytosol, immunohistochemistry, tissue<br />
microarray, 1151<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Whole-brain radiotherapy, palliative radiotherapy, brain<br />
metastases, survival prediction, 3965<br />
Wide margin, malignant sacral tumors, tumor distal to S2,<br />
modified threadwire saw, sacral canal osteotomy, 4143<br />
Wilms’ tumour, image DNA analysis,<br />
immunohistochemistry, p53, p57 kip2 , Ki-67, 751<br />
Wnt, vitamin D, β-catenin, Dickkopf, colon cancer, review,<br />
2613<br />
Wnt, β-catenin, acute leukemia, self-renewal, Notch, 2701<br />
WT1, KGF, FAK, Grb2, Erk1,2, breast cancer cell motility,<br />
133<br />
WT1, tumor suppressor, MCF10AT3B cells, proliferative<br />
breast disease, breast cancer, 2155<br />
Xanthorrhizol, antiproliferative property, apoptotic effect,<br />
MDA-MB-231, 3677<br />
Xenograft, anaplastic large cell lymphoma, small animal<br />
PET, FDG, NOD/SCID, 981<br />
Xenograft, omega-3, omega-6, colon cancer, SW620, lipids,<br />
3717<br />
XPC, bladder cancer, single nucleotide polymorphism,<br />
allelic discrimination, ERCC2, XRCC1, XRCC3, 1853<br />
X-ray, primary breast cancer, metastatic disease, bone scan,<br />
liver ultrasound, staging, 2397<br />
XRCC1, bladder cancer, single nucleotide polymorphism,<br />
allelic discrimination, ERCC2, XPC, XRCC3, 1853<br />
XRCC3, bladder cancer, single nucleotide polymorphism,<br />
allelic discrimination, ERCC2, XPC, XRCC1, 1853<br />
XRCC4, polymorphism, breast cancer, carcinogenesis,<br />
267<br />
XRCC4, polymorphism, oral cancer, carcinogenesis, 1687<br />
Zapotin, two-stage mouse skin carcinogenesis, antiinitiation,<br />
anti-promotion, 3705<br />
Zinc, alcohol, cancer, risk, diet, iron, legumes, meat,<br />
smoking, supplements, urban, ultraviolet-B, vitamin D,<br />
whole grains, 1955<br />
ZO-1, separation, subpopulation, colon cancer,<br />
heterogeneity, claudin, 3665<br />
Zoledronic acid, angiogenesis, TNP-470, neuroblastoma,<br />
SH-SY5Y, 1551<br />
Zoledronic acid, bisphosphonates, bone metastases, nonsmall<br />
cell lung cancer, small cell lung cancer, 529<br />
4269
Authors <strong>Index</strong><br />
(Figures refer to page numbers)<br />
Abbate I, 223<br />
Abdalla F, 3985<br />
Abdullah NR, 3677<br />
Abe H, 407<br />
Abrzua F, 159<br />
Ackermann H, 2239<br />
Acosta G, 2499<br />
Adachi A, 415<br />
Adam M, 1325<br />
Adam-Campbell L, 3119<br />
Adamicová K, 2819<br />
Adamopoulou M, 2233<br />
Addamo G, 3993<br />
Addeo D, 3143<br />
Adleff V, 3051<br />
Aerts M, 2459<br />
Agafonova IG, 927<br />
Agawa M, 261<br />
Aggarwal BB, 3647<br />
Aggeli C, 3945<br />
Agger R, 571<br />
Agnantis NJ, 295, 343<br />
Agostini M, 1805, 4095,<br />
4129<br />
Aguilera Ó, 2613<br />
Ahmed T, 3139<br />
Aiba M, 1841, 4137<br />
Aiello A, 1565<br />
Aiello C, 813<br />
Airoldi M, 2519<br />
Aizawa M, 373<br />
Akahoshi T, 715<br />
Akasu T, 145<br />
Akbarsha MA, 785<br />
Akhgar A, 3119<br />
Akhter J, 105, 3757<br />
Akimoto T, 3859<br />
Akisue T, 825<br />
Akiyama H, 1309, 2473<br />
Akiyoshi T, 731<br />
Akrish S, 2981<br />
Akter S, 3119<br />
Akutsu Y, 665<br />
Alabiso I, 3055<br />
Alabiso O, 1813, 2513<br />
Alamara C, 529<br />
Al-Awadi F, 2541<br />
Al-Batran5 S-E, 1329<br />
Aleandri V, 3941<br />
4270<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Aleknavicius E, 1139<br />
Alexander J, 3771<br />
Al-Hendy A, 2181<br />
Ali IU, 3119<br />
Ali T, 577, 1483<br />
Alonso DF, 2607<br />
Altavista P, 763<br />
Amann K, 1361<br />
Amano O, 229, 1069, 2197,<br />
2577<br />
Amano R, 629<br />
Amarantidis K, 3019<br />
Amatu A, 1365, 2987, 3835<br />
Ambrosini V, 981<br />
Amini E, 2437<br />
Amini S, 1441<br />
Ammar K, 283<br />
An HJ, 865<br />
Anagnostou V, 1411<br />
Andera L, 843<br />
Andersson KL, 3871<br />
Andolf E, 1259<br />
Andreadis C, 1421<br />
Andriamisandratsoa N, 2859<br />
Androulakis N, 1303<br />
Angiero F, 1181, 1725, 2535,<br />
3847<br />
Angleitner-Boubenizek L,<br />
3977<br />
Annane K, 2447<br />
Annovazzi L, 109<br />
Antonacopoulou AG, 1221<br />
Antonopoulos G, 2233<br />
Aono H, 69<br />
Aota K, 3637<br />
Apessos A, 843, 1341<br />
Arai A, 171<br />
Arakawa M, 721<br />
Araki K, 1821<br />
Arapantoni-Dadioti P, 2077<br />
Arasada BL, 129<br />
Aravantinos G, 1421<br />
Ardavanis A, 539, 2409, 3087<br />
Ardizzoni A, 507<br />
Argento M, 3135<br />
Arienti C, 315<br />
Arkoumani E, 343<br />
Arnoldner C, 2239, 2349<br />
Asaka S, 1841, 2321<br />
Asao T, 1821<br />
Ashktorab H, 3119<br />
Asmane I, 3041<br />
Astner ST, 1325<br />
Atakilit A, 2049<br />
Ater JL, 2437<br />
Athanasiou E, 2421<br />
Au WW, 2181<br />
Auer D, 2213<br />
Aung HH, 2545<br />
Aust G, 873<br />
Avenia N, 2885<br />
Avgoustidis D, 1675<br />
Ayabe T, 1947<br />
Ayadi W, 2161<br />
Azarbayjani F, 1551<br />
Azemar M, 1467<br />
Azimahtol HLP, 3677<br />
Azzaretti A, 3835<br />
Baak JPA, 1151<br />
Baccos A, 1883<br />
Bäckman U, 1551<br />
Backner A, 1733<br />
Badowska W, 1927<br />
Bae SJ, 1271<br />
Baggio G, 2765<br />
Baghi M, 687, 2239, 2349<br />
Bai M, 295<br />
Baiardi P, 3835<br />
Bajetta E, 1813, 2513<br />
Baj-Krzyworzeka M, 187<br />
Bak M, 1641<br />
Bakken NTG, 3601<br />
Balaneva NN, 927<br />
Balcerska A, 1927<br />
Baldus SE, 367, 1525<br />
Balestra A, 3743<br />
Balwierz W, 1927<br />
Bamias A, 2479<br />
Bandapalli OR, 1459<br />
Banelli E, 1335<br />
Banerjee S, 3621<br />
Banis K, 2077<br />
Bansal N, 1763<br />
Baratsis S, 843, 1341<br />
Baratz M, 3147<br />
Barbarisi A, 2885<br />
Barken I, 3701<br />
Barnea I, 3147<br />
Barone C, 1285<br />
Baronnet M-M, 577<br />
Barroso Duarte EC, 1101<br />
Barten-Van Rijbroek AD,<br />
1129<br />
Bartoli F, 3921<br />
Bartolini G, 283<br />
Barzanò E, 1565<br />
Bascones-Martínez A, 1197,<br />
3733<br />
Ba-Ssalamah A, 4101<br />
Bassi R, 2679<br />
Basso U, 491, 1383, 1805,<br />
2513, 4095, 4129<br />
Basto D, 913<br />
Bathen TF, 3717<br />
Batistatou A, 3815<br />
Battanello W, 471<br />
Bau D-T, 267, 1687<br />
Bauerfeind I, 1107<br />
Beghini A, 2745<br />
Bekaert V, 2859<br />
Bellini E, 3055<br />
Bellini MF, 3793<br />
Bellocq J-P, 2447<br />
Belogianni I, 1341<br />
Bendardaf R, 3865<br />
Benedicenti S, 1725<br />
Benetti A, 2535<br />
Ben-Izhak O, 2981<br />
Bentz E-K, 3131<br />
Ben-Yosef R, 3147<br />
Berardi AC, 763<br />
Berenzi A, 2535<br />
Beretta E, 2885<br />
Bergamo F, 1383<br />
Bergerat J-P, 55, 3041<br />
Bergnolo P, 2327<br />
Bernard-Gallon DJ, 1853,<br />
3079<br />
Bernardo G, 2987, 3835<br />
Berndt A, 2265<br />
Berner A, 465<br />
Bernetiere S, 577<br />
Berno E, 2327<br />
Berrone S, 1285<br />
Berruti A, 3055<br />
Bertaccini A, 395, 1369,<br />
1883
Bertetto O, 1285<br />
Bertona E, 2513<br />
Bethwaite P, 3891<br />
Betre K, 2271<br />
Beuth J, 523<br />
Biagi E, 1883<br />
Bianchino G, 2941<br />
Bianconi M, 2893<br />
Biason R, 1813, 2513<br />
Bień S, 3011<br />
Bifulco G, 2309<br />
Bignon J, 2813<br />
Bignon Y-J, 1853, 3079<br />
Bilo HJG, 1373<br />
Bilski A, 465<br />
Biondi A, 3743<br />
Birnboim HC, 2175<br />
Birocco N, 1285<br />
Biscardi M, 2327<br />
Bisdas S, 2239, 2349<br />
Bissoon-Haqqani S, 2175<br />
Bitossi R, 3055<br />
Bjønnum AB, 3557<br />
Bjørnholm T, 571<br />
Blanca A, 2893<br />
Blanché-Koch H, 3609<br />
Blandamura S, 471, 551<br />
Blank S, 3143<br />
Blatt J, 1509<br />
Blomberg J, 593<br />
Bode AM, 927<br />
Boder J, 3985<br />
Bodner K, 3083<br />
Bodner-Adler B, 3083<br />
Bodrogi I, 1641<br />
Boehm DU, 1207<br />
Boehmer D, 1943<br />
Boffetta P, 2499<br />
Bogart JA, 3909<br />
Boglione A, 2327<br />
Boiteux J-P, 1853<br />
Bölling T, 3885<br />
Bollschweiler E, 1525<br />
Bommareddy A, 129<br />
Boncompagni E, 813<br />
Bonfrer JMG, 2297<br />
Bonginelli P, 2513<br />
Bonifacio D, 1405<br />
Bonora MR, 3835<br />
Bonovas S, 1857<br />
Bontcheva-Diaz VD, 2625<br />
Borloni R, 3847<br />
Born W, 673<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Bossi M, 335<br />
Bosviel R, 1853<br />
Bottin R, 1383<br />
Boudawara T, 2161<br />
Boufas A, 529<br />
Bouka M, 305<br />
Boukovinas I, 495<br />
Boulikas T, 3961<br />
Bouros D, 1349<br />
Bouska JJ, 2625<br />
Bovaretos N, 3697<br />
Bovo G, 2885<br />
Bowitz-Lothe IM, 2289<br />
Bozzi F, 1565<br />
Brabender J, 367<br />
Braga M, 1603<br />
Brand F-X, 3067<br />
Brand K, 1459<br />
Brandén E, 2851<br />
Branke B, 119<br />
Brasse D, 2859<br />
Brazowski E, 3785<br />
Brekke Li K, 2289<br />
Bremer M, 3965<br />
Bremmon K, 129<br />
Bremner TA, 2093<br />
Brenner W, 2561<br />
Briasoulis E, 1341, 2913<br />
Brisson C, 55<br />
Brivio F, 1377, 1951, 3743<br />
Brizzi MP, 3055<br />
Brooks R, 665<br />
Bruland ØS, 3557<br />
Brunello A, 491<br />
Brunet J, 3671<br />
Bruni E, 2765<br />
Brunner A, 125<br />
Brunner AH, 4091<br />
Brunner B, 125<br />
Büchler MW, 1499<br />
Buffoni L, 1285<br />
Buhmeida A, 3865, 3985<br />
Bukofzer G, 2625<br />
Bupha-Intr O, 3891<br />
Burgermeister E, 895<br />
Burges A, 2303<br />
Burnett GT, 2093<br />
Burra P, 2507<br />
Bush JE, 1733<br />
Bussani R, 3921<br />
Büssing A, 1893<br />
Busson P, 2161<br />
Butler C, 957<br />
Buzzi F, 1813, 2513<br />
Byrne DH, 2067<br />
Byrski T, 3011<br />
Caderni G, 3771<br />
Cafferata MA, 507<br />
Caillaud D, 21<br />
Cairoli R, 2745<br />
Caldera V, 109<br />
Calzolari F, 2885<br />
Camara J, 577<br />
Campora E, 3993<br />
Campo-Trapero J, 1197,<br />
3733<br />
Cancela-Rodríguez P, 3733<br />
Candura SM, 1365<br />
Cano-Sánchez J, 1197<br />
Canta A, 335, 1365<br />
Cao J, 479<br />
Caprio G, 419<br />
Caprotti R, 1951<br />
Carboni S, 3941<br />
Caristo R, 1767<br />
Cariveau MJ, 3601<br />
Carlini P, 1245<br />
Caron L, 751<br />
Carozzi V, 335<br />
Carreon RR, 1<br />
Caruso RA, 1417<br />
Cassano A, 813<br />
Cassatella C, 3061<br />
Cassidy J, 9<br />
Castagnola C, 2745<br />
Catala L, 2869<br />
Catalano G, 4121<br />
Cattel L, 2519<br />
Cavalcanti TCS, 1023<br />
Cavaletti G, 335<br />
Cavalli IJ, 1023<br />
Cavalot A, 1285<br />
Cejka D, 3801<br />
Cerbone L, 1767<br />
Cercato MC, 2953<br />
Cerero-Lapiedra R, 3733<br />
Chalabi N, 1853, 3079<br />
Chamoux A, 1853<br />
Chamson M, 2975<br />
Chan S-H, 907<br />
Chander SK, 1517<br />
Chang H-W, 2001<br />
Chang N-W, 1687, 1701<br />
Chang P-L, 1969, 1977,<br />
1993, 2001<br />
Chang S-Y, 1989<br />
Chang Y-H, 1093<br />
Chao C-H, 1969<br />
Char D-L, 1989<br />
Characiejus D, 1139<br />
Charalabopoulos A, 3815<br />
Charalabopoulos K, 3815<br />
Charfi S, 2161<br />
Charpidou A, 529, 1411<br />
Chaudhuri JP, 3573<br />
Chaves VN, 1023<br />
Cheah YH, 3677<br />
Chekerov R, 1329<br />
Chen A, 1317<br />
Chen B, 1119<br />
Chen C-A, 1887<br />
Chen C-L, 1355<br />
Chen C-M, 3093<br />
Chen G, 327, 621<br />
Chen G-W, 1045<br />
Chen H-C, 97<br />
Chen H-I, 1989<br />
Chen I-S, 1317<br />
Chen J, 681<br />
Chen Jung-Chin, 4149<br />
Chen Jung-Chou, 1093<br />
Chen J-Y, 3093<br />
Chen P, 479<br />
Chen S, 2109<br />
Chen S-MS, 1299<br />
Chen T-A, 97<br />
Chen TC, 2009, 2015<br />
Chen X-S, 3093<br />
Chen Z, 3897<br />
Chenard M-P, 2447<br />
Cheng A-L, 1293<br />
Cheng HO-L, 4149<br />
Cheng H-X, 1575<br />
Cheng L, 2893<br />
Cheng Y-H, 2001<br />
Chetrí MC, 1813, 2513<br />
Chetrite G, 2129<br />
Cheung E, 425<br />
Chi C-W, 907<br />
Chiang S-Y, 267<br />
Chiappelli M, 395<br />
Chiaramondia M, 507<br />
Chiarion-Sileni V, 1383<br />
Chien H-F, 1355<br />
Chiriva-Internati M, 1119<br />
Chiu C-F, 267, 1687<br />
Chiu T-H, 833, 2791<br />
Cho CH, 563<br />
Cho HJ, 2807<br />
4271
Cho S-H, 2649<br />
Choi MS, 3777<br />
Chorti M, 2479<br />
Chou S-T, 1701<br />
Chow N-H, 4149<br />
Christofferson RH, 1551<br />
Christofiridis CV, 3107<br />
Chuah S-K, 1317<br />
Chuang L-Y, 2001<br />
Chung J-G, 833, 1045, 1093,<br />
1701, 2791<br />
Chung L-C, 1969, 1977,<br />
1993<br />
Ciccarese M, 1429<br />
Cihlo J, 2189<br />
Cillo U, 2507<br />
Cimpean AM, 2997<br />
Cinieri S, 3061<br />
Ciolli P, 3941<br />
Ciotti M, 1405<br />
Cisneros-Zevallos L, 2067<br />
Cittadini A, 2941<br />
Citterio A, 3991<br />
Ciuffreda L, 1285<br />
Cocchio S, 4095<br />
Coccorullo Z, 3993<br />
Cochrane CB, 965<br />
Cognetti F, 1245, 1429<br />
Cohen CJ, 1763<br />
Cohen G, 2981<br />
Cohen SC, 3843<br />
Colapietro P, 2745<br />
Colciago M, 1377, 1951<br />
Colella E, 2953<br />
Collan Y, 3865, 3985<br />
Collea R, 1733<br />
Collie-Duguid E, 9<br />
Collini P, 1565<br />
Colloca G, 3993<br />
Colomer R, 3671<br />
Colon-Lopez M, 2625<br />
Comandone A, 2327<br />
Compostella A, 4095, 4129<br />
Constantopoulos S, 343<br />
Conti M, 315<br />
Coppi A, 2765<br />
Coppola D, 485<br />
Cordazzo C, 813<br />
Cordero OJ, 2333<br />
Corosu R, 3941<br />
Cortesina G, 1285<br />
Cory AH, 681<br />
Cory JG, 681<br />
4272<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Coulter DW, 1509<br />
Coviello M, 223<br />
Craig BA, 3705<br />
Crépin M, 1029<br />
Cricca A, 1369<br />
Crisafulli C, 1417<br />
Critselis E, 1675<br />
Croce S, 2859<br />
Cronje SJ, 2781<br />
Csejtei A, 1917<br />
Csuka O, 2769<br />
Cuendet M, 3705<br />
Cui R, 1633<br />
Cui Z-G, 609<br />
Cuneo A, 2745<br />
Cury PM, 3793<br />
Cushman M, 3705<br />
Cutin SC, 2327<br />
Cyr L, 2753<br />
Czeglédy J, 2169<br />
Czyzewska J, 1399<br />
Czyzewski K, 1927<br />
D’Ajello M, 2885<br />
D’Amico G, 3743<br />
D’Andrea M, 1813, 2513<br />
D’Ercole AJ, 1509<br />
Dafni U, 2913<br />
Dahlstrand H, 1133, 2077<br />
Dahse R, 2265<br />
Dakouras A, 1039<br />
Dal Canton O, 2327<br />
Dalavanga Y, 295, 343<br />
D'Alessandro E, 471, 551<br />
Dalianis T, 1133, 2077<br />
Damodaran C, 785<br />
Danenberg KD, 425<br />
Danenberg PV, 425<br />
Dang D, 2049<br />
Daniele A, 223<br />
Danska-Bidzinska A, 989<br />
Dansonka-Mieszkowska A,<br />
989<br />
Daoud A, 1005<br />
Daoud J, 2161<br />
Daponte A, 1905<br />
Darbinian N, 1441<br />
Dass S, 3647<br />
Daxenbichler G, 2213<br />
De Angelis PM, 583<br />
De Braud F, 4121<br />
De Cecio R, 2309<br />
De Chiara L, 2333<br />
De Coster L, 2459<br />
De Gast GC, 2297<br />
De Grève J, 2459<br />
De Iudicibus S, 3921<br />
De Jong H-J, 237<br />
De La Cadena MP, 2333<br />
De La Rosa G, 3909<br />
De La Rosette J, 237<br />
De La Roza G, 3007<br />
De Lange Davies C, 3557<br />
De Laurentiis M, 1245<br />
De Menezes RP, 1023<br />
De Mey J, 2459<br />
De Miguel J, 2947<br />
De Munck F, 2459<br />
De Pas T, 4121<br />
De Pellegrin A, 3921<br />
De Ridder M, 2459<br />
De Salvo GL, 1813<br />
De Souza Fonseca Ribeiro<br />
EM, 1023<br />
De Stefani E, 2499<br />
De Syllos Cólus IM, 1023<br />
Decorti G, 3921<br />
Degrate L, 1951<br />
Deibl M, 3977<br />
Del Sordo R, 2535<br />
Delahunt B, 3891<br />
Delongchamps NB, 3007,<br />
3909<br />
Delort L, 1853, 3079<br />
Delvaux G, 2459<br />
Delvoux B, 2569<br />
Demidem A, 21<br />
Den Otter W, 1139<br />
Deneo-Pellegrini H, 2499<br />
Deng H, 29, 479<br />
Denkert C, 2453<br />
Derka S, 271, 309, 1675<br />
DesBordes C, 2067<br />
Descamps P, 2869<br />
Dessy E, 2535<br />
Devries A, 1213<br />
Di Benedetto M, 1029<br />
Di Bona E, 2745<br />
Di Bonito L, 1405<br />
Di Cristofaro L, 491<br />
Di G-H, 3093<br />
Dick Jr E, 193<br />
Diehl P, 3877<br />
Dierkes J, 757<br />
Dietel M, 2967<br />
Dietl J, 1719<br />
Díez M, 2947<br />
Dimberg J, 1789<br />
Dimopoulos MA, 2479, 2913<br />
Ding Y, 1085<br />
Diodoro MG, 2953<br />
Diolez C, 577<br />
Diomedi-Camassei F, 763<br />
Dirksen U, 3885<br />
Distelmaier B, 3885<br />
Ditsch N, 1107, 2303<br />
Divella R, 223<br />
Dlużniewska A, 1927<br />
Dogliotti L, 3055<br />
Doi T, 69<br />
Dolara P, 3771<br />
Dominici C, 763<br />
Domoto K, 4137<br />
Donach M, 1383<br />
Donawho CK, 2625<br />
Dong J-H, 2219<br />
Dong Z, 927<br />
Dongiovanni D, 1285<br />
Dono K, 179<br />
Donta I, 2253<br />
Dosio F, 2519<br />
Doufexis D, 3087<br />
Doukas M, 295<br />
Drag M, 2967<br />
Drebber U, 367<br />
Drevs J, 933<br />
Drosos T, 1857<br />
Du Plessis WC, 2781<br />
Du W, 2545<br />
Duan F-L, 1575<br />
Duan R-D, 3631<br />
Duclos B, 3041<br />
Dudek AZ, 3099, 3937<br />
Dumontet C, 1161<br />
Durczynski A, 465<br />
Dürr-Stözer S, 779<br />
Dutta S, 431<br />
Dwivedi C, 129<br />
Dzięgiel P, 1113<br />
Dziegiel P, 2959<br />
Ebert MP, 757, 895<br />
Economopoulos T, 1421,<br />
2317<br />
Edler D, 1741<br />
Egami T, 2205<br />
Egawa K, 799<br />
Egawa S, 2669<br />
Eisenthal A, 3785<br />
Eisterer W, 1213, 2901<br />
El Khalfaoui K, 1943
Elangovan S, 2641<br />
Ellenrieder V, 1531<br />
Elopre M, 2437<br />
Elzagheid A, 3985<br />
Ember A, 1917<br />
Ember I, 1917<br />
Endo I, 1559<br />
Endo K, 2343<br />
Endo M, 3855<br />
Endou H, 2649<br />
Engel SC, 1<br />
Enomoto Y, 1831<br />
Ensinger C, 125<br />
Erikson A, 3557<br />
Ermani M, 491<br />
Ernst I, 3885<br />
Eser S, 1541<br />
Esparza-Gómez G, 3733<br />
Esser N, 933<br />
Esumi H, 37<br />
Eto Y, 51, 2785<br />
Etoh T, 2385<br />
Evans MJ, 3601<br />
Everaert H, 2459<br />
Ewers S-B, 2851<br />
Eytan K, 3785<br />
Fabbri F, 315<br />
Fabi A, 1245<br />
Fabre M, 55<br />
Facoetti A, 15<br />
Fagiuoli S, 2507<br />
Fagundes RB, 2499<br />
Fajkus J, 3125<br />
Falci C, 1813, 2513<br />
Falkay G, 2737<br />
Fallani MG, 3871<br />
Faller DV, 2009<br />
Fambrini M, 3871<br />
Fan AX-C, 921<br />
Fan B-L, 1575<br />
Fanti S, 981<br />
Faried A, 165<br />
Farinati F, 2507<br />
Farjami S, 3139<br />
Fasolis M, 1285<br />
Fassan M, 2507<br />
Favalli C, 1405<br />
Fazzari C, 1417<br />
Fedele F, 1417<br />
Fedele P, 1813, 2513<br />
Fedorov SN, 927<br />
Feher G, 1917<br />
Fehm T, 779, 949, 1797<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Feki L, 2161<br />
Felici A, 1245<br />
Felisi MG, 3835<br />
Feller AC, 119<br />
Femia AP, 3771<br />
Feng C-J, 3763<br />
Feng G, 321<br />
Feng T-H, 1969, 1977, 1993<br />
Fenoglio C, 813<br />
Fernandes N, 1005<br />
Ferrara F, 2745<br />
Ferraresi V, 1429, 2953<br />
Ferrari A, 1565<br />
Ferreri AM, 283<br />
Ferrero A, 3055<br />
Ferretti G, 1245<br />
Filiberti R, 507<br />
Fini M, 981<br />
Fischer DC, 2569<br />
Fischer S, 1207<br />
Fiszer-Kierzkowska A, 501<br />
Flanagan JN, 2009<br />
Fleischer M, 2213<br />
Foell JL, 887<br />
Fontaine C, 2459<br />
Fontana L, 1853<br />
Formenti S, 3143<br />
Foster PA, 577, 1483<br />
Fostira F, 843<br />
Fotopoulou C, 1943, 2453<br />
Foucher F, 2869<br />
Fountzilas G, 2913, 1421<br />
Fourre L, 1<br />
Fragos I, 2409, 3087<br />
Franceschelli A, 1883<br />
Franekova J, 1389<br />
Frank C, 431<br />
Franksson L, 2851<br />
Franzoni M, 283<br />
Frasnelli M, 315<br />
Freemerman AJ, 2019<br />
Freudenberg MA, 1467<br />
Freudlsperger C, 209<br />
Frezza EE, 1119<br />
Friese K, 1107, 2303<br />
Friesland S, 2851<br />
Friess H, 1541<br />
Frikha M, 2161<br />
Friso ML, 1805, 4095, 4129<br />
Fritzsch C, 2055<br />
Frizelle SP, 1<br />
Frost DJ, 2625<br />
Froudarakis ME, 1349<br />
Fuchino K, 2401<br />
Fuchs B, 673<br />
Fuereder T, 3801<br />
Fuessel S, 2259<br />
Fujii H, 1831<br />
Fujii S, 1309, 2473<br />
Fujii Y, 1559<br />
Fujimori M, 1239<br />
Fujimoto D, 847<br />
Fujimoto Takashi, 373, 559<br />
Fujimoto Takuya, 825<br />
Fujisawa S, 699<br />
Fujita H, 2205<br />
Fujita S, 145<br />
Fujita Y, 2373<br />
Fujitani K, 2379<br />
Fukai Y, 165<br />
Fukuchi M, 165<br />
Fukuda Kazumasa, 1651<br />
Fukuda Ken-ichirou, 1169<br />
Fukuda Y, 4117<br />
Fukuhara T, 2353<br />
Fukunaga S, 4117<br />
Fukushima T, 407<br />
Fumagalli L, 1377, 1951,<br />
3743<br />
Funaioli C, 3991<br />
Fürstenberger G, 2825<br />
Furui S, 1899<br />
Futagawa Y, 51<br />
Futani H, 4117<br />
Futawatari N, 2907<br />
Gaal D, 2769<br />
Gabriel B, 3567<br />
Gadaleta C, 223<br />
Gaggeri R, 3835<br />
Galanis P, 343<br />
Gall C, 1797<br />
Gáll T, 2169<br />
Gallion HH, 1733<br />
Gambirasio F, 1565<br />
Gamper C, 3977<br />
Gandini S, 4121<br />
Gansukh T, 2967<br />
Gao F, 2991<br />
Gao J, 1659<br />
Gao Q, 621, 2991<br />
Gao S, 3631<br />
Garassino M, 1767<br />
García Díaz JD, 2947<br />
Garcia H, 3579<br />
García-Núñez JA, 3733<br />
Garetto F, 2327<br />
Garibaldi E, 1285<br />
Garofalo M, 1369<br />
Garrisi VM, 223<br />
Garzaro M, 2519<br />
Garzinodemo P, 1285<br />
Gaspar MJ, 2947<br />
Gasparini G, 1813, 2513<br />
Gatalica Z, 479<br />
Gattringer K, 2901<br />
Gauchez A-S, 3067, 3135<br />
Gavalas E, 3107<br />
Gawrychowski J, 501<br />
Gazouli M, 305, 3697<br />
Géczi L, 1641<br />
Geinitz H, 3015<br />
Geller J, 3701<br />
Genin C, 321<br />
Gennatas C, 543, 1923<br />
Gennatas S, 1923<br />
Gentil-Perret A, 321<br />
Georgoulias V, 495, 1303,<br />
3019<br />
Ger L-P, 97<br />
Gerace TG, 1369<br />
Gerardini M, 1365<br />
Gergely L, 2169<br />
Geurts-Moespot A, 2721<br />
Gharabaghi A, 2033<br />
Ghiconti I, 1079<br />
Ghoneum A, 1603<br />
Ghoneum M, 1603<br />
Ghorbel A, 2161<br />
Ghous Z, 3757<br />
Giacomelli L, 471, 551, 2507<br />
Giamarellos-Bourboulis EJ,<br />
1411<br />
Giampaolino P, 2309<br />
Giannakopoulos A, 3697<br />
Giannopoulos G, 1875<br />
Giatromanolaki A, 3035<br />
Giavaresi G, 981<br />
Giersberg C, 887<br />
Gil L, 1927<br />
Gilardini A, 335<br />
Giordano C, 1285<br />
Giordano M, 1813, 2513<br />
Gioulbasanis I, 3019<br />
Giovannini C, 1369<br />
Giranda VL, 957, 2625<br />
Giri R, 3749<br />
Giron S, 2607<br />
Gitsch G, 3567<br />
Giudice S, 2765<br />
4273
Giuliani L, 1405<br />
Goda T, 2343<br />
Goessl E, 9<br />
Goetz M, 353<br />
Gogas H, 2913<br />
Göhring P, 1107<br />
Goi T, 847<br />
Gollapudi S, 1603<br />
Gomathinayagam R, 785<br />
Gomez DE, 2607<br />
Gomez MV, 1101<br />
Gomez RS, 1101<br />
González-Moles MA, 1197<br />
González-Sancho JM, 2613<br />
Gopalakrishnan V, 2437<br />
Gore JM, 3843<br />
Górski B, 3011<br />
Gorzegno G, 3055<br />
Gosheger G, 3885<br />
Goto T, 1581, 2697<br />
Gounaris A, 2421<br />
Goussia A, 295<br />
Goutas N, 305<br />
Góźdź S, 3011<br />
Granchi S, 1883<br />
Grant WB, 1955, 4003<br />
Grassetto G, 981<br />
Graziano V, 1245<br />
Greenberg J, 3147<br />
Greil R, 1213, 2901<br />
Greten J, 209<br />
Gribbestad IS, 3717<br />
Grieco V, 2941<br />
Griffon C, 289<br />
Grillo G, 2745<br />
Grillo R, 1285<br />
Grimm C, 515, 3131<br />
Grimm M-O, 2259<br />
Grivas PD, 1221<br />
Groen H, 1867<br />
Groshen S, 425<br />
Grossi F, 507<br />
Grosso A, 813<br />
Gruber IV, 779<br />
Grucker D, 2859<br />
Grzebieniak Z, 2959<br />
Gstöttner W, 2239, 2349<br />
Guan J, 943<br />
Guan R, 2625<br />
Guan Y-F, 1061, 2225<br />
Guarneri D, 3993<br />
Gudlaugsson E, 1151<br />
Guembarovski AL, 1023<br />
4274<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Guido M, 2507<br />
Gundersen HJ, 571<br />
Guo X, 9<br />
Gurrado A, 2885<br />
Gustke H, 2561<br />
Guthrie OW, 2637<br />
Guy L, 1853<br />
Guyonnet J-L, 2859<br />
Guzinska-Ustymowicz K,<br />
451, 1399<br />
Guzzardo V, 471, 551<br />
Haane C, 2561<br />
Haanen JBAG, 2297<br />
Haas GP, 3007, 3909<br />
Hacher B, 577<br />
Hadjikokolis S, 1079<br />
Hagen PC, 2289<br />
Hagiwara A, 1169<br />
Hagiwara Y, 3933<br />
Haglund C, 2279<br />
Hahn S, 921<br />
Hajem N, 2813<br />
Hakenberg OW, 2259<br />
Halama N, 4111<br />
Halatsch M-E, 3725, 3729<br />
Hall P, 2529<br />
Hallström M, 1741<br />
Hamacher R, 1541<br />
Hamada T, 1277<br />
Hambek M, 687, 2239, 2349<br />
Hammami A, 2161<br />
Han EK-H, 957<br />
Han N, 1575<br />
Han Q, 2541<br />
Han SB, 3777<br />
Han S-M, 833<br />
Han Z, 327<br />
Hanjarappa N, 3827<br />
Hansen T, 571<br />
Hansmann ML, 879<br />
Hanssen S, 2865<br />
Hanyu K, 2785<br />
Hao X, 1659<br />
Hara H, 825<br />
Hara M, 1947<br />
Hara T, 2225, 3929<br />
Harada T, 601<br />
Hardavella G, 343<br />
Harikumar KB, 3647<br />
Harnack U, 2831<br />
Haro D, 3671<br />
Hasegawa H, 145, 3593<br />
Hasegawa K, 2933<br />
Hasegawa S, 4117<br />
Hasenburg A, 3567<br />
Hasezawa K, 799<br />
Hashimoto K, 151, 171, 229,<br />
1069, 1713, 2577, 2657<br />
Hashmi H, 3985<br />
Hassan MA, 1693<br />
Hastie C, 2843<br />
Hasumi K, 1785<br />
Hata H, 37, 2101<br />
Hatano H, 535<br />
Hatate K, 1933<br />
Haug K, 583<br />
Hauss J, 873<br />
Hawes D, 425<br />
Hayakawa K, 3929<br />
Hayama M, 415<br />
Hayashi C, 2087<br />
Hayashida Y, 2663<br />
Hayasizaki H, 1169<br />
Hazama S, 379<br />
He E, 3897<br />
He H, 2545<br />
He T-C, 2545<br />
HeCoG, 2913<br />
Hedman H, 1493<br />
Hefler LA, 515, 519, 1849,<br />
3131, 4091<br />
Heinze G, 771<br />
Hejna M, 1213, 4101<br />
Helbig M, 2349<br />
Hellberg D, 1793<br />
Hellerstedt B, 1733<br />
Henrich W, 2453<br />
Henriksson R, 1493<br />
Heo MY, 2181<br />
Hermo GA, 2607<br />
Herrmann C, 4111<br />
Herrmann T, 4111<br />
Hertkorn C, 1467<br />
Herzog TJ, 1763<br />
Heymann S, 3041<br />
Hibi K, 1581, 2697<br />
Hicklin DJ, 2679<br />
Hielscher T, 3725, 3729<br />
Higgins LS, 3827<br />
Hilbe W, 2901<br />
Hildenbrand B, 1467<br />
Hiles MC, 2529<br />
Hillerdal G, 2851<br />
Hilska M, 3865<br />
Hindenburg H-J, 1329<br />
Hino O, 3933<br />
Hinoda Y, 379<br />
Hirakawa C, 3665<br />
Hirakawa K, 629<br />
Hirakawa S, 139<br />
Hiraki Y, 2369<br />
Hirama M, 3933<br />
Hiramatsu Y, 159<br />
Hirano A, 4137<br />
Hirao M, 2379<br />
Hirata K, 1277<br />
Hirayama I, 389<br />
Hirokawa Y, 3711<br />
Hirono S, 2373<br />
Hirono Y, 847<br />
Hitora T, 825<br />
Hiwasa T, 415<br />
Hjelstuen MH, 3717<br />
Ho C-C, 2791<br />
Ho C-L, 4149<br />
Hoang A, 3139<br />
Höcker M, 757<br />
Hoefig KP, 119<br />
Hoelscher AH, 1525<br />
Hoffman P, 3135<br />
Hoffman RM, 2541<br />
Hoffmann K, 1499<br />
Höger H, 2705<br />
Hohmann J, 2737<br />
Hokland M, 571<br />
Holick MF, 2009<br />
Holmes FA, 1733<br />
Holmgren K, 3717<br />
Hölscher AH, 367<br />
Holubec Jr L, 1389<br />
Holzgreve W, 921<br />
Honda T, 609<br />
Hong JT, 3777<br />
Hong R-L, 3115<br />
Hongo A, 159<br />
Honkavuori M, 2715<br />
Hoo G. C, 3139<br />
Hooper AT, 2679<br />
Hopman A, 237<br />
Horie S, 639, 1899, 2487<br />
Horiguchi-Yamada J, 261<br />
Horikoshi H, 389, 1477<br />
Horimi T, 1433<br />
Horiuchi A, 69<br />
Hornung R, 1797<br />
Hornychovα H, 2389<br />
Horvat R, 4091<br />
Horvath OP, 1917<br />
Hoshiai H, 2385
Hoshino I, 665<br />
Hosokawa S, 1651<br />
Hotta T, 535<br />
Hour T-C, 2039<br />
Hsia T-C, 1093, 2791<br />
Hsiao S-M, 1887<br />
Hsieh C-Y, 1887<br />
Hsieh M-L, 1985<br />
Hsieh T-C, 29, 2641<br />
Hsu C, 1887<br />
Hsu C-H, 1293<br />
Hsu HH, 2009<br />
Hsu P-I, 97, 1317<br />
Hsu P-N, 1317<br />
Hsu S-C, 833, 1045, 1093,<br />
1701<br />
Hsu S-Y, 1977<br />
Hsu W, 1299<br />
Hu J, 1659, 3897<br />
Hu W, 621<br />
Huang A-C, 1093<br />
Huang C-C, 1299<br />
Huang C-Y, 1687, 2039<br />
Huang S-T, 1985<br />
Huang T-C, 1293<br />
Hubalek M, 2213<br />
Hubbard GB, 193<br />
Huber J, 2679<br />
Hugander A, 1789<br />
Huiskamp R, 571<br />
Hullán L, 2769<br />
Hung C-C, 2109<br />
Hutawatari N, 2875<br />
Hwang J-J, 2109<br />
Hwang SG, 1271, 2807<br />
Hyšpler R, 2389<br />
Iacomino G, 855<br />
Ibeh C, 2067<br />
Ichihara H, 1187<br />
Ichikawa M, 3933<br />
Ichikawa T, 3711<br />
Ichikawa Y, 1309, 1559<br />
Ide H, 639, 1841, 1899, 2487<br />
Ide-Kanematsu M, 2687<br />
Igawa S, 3855<br />
Ignatiadis M, 3019<br />
Iguchi T, 2353, 3007<br />
Ihara A, 1933<br />
Ihara M, 2687<br />
Ii S, 645<br />
Iida T, 51, 2785, 3809<br />
Iizasa T, 1229<br />
Ikeda D, 721<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Ikenaga M, 2379<br />
Ilic V, 2813<br />
Imabori M, 825<br />
Imada T, 139<br />
Improta G, 2941<br />
Ina S, 2373<br />
Inaba K, 1593<br />
Inada Y, 1229<br />
Inagaki Y, 2219<br />
Inamura K, 2121<br />
Indovina P, 1013<br />
Ingolic E, 2705<br />
Inguì M, 2327<br />
Ingvar C, 1259<br />
Inose T, 165<br />
Inoshima N, 601<br />
Inoue H, 721<br />
Inoue M, 2493<br />
Inoue Y, 1277<br />
Insabato L, 2309<br />
Introna M, 1245<br />
Ip S-W, 833, 1093, 1701<br />
Isaac S, 1161<br />
Ise T, 75<br />
Ishibashi K, 1581, 2697<br />
Ishibashi Y, 215<br />
Ishida H, 1633<br />
Ishihara M, 151, 229, 277,<br />
997, 2197<br />
Ishii H, 699<br />
Ishii Y, 3593<br />
Ishikawa A, 1229<br />
Ishikawa H, 3153<br />
Ishikawa Y, 2121<br />
Ishiwata T, 3933<br />
Ishizu A, 2385<br />
Ismail Z, 3677<br />
Isogaki J, 1593<br />
Isohata N, 1841, 2321<br />
Isotani S, 2487<br />
Issing WJ, 973<br />
Itagaki H, 373, 559<br />
Ito S, 699<br />
Iwadate Y, 415<br />
Iwai S, 3637<br />
Iwakami S, 1633, 3933<br />
Iwamoto Y, 1585<br />
Iwase A, 3933<br />
Iwase S, 261<br />
Izumi N, 2687<br />
Jaeger D, 4111<br />
Jager PL, 1867<br />
Jäger R, 2825<br />
Jakubowicz J, 3027<br />
Jakubowska A, 3011<br />
Jamieson D, 2009<br />
Janssen EAM, 1151<br />
Jarvis K, 2625<br />
Jastrzebski T, 465<br />
Jaworowska E, 3011<br />
Jehn CF, 3961<br />
Jeleń M, 1113<br />
Jensen MR, 571<br />
Jeong K-S, 2837<br />
Jereczek-Fossa BA, 4121<br />
Jetté L, 2175<br />
Jeziorski A, 465<br />
Jhalli R, 1517<br />
Jiang GW, 2135<br />
Jiang JI, 3997<br />
Jiang W, 4105<br />
Jin J, 2061<br />
Jin J-O, 927<br />
Jin L, 37<br />
Jirillo A, 1383<br />
Johnke RM, 3601<br />
Johnsen E, 2289<br />
Johnson EF, 2625<br />
Johnson EM, 1441<br />
Johnson LA, 105<br />
Johnson TRC, 2303<br />
Jonak C, 4101<br />
Jonas D, 2443<br />
Jones C, 913<br />
Jonusauskaite R, 1139<br />
Jouhra F, 2135, 4105<br />
Joura E, 515, 519, 4091<br />
Ju Y, 2245<br />
Juang H-H, 1969, 1977, 1993<br />
Juhász K, 2737<br />
Jung HM, 865<br />
Jung HY, 3777<br />
Jung M, 1005<br />
Juraszewska E, 1927<br />
Jürgens H, 3885<br />
Jwo J-J, 1317<br />
Kaehler C, 119<br />
Kagohashi K, 3153<br />
Kahlert C, 1459<br />
Kaibori M, 1749<br />
Kajo K, 2819<br />
Kakeji Y, 1779<br />
Kakimoto K, 3913<br />
Kakita S, 3929<br />
Kakolyris S, 3019<br />
Kal HB, 1129<br />
Kalábovα H, 2389<br />
Kalbakis K, 495, 3019<br />
Kalfert D, 1389<br />
Kalofonos HP, 1221, 2913<br />
Kalofonos M, 1221<br />
Kalykaki A, 495, 3019<br />
Kameda C, 2401<br />
Kamij A, 2045<br />
Kamimura M, 4137<br />
Kaminaga T, 1899<br />
Kaminski R, 1441<br />
Kamiyama Y, 639, 1749,<br />
1899, 2487<br />
Kammerer U, 1719<br />
Kamoshida S, 1593<br />
Kanai Y, 2649<br />
Kanavaros P, 295<br />
Kanazawa Y, 645, 655<br />
Kancherla R, 3139<br />
Kanda Y, 229, 1069, 2197<br />
Kandelhart E, 1207<br />
Kanemoto K, 3153<br />
Kanemura K, 2385<br />
Kang H, 1271<br />
Kang W-Y, 2039<br />
Kang X, 2679<br />
Kanoh M, 715<br />
Kanoh Y, 715<br />
Kao W-T, 2109<br />
Kapp M, 1719<br />
Kapuscinska L, 1927<br />
Karagiannidis A, 3107<br />
Karahontzitis P, 1383<br />
Karakitsos P, 1039<br />
Karakosta A, 1875<br />
Karamanov S, 3573<br />
Karapanagiotou EM, 1411<br />
Karatzas G, 543<br />
Karatzias G, 295<br />
Karatzoglou P, 3107<br />
Karavalaki M, 3107<br />
Karita M, 1449<br />
Karlsson U, 431<br />
Karray-Hakim H, 2161<br />
Karstens JH, 3965<br />
Karydas E, 1341<br />
Kasaoka S, 1449<br />
Kashiwagi H, 215<br />
Kashiwazaki M, 2379<br />
Kásler M, 1641<br />
Kasprowicz NS, 1943<br />
Kastritis E, 2479<br />
Katada N, 435, 2875<br />
4275
Katano M, 731, 2401<br />
Katayama K, 847<br />
Katayama T, 151<br />
Katayose Y, 2669<br />
Kato H, 165<br />
Katoh H, 1933<br />
Katoh T, 3711<br />
Katsube T, 559, 1841, 2321<br />
Katsuda S, 655<br />
Katsuki T, 1277<br />
Katsuta S, 645<br />
Katz B-Z, 3785<br />
Kavantzas N, 2479<br />
Kavatzas N, 1875<br />
Kawachi K, 69<br />
Kawada M, 721<br />
Kawaguchi Y, 825<br />
Kawaguchi-Ihara N, 2701<br />
Kawahara M, 1449, 1681<br />
Kawai M, 2373<br />
Kawamoto T, 825<br />
Kawaoka T, 379<br />
Kawase M, 997<br />
Kawashima H, 709<br />
Kawasoe Y, 2147<br />
Kayashima H, 2353<br />
Kazlauskaite N, 1139<br />
Ke F-C, 2109<br />
Keidar Y, 3147<br />
Keil F, 1213<br />
Kemona A, 451, 1399<br />
Keohavong P, 2061<br />
Kéri GY, 2769<br />
Kerr I, 3827<br />
Ketonen L, 741<br />
Khabir A, 2161<br />
Khaled Y, 3139<br />
Khalili K, 1441<br />
Khatoon N, 2181<br />
Kiagia M, 529<br />
Kida M, 2907<br />
Kidani T, 2081, 2361<br />
Kieback DG, 2569<br />
Kiecker F, 563<br />
Kiess W, 1055<br />
Kiesslich R, 353<br />
Kigawa G, 1581, 2697<br />
Kijima H, 1627<br />
Kikuchi H, 151, 229, 1069,<br />
2197<br />
Kikuchi S, 435, 2875, 2907<br />
Kilburn JM, 3601<br />
Kim CS, 2649<br />
4276<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Kim DK, 2649<br />
Kim H-A, 2837<br />
Kim HJ, 865, 2807<br />
Kim H-K, 2649<br />
Kim IH, 865<br />
Kim JK, 865<br />
Kim JW, 1271<br />
Kim NK, 1271, 2807<br />
Kim S-G, 2649<br />
Kim SJ, 865<br />
Kim UK, 2807<br />
Kim YK, 2837<br />
Kimura H, 165, 1229<br />
Kimura K, 4137<br />
Kimura M, 1229, 1239<br />
Kin S, 1169<br />
Kinoshita J, 4137<br />
Kinoshita T, 2493<br />
Kinouchi T, 3913<br />
Kishimoto K, 825<br />
Kishino K, 2577<br />
Kiss I, 1917<br />
Kita M, 3859<br />
Kitagawa H, 609<br />
Kitagawa Y, 145, 1651, 3593<br />
Kitajima M, 1651, 3593<br />
Kittas C, 1039<br />
Kiyokawa T, 1187<br />
Klar M, 3567<br />
Klare P, 1329<br />
Kleefstra N, 1373<br />
Klein MA, 1<br />
Klein-Soyer C, 289<br />
Klepzig M, 2443<br />
Klinghofer V, 2625<br />
Klintenberg C, 2851<br />
Klotz R, 2975<br />
Klouvas G, 2913<br />
Klutmann S, 2561<br />
Klüttermann K, 2585<br />
Knecht R, 687, 2239<br />
Knüpfer H, 1055<br />
Knüpfer M, 1055<br />
Ko JJ, 865<br />
Ko S-F, 1299<br />
Kobayashi H, 535<br />
Kobayashi K, 215<br />
Kobayashi M, 197<br />
Kobayashi N, 435<br />
Kobayashi R, 373<br />
Kobayashi S, 2691<br />
Kobayashi T, 1821, 2087,<br />
2433<br />
Kochi M, 229, 2577<br />
Kodama J, 159<br />
Koeffler HP, 3579<br />
Koelbl H, 1207<br />
Koensgen D, 1329<br />
Kofla G, 3961<br />
Koga K, 731, 2401<br />
Koga M, 2433<br />
Kohlberger P, 519<br />
Köhler G, 2397<br />
Kojima M, 389, 1477<br />
Kojima Y, 609<br />
Kokai G, 763<br />
Kokawa K, 2933<br />
Koketsu S, 389, 1477<br />
Kokkola A, 2279<br />
Kokuba Y, 1933<br />
Kokudo N, 2219<br />
Kolialexi A, 401, 1263<br />
Kollen BJ, 1373<br />
Kolodziej B, 1927<br />
Kołodziej J, 2967<br />
Kolosza Z, 501<br />
Koltai K, 1917<br />
Komatsu A, 665<br />
Komatsu F, 407<br />
Komiya S, 2147<br />
Komlósi V, 3051<br />
Komori Y, 1593<br />
Komorowski J, 2813<br />
Kon Y, 389, 1477<br />
Konatkowska B, 1927<br />
Kondo E, 3971<br />
Kondo H, 379<br />
Kondo T, 609, 1693<br />
Könemann S, 3885<br />
Kong B, 2991<br />
Konishi I, 2933<br />
Konno H, 693<br />
Konno S, 1841, 2321<br />
Koopmans KP, 1867<br />
Korholz D, 887<br />
Korkolopoulou P, 3697<br />
Körner H, 1151<br />
Korzeniowski S, 3027<br />
Kosaka T, 1309, 2473<br />
Kosmas C, 543<br />
Kosmehl H, 2265<br />
Kosmidis P, 1341, 2913<br />
Kostopoulou E, 1905<br />
Kotsakis A, 495<br />
Kotteas E, 529<br />
Kotzsch M, 2259<br />
Koufaliotis N, 2233<br />
Kouklakis G, 3035<br />
Kouklis P, 843<br />
Koukoulis G, 1905<br />
Koukourakis MI, 1349, 3035<br />
Koumarianou A, 2317<br />
Koumna S, 2409<br />
Kountourakis P, 539, 3087<br />
Kountouras J, 3107<br />
Kourvetaris A, 3961<br />
Koussis H, 1383<br />
Koutras AK, 2913<br />
Koutsilieris M, 3945<br />
Kovács G, 3051<br />
Kowalczyk J, 1927<br />
Koyama F, 1831<br />
Kraehn-Senftleben G, 973<br />
Kraemer K, 2259<br />
Kraemer M, 1029<br />
Kralovánszky J, 3051<br />
Kraszewska E, 989<br />
Kratz F, 3567<br />
Kratzke MG, 1<br />
Kratzke RA, 1<br />
Krause C, 2585<br />
Krause FS, 1361<br />
Kravik KL, 583<br />
Krawczuk-Rybak M, 1927<br />
Krawczyk Z, 501<br />
Krčmová L, 2389<br />
Kreft E, 2781<br />
Krokan HE, 3717<br />
Kronholz H-L, 3885<br />
Kroon BBR, 2297<br />
Kropf S, 757<br />
Krzymuski MJ, 2607<br />
Krzyzowska-Gruca S, 501<br />
Kuasne H, 1023<br />
Kubatka P, 2819<br />
Kubicka M, 1927<br />
Kubo M, 731<br />
Kubota S, 2343<br />
Kubota T, 1651, 3593<br />
Kudo H, 1627<br />
Kuhara K, 373<br />
Kuhnen C, 2055<br />
Kühr T, 2901<br />
Kulpa JK, 3027<br />
Kumai K, 1651<br />
Kumar R, 785<br />
Kumon H, 159<br />
Kümper C, 2303<br />
Kunická Z, 3125
Kunii S, 229, 1069, 2197<br />
Kunisaki C, 1309, 2473<br />
Kunze D, 2259<br />
Kuo C-L, 1045<br />
Kuo H-M, 833<br />
Kuo Y-Z, 2039<br />
Kupryjanczyk J, 989<br />
Kurahara H, 2369<br />
Kuranami M, 3929<br />
Kure EH, 2289<br />
Kurihara T, 171, 1069, 2657<br />
Kurio N, 2343<br />
Kurishima K, 3153<br />
Kurokawa H, 2663<br />
Kuroki S, 731<br />
Kurosaka M, 825<br />
Kurth AA, 879<br />
Kurtz J-E, 3041<br />
Kusinski M, 2813<br />
Kusumi T, 1627<br />
Kuwada E, 799<br />
Kuwano H, 165, 1821<br />
Kuzdak K, 2813<br />
Kuzmicz M, 1927<br />
Kwagyan J, 3119<br />
Kwak J-Y, 927<br />
Kwak SY, 2807<br />
Kwiatkowski F, 1853, 3079<br />
Kyriakou F, 2409, 2479<br />
Kyroudi-Voulgari A, 2479<br />
La Torre G, 2941<br />
Laato M, 3865<br />
Lacalamita R, 223<br />
Lackey KE, 2019<br />
Lafanéchère L, 1161<br />
Lage H, 2967<br />
Lai K-H, 97, 1317<br />
Lake D, 3139<br />
Lalmuanpuii J, 3139<br />
Lamb DS, 3891<br />
Lamberg K, 2851<br />
Lan Q, 2061<br />
Landman GWD, 1373<br />
Landréat V, 2869<br />
Landuzzi L, 763<br />
Lange TJ, 1055<br />
Langler R, 2753<br />
Langsam B, 673<br />
Lapaire O, 921<br />
Larsen L, 2553<br />
Lass H, 3977<br />
Lassmann S, 3567<br />
Laster Z, 2981<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Lavigne C, 2753<br />
Lazaris AC, 305<br />
Laznicek M, 2189<br />
Laznickova A, 2189<br />
Lazzarino M, 2745<br />
Le C, 2271<br />
Le François B, 2175<br />
Lea MA, 2067<br />
Lebrecht A, 1207<br />
Lee EL, 75<br />
Lee H, 431<br />
Lee HK, 2807<br />
Lee J, 3579<br />
Lee J-H, 1701<br />
Lee LJ, 943<br />
Lee LMJ, 479<br />
Lee L-T, 2109, 2599<br />
Lee M-T, 2109, 2599<br />
Lee P-H, 2599<br />
Lee P-P, 2109, 2599<br />
Lee RJ, 793, 943, 2801<br />
Lee S, 865<br />
Leese MP, 577, 1483<br />
Leichsenring A, 1023<br />
Leite M, 3793<br />
Lelong-Rebel I, 55<br />
Lembessis P, 3945<br />
Lemos-González Y, 2333<br />
Lenhard MS, 2303<br />
Leo FR, 4121<br />
Leon ME, 3061<br />
Leone JP, 3937<br />
Lesniak MS, 1143<br />
Lev-Ari S, 3147<br />
Levêque D, 3075<br />
Levêque J, 2869<br />
Li AF-Y, 907<br />
Li B, 3631<br />
Li G, 321<br />
Li H, 2801<br />
Li H-J, 3763<br />
Li J-N, 3763<br />
Li L, 3827<br />
Li Q, 327<br />
Li S, 2541, 3897<br />
Li X-H, 1061, 2225<br />
Li X-L, 2545<br />
Li Y, 1585, 3621<br />
Li Y-C, 1701<br />
Li Z, 2705<br />
Liakakos T, 1079<br />
Liang S-Y, 1687<br />
Liang X, 1659<br />
Liao G-Q, 3763<br />
Licastro F, 395<br />
Lichtenegger W, 1329, 2453<br />
Lichtensteiger W, 85<br />
Liebhardt S, 1107<br />
Liebow C, 2599<br />
Liégeois P, 2859<br />
Lin Cheng-Chieh, 267<br />
Lin Chia-Chi, 2039<br />
Lin Chin-Chung, 1701<br />
Lin C-Y, 2109<br />
Lin H-H, 1887<br />
Lin J-P, 833<br />
Lin L-I, 1355<br />
Lin M-W, 1045, 1093<br />
Lin S-S, 1701<br />
Lin S-Y, 2791<br />
Lin T-C, 1355<br />
Lin W-C, 907<br />
Lin W-S, 97<br />
Lin YC, 2801<br />
Lin Y-S, 2109<br />
Lin Y-T, 2791<br />
Lindahl B, 1259<br />
Lindén C-J, 2851<br />
Lindquist D, 1133<br />
Linke R, 2303<br />
Linné T, 2851<br />
Liscovitch M, 895<br />
Lissoni P, 1377, 1951, 3743<br />
Litique V, 3041<br />
Little S, 913<br />
Liu B, 1085<br />
Liu D-L, 1575<br />
Liu G-Y, 2039, 3093<br />
Liu H-S, 3749, 4149<br />
Liu J-M, 2813<br />
Liu K-C, 833<br />
Liu Peishu, 1119<br />
Liu Ping, 327<br />
Liu W, 3613<br />
Liu WK, 2577<br />
Liu X, 2625<br />
Liu Yang, 2061<br />
Liu Yu, 229, 2197<br />
Ljuslinder I, 1493<br />
Llamas-Martínez S, 3733<br />
Lo G-H, 97<br />
Lobstein A, 289<br />
Lödén B, 2851<br />
Löfgren S, 1789<br />
Lönn U, 2851<br />
Lopes C, 443<br />
Lopes JM, 913<br />
Lopez-Beltran A, 2893<br />
Loprevite M, 507<br />
Lora O, 1383<br />
Loreggian L, 1383<br />
Lorenzen D, 1467<br />
Losi-Guembarovski R, 1023<br />
Löw S, 3725, 3729<br />
Lozano P, 3083<br />
Lozza V, 3871<br />
Lu D, 943<br />
Lu H-F, 1045, 1093, 2791<br />
Lu J-H, 1045<br />
Lu J-S, 3093<br />
Lu K-W, 1093<br />
Lu P-J, 97<br />
Lu Y, 327, 2801<br />
Lu Y-J, 3763<br />
Lubiński Jakub, 3011<br />
Lubiński Jan, 3011<br />
Lucas AR, 2595<br />
Lucchini R, 2885<br />
Luchena G, 1813, 2513<br />
Ludvikova Jr M, 1389<br />
Ludvikova M, 1389<br />
Lüftner D, 3961<br />
Luke B, 3119<br />
Luksch R, 1565<br />
Lumachi F, 491<br />
Lundemo AG, 3717<br />
Lundgren E, 593<br />
Lundin J, 2279<br />
Luo Y, 957, 2625<br />
Luo Z, 2009<br />
Lurje G, 367<br />
Lyratzopoulos N, 3035<br />
Ma C, 2991<br />
Ma C-D, 3093<br />
Ma D, 327, 621<br />
Ma JY, 3827<br />
Macchi M, 3847<br />
Machino M, 699<br />
Maciejczyk A, 2967<br />
Mack MG, 879<br />
Madelmont JC, 21<br />
Maebayashi K, 3859<br />
Maeda M, 91<br />
Maeda O, 3913<br />
Maeda S, 2369<br />
Maeda Y, 2045<br />
Maehara T, 69<br />
Maehara Y, 1779, 2353<br />
Maemura K, 2369<br />
4277
Mahajan A, 741<br />
Maiti A, 3705<br />
Majka M, 187<br />
Major T, 2169<br />
Makino H, 1309, 2473<br />
Makuuchi H, 2045<br />
Malaimare L, 3965<br />
Malfertheiner P, 757<br />
Malinowska I, 1927<br />
Malliou S, 2409, 3087<br />
Maltaris T, 1207<br />
Malusecka E, 501<br />
Malvi D, 981<br />
Malνřovα E, 2389<br />
Mancuso A, 1767<br />
Manda R, 165<br />
Mandato VD, 2309<br />
Mándoky L, 1641<br />
Manferrari F, 1369<br />
Manifikos G, 843<br />
Mann M, 2553<br />
Manolas K, 3035<br />
Mantzaris GJ, 3697<br />
Mantzaris I, 2409, 3087<br />
Mao Z, 1659<br />
Marcellin L, 3041<br />
Marchionni M, 3871<br />
Marchiori D, 395, 1369,<br />
1883<br />
Marcus HE, 367<br />
Mardhatillah F, 785<br />
Mariggio MA, 813<br />
Marino F, 491<br />
Marioni G, 551, 1383<br />
Markert S, 3567<br />
Marks LS, 2271<br />
Marocchi A, 2745<br />
Maroun JA, 2175<br />
Marrero PF, 3671<br />
Marroni P, 507<br />
Marsilio S, 763<br />
Martelli O, 1767<br />
Märten A, 1499<br />
Marth C, 2975, 3977<br />
Martin B, 879<br />
Martinelli G, 3061<br />
Martinez T, 431<br />
Martínez-Arribas F, 2595<br />
Martín-Garabato E, 2595<br />
Martorana G, 1369, 1883<br />
Martorana G, 395<br />
Marubashi S, 179<br />
Masotti L, 1883<br />
4278<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Masoudi A, 2437<br />
Massara G, 1813, 2513<br />
Massuger LFAG, 2721<br />
Mastronikolis NS, 245<br />
Masuda K, 2669<br />
Masuda M, 139<br />
Masuda N, 165, 1821<br />
Masuda S, 2225<br />
Masudo K, 139<br />
Masuno H, 2081<br />
Mataki Y, 2369<br />
Mathelin C, 2447, 2859<br />
Matsson L, 1911<br />
Matsubara A, 2141<br />
Matsubara H, 665<br />
Matsubayashi K, 1229<br />
Matsui K, 1749<br />
Matsumoto A, 559<br />
Matsumoto K, 1277<br />
Matsumoto S, 2663<br />
Matsumoto T, 2087<br />
Matsumoto Y, 1187<br />
Matsumura K, 709<br />
Matsumura Y, 145<br />
Matsunaga K, 3929<br />
Matsuno K, 2663<br />
Matsuo T, 159<br />
Matsushita H, 145<br />
Matsushita K, 665<br />
Matsutani T, 415<br />
Matsuyama R, 1559<br />
Matsuzaki H, 4143<br />
Matsuzu K, 139<br />
Matysiak M, 1927<br />
Mauricas M, 1139<br />
Mauz-Körholz C, 2585<br />
Mavrou A, 401, 1263<br />
Mavroudis D, 495, 3019<br />
Max D, 887<br />
May A, 2239, 2349<br />
Mazur G, 1113<br />
Mazzucchelli R, 2893<br />
McDowell HP, 763<br />
McGill JR, 3573<br />
McGonigal T, 957<br />
McKeehan WL, 2141<br />
Meagher-Villemure K, 751<br />
Meazza C, 1565<br />
Medicherla S, 3827<br />
Medici MC, 855<br />
Meert V, 2459<br />
Meguro N, 3913<br />
Mehrle S, 1499<br />
Mei-Dueyang, 833<br />
Meisner C, 949<br />
Melichar B, 2389<br />
Melicharová L, 2189<br />
Melicharovα K, 2389<br />
Mellai M, 109<br />
Melnick SJ, 965<br />
Mendilaharsu M, 2499<br />
Meng L, 327, 621<br />
Mensi M, 1365<br />
Merfort I, 933<br />
Merimsky O, 3147<br />
Merle P, 21<br />
Merz H, 119<br />
Messina G, 1377, 1951, 3743<br />
Messinis IE, 1905<br />
Métivier A-C, 3041<br />
Metro G, 1245<br />
Metzger R, 367, 1525<br />
Meye A, 2259<br />
Meyer A, 3965<br />
Mi Z, 1733<br />
Michalaki V, 1923<br />
Miele E, 419<br />
Mignogna C, 2309<br />
Milanezi F, 913<br />
Milla P, 2519<br />
Millard C, 431<br />
Minagawa N, 1277<br />
Minami S, 2147<br />
Minami T, 601<br />
Minamoto T, 2493<br />
Minas M, 1905<br />
Mingazzini P, 419<br />
Minoia C, 2987, 3835<br />
Minopoulos G, 3035<br />
Minorics R, 2737<br />
Miraglia S, 1813, 2513<br />
Mirkhat S, 2141<br />
Misawa T, 51, 3809<br />
Mishima H, 2379<br />
Mishra DK, 3579<br />
Misso C, 2885<br />
Miternique-Grosse A, 289<br />
Mitsuhashi N, 3859<br />
Mitsumori N, 215<br />
Mitsuya H, 37<br />
Mittelmeier W, 3877<br />
Mittler G, 2553<br />
Miwa H, 2087<br />
Miyagaki H, 2379<br />
Miyagawa K, 1169<br />
Miyagi Y, 139<br />
Miyahara K, 1069, 2657<br />
Miyamoto A, 179<br />
Miyamoto K-I, 1681<br />
Miyazaki M, 2379<br />
Miyazaki T, 165, 2361<br />
Miyazawa M, 2373<br />
Mizukami H, 1581, 2697<br />
Mizuki E, 91<br />
Mizuma M, 2669<br />
Mizumoto K, 2205<br />
Mizuno LT, 1023<br />
Mo H, 1005<br />
Moats-Staats BM, 1509<br />
Möbius C, 873<br />
Mochizuki H, 2141<br />
Moen M-AN, 459<br />
Mokbel K, 2135, 4105<br />
Molls M, 3015<br />
Molnár J, 2737<br />
Moltz CC, 431<br />
Momiyama N, 1559<br />
Monacelli M, 2885<br />
Monaco A, 1335<br />
Monden M, 179<br />
Monfardini S, 1805, 1813,<br />
2513, 4095, 4129<br />
Montagna M, 3835<br />
Montironi R, 2893<br />
Mooi WJ, 2297<br />
Moon DC, 3777<br />
Moon RC, 3705<br />
Moon S-Y, 2649<br />
Moreno-López LA, 3733<br />
Morgan JL, 2271<br />
Mori R, 425, 1559<br />
Morisaki T, 2401<br />
Morita K, 2353<br />
Morita M, 1433<br />
Morita N, 2687<br />
Morita S, 1433<br />
Morita T, 535<br />
Moriya Y, 145<br />
Morra E, 2745<br />
Morris DL, 105, 2775, 3757<br />
Mortensen MW, 571<br />
Morvan D, 21<br />
Mössner J, 873<br />
Motegi K, 389, 1477<br />
Motohashi N, 171, 1069,<br />
2657<br />
Motoi F, 2669<br />
Mouratidou D, 543, 1421<br />
Mourouzis C, 2253
Mourra N, 3609<br />
Mousseau M, 3067<br />
Moyer MP, 2067<br />
Mrazek E, 2851<br />
Mucha I, 3125<br />
Muggia F, 3143<br />
Mukogawa T, 1831<br />
Müller D, 2397<br />
Müller J, 3051<br />
Müller O, 2055<br />
Müller-Holzner E, 2975<br />
Mumford J, 2061<br />
Mumtaz M, 1789<br />
Muñoz A, 2613<br />
Munoz F, 1285<br />
Munroe DJ, 3119<br />
Murakami H, 3855<br />
Murakami K, 665<br />
Murakami Y, 699<br />
Muramatsu H, 3859<br />
Murata T, 3711<br />
Murawa D, 2967<br />
Murayama C, 2045<br />
Murayama H, 1069, 2657<br />
Murayama M, 1841, 2321,<br />
2921<br />
Murayama T, 2147<br />
Murohashi I, 2701<br />
Murray J, 3891<br />
Murray S, 2479<br />
Mutaguchi K, 2141<br />
Muto S, 639, 1899, 2487<br />
Mytar B, 187<br />
Nacey J, 3891<br />
Nadali G, 2745<br />
Nadrowitz R, 771<br />
Nagahori Y, 2473<br />
Nagai E, 2205<br />
Nagai S, 2401<br />
Nagai Y, 415<br />
Nagami H, 1187<br />
Nagano H, 179<br />
Nagano Y, 1309<br />
Nagao K, 3971<br />
Nagashima N, 1277<br />
Nagata J, 1277<br />
Nagata N, 1277<br />
Nagel ME, 2437<br />
Nagler RM, 2981<br />
Nakabeppu Y, 1585<br />
Nakadate T, 2101<br />
Nakadozono M, 2433<br />
Nakagawa T, 639, 1831<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Nakagomi H, 1239<br />
Nakahira S, 179<br />
Nakai H, 2385<br />
Nakajima M, 165<br />
Nakajima Y, 1831<br />
Nakajo M, 2369<br />
Nakamori S, 179, 2379<br />
Nakamura K, 159<br />
Nakamura Masafumi, 731,<br />
2401<br />
Nakamura Miki, 37<br />
Nakamura R, 1651<br />
Nakamura S, 1831<br />
Nakamura Takatoshi, 1933<br />
Nakamura Tomoyuki, 1585<br />
Nakamura Yukiko, 3855<br />
Nakamura Yukio, 1069, 2197<br />
Nakanishi Y, 601<br />
Nakano T, 609<br />
Nakano Y, 2219<br />
Nakase Y, 1169<br />
Nakashima H, 731, 2401<br />
Nakashima M, 609<br />
Nakashima S, 1169<br />
Nakata M, 2219<br />
Nakatani T, 709, 3007<br />
Nakayama H, 139<br />
Nakayama K, 2433<br />
Nakayama R, 215<br />
Nakayama Y, 1277<br />
Nakopoulou L, 1079<br />
Nangami GN, 3601<br />
Nanni C, 981<br />
Nano R, 15<br />
Naohara T, 69<br />
Nappi C, 2309<br />
Nara N, 2701<br />
Naritaka Y, 559, 1841, 2321<br />
Nasi P, 2885<br />
Nasioulas G, 305, 843, 1341<br />
Näsman A, 1133, 2077<br />
Nasu Y, 159<br />
Natsugoe S, 2369<br />
Navas TA, 3827<br />
Negishi T, 1239<br />
Negru ME, 2513<br />
Nejc D, 465<br />
Németh K, 3051<br />
Nemoto H, 1581, 2697<br />
Nesselhut T, 1467<br />
Neubauer H, 949, 1797<br />
Neukam FW, 271, 309, 1675<br />
Neumann U, 1329<br />
Newbold RF, 2135<br />
Newman SP, 577, 1483<br />
Neyns B, 2459<br />
Ng P-S, 2343<br />
Nguyen AN, 3827<br />
Nguyen LM, 431<br />
Nguyen NP, 431<br />
Nguyen S, 3099<br />
Ni J, 601<br />
Nieder C, 1325, 3015<br />
Nieuwland R, 1107<br />
Nieweg OE, 2297<br />
Niibe Y, 3929<br />
Nikiteas N, 1039<br />
Nikolaou M, 2317<br />
Nilsson PJ, 2469<br />
Ninfo V, 471<br />
Ninomiya H, 2121<br />
Nishi T, 1627<br />
Nishibori H, 3593<br />
Nishida T, 2343<br />
Nishimori T, 665<br />
Nishimura T, 3913<br />
Nishio K, 1899, 2487<br />
Nishioka R, 2373<br />
Nishishiro M, 171<br />
Nishiyama K, 3913<br />
Nitori N, 3593<br />
Niwa M, 3665<br />
Nkenke E, 271, 309, 1675<br />
Nobili C, 1951<br />
Noda T, 2121<br />
NOGGO, 1329<br />
Nogi H, 2433<br />
Noguchi K, 799<br />
Noma H, 2369<br />
Nomura M, 731, 2691<br />
Noni A, 2479<br />
Nonomura A, 1831<br />
Nordin FJ, 3677<br />
Nordling S, 2279<br />
Norrild B, 2553<br />
Norum J, 459, 2865<br />
Nosáľová G, 2819<br />
Noske A, 563<br />
Nowotny G, 519<br />
Nukariya K, 2433<br />
Nuzzo C, 1245, 1429<br />
O’Brien V, 9<br />
Ochiai H, 3593<br />
Ochiai T, 665<br />
Ocsovszki I, 2737<br />
Oda A, 2669<br />
Oei ALM, 2721<br />
Ogawa F, 3637<br />
Ogawa K, 373, 559, 1773,<br />
1841, 2321, 2921, 4137<br />
Oggioni N, 335<br />
Ognio E, 813<br />
Ogose A, 535<br />
Oh D, 1271<br />
Oh JH, 3777<br />
Ohara T, 715<br />
Ohashi T, 51, 2785, 3809<br />
Ohba M, 91<br />
Ohgushi A, 91<br />
Ohhashi S, 2205<br />
Ohira M, 629<br />
Ohlinger R, 2397<br />
Ohmura T, 407<br />
Ohno S, 2493<br />
Ohno Y, 2493<br />
Öhrling K, 1741<br />
Ohtsuka H, 2669<br />
Ohtsuki K, 1831<br />
Ohtsuki Y, 197<br />
Ohuchida K, 2205<br />
Oikonomou E, 843<br />
Ojima H, 165<br />
Oka M, 379<br />
Okabayashi K, 3593<br />
Okada H, 1899<br />
Okada T, 389, 1477, 1585<br />
Okada Y, 75<br />
Okaichi K, 2687<br />
Okami J, 179<br />
Okamoto K, 1433<br />
Okamoto T, 51<br />
Okamura M, 253<br />
Okazaki Y, 1169<br />
Okie WR, 2067<br />
Okugawa T, 3971<br />
Okumura Y, 2687, 4117<br />
Olejnik I, 1927<br />
Oliva C, 2327<br />
Oliveira BW, 1023<br />
Oliveira PA, 443<br />
Ollig S, 2569<br />
Olschwang S, 3609<br />
Olson A, 2625<br />
Omatsu K, 1785<br />
Oniga F, 1813, 2513<br />
Onitsuka T, 1947<br />
Ono A, 3855<br />
Ono HA, 1309, 2473<br />
Ono Y, 3913<br />
4279
Onogawa T, 2669<br />
Onouchi S, 145<br />
Onozato W, 1933<br />
Ooki A, 435, 2875<br />
Opanasopit P, 793<br />
Orecchia R, 4121<br />
Oremek GM, 2443<br />
Orlandi M, 283<br />
Orphanos G, 539<br />
Orsos Z, 1917<br />
Osada S, 45<br />
Osaka E, 4143<br />
Osaka S, 4143<br />
Osawa G, 373, 559<br />
O'Shaughnessy JA, 1733<br />
Oshima T, 1309, 2087, 2473<br />
Oshiro S, 407<br />
Oskay-Oezcelik G, 1329,<br />
1943<br />
Ostatíνková D, 2819<br />
Osterheld M-C, 751<br />
Ota T, 1785<br />
Otani T, 373, 559, 1773<br />
Oteham CP, 3705<br />
Otsuji E, 1169<br />
Otsuka Y, 1309<br />
Ottone A, 3055<br />
Ou D-L, 1355<br />
Oudar O, 1029<br />
Oue N, 1169<br />
Overholt BF, 485<br />
Overholt S, 485<br />
Owsijewitsch M, 2561<br />
Ozawa H, 1933<br />
Pääkkö P, 1757<br />
Pacchiarotti A, 3941<br />
Paganuzzi M, 507<br />
Paillocher N, 2869<br />
Palacios-Sánchez B, 1197<br />
Palma JP, 2625<br />
Palmeira CA, 443<br />
Palumbo I, 2987, 3835<br />
Panagos C, 3697<br />
Panjehpour M, 485<br />
Pantazopoulos K, 529<br />
Pap É, 3051<br />
Papadakis E, 1039<br />
Papadas TA, 245<br />
Papadoniou N, 543<br />
Papadopoulou E, 1341<br />
Papadopoulou P, 495<br />
Papageorgakopoulou N, 245<br />
Papakosta V, 2253<br />
4280<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Papakostas P, 2913<br />
Papakotoulas P, 495<br />
Papalambros E, 543, 1923<br />
Papaldo P, 1245<br />
Papastratis G, 543<br />
Papaxoinis G, 1421<br />
Papazisis K, 1341<br />
Papi A, 283<br />
Papoudou-Bai A, 295<br />
Paradiso A, 223<br />
Parasi A, 1875<br />
Pardal F, 913<br />
Parisi A, 1417<br />
Park N-S, 2649<br />
Parmeggiani D, 2885<br />
Parolini D, 1377, 1951, 3743<br />
Parsons MFC, 1517<br />
Pasetto LM, 1383, 1805,<br />
1813, 2513, 4095, 4129<br />
Pasqualini JR, 2129<br />
Pasquier D, 3067<br />
Passerini R, 3061<br />
Pasukoniene V, 1139<br />
Pasz-Walczak G, 465<br />
Patani N, 2135, 4105<br />
Patel D, 2679<br />
Patrosso MC, 2745<br />
Patrucco A, 109<br />
Patsiaoura K, 3107<br />
Patsouris E, 271, 309, 1675,<br />
2253<br />
Patsouris ES, 2479<br />
Paulraj P, 3573<br />
Paulsen JE, 3771<br />
Pavlakis K, 1079, 1875<br />
Pawełczyk K, 2967<br />
Payan R, 3067<br />
Peccatori FA, 3061<br />
Pecher G, 2831<br />
Pecorari G, 1285<br />
Pectasides D, 1421, 2317,<br />
2913<br />
Pectasides E, 1421, 2317<br />
Pedani F, 2519<br />
Pedrazzoli P, 3991<br />
Peldschus K, 2561<br />
Pelekanou E, 1411<br />
Pellegrini D, 1245, 1429<br />
Penco S, 2745<br />
Pendás-Franco N, 2613<br />
Penna C, 3871<br />
Penning TD, 2625<br />
Pento JT, 133, 2733<br />
Perakis M, 1039<br />
Pereira F, 2613<br />
Perla FM, 763<br />
Pernetti R, 395, 1369, 1883<br />
Perno CF, 1405<br />
Peros G, 1039, 1875<br />
Perrea D, 2253<br />
Persons KS, 2009<br />
Peschos D, 3815<br />
Pession A, 283<br />
Peters JH, 1467<br />
Peters SO, 771<br />
Petersen CC, 571<br />
Petersen MS, 571<br />
Petraki K, 3697<br />
Petrik M, 2189<br />
Petrillo G, 813<br />
Petru E, 3047, 3977<br />
Petry M, 1849<br />
Petsas T, 2913<br />
Pezzetti L, 2745<br />
Pezzullo L, 2885<br />
Pezzuto JM, 3705<br />
Pfragner R, 2705<br />
Piekarski J, 465<br />
Pieralli A, 3871<br />
Pietzner K, 563<br />
Pinski JK, 425<br />
Pintzas A, 843<br />
Pippen J, 1733<br />
Pires MA, 443<br />
Pisiotis C, 1341<br />
Pissimissis N, 3945<br />
Pitiakoudis M, 3035<br />
Pizzi G, 1417<br />
Pizzolo G, 2745<br />
Plachouras D, 1411<br />
Platania M, 1813, 2513<br />
Plisiecka-Halasa J, 989<br />
Plukker JTM, 1867<br />
Pluta P, 465<br />
Pochettino P, 2327<br />
Podda M, 1565<br />
Poggi G, 1365, 2987, 3835<br />
Poirier R, 3119<br />
Poliseli F, 1023<br />
Polterauer S, 515, 519, 1849,<br />
3131, 4091<br />
Polychronidis A, 3035<br />
Polykretis L, 2077<br />
Polyzos A, 543<br />
Pommert A, 2561<br />
Porcellini E, 395<br />
Possinger K, 3961<br />
Potter BVL, 577, 1483, 1517<br />
Pourgholami MH, 2775,<br />
3757<br />
Povysil C, 1389<br />
Pradhan P, 943<br />
Prados E, 2859<br />
Prager G, 4101<br />
Prelog M, 125<br />
Preusser M, 3801<br />
Proschek D, 879<br />
Proschek P, 879<br />
Protter AA, 3827<br />
Provata A, 529<br />
Provatopoulou X, 2421<br />
Pryczynicz A, 1399<br />
Pu Y-S, 2039<br />
Pucciarelli S, 1805, 4095,<br />
4129<br />
Puccio C, 3139<br />
Pudełko M, 2967<br />
Puig T, 3671<br />
Puistola U, 2715<br />
Pultrum BB, 1867<br />
Purohit A, 577, 1483, 1517<br />
Puxeddu E, 2885<br />
Pyrhönen S, 3865<br />
Qian X, 1085<br />
Qin J, 2245<br />
Quaranta M, 223<br />
Quaretti P, 2987, 3835<br />
Quarta C, 981<br />
Quek ML, 425<br />
Qureshi Z, 3139<br />
Rabiau N, 1853, 3079<br />
Radchenko OS, 927<br />
Raderer M, 4101<br />
Radomski N, 2033<br />
Raffetto N, 1335<br />
Rafinska B, 1927<br />
Ragnhammar P, 1741<br />
Ragos V, 1675<br />
Raica M, 2997<br />
Rainaldi G, 1013<br />
Rallis G, 1039, 2253<br />
Ramachandran C, 965<br />
Ramawat KG, 3647<br />
Ramos DM, 2049<br />
Ramos G, 1023<br />
Ramos K, 3793<br />
Ramos-Jorge ML, 1101<br />
Rampino M, 1285<br />
Ramqvist T, 1133, 2077
Ranieri E, 419<br />
Rank A, 1107<br />
Ranstam J, 1259<br />
Ranza E, 15<br />
Rappaport J, 1441<br />
Ratti R, 3993<br />
Raul F, 289<br />
Ravanel N, 3067<br />
Raveendran Nair PK, 965<br />
Ravelli E, 2745<br />
Rebel G, 55<br />
Reddy M, 3827<br />
Reed MJ, 577, 1483, 1517<br />
Regitnig P, 3047<br />
Reiman T, 1161<br />
Reimer D, 2975<br />
Reinthaller A, 515, 519,<br />
1849, 3131, 3977, 4091<br />
Reis RM, 913<br />
Relat J, 3671<br />
Ren D, 2061<br />
Repele M, 471<br />
Repsilber D, 119<br />
Resek AP, 965<br />
Reske SN, 3613<br />
Réthy B, 2737<br />
Ribatti D, 2997<br />
Ribeiro DC, 1101<br />
Ricardi U, 1285<br />
Riccardi A, 3835<br />
Ricotta R, 1813, 2513<br />
Rigatos G, 539, 2409, 3087<br />
Riggio D, 3061<br />
Rikiyama T, 2669<br />
Rino Y, 139<br />
Rio M-C, 2447<br />
Riordan SM, 105<br />
Ripamonti CB, 2745<br />
Ripoll GV, 2607<br />
Ritz R, 2033<br />
Rizzo E, 1813<br />
Rocchi P, 283<br />
Röcken C, 757<br />
Rodolico G, 3835<br />
Rodrigues M, 3691<br />
Rodriguez LE, 2625<br />
Rodríguez-Berrocal FJ, 2333<br />
Rodriguez-Menendez V, 335<br />
Roehle A, 119<br />
Roessler J, 2213<br />
Rofani C, 763<br />
Rogosnitzky M, 3701<br />
Rolle CE, 1143<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Roma A, 491<br />
Roma E, 401<br />
Romanidis K, 3035<br />
Romaniello I, 1813, 2513<br />
Romanitan M, 1133, 2077<br />
Romano A, 2569<br />
Ron IG, 3147<br />
Ronchi A, 3835<br />
Ronci C, 1405<br />
Ronco AL, 2499<br />
Rontogianni D, 295, 2479<br />
Rosato L, 2885<br />
Rosenberg SH, 2625<br />
Rosenstierne MW, 2553<br />
Roser F, 2033<br />
Rosetti M, 315<br />
Rossi E, 2535, 4129<br />
Rossi T, 2765<br />
Rovelli F, 1377<br />
Rubello D, 981<br />
Ruberto A, 2765<br />
Rubio CA, 193, 1571, 1911,<br />
2417, 2469<br />
Rugge M, 1805, 2507, 4095,<br />
4129<br />
Ruo Redda MG, 1285<br />
Ruol A, 1383<br />
Russell G, 3891<br />
Russillo M, 1245<br />
Russo GL, 855<br />
Ruuth K, 593<br />
Rydlova M, 1389<br />
Ryška A, 2389<br />
Ryu J, 4143<br />
Sacchetta S, 1767<br />
Sadahiro S, 2045<br />
Sadatomi S, 2205<br />
Sadloňová V, 2819<br />
Sæbø M, 2289<br />
Saeki N, 415<br />
Sagawa N, 3971<br />
Saikawa Y, 1651<br />
Sailes V, 2529<br />
Saito K, 1899, 2487<br />
Saito M, 1581, 2697<br />
Saito T, 1749, 1837<br />
Sakagami H, 151, 171, 229,<br />
253, 277, 997, 1069, 1713,<br />
2197, 2577, 2657<br />
Sakaki T, 2009<br />
Sakakura C, 1169<br />
Sakamoto S, 407<br />
Sakashita F, 45<br />
Sakata H, 665, 1779<br />
Sakata M, 1581, 2697<br />
Sakayama K, 2081, 2361<br />
Sakellariou S, 1079<br />
Sakimura R, 1585<br />
Sako T, 1277<br />
Sakon M, 179<br />
Sakuraba K, 1581<br />
Sakuragi N, 865<br />
Sakurai M, 51, 3809<br />
Sakurai Y, 1593<br />
Sakuramoto S, 435, 2875,<br />
2907<br />
Salama SA, 2181<br />
Salavoura K, 1263<br />
Sallah S, 431<br />
Saltarelli MJ, 2625<br />
Saluzzo CM, 3835<br />
Salvador S, 2859<br />
Salvatici M, 3061<br />
Salvucci O, 763<br />
Samantas E, 2913<br />
Sameshima S, 389, 1477<br />
Sanada Y, 1581<br />
Sanada Y, 2697<br />
Sánchez J, 2595<br />
Sánchez-Gutierrez JJ, 1197<br />
Sandri MT, 3061<br />
Sanefuji K, 2353<br />
Sanguedolce F, 395<br />
Sano M, 1239<br />
Santala M, 2715<br />
Santini MT, 1013<br />
Santos D, 593<br />
Santos L, 443<br />
Sarid D, 3147<br />
Saridaki Z, 3019<br />
Sarkar FH, 3621<br />
Sartori PV, 2885<br />
Sasaki A, 2343<br />
Sasaki H, 1837<br />
Sasaki M, 1627<br />
Sasaki T, 2669<br />
Sas-Korczyńska B, 3027<br />
Satih S, 1853, 3079<br />
Sato F, 1627<br />
Sato K, 69<br />
Sato N, 731, 1239<br />
Sato S, 1603<br />
Sato T, 535, 2473<br />
Satoh H, 3153<br />
Satoh K, 151, 171, 2657<br />
Satoh T, 1933<br />
Sauer B, 1467<br />
Sauer-Eppel H, 2443<br />
Saur D, 1541<br />
Sawada T, 389, 1477<br />
Sawyer M, 1161<br />
Scardamaglia P, 3941<br />
Scarpelli M, 2893<br />
Scarselli G, 3871<br />
Scelsi M, 2987, 3835<br />
Schächtele C, 933<br />
Schaefer G, 125<br />
Schallier D, 2459<br />
Schally AV, 2599<br />
Schauer M, 361<br />
Schauwecker J, 3877<br />
Schefold JC, 2453<br />
Schena M, 1285<br />
Schenkel J, 2825<br />
Schiavina R, 1883<br />
Schierholz JM, 523<br />
Schietzel M, 1893<br />
Schiffer D, 109<br />
Schirmacher P, 1459<br />
Schlegel AA, 309<br />
Schlenska-Lange A, 1055<br />
Schlumpf M, 85<br />
Schmalfeldt B, 1329<br />
Schmid RM, 1541<br />
Schmidt J, 1499<br />
Schmidt M, 1207, 1719<br />
Schmidt U, 3725, 3729<br />
Schmitt M, 3877<br />
Schmutz S, 673<br />
Schneider B, 523<br />
Schneider G, 1541<br />
Schneider J, 2595<br />
Schneider PM, 367<br />
Schneuber SE, 3047<br />
Scholz HS, 3047<br />
Schønberg SA, 3717<br />
Schoots C, 237<br />
Schraml E, 2705<br />
Schreurs LM, 1867<br />
Schrott K-M, 1361<br />
Schuck A, 3885<br />
Schüller P, 3885<br />
Schumacher U, 209, 2561<br />
Schüttler K, 757<br />
Schwab R, 2769<br />
Scialfa GG, 3991<br />
Scola A, 1383<br />
Scopa CD, 1221<br />
Scorilas A, 2409<br />
4281
Scotti M, 1951<br />
Sculli CM, 3055<br />
Secondino S, 3991<br />
Sederholm C, 2851<br />
Seebacher V, 515, 1849<br />
Segawa H, 535<br />
Segerer F, 741<br />
Sehouli J, 563, 1329, 1943,<br />
2453<br />
Seiter K, 3139<br />
Seixas F, 443<br />
Sek P, 465<br />
Seki M, 2141<br />
Sekiguchi K, 3929<br />
Sekikawa T, 261<br />
Sekine T, 171<br />
Sekizawa K, 3153<br />
Serefoglou Z, 271, 309, 1675<br />
Seto Y, 1603<br />
Sève P, 1161<br />
Sgambato A, 2941<br />
Shao Y-Y, 3115<br />
Shao Z-M, 3093<br />
Shapiro A, 3909<br />
Shapiro O, 3909<br />
Shekels LL, 1<br />
Shen C, 3613<br />
Shen C-Y, 267<br />
Shen K-W, 3093<br />
Shen M, 2061<br />
Shen Z-Z, 3093<br />
Shi L, 3997<br />
Shi W, 2027<br />
Shi Y, 2625<br />
Shiba H, 51, 2785, 3809<br />
Shibahara K, 1779<br />
Shibao K, 1277<br />
Shida A, 215<br />
Shima Y, 1433<br />
Shimada H, 425, 1309, 1559,<br />
2473<br />
Shimada J, 253<br />
Shimakawa T, 1841, 2321<br />
Shimasaki M, 645, 655<br />
Shimizu T, 75, 1947, 4137<br />
Shimo T, 2343<br />
Shimoji T, 2121<br />
Shimomura K, 1169<br />
Shimura T, 1821<br />
Shina S, 3147<br />
Shinchi H, 2369<br />
Shingyouji M, 1229<br />
Shiomi K, 3933<br />
4282<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Shiozaki T, 3971<br />
Shiozawa S, 559, 1841, 2321<br />
Shirahata A, 1581, 2697<br />
Shiraishi T, 3711<br />
Shirasaka T, 1433<br />
Shiraso S, 2669<br />
Shirazi I, 3785<br />
Shishodia S, 3647<br />
Shoji M, 609<br />
Shoshan L, 3147<br />
Shubina LK, 927<br />
Shukuya T, 3855<br />
Shun C-T, 2039<br />
Sidoni A, 2535<br />
Siegel L, 289<br />
Sieghart W, 3801<br />
Siegl V, 2705<br />
Siemann DW, 2027<br />
Siena S, 1813, 2513, 3991<br />
Sievers S, 2055<br />
Siewert JR, 361<br />
Siggelkow W, 1207<br />
Silva AE, 3793<br />
Simone G, 223<br />
Simopoulos C, 3035<br />
Sinha AA, 2271<br />
Sinigaglia G, 1805, 4095,<br />
4129<br />
Sinzinger H, 3691<br />
Siołek M, 3011<br />
Sirzén F, 2851<br />
Sitaras NM, 1857<br />
Sivridis E, 3035<br />
Six L, 515<br />
Sjödin A, 1493<br />
Sjögren A, 2851<br />
Skaland I, 1151<br />
Skandalis SS, 245<br />
Skarlas L, 1221<br />
Skinner MA, 2019<br />
Skjelbred CF, 2289<br />
Skog S, 3897<br />
Skopelitis E, 543<br />
Skornick Y, 3785<br />
Sliutz G, 515, 519<br />
Smedts F, 237<br />
Smit LHM, 2297<br />
Smith ES, 3601<br />
Smith HJ, 431<br />
Smoot D, 3119<br />
Sobal G, 3691<br />
Sohda M, 165<br />
Søiland H, 1151<br />
Solichová D, 2389<br />
Solomayer EF, 779, 949,<br />
1797<br />
Soltau J, 933<br />
Sonabend AM, 1143<br />
Song A, 327<br />
Song G, 2245<br />
Sonta-Jakimczyk D, 1927<br />
Søreide JA, 1151<br />
Sørensen PG, 571<br />
Sottotetti F, 3835<br />
Sougioultzis S, 543<br />
Souglakos J, 1303<br />
Sowmyalakshmi S, 785<br />
Spaggiari L, 4121<br />
Speiser P, 519<br />
Sperlongano P, 2885<br />
Spinelli D, 813<br />
Spinelli GP, 419<br />
Spyridonidou S, 271, 309<br />
Staege MS, 887<br />
Staffieri A, 551<br />
Staffieri C, 551<br />
Stanczak E, 1927<br />
Stankiewicz D, 187<br />
Stathopoulos GP, 1303<br />
Stathopoulos J, 1303<br />
Stavropoulos JA, 2625<br />
Stefanaki K, 295<br />
Stefani M, 1181, 1725, 2535,<br />
3847<br />
Stefaniak J, 1927<br />
Stefanou D, 343<br />
Stefanova M, 949<br />
Stein H, 1213<br />
Steinig K, 1107<br />
Steinmann D, 3965<br />
Steinmann P, 673<br />
Stella G, 1365<br />
Stempfl A, 3977<br />
Stendahl U, 1793<br />
Stengel C, 1483<br />
Stephan D, 289<br />
Stępień E, 451<br />
Stepien H, 2813<br />
Stieber P, 1107, 2303<br />
Stocco G, 3921<br />
Stoelting S, 771<br />
Stonik VA, 927<br />
Strasser H, 1361<br />
Strauss WSL, 2033<br />
Strommer S, 3801<br />
Struikmans H, 1129<br />
Stumpf C, 1893<br />
Stuppner H, 2705<br />
Sturm S, 2705<br />
Styczynski J, 1927<br />
Stylianou M, 245<br />
Su C-C, 1045<br />
Suckow MA, 2529<br />
Suda T, 2493<br />
Sugano K, 3933<br />
Suganuma N, 139<br />
Sugawara Y, 2219, 2361<br />
Sugimachi K, 2353<br />
Sugimoto K, 179<br />
Sugimura Y, 3711<br />
Sulikowski M, 3011<br />
Sun G-H, 1989<br />
Sun H, 2679<br />
Sun S, 2545<br />
Sun W, 2991<br />
Sun Y, 1667<br />
Sun Z, 3119<br />
Sung H-C, 1993<br />
Sunheimer R, 3007<br />
Surowiak P, 1113, 2967<br />
Sutmuller M, 571<br />
Suwa D, 693<br />
Suzuki C, 1911<br />
Suzuki F, 151<br />
Suzuki Hideaki, 261<br />
Suzuki Hideki, 1821<br />
Suzuki Hiroyoshi, 3711<br />
Suzuki N, 2493<br />
Suzuki T, 2045<br />
Svejda B, 2705<br />
Svensson Å, 1551<br />
Swarts JC, 2781<br />
Sweep FCGJ, 2721<br />
Sygut J, 3011<br />
Sykoutri D, 3087<br />
Syrigos KN, 529, 1411<br />
Syrjänen K, 1405, 3865<br />
Syrjänen S, 3865<br />
Szajerka A, 2959<br />
Szajerka T, 2959<br />
Szarka K, 2169<br />
Szczepanek J, 1927<br />
Szczepanski T, 1927<br />
Szczuraszek K, 1113<br />
Szende B, 1641<br />
Szendi K, 349<br />
Sziklai I, 2169<br />
Szokoloczi O, 2769<br />
Tabata T, 3971
Tabuchi Y, 609<br />
Tachimori A, 629<br />
Tadano T, 715<br />
Tagawa Y, 3665<br />
Tagliaferri B, 3835<br />
Tajima K, 3933<br />
Takada N, 699<br />
Takagawa R, 1309, 2473<br />
Takahashi F, 1633<br />
Takahashi H, 1061, 2225<br />
Takahashi J, 171<br />
Takahashi K, 1633, 3933<br />
Takahashi M, 2473<br />
Takahashi Takao, 45<br />
Takahashi Tatsuo, 2691<br />
Takahashi Toshiaki, 3855<br />
Takahashi Yuji, 179<br />
Takahashi Yuri, 1681<br />
Takamoto N, 159<br />
Takano S, 3593<br />
Takano Y, 1061, 2225<br />
Takao S, 2369<br />
Takaoka H, 3637<br />
Takasaki I, 609<br />
Takasaki M, 1585<br />
Takashima M, 379<br />
Takaya M, 3929<br />
Takaya Y, 3665<br />
Takayama K, 601<br />
Takazawa K, 645, 1681<br />
Takeda S, 179<br />
Takeda Y, 179<br />
Takenouchi T, 535<br />
Takeshima N, 1785<br />
Takeshita M, 601<br />
Taketomi A, 2353<br />
Takeuchi T, 197<br />
Takigawa M, 2343<br />
Takizawa K, 1785, 2933<br />
Talarico C, 2885<br />
Talvensaari-Mattila A, 2715<br />
Tampellini M, 3055<br />
Tamura T, 1831<br />
Tamvakis N, 2479<br />
Tan T-W, 2791<br />
Tan Y, 2541<br />
Tanaka A, 2045<br />
Tanaka E, 3913<br />
Tanaka Haruo, 2401<br />
Tanaka Hidenori, 45<br />
Tanaka Kazuhiro, 1585<br />
Tanaka Kunihiko, 3665<br />
Tanaka Masanori, 1627<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Tanaka Masao, 731, 2205,<br />
2401<br />
Tanaka N, 165<br />
Tanaka R, 2691<br />
Tanaka S, 699<br />
Tanaka Tetsuo, 693<br />
Tanaka Tomoaki, 709<br />
Tanaka Toshiko, 2663<br />
Tanaka Yoshihiro, 45<br />
Tanaka Yoshimasa, 2921<br />
Tang N-Y, 1701<br />
Tang S-H, 1989<br />
Tang W, 2219<br />
Tani M, 2373<br />
Tanida K, 3971<br />
Taniguchi K, 1559<br />
Tanji N, 2081<br />
Taper HS, 2727<br />
Tarabolous C, 425<br />
Tari AM, 133<br />
Tarnowska C, 3011<br />
Tarsitano F, 2309<br />
Tasopoulos G, 2077<br />
Tatagiba M, 2033<br />
Tatemichi M, 2101<br />
Tauchi H, 2361<br />
Taylor TE, 2093<br />
Tazawa H, 2101<br />
Tee TT, 3677<br />
Teishima J, 2141<br />
Tejeda M, 2769<br />
Tejerina A, 2595<br />
Tell R, 2851<br />
Tempfer C, 515, 519, 1849,<br />
3131, 4091<br />
Tencer L, 895<br />
Terado Y, 639, 1899<br />
Teragni C, 2987, 3835<br />
Tesei A, 315<br />
Testini M, 2885<br />
Thaler CJ, 1107<br />
Thaler J, 2901<br />
Thant AA, 3579<br />
The Italian Group for Rare<br />
Tumors, 2327<br />
Theocharis DA, 245<br />
Thiere M, 119<br />
Thomas CMG, 2721<br />
Thomas G, 3609<br />
Thorns C, 119<br />
Tibold A, 1917<br />
Tiniakos D, 1875<br />
Tintori A, 3743<br />
Tiseo M, 507<br />
Toba M, 3933<br />
Tobino K, 3933<br />
Togashi Y, 2121<br />
Togo S, 425, 1559<br />
Tohda S, 2701<br />
Tokuda K, 2361<br />
Tokunaga Y, 1837<br />
Tokuno K, 379<br />
Tokuyama Y, 45<br />
Toma H, 2205<br />
Tomao F, 419<br />
Tomao S, 419<br />
Tomasetto C, 2447<br />
Tombolan V, 491<br />
Tomita H, 45<br />
Tomita K, 645, 655, 1449,<br />
1681<br />
Tomita M, 1947<br />
Tommasi S, 223<br />
Tomozawa S, 389, 1477<br />
Tonachella R, 2953<br />
Tonelli R, 283<br />
Tonello S, 1383<br />
Tonini S, 3835<br />
Toppan P, 1805, 4095, 4129<br />
Toriumi Y, 215<br />
Torricelli P, 981<br />
Tostain J, 321<br />
Tot T, 1793<br />
Toth B, 1107<br />
Totzke F, 933<br />
Tozawa K, 2087<br />
Traficante A, 2941<br />
Traverso E, 3835<br />
Treisser A, 2447<br />
Tremolizzo L, 335<br />
Triantafillidis JK, 1341<br />
Trillet-Lenoir V, 1161<br />
Troch M, 4101<br />
Tröger W, 1893<br />
Trojani A, 2745<br />
Trompetter M, 237<br />
Tsaganos T, 1411<br />
Tsai C-W, 1687<br />
Tsai H-W, 4149<br />
Tsai M-H, 1687<br />
Tsai M-L, 1093<br />
Tsang S, 3119<br />
Tsangaris GT, 401, 1263<br />
Tsanou E, 3815<br />
Tsantes A, 1857<br />
Tsavaris N, 543<br />
Tsay F-W, 97<br />
Tseng H-C, 1687<br />
Tsigkris C, 1039<br />
Tsouma A, 3945<br />
Tsousis S, 495<br />
Tsoutsou PG, 1349<br />
Tsuchiya H, 645, 655, 1449,<br />
1681<br />
Tsugu H, 407<br />
Tsui K-H, 1969, 1977, 1989,<br />
1993, 2001<br />
Tsuji A, 1433<br />
Tsuji I, 2385<br />
Tsuji M, 3711<br />
Tsujie M, 179<br />
Tsujinaka T, 2379<br />
Tsukada K, 165<br />
Tsutsumi S, 1821<br />
Tsutsumi Y, 1593<br />
Tsuya A, 3855<br />
Tufto I, 3557<br />
Türe-Özdemir F, 3697<br />
Turpeenniemi-Hujanen T,<br />
1757, 2715<br />
Tveit KM, 2289<br />
Tzai T-S, 4149<br />
Tzanakis N, 1039, 1875<br />
Tzivras M, 543, 3697<br />
Ubink-Veltmaat LJ, 1373<br />
Uccini S, 763<br />
Uchida M, 1433<br />
Uchimoto K, 1831<br />
Uchino J, 601<br />
Uchiyama T, 535, 2921<br />
Ueda M, 1559<br />
Ueda S, 2353<br />
Ueda Y, 645, 655<br />
Uemori A, 91<br />
Ueno T, 379<br />
Ueno Y, 2147<br />
Ueoka R, 1187<br />
Uesugi A, 2691<br />
Uggeri F, 1951, 2885<br />
Umehara A, 559<br />
Umekawa T, 3971<br />
Umesaki N, 2933<br />
Umeshita K, 179<br />
Unger C, 933, 1467<br />
Unno M, 2669<br />
Unterberg A, 3725, 3729<br />
Urano T, 693<br />
Urbánek L, 2389<br />
Urushino N, 2009<br />
4283
Usami M, 3913<br />
Ushijima R, 601<br />
Usui T, 2141<br />
Uyama I, 1593<br />
Vadgama JV, 3579<br />
Vairaktaris E, 271, 309, 1675,<br />
2233, 2253<br />
Valavanis C, 2077, 2317<br />
Valentiner U, 2561<br />
Valis D, 1039<br />
Vallböhmer D, 367<br />
Vamvakas L, 495, 3019<br />
Vamvakas P, 2077<br />
Van Dam GM, 1867<br />
Van Der Jagt EJ, 1867<br />
Van Der Wijk J, 237<br />
Van Lier JE, 2781<br />
Van Nieuwenhove Y, 2459<br />
Van Rensburg CEJ, 2781<br />
Van Tienoven D, 2721<br />
Vandenbroucke F, 2459<br />
Vanderauwera J, 2459<br />
Vannini I, 315<br />
Vardakis N, 495<br />
Varga A, 2737<br />
Varga C, 349<br />
Varga Z, 1917<br />
Varhaug JE, 1151<br />
Vasala K, 1757<br />
Vassiliou S, 271, 309, 1675<br />
Veits L, 125<br />
Venturino A, 3993<br />
Verhoef CC, 1867<br />
Veronesi G, 4121<br />
Verrico M, 3941<br />
Vetrano G, 3941<br />
Viale M, 813<br />
Viana-Pereira M, 913<br />
Vici P, 1245<br />
Vigoré L, 1377<br />
Villani L, 2987, 3835<br />
Villemain D, 3067<br />
Vinther J, 2553<br />
Viola A, 2745<br />
Vizzotto M, 2067<br />
Vlachodimitropoulos D, 305<br />
Vo-Dinh T, 485<br />
Voelker H-U, 1719<br />
Vogel U, 1797<br />
Vogelsang H, 361<br />
Vogiatzis P, 2077<br />
Vogl TJ, 879<br />
Volgger B, 3977<br />
4284<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Von Bueren AO, 85<br />
Von Mensdorff-Pouilly S,<br />
2721<br />
Vos P, 431<br />
Vosloo TG, 2781<br />
Vougioukas VI, 3725, 3729<br />
Vougiouklis N, 3107<br />
Vourli G, 2913<br />
Vylliotis A, 271, 309, 1675<br />
Vynios DH, 245<br />
Wacheck V, 3801<br />
Wachowiak J, 1927<br />
Wachtel MS, 1119<br />
Wada J, 2401<br />
Wada N, 139<br />
Wagenblast J, 687, 2239,<br />
2349<br />
Wagner T, 771<br />
Waheed F, 3139<br />
Wakabayashi H, 171, 1069,<br />
2657<br />
Wallwiener D, 779, 949,<br />
1797<br />
Walters DK, 673<br />
Walther J-U, 3573<br />
Wang C-H, 267, 1687<br />
Wang C-L, 267, 1687<br />
Wang C-W, 2039<br />
Wang CY, 3007<br />
Wang C-Z, 2545<br />
Wang E-M, 97<br />
Wang H, 1441<br />
Wang H-C, 267<br />
Wang J-L, 1299<br />
Wang Lei, 2155<br />
Wang Lifeng, 1085<br />
Wang Lilin, 2009<br />
Wang PG, 943<br />
Wang Qingcai, 425<br />
Wang Quansheng, 621<br />
Wang Qun, 2991<br />
Wang S, 327<br />
Wang S, 327, 621<br />
Wang T, 1085<br />
Wang W, 9<br />
Wang Xiaoyan, 2991<br />
Wang Xuping, 1119<br />
Wang Y, 1119<br />
Wang Z-G, 1061<br />
Wang Zhen, 1667<br />
Wang Zhirong, 29<br />
Wang Zhiwei, 3621<br />
Wang Z-Y, 479, 2155<br />
Wangoo KT, 2775<br />
Warnecke-Eberz U, 1525<br />
Watanabe Masahiko, 435,<br />
1933, 2875, 2907, 3593,<br />
3929<br />
Watanabe Masatoshi, 3711<br />
Watanabe O, 4137<br />
Watanabe Yoh, 2385<br />
Watanabe Yuji, 69, 2361<br />
Wdzieczak-Bakala J, 2813<br />
Weathersby DC, 2093<br />
Weecharangsan W, 793<br />
Wei H-C, 833<br />
Wei J, 327<br />
Wei L-H, 1887<br />
Wei Z, 2991<br />
Wei Z-L, 1693<br />
Weigert M, 3977<br />
Weiher H, 2825<br />
Weitz J, 1459<br />
Wells A, 1733<br />
Wen C-H, 2001<br />
Weng Y-S, 2791<br />
Werner M, 3567<br />
Werzowa J, 3801<br />
Wesche KO, 119<br />
Wex T, 757<br />
White MK, 1441<br />
Wieczorek M, 1927<br />
Wiedmann M, 873<br />
Wight E, 921<br />
Wiksten J-P, 2279<br />
Wilke F, 2561<br />
Willén R, 1259<br />
Willich N, 3885<br />
Wilson MJ, 2271<br />
Wimmer E, 973<br />
Winkelmann W, 3885<br />
Winowski J, 2959<br />
Winter R, 3047<br />
Wirth MP, 2259<br />
Wittekind C, 873<br />
Witzigmann H, 873<br />
Wójcik E, 3027<br />
Wolf C, 2453<br />
Wolff JEA, 741, 2437<br />
Wöll E, 1213, 2901<br />
Wolter W, 2529<br />
Woo LWL, 1517<br />
Worku D, 2135<br />
Wright JD, 1763<br />
Wu C, 3997<br />
Wu C-H, 3749<br />
Wu C-W, 907<br />
Wu D-C, 1317<br />
Wu J, 2801, 3093<br />
Wu JM, 29, 2641<br />
Wu M, 327<br />
Wu S-T, 1989<br />
Wu W-J, 2039<br />
Wu Y, 3579<br />
Wuttig D, 2259<br />
Wysocki M, 1927<br />
Xi L, 621<br />
Xiang C-H, 2219<br />
Xie J-T, 2545<br />
Xiros N, 2479, 2913<br />
Xu G, 327, 621<br />
Xu N, 3997<br />
Yaal-Hahoshen N, 3147<br />
Yabuuchi S, 2669<br />
Yagi J, 2921<br />
Yalamanchili K, 3139<br />
Yamada H, 215, 261<br />
Yamada N, 629<br />
Yamagishi H, 1169<br />
Yamaguchi A, 847<br />
Yamamoto H, 2081, 2361<br />
Yamamoto Kaichiro, 2933<br />
Yamamoto Kuniharu, 2669<br />
Yamamoto M, 1779<br />
Yamamoto Nobuyuki, 3855<br />
Yamamoto Norio, 655<br />
Yamamoto Noriyasu, 2087<br />
Yamamoto Seiichiro, 145<br />
Yamamoto Shunsaku, 1585<br />
Yamamoto Tetsuji, 825<br />
Yamamoto Toshiharu, 139<br />
Yamaoka M, 1749<br />
Yamasaki A, 2401<br />
Yamashita K, 435, 1933,<br />
2875<br />
Yamashita Y, 2147<br />
Yamashita Y-I, 2353<br />
Yamaue H, 2373<br />
Yamazaki H, 3913<br />
Yamazaki M, 3933<br />
Yanaga K, 51, 215, 2785,<br />
3809<br />
Yanagawa M, 3711<br />
Yanagita Y, 1239<br />
Yanai K, 2401<br />
Yang C-H, 2001<br />
Yang C-L, 1317<br />
Yang D, 1659<br />
Yang H-B, 97, 1317
Yang J-S, 833, 1045, 1701,<br />
2791<br />
Yang M, 2541<br />
Yang W-H, 4149<br />
Yang W-T, 3093<br />
Yang Xiang-Hong, 1061<br />
Yang Xiao-Hong, 2225<br />
Yannoukakos D, 843<br />
Yao C, 2245<br />
Yao P, 105<br />
Yapijakis C, 271, 309, 1675,<br />
2233<br />
Yasuda M, 639, 2487<br />
Yasui M, 2379<br />
Yasui W, 1169<br />
Yasumoto H, 2141<br />
Yasutake K, 91<br />
Ye W, 425, 2801<br />
Yeh H-H, 3749<br />
Yeh K-H, 1293<br />
Yen C-Y, 1989<br />
Yokogawa K, 1681<br />
Yokomizo H, 373, 559, 1773<br />
Yokouchi M, 2147<br />
Yoneda K, 2889<br />
Yoneyama Y, 665<br />
Yoshida A, 139<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Yoshida I, 1593<br />
Yoshida K, 1773<br />
Yoshida M, 69<br />
Yoshida S, 379<br />
Yoshida Y, 4143<br />
Yoshihama Y, 2343<br />
Yoshikawa T, 1169<br />
Yoshimatsu K, 373, 1773,<br />
1841, 2321<br />
Yoshimatsu K, 559<br />
Yoshino M, 1229<br />
Yoshino S, 379<br />
Yoshino T, 2889<br />
Yoshioka M, 1633, 3933<br />
Yoshiya S, 4117<br />
Youngquist L, 1<br />
Yousfi SE, 779<br />
Yu B, 2801<br />
Yu C-S, 1701, 2791<br />
Yu D-S, 1989<br />
Yu D-Y, 609, 1693<br />
Yu G, 229, 2197<br />
Yu J, 2205<br />
Yuan C-S, 2545<br />
Yuk DY, 3777<br />
Yukumi S, 69<br />
Yura Y, 3637<br />
Zabel M, 1113, 2959, 2967<br />
Zabernigg A, 2901<br />
Zacherl J, 1213, 4101<br />
Zanetti-Dällenbach R, 921<br />
Zang X-P, 133, 2733<br />
Zapardiel I, 2595<br />
Zappoli F, 2987<br />
Zavos C, 3107<br />
Zeimet AG, 2975<br />
Zeisler H, 3083<br />
Zeitoun G, 3609<br />
Zembala M, 187<br />
Zeuli M, 1429<br />
Zhai G, 2801<br />
Zhang A, 621<br />
Zhang B, 2545<br />
Zhang K-M, 2219<br />
Zhang L, 2991<br />
Zhang M, 741<br />
Zhang P, 3631<br />
Zhang W, 229, 2197, 2219<br />
Zhang Xia, 2991<br />
Zhang Xiaoying, 129<br />
Zhang Y, 327<br />
Zhao L, 327<br />
Zhao Q-L, 609, 1693<br />
Zhao X, 2801<br />
Zhao Y, 1085<br />
Zheng H-C, 1061, 2225<br />
Zheng Y-S, 2225<br />
Zhong XY, 921<br />
Zhou Caicun, 601<br />
Zhou Chengjun, 2991<br />
Zhou H, 3897<br />
Zhou Ji, 3897<br />
Zhou Jianfeng, 327, 621<br />
Zhou L, 1119<br />
Zhou Y, 3613<br />
Zhu F, 2991<br />
Zhu G-D, 2625<br />
Zhu T, 327<br />
Zhu W-L, 1575<br />
Zhu W-X, 1575<br />
Zinzani PL, 981<br />
Zirrgiebel U, 933<br />
Zivi A, 1767<br />
Zografos GN, 3945<br />
Zoli W, 315<br />
Zorzino L, 3061<br />
Zullo A, 419<br />
Zupa A, 2941<br />
Zupkó I, 2737<br />
Zwirner M, 949<br />
4285
Errata<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Volume 27 (2007), No 6B, pages 4152, 4153: Figures 1 and 2 should be printed in color:<br />
4287
Figure 1. SD-208 reduces growth kinetics of the primary tumor and<br />
inhibits formation of metastatic lesions: A) tumor growth kinetics of the<br />
primary tumor monitored by measuring bioluminescence intensity in<br />
vehicle and SD-208 at 60 mg/kg/po/bid treated mice with pancreatic<br />
cancer. Data was collected in a longitudinal mode from each animal<br />
repeatedly through the study period. SD-208 time-dependently reduced<br />
bioluminescence intensity in the primary tumor and the data is statistically<br />
significant during the last two-thirds of the study (*p
Medicherla et al: TGF-‚ Inhibitor in a Mouse Model of Pancreatic Cancer<br />
4153
4290<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Volume 27 (2007), No 6B, page 4207:<br />
Line 11: The data of Gender-MVD should move one column left (Table I):<br />
Table I. continued<br />
Tumour Tissue Gender Age PCNA* Ki-67* GHR* MVD**<br />
Angiosarcoma<br />
01-5548A7 Flank, Grade I-II M 50 – /+ – (+) +/– 3+<br />
98-4700#1 Liver M 67 +/– – /+ + 4+<br />
97-539 Breast F 44 +/– – /+ +(– ) 4+<br />
97-6023 Skin M 38 – /+ – /+ +/– 3+<br />
97-2412A#1 Bladder F 42 – /+ – /+ +/– 5+<br />
97-7736#1 Anorectal M 64 +/– – /+ +/– 5+<br />
93-120E#1– 3 Skin, Grade III M 63 – /+ – /+ +/– 3+<br />
93-120E#1-5 Chest, GradeIII M 63 +(– ) – /+ + 4+<br />
93-120 E#10 Skin, Grade III M 63 +/– – (+) +/– 4+<br />
93-337A#3-2 Axillary mass F 59 +/– – /+ +(– ) 3+<br />
Haemangiopericytoma<br />
98-7684A#1 Neck mass M 56 – /+ – (+) – /+ 5+<br />
98-7684B Neck mass M 56 +/– – /(+) +(– ) 5+<br />
97-814A#1 Abdomen F 29 + – (+) + 5+<br />
96-868 Trunk mass M 63 +/– – /+ +/– 4+<br />
*Labelling of proliferating cell nuclear antigen (PCNA), cycling nuclear protein (Ki-67) and growth hormone-receptor (GHR): + = labelling of<br />
great majority; +(– ) = labelling of great majority, some negative; +/– = positive labelling is between 50-70%; – /+ = more than 50% are<br />
negative; – (+) = more than 90% are negative; – = no labelling. **MDV-microvascular density (CD-31+ve), the maximum number of<br />
microvessels staining positive at X200 was graded using the following scoring system: up to 25 vessels = 1+, 26-50 vessels = 2+, 51-75 = 3+, 76-<br />
100 = 4+, while >100 vessels was graded 5+.<br />
Volume 28 (2008), No 1A, page 9:<br />
The authors’ names should read:<br />
XIAOXIA GUO 1 , ELISABETH GOESSL 1 , GANG JIN 1* , ELAINA S.R. COLLIE-DUGUID 2 ,<br />
JAMES CASSIDY 3 , WEIGUANG WANG 1 and VINCENT O’ BRIEN 3<br />
Volume 28 (2008), No 1A, page 9:<br />
The following note should be inserted before the correspondence address:<br />
*Visiting fellow from the College of Applied Chemistry and<br />
Biotechnology, Shenzhen Polytechnic, China. The project is<br />
partially supported by Shenzhen Science and Technology<br />
Project (06KJba042).<br />
Volume 28 (2008), No 2A, page 656, left column, Materials and Methods, 1st paragraph:<br />
Line 12: Please correct 50 Bl to 50 μl.<br />
Line 17: Please correct 200 Bm to 200 μm<br />
Volume 28 (2008), No 2A, page 656, right column, 2nd paragraph:<br />
Line 10: Please correct 0.5 Bg to 0.5 μg.<br />
Line 14: Please correct 1 Bl to 1 μl.<br />
Line 15: Please correct 50 Bl to 50 μl.<br />
Volume 28 (2008), No 2A, page 657, right column:<br />
Line 1: Please correct 4-Bm to 4 μm.
Volume 28 (2008), No 2A, page 1072:<br />
Please correct the structure of compound 15 in Figure 1 to:<br />
15: R 6 =OAc; R 8 , R 10 =H<br />
Volume 28 (2008), No 2A, Contents, page 1119:<br />
Please correct the name of the 6th author:<br />
M. CHIRIVA-INTERNATI<br />
Volume 28 (2008), No 3A, page 1477:<br />
Oroteta should be corrected to Orotate, throughout pp 1477-1482.<br />
Volume 28 (2008), No 4A, page 2009:<br />
Please correct the names of the 8th and 9th authors to:<br />
Volume 28 (2008), No 5A, page 2569:<br />
The authors should be corrected as follows:<br />
TOSHIYUKI SAKAKI 3 , NAOKO URUSHINO 3<br />
D.G. KIEBACK and S. OLLIG<br />
Volume 28 (2008), No 5A, page 2706:<br />
Right column, 3rd line should read:<br />
WST-1 labeling mixture per well was then added. After incubation<br />
Right column, line 13 should read:<br />
Madison, WI, USA Cat #G7570). One ml of cell was seeded into<br />
Volume 28 (2008), No 5A, page 2707:<br />
Left column, line 8 should read:<br />
One ml MTC-SK cells was seeded into 24-well plates at a density<br />
Left column, lines 48-49 should read:<br />
modified routine methods. Photographs were taken with a FEI Technai 12 equipped with a Gatan CCD Camera Bioscan.<br />
Right column, line 8 should read:<br />
evaluated for their antiproliferative activities in the human<br />
Right column, line 36: Please correct (3) to (20).<br />
Volume 28 (2008), No 5A, page 2709:<br />
Left column, line 9 should read:<br />
were observed after 24 h treatment with C. gracilis extracts.<br />
Volume 28 (2008), No 5A, page 2745: The title should read:<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Molecular Analysis of PDGFRA and PDGFRB Genes<br />
by Rapid Single-strand Conformation Polymorphism (SSCP)<br />
in Patients with Core-binding Factor Leukaemias<br />
without KIT or FLT3 Mutation<br />
4291
Instructions to Authors<br />
General Policy. ANTICANCER RESEARCH (AR) will accept high quality original works and reviews on all aspects of experimental and clinical<br />
cancer research. The Editorial Policy advises that priority should be given to papers advancing the understanding of cancer causation, and to<br />
papers applying the results of basic research to cancer diagnosis, prognosis and therapy. AR will also accept the following for publication: (a)<br />
abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) announcements of meetings related<br />
to cancer research; (c) short reviews (of approximately 1,200 words) and announcements of newly published books and journals related to cancer;<br />
and (d) announcements of awards and prizes.<br />
The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four<br />
months after publication in AR, for public archiving in PubMed Central.<br />
A main aim of AR is to ensure the prompt publication of high quality original works, generally within 1-2 months from final acceptance.<br />
Manuscripts will be accepted on the understanding that they report original unpublished works on cancer that are not under consideration for<br />
publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review,<br />
when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve<br />
manuscripts in terms of grammar and style.<br />
Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) short papers. Additionally, the Editors<br />
may invite review articles concerning fields of recognisable progress. Papers should contain all the essential data in order to make the presentation<br />
clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear,<br />
concise English. Spelling should follow that of the "Oxford English Dictionary".<br />
Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced page), including<br />
abstract, text, tables, figures and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess<br />
page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding<br />
fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an<br />
abbreviated running title, indication of the study type "clinical", "epidemiological", or "experimental", and date of submission. (Note: The order<br />
of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate<br />
section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials<br />
and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results;<br />
(f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review<br />
articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages<br />
(approximately 250 words per double-spaced page) including all tables, figures and references.<br />
Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal:<br />
8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be<br />
submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and<br />
lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and<br />
photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should<br />
be numbered with Arabic numerals and include a short title, and legend if appropriate.<br />
Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include<br />
a short title, and legend if appropriate.<br />
Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations are preferable. If a<br />
new abbreviation is used, it must be defined on first usage.<br />
References. Citations for the reference section of submitted works should follow the standard form of “<strong>Index</strong> Medicus” and must be numbered<br />
consecutively in the order that they appear in the text. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for<br />
cancer research. <strong>Anticancer</strong> Res 1: 205-216, 1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. In:<br />
Receptors for Reproductive Hormones. O' Malley BW and Chamnes GC (eds.). New York, Plenum Publ Corp, pp. 113-136, 1973. In the text,<br />
references should be denoted as: (1), (2-5), (6, 7) etc.<br />
Submission of Manuscripts. An original and two copies of the manuscript (including all photographs and graphs) should be sent to:<br />
Dr. J.G. Delinassios, Managing Editor, <strong>Anticancer</strong> <strong>Research</strong>, Editorial Office, International Institute of <strong>Anticancer</strong> <strong>Research</strong>, 1st km<br />
Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. A CD-ROM, floppy disc, USB stick or ZIP-disc should also be<br />
submitted indicating the computer-processing program. Additionally, for speed of processing, manuscripts may be sent by e-mail to journals@iiaranticancer.<br />
Authors are invited to submit, along with their manuscripts, a short list of possible reviewers and any previous publications which<br />
could facilitate reviewing. Only the original copy of the submitted manuscript will be returned to the Authors upon rejection. The number of<br />
recently accepted manuscripts will be entered in the <strong>Anticancer</strong> <strong>Research</strong> page "Author's Service" as soon as a decision has been reached.<br />
Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley<br />
proofs should be limited to typographical errors.<br />
Reprints. Twenty-five copies of each published article will be provided free-of-charge. Additional copies may be ordered after acceptance of the<br />
paper. Requests for additional reprints should be addressed to the Editorial Office.
Publication Data: ANTICANCER RESEARCH (AR) is<br />
published bimonthly. Each annual volume contains six issues.<br />
Annual Authors and Subject <strong>Index</strong>es are included in the sixth<br />
issue of each volume.<br />
Copyright: Once a manuscript has been published in AR, which<br />
is a copyrighted publication, the legal ownership of all published<br />
parts of the paper has passed from the Author to the Journal.<br />
Annual Subscription Rates 1981, 1982, 1983, 1984, 1985, 1986,<br />
1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996,<br />
1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006,<br />
2007, 2008: Institutional subscription for Europe: Euro 1634 per<br />
volume. Institutional subscription for all other continents: Euro<br />
1742 per volume. Personal subscription for Europe: Euro 785 per<br />
volume. Personal subscription for all other continents: Euro 846<br />
per volume. Prices include rapid delivery and insurance. The<br />
complete previous volumes of <strong>Anticancer</strong> <strong>Research</strong> (Vol. 1-27,<br />
1981-2007) are available at 50% discount on the above rates.<br />
Subscription Orders: Orders can be placed at agencies,<br />
bookstores, or directly with the publisher. Cheques should be made<br />
payable to J.G. Delinassios, Executive Publisher of <strong>Anticancer</strong><br />
<strong>Research</strong>, Athens, Greece and should be sent to the Editorial Office.<br />
ANTICANCER RESEARCH will become available online<br />
through Stanford University HighWire Press starting January<br />
2009. For 2009 online/print subscription rates, please visit the<br />
IIAR website: www.iiar-anticancer.org<br />
Correspondence: (subscription orders, reprint orders, change of<br />
address, disposition of submitted manuscripts, and general<br />
editorial matters) should be directed to Dr. J. G. Delinassios,<br />
Executive Publisher and Managing Editor, Editorial Office.<br />
Advertising: Correspondence and rate requests should be<br />
addressed to the Editorial Office.<br />
Book Reviews: Recently published books and journals should<br />
be sent to the Editorial Office. Reviews will be published within<br />
2-4 months.<br />
ANTICANCER RESEARCH 28: <strong>Index</strong> (2008)<br />
Editorial Staff<br />
Managing Editor and Executive Publisher: J.G. DELINASSIOS, Athens, Greece<br />
Assistant Managing Editor: S. AZOUDIS<br />
Production Editor: E. ILIADIS, Athens, Greece<br />
Editorial Office<br />
International Institute of <strong>Anticancer</strong> <strong>Research</strong>,<br />
1st km Kapandritiou-Kalamou Rd.,<br />
Kapandriti, P.O.Box 22, Attiki 19014, Greece<br />
Telephone and Fax: 0030-22950-53389<br />
Please visit the IIAR website: www.iiar-anticancer.org<br />
e-mails:<br />
Editor: editor@iiar-anticancer.org<br />
Journals: journals@iiar-anticancer.org<br />
IIAR: iiar@iiar-anticancer.org<br />
Articles in ANTICANCER RESEARCH are regularly indexed in<br />
all bibliographic services, including Current Contents (Life<br />
Sciences), Science Citation <strong>Index</strong>, PubMed/Medline, <strong>Index</strong> Medicus,<br />
Biological Abstracts, Chemical Abstracts, Excerpta Medica,<br />
University of Sheffield Biomedical Information Service, Current<br />
Clinical Cancer, AIDS Abstracts, Progress in Palliative Care,<br />
Cambridge Scientific Abstracts, Cancergram (International Cancer<br />
<strong>Research</strong> Data Bank), Reference Update - RIS Inc., PASCAL-<br />
CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology<br />
Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition <strong>Research</strong><br />
Newsletter, Dairy Science Abstracts, Current Titles in Dentistry,<br />
Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global<br />
Health Databases and Investigational Drugs Database, VINITI<br />
Abstracts Journal, Leeds Medical Information, PubsHub.<br />
Authorization to photocopy items for internal or personal use,<br />
or the internal or personal clients, is granted by ANTICANCER<br />
RESEARCH, provided that the base fee of $2.00 per copy, plus<br />
0.40 per page is paid directly to Copyright Clearance Center, 27<br />
Congress Street, Salem, MA 01970, USA. For those<br />
organizations that have been granted a photocopy license by<br />
CCC, a separate system of payment has been arranged. The fee<br />
code for users of the Transactional Reporting Service is 0250-<br />
7005/2008 $2.00 +0.40.<br />
The Editors and Publishers of the journal ANTICANCER<br />
RESEARCH accept no responsibility for the opinions expressed<br />
by the contributors or for the content of the advertisements<br />
appearing herein.<br />
Editorial Office<br />
International Institute of <strong>Anticancer</strong> <strong>Research</strong>,<br />
1st km Kapandritiou-Kalamou Rd.,<br />
Kapandriti, P.O.Box 22, Attiki 19014, Greece<br />
Telephone and Fax: 0030-22950-53389<br />
PHOTOCOMPOSITION BY IIAR<br />
PRINTED BY ENTYPO, GREECE<br />
PRINTED ON ACID - FREE PAPER
Change language